{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {
    "heading_collapsed": true
   },
   "source": [
    "# Introduction"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "hidden": true
   },
   "source": [
    "Welcome to Module 5 of the Text Mining Track! This module will explore predictive analysis of text data. With a preprocesed data, we will build machine learning models to predict triage decision for systematic review regarding to the topic of ACE Inibitors. You will do so through a combination of video lectures, interactive notebooks, and hands-on coding exercises.\n",
    "\n",
    "Lets begin!"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "heading_collapsed": true,
    "hidden": true
   },
   "source": [
    "## How to Run the Module"
   ]
  },
  {
   "attachments": {
    "run_cell.png": {
     "image/png": "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"
    }
   },
   "cell_type": "markdown",
   "metadata": {
    "hidden": true
   },
   "source": [
    "Throughout this module you will encounter both text and code cells. Please run each cell in this Notebook by clicking \"Run\" button in the Toolbar or by pushing Shift+Enter keys  \n",
    "![run_cell.png](attachment:run_cell.png)\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "hidden": true
   },
   "source": [
    "The cell below is an example of a code cell. You will be running numerous code cells like the one below throughout the case. Select the cell and select the run button above."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {
    "hidden": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Congratulations!\n",
      "You've run your first code cell.\n"
     ]
    }
   ],
   "source": [
    "# This is an example of a code cell\n",
    "print('Congratulations!')\n",
    "print('You\\'ve run your first code cell.')"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "heading_collapsed": true,
    "hidden": true
   },
   "source": [
    "## Lecture Video"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "hidden": true
   },
   "source": [
    "**Please run the code cell below to reveal the video.**"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {
    "hidden": true,
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<iframe width=\"705\" height=\"537\" src=\"https://www.youtube.com/embed/STz8SnDeEWo?list=PL6IN6GlGifEytPcv5HR_iaNBekwXYZIpR\" frameborder=\"0\" allowfullscreen></iframe>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "execution_count": 4,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Set Up\n",
    "import warnings\n",
    "warnings.filterwarnings('ignore')\n",
    "%matplotlib inline\n",
    "from IPython.display import HTML\n",
    "\n",
    "# Display Video\n",
    "HTML('<iframe width=\"705\" height=\"537\" src=\"https://www.youtube.com/embed/STz8SnDeEWo?list=PL6IN6GlGifEytPcv5HR_iaNBekwXYZIpR\" frameborder=\"0\" allowfullscreen></iframe>')"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "hidden": true
   },
   "source": [
    "In this module, we will predict whether an article in the dataset will be included for the systematic review of ACE Inbibitors. To this end, we will use only a part of the dataset 'epc-ir_clean_19.csv' to get the articles whose topics are 'ACEIhibitors.'  \n",
    "  \n",
    "In this pipeline, we go through the following steps:  \n",
    "    \n",
    "1. Building a bag-of-word matrix\n",
    "2. Predictive analysis   \n",
    "   a. Dimensionality reduction (feature selection)     \n",
    "   b. Splitting data into training and testing data  \n",
    "   c. Building prediction models - logistic regression and k-nearest neighbor  \n",
    "   d. performance evaluation - accuracy and AUC  \n",
    "  \n",
    "Throughout this module, features will be represented by bag-of-words in uni-, bi-, or trigrams."
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "heading_collapsed": true
   },
   "source": [
    "# Building a Bag-of-Word Matrix"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "hidden": true
   },
   "source": [
    "**Transforming DataFrame into list**  \n",
    "  \n",
    "Run data file 'epc-ir_clean_10k.csv.'  \n",
    "We will use articles whose topics are **'ACEIhibitors'** only."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "metadata": {
    "hidden": true
   },
   "outputs": [],
   "source": [
    "import pandas as pd\n",
    "\n",
    "# Our dataset is \"df,\" a DataFrame imported from a csv file.\n",
    "df = pd.read_csv('epc-ir_clean_10k.csv', index_col = 'index') \n",
    "# copy rows whose topics are 'ACEInhibitors'\n",
    "df_acei = df.loc[(df['topic']=='ACEInhibitors')].copy() "
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "hidden": true
   },
   "source": [
    "There are 2235 instances in the dataset"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 35,
   "metadata": {
    "hidden": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "2235"
      ]
     },
     "execution_count": 35,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(df_acei)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "hidden": true
   },
   "source": [
    "Transform the column 'clean_abs' into a list"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 36,
   "metadata": {
    "hidden": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['hypercholesterolemia hypertension frequently associate elevate sympathetic activity independent cardiovascular risk factor affect endotheliummediated vasodilation identify effect cholesterollowering antihypertensive treatments vascular reactivity vasodilative capacity study hypercholesterolemic hypertensive subject receive placebo weeks either enalapril simvastatin weeks finally medications additional weeks postischemic forearm blood flow mfbf minimal vascular resistance mfvr use indices vasodilative capacity structural vascular damage respectively total restingstressrecovery phase cardiovascular blood pressure [ bp ] heart rate [ hr ] regional hemodynamic fbf fvr reactivity stressful stimuli calculate areaunderthecurve auc valuextime compare baseline level simvastatin reduce total totc ldl cholesterol ldlc mmoll p mmoll p respectively enalapril also reduce totc ldlc mmoll p mmoll p respectively mfbf increase substantially treatments p enalapril greater effect arbitrary units au p simvastatin au p mfvr stress fbf increase enalapril fbfxminutes p simvastatin fbfxminutes p conversely fvr stress response reduce enalapril fvrxminutes p simvastatin fvrxminutes p combination treatment significant p additive effect hypercholesterolemia structural vascular damage bp fvr show find suggest angiotensinconverting enzyme ace inhibition induce larger reduction hmgcoa reductase blockade vascular reactivity structural damage hypercholesterolemic hypertensive subject',\n",
       " 'implement measure effect automatic computerize laboratory signal als detection support tool adverse drug reactions adrs hospital',\n",
       " 'patients insulindependent diabetes mellitus iddm overt nephropathy glomerular barrier sizeselectivity progressively deteriorate time effectively improve angiotensin convert enzyme ace inhibition whether similar glomerular functional change develop proteinuric patients noninsulindependent diabetes mellitus niddm whether antihypertensive agents favorably affect glomerular filtration macromolecules patients not document yet',\n",
       " 'aortic root flow pressure estimate obtain noninvasively doppler echocardiography calibrate subclavian artery pulse trace subject ambulatory hypertension randomize crossover study weeks treatment washout periods total arterial compliance assess use threeelement windkessel model arterial tree increase atenolol mg daily p ns captopril mg twice daily atenolol reduce mean arterial pressure heart rate cardiac output increase acceleration time aortic root flow stroke volume ejection time captopril reduce mean arterial pressure total peripheral resistance acceleration time aortic root flow ejection time heart rate stroke volume cardiac output not significantly change captopril conclude total arterial compliance operational blood pressure increase selective betaadrenergic receptor blockade subject ambulatory hypertension although main mechanism may reduction mean arterial pressure consider whether reduce heart rate may play additional role nonsignificant increase total arterial compliance angiotensinconverting enzyme inhibition may primarily consequence modest reduction mean arterial pressure',\n",
       " 'populationbased study find black patients congestive heart failure higher mortality rate white condition find attribute differences severity cause management heart failure prevalence coexist condition socioeconomic factor although factor probably account higher mortality due congestive heart failure among black hypothesize racial differences natural history leave ventricular dysfunction might also role',\n",
       " 'exfoliative dermatitis also know erythroderma uncommon serious skin disorder family physicians must able recognize treat appropriately although etiology often unknown exfoliative dermatitis may result drug reaction underlie malignancy approach treatment include discontinuation potentially causative medications search underlie malignancy one common malignancies associate exfoliative dermatitis cutaneous tcell lymphoma may not manifest months even years onset skin condition hospitalization usually necessary initial evaluation treatment hospital special attention must give maintain temperature control replace lose fluids electrolytes prevent treat infection longterm prognosis good patients druginduced disease although course tend remit relapse idiopathic case prognosis case associate malignancy typically depend outcome underlie malignancy',\n",
       " 'angiotensinconvertingenzyme ace inhibitors use decade treat high blood pressure despite lack data randomise intervention trials show treatment affect cardiovascular morbidity mortality captopril prevention project cappp randomise intervention trial compare effect ace inhibition conventional therapy cardiovascular morbidity mortality patients hypertension',\n",
       " 'investigate effect shortacting loop diuretic furosemide longacting loop diuretic azosemide heart rate variability fluid balance neurohormonal responses patients mild moderate chronic congestive heart failure',\n",
       " 'outpatients essential hypertension randomize receive antihypertensive treatment either mibefradil enalapril ambulatory blood pressure measurement abpm video capillary microscopy finger nailfold perform baseline weeks treatment enalapril group n baseline abp mm hg decrease mm hg weeks mibefradil group n mean h abp decrease mm hg capillary blood cell velocity cbv without treatment mms mean sd mms rest mms immediately local finger cool mibefradil enalapril group respectively enalapril group cbv week mms n rest mms immediately local cool p compare mms without treatment twelve weeks initiation treatment cbv mms n rest mms n immediately local cool mibefradil group finger nailfold cbv immediately local finger cool increase enalapril compare baseline tchannelinhibiting calcium antagonist mibefradil not change cbv finger nailfold capillaries',\n",
       " 'incomplete suppression reninangiotensin system longterm ace inhibition may contribute symptomatic deterioration patients severe congestive heart failure chf combine angiotensin ii type receptor blockade ace inhibition completely suppress activate reninangiotensin system either intervention alone sodiumdepleted normal individuals whether receptor blockade losartan improve exercise capacity patients severe chf already treat ace inhibitors unknown',\n",
       " 'recent report suggest calciumchannel blockers may harmful patients diabetes hypertension previously report antihypertensive treatment calciumchannel blocker nitrendipine reduce risk cardiovascular events post hoc analysis compare outcome treatment nitrendipine diabetic nondiabetic patients',\n",
       " 'assess efficacy safety bisoprolol mg hydrochlorothiazide hctz amlodipine enalapril black nonblack patients data two comparative study pool subgroup analyse perform study similar design include three active treatments second study also include placebo group subject n sit diastolic blood pressure mmhg titrate achieve diastolic blood pressure mmhg study include black nonblacks result intentiontotreat analysis mean change baseline weeks treatment show follow blood pressure significantly lower three active drug compare baseline placebo black bisoprolol mg hctz result significantly greater reductions systolic diastolic blood pressure enalapril placebo not significantly different amlodipine nonblacks bisoprolol mg hctz result significantly greater reduction diastolic blood pressure amlodipine enalapril placebo placebocorrected change blood pressure greater black white bisoprolol mg hctz combination not statistically significant bisoprolol mg hctz control diastolic blood pressure mmhg significantly patients enalapril placebo black nonblacks difference control rat not significant versus amlodipine incidence drugrelated adverse events similar treatments however bisoprolol mg hctz lower discontinuation rate due lack blood pressure control adverse experience black nonblacks',\n",
       " 'describe case linear iga bullous dermatosis labd patient acute lymphocytic leukemia treatment granulocyte colonystimulating factor gcsf drug eruption due imipenem cilastatin sodium disappear bullous lesions appear trunk result histopathological study direct immunofluorescence study lesion consistent labd reinstitution gcsf resolution however not reproduce bullous eruptions suggest addition gcsf presence precipitate factor synergistically enhance accelerate outbreak disease require development bullous lesions various cytokines interleukin il interferongamma ifngamma endogenously produce activate lymphocytes drug eruption might provide favorable milieu onset gcsfinduced labd suggest patients labd need special attention respect type cytokines combination cytokines give therapeutic modalities',\n",
       " 'assess antihypertensive efficacy safety novel receptor antagonist telmisartan compare enalapril elderly patients mild moderate hypertension',\n",
       " 'longterm angiotensinconverting enzyme ace inhibition may reduce ischemic events patients coronary artery disease whether protect acute ischemia effect preexist leave ventricular lv dysfunction potential antiischemic properties unknown perform doubleblind trial patients exerciseinduced ischemia effect perindoprilat pacinginduced myocardial ischemia examine fourteen patients receive perindoprilat patients receive placebo base lv function subgroups form perindoprilat group patients lv dysfunction lv ejection fraction patients normal lv function receive study medication pace test repeat first pace test group develop ischemia perindoprilat administration increase systemic vascular resistance lv enddiastolic pressure significantly blunt p ischemiainduced increase arterial cardiac uptake norepinephrine inhibit perindoprilat increase atrial natriuretic peptide less pronounce also stsegment depression reduce compare placebo p group lv dysfunction perindoprilat reduce lv enddiastolic pressure significantly myocardial lactate production prevent not happen group normal lv function addition increase arterial norepinephrine reduce respectively p result indicate perindoprilat reduce acute pacinginduced ischemia normotensive patients patients asymptomatic lv dysfunction effect pronounce patients normal lv function',\n",
       " 'cough one frequent side effect associate angiotensin convert enzyme inhibitors aceis not think associate losartan angiotensin ii receptor antagonist ara study compare report cough losartan three aceis use general practice',\n",
       " 'angiotensinconverting enzyme inhibitors prove clinical benefit congestive heart failure whether also provide benefit patients coronary artery disease absence congestive heart failure via antiatherosclerotic mechanism question quinapril ischemic event trial quantitative coronary angiography qca study attempt answer patients normal leave ventricular function undergo coronary angiography angioplasty randomize mgday quinapril versus placebo follow years cardiac end point randomly select subgroup total cohort undergo followup angiography primary qca end point categorical designation progression versus nonprogression define either qca cardiac event patients select qca trial no usable followup xray film secondary end point patients angiograms new stenosis development change minimum lumen diameter index change percent diameter stenosis index progressors among placebotreated patients progressors among quinapriltreated patients p ns patients new stenosis development placebo group quinapril group p ns change minimum lumen diameter index mm placebo group mm quinapril group p ns finally change percent diameter stenosis index placebo group quinapril group p ns potential confounders trial present discuss',\n",
       " 'patients acute myocardial infarction evidence heart failure leave ventricular dysfunction acute phase excessive mortality risk therapy angiotensinconverting enzyme inhibitors attenuate detrimental effect angiotensin ii show substantially reduce morbidity mortality population selective angiotensin type receptor antagonism losartan inhibit effect angiotensin ii regardless source receptor level may provide complete blockade reninangiotensin system optimal therapy myocardial infarction angiotensin ii antagonist losartan optimaal study multicenter doubleblind randomize parallel captoprilcontrolled trial primary hypothesis compare captopril losartan decrease risk allcause mortality highrisk patients acute myocardial infarction study population consist patients years age heart failure acute phase new qwave anterior infarction reinfarction patients randomize treatment either losartan captopril patients follow deaths occur eventdriven primary end point total mortality allcause mortality secondary tertiary end point sudden death andor resuscitate cardiac death fatalnonfatal reinfarction base assume event rate treatment effect power detect reduction allcause mortality significance level sided adjust interim analyse trial enroll least patients continue total number events reach intentiontotreat analysis',\n",
       " 'patients chronic heart failure fatigue independent haemodynamic neuroendocrine change possibly may due impair muscle metabolism propionyllcarnitine carnitine derivative show previous study improve muscle metabolism objective study evaluate effect propionyllcarnitine exercise capacity mild moderate chronic heart failure patients treat ace inhibitors diuretics',\n",
       " 'patients essential hypertension healthy control subject evaluate blood concentrations b cell leukemia bcl protooncogene reduce apoptosis bcl concentrations higher hypertensive normotensive subject increase pressure due cold pressor test cause increase blood bcl concentrations hypertensive normotensive subject treatment hypertensive patients hypotensive drug cause reduction bcl concentrations mark administration lisinopril nifedipine result suggest concentrations bcl increase patients hypertension could important factor cell proliferation underlie posthypertensive vascular remodel moreover lisinopril nifedipine appear capable reduce bcl concentrations potentially beneficial effect vascular modifications patients hypertension',\n",
       " 'several study show angiotensinconverting enzyme ace inhibitors confer significant mortality morbidity benefit heart failure firstdose hypotension may necessitate interruption therapy likely occur ace inhibitor administer early coronary artery bypass graft cabg purpose study analyse haemodynamic tolerance early postoperative treatment perindopril enalapril patients impair renal ventricular function',\n",
       " 'measure quality life qol patients mild moderate heart failure treat angiotensin convert enzyme ace inhibitors cilazapril captopril',\n",
       " 'longterm prognostic importance hyperkinesia unknown follow acute myocardial infarction ami american society echocardiography recommend hyperkinesia not include calculation wall motion index wmi objective present study determine hyperkinesia include wmi estimate prognostic purpose follow ami six thousand six hundred seventysix consecutive patients screen days ami danish hospitals wmi measure patients apply segment model follow score system hyperkinesia normokinesia hypokinesia akinesia dyskinesia patients follow respect mortality least years wmi calculate different ways include hyperkinetic segment hyperkineticwmi exclude nonhyperkinetic segment nonhyperkineticwmi convert hyperkinetic segment normokinetic segment hyperkinesia occur patients wmi important prognostic factor relative risk p longterm mortality together heart failure history hypertension angina diabetes previous ami age thrombolytic therapy arrhythmias bundle branch block multivariate analysis include nonhyperkineticwmi hyperkinesia associate relative risk statistically significant confidence intervals p hyperkinesia include wmi hyperkineticwmi independent variable no additional prognostic information relative risk p obtain echocardiographic evaluation shortly ami give important prognostic information especially information concern hyperkinesia include wmi use prognostic purpose hyperkinesia include calculation index',\n",
       " 'estimate effect angiotensin convert enzyme ace inhibitors risk sudden cardiac death scd follow myocardial infarction mi',\n",
       " 'angiotensinconverting enzyme ace inhibitors show slow progression chronic renal failure however value ace inhibitors treatment hypertension renal allograft recipients not establish ace inhibitors dilate efferent glomerular arteriole effect may aggravate decrease glomerular filtration rate result cyclosporineinduced vasoconstriction afferent glomerular arteriole therefore goal doubleblind randomize study compare antihypertensive renal effect ace inhibitor quinapril betablocker atenolol renal allograft recipients hypertension develop weeks transplantation patients receive cyclosporine immunosuppressant stable graft function serum creatinine concentration micromoll entry study twentynine patients receive quinapril daily dose titrate mg patients receive atenolol daily dose titrate mg complete month study two group not differ age sex ratio height weight entry study quinapril decrease diastolic blood pressure mm hg average throughout treatment period atenolol decrease diastolic blood pressure mm hg serum creatinine concentration not change significantly either group months micromoll entry micromoll months quinapril group micromoll entry micromoll months atenolol group pns group months change urinary albumin excretion baseline mgd quinapril group mgd atenolol group p result show quinapril atenolol effective antihypertensive drug use renal transplantation moreover compare atenolol quinapril no adverse effect graft function relative reduction albuminuria observe quinapril compare atenolol could indicate beneficial effect quinapril longterm graft function',\n",
       " 'tcells involve pathogenesis cutaneous drug reactions tcell phenotype cytokine release pattern rivo vitro might correlate type immune response involve cutaneous drug reactions vitro release interferongamma macrophage migration inhibition factor mif peripheral blood lymphocytes follow vitro challenge suspect unmodified drug study patients druginduced urticaria andor angioedema two groupmatched control occurrence positive interferongamma mif responses significantly higher patients druginduced urticaria andor angioedema control sensitivity specificity interferongamma test respectively similar mif test respectively percentage agreement test kappa vitro release interferongamma mif druginduced urticaria andor angioedema suggest drugspecific immune response may implicate drug possible inducer reaction',\n",
       " 'rima rimodellamento infarto miocardico acuto study design assess relative effect angiotensinconverting enzyme ace inhibition captopril betablocker therapy metoprolol combination patients first acute myocardial infarction echocardiographically detect leave ventricular remodel prognosis second goal argument present paper twohundred fifty years consecutive patients mean age yrs males acute myocardial infarction randomly allocate receive months captopril mgday group metoprolol mgday group captopril metoprolol group start first hours onset symptoms intravenous betablockers acute phase myocardial infarction cardioactive drug allow effect randomize therapy six months admission coronary care unit consider relation recurrence spontaneous cardiac events elective revascularization procedures adverse reactions hypotension atrioventricular block cough allergy need betablockers group need ace inhibition group require treatment modification base physician decision',\n",
       " 'examine longterm effect angiotensinconverting enzyme ace inhibitor enalapril chronic heart failure patients men women mean age years chronic stable heart failure classify new york heart association nyha functional class months leave ventricular ejection fraction less treat mg enalapril day months mean months cause heart failure old myocardial infarction n hypertension n atrial fibrillation n radioiodinated metaiodobenzyl guanidine imibg image radionuclide angiography treadmill exercise test perform treatment enalapril treatment leave ventricular ejection fraction lvef increase significantly submaximal exercise time increase significantly second heart mediastinum hm ratio imibg increase significantly early image versus delay image versus washout rate imibg decrease slightly improvement rate lvef significantly correlate improvement rat hm ratio washout rate treatment enalapril thus longterm effect enalapril observe cardiac sympathetic nervous system imibg image appear useful evaluate therapeutic effect enalapril cardiac sympathetic nervous system patients chronic heart failure',\n",
       " 'concern base report shortterm adverse effect antihypertensive agents plasma lipid lipoprotein profile plpps complicate therapy hypertension',\n",
       " 'singlecenter prospective doubleblind randomize trial conduct compare efficacy safety calcium channel blocker nisoldipine sustain release coatcore formulation cc titrate mg mg daily angiotensin convert enzyme inhibitor enalapril titrate mg daily treatment black south african patients severe hypertension sit diastolic blood pressure [ dbp ] mm hg confirm h ambulatory blood pressure monitor treatment target sit dbp mm hg th week treatment follow month open phase use nisoldipine cc mg daily ninetysix patients complete data baseline end doubleblind open phase include analysis group patients require titration maximal dose doubleblind medication monotherapy nisoldipine cc not enalapril significantly reduce sit h ambulatory blood pressure bp twentyfourhour bp nisoldipine cc group decrease mm hg p versus mm hg enalapril group p ns profound decrease blood pressure achieve nisoldipine cc accompany significant reduction leave ventricular [ lv ] mass index observe months treatment gm p contrast enalapril no effect lv mass gm p ns antihypertensive effect nisoldipine cc demonstrate open phase h bp decrease mm hg baseline mm hg end week open phase p effect sustain troughtopeak ratio systolic diastolic bp regression lv mass reduction h systolic bp mm hg associate greater degree regression lv mass index patients treat nisoldipine cc incidence adverse events group low nisoldipine cc enalapril well tolerate incidence significant ventricular arrhythmia also low not change treatment conclusion find suggest nisoldipine cc administer daily could consider suitable firstline antihypertensive agent black patients severe hypertension base profound sustain bloodpressurelowering effect associate significant regression leave ventricular mass low side effect profile',\n",
       " 'angiotensin convert enzyme inhibitors acei mainstay treatment heart failure diabetic microalbuminuria recently acei find decrease plasma level circulate vascular cell adhesion molecule cvcam patients congestive heart failure increase cvcam level pathognomonic diabetics microangiopathy investigate effect acei plasma level cvcam intercellular adhesion molecule cicam ceselectin microalbuminuric diabetics addition effect acei plasma level plasminogen activator inhibitor pai tissue plasminogen activator tpa study fosinopril mgday administer weeks microalbuminuric patients noninsulindependent diabetes mellitus niddm expect baseline plasma concentrations ceselectin cicam cvcam markedly higher patients healthy control subject n p pai level niddm similar control subject whereas tpa level lower patients control subject p serum level cvcam decrease ci treatment fosinopril p no longer different control group contrast plasma level ceselectin cicam pai tpa unaffected expect microalbuminuria decrease ci p conclusion fosinopril lower cvcam level along microalbuminuria niddm may represent novel mechanism action acei diabetesassociated endothelial dysfunction whether decrease vcam expression responsible observe reduction microalbuminuria deserve investigation',\n",
       " 'analysis perform assess whether betaadrenergic block agent use associate reduce mortality study leave ventricular dysfunction solvd determine relationship alter angiotensinconverting enzyme ace inhibitor use',\n",
       " 'purpose study evaluate relationship baseline pulse pressure mean arterial pressure mortality patients leave ventricular dysfunction',\n",
       " 'aim study determine qualitative tcmdtpa captopril radionuclide test crt help predict acute detrimental effect angiotensinconverting enzyme ace inhibitors renal function hypertensive patients solitary kidneys chronic renal failure eight consecutive patients males females age years mean years know chronic renal failure solitary kidney refer ace treatment include tcmdtpa renography perform baseline h administration mg captopril within week crt perform accordance criteria work party diagnostic criteria renovascular hypertension captopril renography beneficial detrimental effect subsequent ace inhibitor treatment renal function determine longterm followup years crt accurately predict outcome eight patients subsequently treat ace inhibitors conclusion result suggest role qualitative tcmdtpa crt prediction renal function patients solitary kidney chronic renal failure subsequently treat ace inhibitors',\n",
       " 'heart failure predominantly disorder older adults large extent epidemiology heart failure reflect convergence agerelated change cardiovascular system rise prevalence agerelated cardiovascular diseases diagnosis heart failure elderly often difficult presence atypical symptomatology comorbid condition similarly optimal treatment frequently pose therapeutic challenge high prevalence confound medical behavioral psychosocial economic factor addition paucity data pharmacotherapy heart failure elderly age large proportion older patients heart failure preserve leave ventricular systolic function despite difficulties number therapeutic options include ace inhibitors digoxin possibly beta blockers angiotensin receptor antagonists show favorably affect clinical course heart failure elderly patients addition several study document efficacy multidisciplinary heart failure disease management program reduce hospital admission rat improve quality life decrease cost care present three greatest challenge manage older heart failure patients effectively implement prove treatments ace inhibitors disease management systems antihypertensive therapy develop effective therapies treatment diastolic heart failure develop effective mean heart failure prevention hop future study address critically important issue',\n",
       " 'compare longterm effect angiotensinconverting enzyme ace inhibitor quinapril cardioselective betaadrenergic block agent metoprolol glycaemic control glycosylated haemoglobin hbac principal variable noninsulindependent diabetes mellitus niddm patients hypertension',\n",
       " 'compare effect calcium channel blocker nisoldipine ace inhibitor lisinopril leave ventricular mass lvm systolic function type diabetic patients diabetic nephropathy',\n",
       " 'present singleblinded placebocontrolled trial effect blood pressure leave ventricular mass safety combine antihypertensive treatment delapril new nonsulfhydryl angiotensinconverting enzyme inhibitor indapamide sulfonamide diuretic study elderly patients age years mean age sit systolicdiastolic blood pressure mm hg end placebo period week placebo runin patients take mg delapril combination mg indapamide daily weeks twentyfourhour ambulatory blood pressure monitor bmode echocardiography perform weeks treatment blood pressure decrease mm hg treatment mm hg treatment total blood pressure burden also decrease percentage measurements systolic blood pressure mm hg diastolic blood pressure mm hg decrease p p area curve hour blood pressure decrease mm hg mm hg p p leave ventricular mass index lvmi patients pretreatment leave ventricular hypertrophy reduce therapy gm gm p positive correlation observe percent change area curve hour diastolic blood pressure percent change lvmi r p patients leave ventricular hypertrophy patients report side effect develop skin rash develop headache safety treatment confirm laboratory test elderly hypertensive patients combination delapril indapamide low dose reduce blood pressure favorable effect lvmi side effect',\n",
       " 'propose worsen heart failure dihydropyridines nicardipine relate activation neuroendocrine system test evaluate patients severe heart failure mean age years new york heart association functional class iii leave ventricular ejection fraction maintenance therapy captopril digoxin diuretics randomize nicardipine mgd placebo month doubleblind protocol follow measurements obtain baseline monthly months last followup visit rest exercise radionuclide ventriculography maximal treadmill time minute walk test distance serum norepinephrine aldosterone concentrations plasma renin activity followup period worsen heart failure occur patients nicardipine group patients placebo group p maximal treadmill time minute walk distance exercise radionuclide ejection fraction last followup visit not change patients not deteriorate heart failure placebo nicardipine group compare baseline value study group patients severe heart failure receive therapy digoxin captopril diuretics nicardipine associate worsen heart failure without apparent activation neurohormones however small number patients significant number patients deteriorate followup period no definitive conclusions make',\n",
       " 'aim study determine whether angiotensinconverting enzyme inhibitor administration improve endothelial function patients previously untreated essential hypertension use highresolution ultrasonography measure arteria brachialis diameter rest reactive hyperemia endotheliumdependent flowmediated dilatation [ fmd ] sublingual nitroglycerin endotheliumindependent dilatator twentyone previously untreated hypertensive patients participate study men women mean age years patients basal fmd two hours first mg benazepril dose fmd month daily mg benazepril administration fmd change not significant compare baseline value nine patients relatively normal fmd whereas patients abnormal fmd baseline latter group first mg benazepril produce significant improvement fmd p mg benazepril daily month result no improvement compare acute effect no difference find group regard age gender blood pressure blood lipids basal arteria brachialis diameter previously untreated patients essential hypertension endothelial dysfunction individual differences find angiotensinconverting enzyme inhibitor treatment improve endothelial function patients endothelial dysfunction treatment',\n",
       " 'assess efficacy safety mg bisoprolol mg hydrochlorothiazide hctz mg amlodipine mg enalapril subject n sit diastolic blood pressure mm hg data two comparative study pool drug titrate diastolic blood pressure mm hg less study doubleblind randomize parallel dose escalation trials similar design include three active treatments second study also placebo group mean change baseline systolic diastolic blood pressure placebo n mm hg amlodipine n mm hg enalapril n mm hg bisoprololhctz n overall efficacy analyse document statistically significant decrease sit diastolic blood pressure bisoprolol mg hctz compare placebo amlodipine enalapril significant reduction sit systolic blood pressure bisoprolol mg hctz compare placebo enalapril not amlodipine also significant decrease sit heart rate bisoprolol mg hctz beatsmin compare placebo beatsmin amlodipine beatsmin enalapril beatsmin control rate diastolic blood pressure mm hg bisoprolol mg hctz significantly better placebo enalapril not amlodipine patients achieve maintain control bisoprolol mg hctz subject lowest two dose compare amlodipine enalapril subject percentages patients report least one drugrelated adverse event week placebo bisoprolol mg hctz amlodipine enalapril not significant lower dose two drug fix combination provide good better blood pressure control compare higher dose single drug similar tolerability safety',\n",
       " 'consensus trial first study show prognostic improvement ace inhibitor patients nyha class iv heart failure treat enalapril placebo study completion average days patients offer openlabel enalapril therapy paper report survival year follow patients randomize consensus trial',\n",
       " 'systolic hypertension europe systeur trial prove blood pressure bp lower therapy start nitrendipine reduce risk cardiovascular complications older years patients isolate systolic hypertension systolic bp mm hg diastolic bp mm hg completion systeur trial february consent patients eligible enrol phase systeur trial open followup study aim confirm safety longterm antihypertensive therapy base dihydropyridine lower sit systolic bp mm hg target bp firstline agent nitrendipine mgday may associate enalapril mgday hydrochlorothiazide mgday addon study drug require antihypertensive agent november patients still follow patients proceed nonsupervised followup die median followup systeur months last available visit systolicdiastolic bp patients formerly randomise placebo n active treatment n decrease mm hg mm hg respectively betweengroup bp difference mm hg systolic ci mm hg p mm hg diastolic cl mm mm hg p begin systeur goal bp reach former placebo activetreatment group last visit proportion respectively moment patients monotherapy nitrendipine take nitrendipine combination study drug end bp control systeur patients improve cardiovascular complications adverse events cancer gastrointestinal bleed monitor validate blind experts',\n",
       " 'blood pressure selfmeasurement increase communities yet role management hypertension poorly understand study devise evaluate behaviour doctor general practice treat patients poorly control essential hypertension use selfmeasurement patients already take antihypertensive medications commence perindopril indapamide doctor discretion randomly allocate selfmeasurement sm use omron hem oscillometric device continuation usual care uc week period observational study without specific set treatment goals doctor follow sixty subject complete study two group equally match age body mass index gender blood pressure bp additional perindopril indapamide produce significant fall bp group study period systolic pressure remain significantly higher sm group sit compare compare mm hg respectively p twentyfour hour daytime ambulatory monitor systolic pressure also significantly higher sm group differences diastolic bp not statistically significant furthermore sm patients less likely medications increase likely reduce cease doctor patients find selfmeasurement convenient useful study suggest doctor prescribe decisions influence evidence selfmeasurement bp consequential increase office bp relate reduce drug use selfbp measurement offer reassurance adequacy control away physicians office best evidence understand target blood pressure come large randomise study use office blood pressure endpoint urgent need study provide arbitration selfmeasurement office blood pressure although measurement must contribute management hypertension',\n",
       " 'role arginine vasopressin avp development maintenance arterial hypertension controversial furthermore remain unclear whether chronic treatment antihypertensive agents modulate level avp potential secondary effect vascular tone fluid homeostasis',\n",
       " 'aim study evaluate effect trandolapril angiotensin convert enzyme inhibitor blood pressure forearm blood flow insulin sensitivity comparison nifedipine gastrointestinal therapeutic system',\n",
       " 'compare therapeutic coverage safety amlodipine perindopril patients mild moderate hypertension diastolic blood pressure mmhg mmhg',\n",
       " 'development implementation active adverse drug reaction report program university teach hospital describe progression solely voluntary system multidisciplinary program consist voluntary involuntary components discuss total adverse reactions report july july common reaction report rash antibiotics commonly implicate reactions report single agent digoxin involve frequently voluntary report physicians nurse pharmacists account approximately adverse reactions report occurrence screen quality assurance department produce approximately report',\n",
       " 'ambulatory monitor use evaluate antihypertensive efficacy effect circadian rhythms blood pressure heart rate single dose longterm administration ramipril patients mild moderate essential hypertension patients initially randomize receive either placebo single mg dose ramipril follow week later mg ramipril daily months systolic sbp diastolic blood pressure dbp heart rate measure every minutes hours singledose ramipril reduce sbp dbp p without affect heart rate longterm treatment produce small additional antihypertensive effect without modify heart rate cosinor analysis demonstrate administrations ramipril effectively lower sbp dbp mesors p compare placebo circadian rhythms remain undisturbed heart rate also not modify circadian parameter significant reduction p blood pressure amplitude however occur longterm treatment may importance term prevent cardiac damage',\n",
       " 'leave ventricular hypertrophy lvh dramatically worsen hypertensive illness genesis lvh appear multifactorial antihypertensive treatment aim reduce not pressor value also hypertrophic ventricular mass result obtain drug able act pathogenetic factor use evaluate effectiveness antihypertensive therapy regression lvh patients stage essential hypertension treat year either atenolol mgd orally cardioselective betablocker without intrinsic sympathomimetic activity ramipril mgd orally angiotensinconverting enzyme inhibitor high tissue activity treatments produce significant control hypertension regression lvh no statistically significant difference treatments note except heart rate substantially unchanged ramipril significantly decrease atenolol drug well tolerate atenolol ramipril major role longterm treatment hypertension regression hypertensionassociated lvh',\n",
       " 'many publications quality life medicine last decades minor fraction devote drug trials frequently investigate class drug within cancer disorder hypertension depressive illness healthrelated qualityoflife qol measurements typically apply chronic subchronic disorder balance effectiveness diseasemodifying drug effect safety adverse drug reactions assess patients term subjective wellbeing context quality life attempt help doctor listen patient components qol measurements find within pcasee model p physical indicators c cognitive indicators affective indicators social indicators e economicsocial stressors negative life events e ego function personality problems variance qol measurements arise operate cognitive e g lack control concentration difficulties affective e g depress mood anxiety components specific component course adverse drug reactions typically gastrointestinal symptoms cancer therapies circulatory symptoms sexual function antihypertensive drug however affective cognitive components also different weight within subclasses drug antihypertensive agents thus angiotensin convert enzyme inhibitors act affective component depression anxiety calcium channel blockers cognitive component neurasthenia general patients cancer hypertension give reliable assessments cognitive affective symptoms doctor patients primary depression less reliable doctor relatives measure change affective components illness ill healthrelated qol measurements not impact doctorpatient relationship also involve holistic approach drug treatment check pcasee components',\n",
       " 'increase number ace inhibitors become available recent years agents similar careful scrutiny require order determine specific advantage particular agents make formulary decisions differences agents regard structure tissue specificity identify clinical relevance differences not clear ace inhibitors vary greatly regard bioconversion distribution elimination disease state congestive heart failure chf hepatic renal insufficiency may affect disposition specific ace inhibitors agents may differ substantially duration action ace inhibitors give daily may optimise patient compliance decrease cost ace inhibitors extensively study patients hypertension chf nephropathy follow myocardial infarction mi differences efficacy agents often result variations study design nonequipotent dosages compare likely benefit ace inhibitors class effect probably reasonable use agent even large scale clinical trials not perform particular drug differences find ace inhibitors regard adverse effect drug interactions factor minor importance make formulary decisions cost availability may vary among agents depend geographical location institutionspecific purchase contract ace inhibitors show positive effect quality life compare agents class qualityoflife study directly compare ace inhibitors produce conflict result set hypertension costeffectiveness evaluations typically find newer longeracting ace inhibitors provide greatest financial benefit differences cost effectiveness postmi patient population typically result variations protocol design include duration treatment nondrug cost ace inhibitors fairly homogeneous selection agents difficult clinical efficacy time course action cost primary concern select agents inclusion formulary',\n",
       " 'diabetic nephropathy one major complications insulindependent diabetes mellitus iddm proteinuria main clinical manifestation diabetic nephropathy patients develop overt proteinuria progress endstage renal disease esrd usually within years esrd necessitate dialysis renal transplantation although relationship blood pressure reduction delay esrd assume long time recently control randomise clinical trial show treatment diabetic nephropathy ace inhibitor significantly delay loss renal function therefore esrd consistent clinical trial economic evaluation base cost consequences alternatives consider patients subject blood pressure control antihypertensive medication without ace inhibitor placebo group ii patients give ace inhibitor therapy captopril group similar blood pressure control placebo group costeffectiveness analysis perform perspective italian national health service [ servizio sanitario nazionale ssn ] accordingly direct cost relate publicly fund healthcare service include number dialysisyears avoid dya clinical endpoint year time horizon consider economic evaluation captopril therapy dominant time effective less costly total cost captopril alternative year period italian lire l value per patient total cost placebo alternative l per patient compare placebo dya per patients treat estimate captopril therapy trial period equivalent months per patient robustness result confirm sensitivity analysis extremes captopril remain dominant economic evaluation request italian ministry health demonstrate save healthcare expenditure use ace inhibitor patients proteinuria',\n",
       " 'estimate cost effectiveness add ace inhibitor ramipril conventional treatment patients heart failure acute myocardial infarction estimate base acute infarction ramipril efficacy aire study complementary swedish healthcare resource use data subset patients average followup period months minimum months maximum years perspective analysis county councils thirdparty payers focus cost drug hospitalisation marginal cost effectiveness treatment estimate treatment periods years costeffectiveness ratios vary sek sek per lifeyear gain us sek pound sek treatment periods add ramipril conventional treatment heart failure acute myocardial infarction therefore cost effective compare favourably cost effectiveness common medical therapies cardiovascular field',\n",
       " 'study prospective observational study adr occurrence evaluation adult internal medicine inpatients conduct day period clinical pharmacists screen adrs county hospital indianapolis patient information review admission every four days hospitalization discharge adrs occur hospital admission assess causality severity pharmacological type e augment pharmacology versus idiosyncratic reaction affect organ system nurse pharmacist report incident report physician consult patient transfer critical care units serum drug concentration report additional mean adr identification overall patients experience adr drug exposures result adr patients age greater years vs younger patients females vs males higher risk adr development p length hospital stay longer days vs days p drug exposures frequent patients experience adrs p furosemide elicit adrs patient exposures diltiazem enalapril heparin trimterenehydrochlorothiazide combination captopril also frequently implicate adrs classify mild moderate severe organ systems commonly affect metabolichematologic gastrointestinal genitourinary cardiovascular events idiosyncratic reactions adr incidence consistent previous literature many frequently implicate medications newer agents severity events less previously report',\n",
       " 'cost effectiveness early treatment lisinopril acute myocardial infarction mi estimate use survival cost data gather prospectively hospitalisation overall population patients enrol third study gruppo italiano per lo studio della sopravvivenza nellinfarto gissi assess efficacy early within hours treatment angiotensinconverting enzyme ace inhibitor lisinopril weeks group relatively unselected patients acute mi statistically significant reduction week mortality achieve among patients treat lisinopril compare patients allocate control group absolute reduction mortality live save per treat patients comparative costeffectiveness ratio use lisinopril express cost per additional survivor among patients randomise receive lisinopril us per life save value sensitivity analysis conduct examine effect vary estimate absolute reduction mortality throughout confidence interval range live save per treat patients show costeffectiveness ratios consequently vary us us per life save cost effectiveness early treatment lisinopril relatively unselected population patients acute mi compare favourably therapies judge worthwhile medical community',\n",
       " 'number new methods recently develop quantify complex heart rate hr dynamics base nonlinear fractal analysis value risk stratification not evaluate study design determine whether select new dynamic analysis methods hr variability predict mortality patients depress leave ventricular lv function acute myocardial infarction ami traditional time frequencydomain hr variability index along shortterm fractallike correlation properties rr intervals exponent alpha powerlaw scale exponent beta study patients depress lv function ejection fraction ami end year followup patients die still alive shortterm scale exponent alpha vs p powerlaw slope beta vs p differ survivors die none traditional hr variability measure differ group among analyze variables reduce scale exponent alpha best univariable predictor mortality relative risk confidence interval p positive negative predictive accuracies respectively multivariable cox proportional hazard analysis mortality independently predict reduce exponent alpha p adjustment several clinical variables lv function shortterm fractallike scale exponent powerful hr variability index predict mortality patients depress lv function reduction fractal correlation properties imply random shortterm hr dynamics patients increase risk death ami',\n",
       " 'earlier study show cardiovascular autonomic regulation impair untreated poorly control systemic hypertension purpose doubleblind randomize parallel trial evaluate whether improve blood pressure bp control reverse impairment study group consist patients age years poor bp control receive randomize metoprolol enalapril monotherapy baroreflex sensitivity brs assess phenylephrine test time frequencydomain measurements heart rate variability hrv analyze hour ambulatory electrocardiographic record monotherapy weeks combination therapy metoprolol felodipine enalaril hydrochlorothiazide lower casual bp mm hg intensify treatment decrease hour systolic diastolic bp mm hg mm hg p brs improve msmm hg msmm hg p measurements hrv e g sd rr intervals ms ms p improve significantly combination therapy change brs hrv similar magnitude treatment arm mean rr intervals comparable intensive antihypertensive therapy ms vs ms p ns data indicate adequate bp control modem antihypertensive combination therapy improve cardiovascular autonomic function may partially explain reduce cardiac mortality observe patients intensify antihypertensive therapy',\n",
       " 'cohort patients acute infarction ramipril efficacy study show ramipril therapy associate significant reduction qt dispersion month period acute myocardial infarction reduction ventricular repolarization inhomogeneity indicate antiarrhythmic effect may important additional mechanism reduce allcause mortality sudden death incidence achieve angiotensinconverting enzyme inhibition acute myocardial infarction',\n",
       " 'leave ventricular hypertrophy powerful predictor cardiovascular morbidity mortality test hypothesis fosinopril angiotensinconverting enzyme inhibitor reduce leave ventricular mass hypertensive patients',\n",
       " 'erectile dysfunction impotence high prevalence among male hypertensive patients whether relate mainly specific drug side effect primary pathogenic disorder unknown present study male patients outpatient hypertension clinic answer detail questionnaires hypertension sexual function patients perceive impotence offer thorough penile evaluation examination perform specialists urology department twentyseven men impotence main cause impotence arterial dysfunction prevalence impotence relate degree secondary organ manifestation reflect world health organization classification iiii p intermittent claudication p ischemic heart disease p best determinants respect twelve impotent patients ascribe onset impotence drug initiation variety drug incriminate occurrence druginduced impotence summary result indicate impotence hypertensive men cause mainly penile arterial vascular change probably atherosclerosis druginduced impotence could well result blood pressure reduction not specific drug side effect',\n",
       " 'study compare effect calcium channel blocker amlodipine angiotensin convert enzyme inhibitor enalapril vivo insulin sensitivity patients essential hypertension fortysix patients mild moderate hypertension study week singleblind placebo phase randomly assign doubleblind therapy either amlodipine mgday enalapril mgday weeks group comparable term demographic characteristics degree obesity metabolic parameters arterial blood pressure insulin sensitivity measure baseline week active phase use euglycemic hyperinsulinemic clamp arterial blood pressure decrease similarly group whole body glucose uptake mvalue increase amlodipine mean sem mgkgmin p similar tendency observe enalapril mgkgmin p trend lower steadystate insulin level second clamp compare baseline observe group clampderived insulin sensitivity index correct steadystate insulin level glucose level clamp increase similarly group amlodipine p enalapril p ldl cholesterol decrease amlodipine mean change mgdl p amlodipine enalapril associate increments insulin sensitivity amlodipine provide additional benefit decrease low density lipoprotein cholesterol level',\n",
       " 'nebivolol compare dose mg daily enalapril mg daily months doubleblind randomise trial essential hypertension two drug similar sustain effect lower systolic diastolic pressure neither orthostatic component drug welltolerated no haematological biochemical urinary abnormalities see',\n",
       " 'one possible intervention interrupt deleterious effect reninangiotensin system suppression angiotensin ii ang ii formation inhibition angiotensinconverting enzyme ace however ace inhibition incompletely suppress ang ii formation also lead accumulation bradykinin angiotensin ii type receptors believe promote know deleterious effect ang ii therefore receptor antagonists recently introduce therapy hypertension congestive heart failure chf although significant differences effect receptor antagonists ace inhibitors include unopposed stimulation angiotensin ii type receptors receptor antagonists discussion whether ace inhibitors receptor antagonists combination superior pharmacotherapy chf still largely theoretical accordingly receptor antagonists still investigational angiotensinconverting enzyme inhibitors remain first line therapy patients chf due systolic dysfunction however patients not able tolerate ace inhibitor induce side effect particular cough receptor antagonism good alternative clinical practice emphasis place increase utilization ace inhibitors patients chf not receive ace inhibitors addition majority ace inhibitors receive dose lower dosage use large clinical trials although not yet completely prove likely high dose ace inhibition superior low dose respect prognosis symptoms',\n",
       " 'primary purpose study determine acute longterm hemodynamic clinical effect irbesartan patients heart failure',\n",
       " 'endothelial function defective hypercholesterolaemia animal model suggest angiotensinconverting enzyme inhibitors may prevent arterial damage study effect months treatment lisinopril endothelial function group patients hypercholesterolaemia forty patients study forearm blood flow responses acetylcholine sodium nitroprusside assess venous occlusion plethysmography subject randomize doubleblind fashion receive either lisinopril mgday n placebo n months plethysmography repeat baseline variables group comparable lisinopril group blood pressure fell significantly [ systolic mmhg p diastolic mmhg p ] improvement find vasodilatory response express ratio infusedcontrol arm acetylcholine e g pre versus post microgml p also nitroprusside e g pre versus post microgml p placebo group vasodilatation not change significantly response acetylcholine nitroprusside responses unchanged data present suggest months lisinopril therapy beneficial effect arterial function subject hyperlipidaemia work investigate whether angiotensinconverting enzyme inhibitors beneficial reduce mortality morbidity hypercholesterolaemia',\n",
       " 'enhance awareness issue affect patients chronic renal failure provide guidance primary care practitioners manage patients',\n",
       " 'compare angiotensinconverting enzyme ace inhibitors elimination temocapril less dependent renal function investigate metabolic antihypertensive effect temocapril diabetic hypertensives patients diabetes mellitus type mild moderate hypertension [ diastolic blood pressure bp mm hg ] without azotemia plasma creatinine microm evaluate prospective randomize doubleblind placebocontrolled study week placebo runin receive temocapril mg daily n placebo n weeks insulin sensitivity index si determine minimal model method bergman serum lipoproteins plasma renin activity fibrinogen microalbuminuria assess end placebo runin phase doubleblind treatment phase temocapril not placebo administration produce significant decrease supine bp vs mm hg p increase plasma renin p variation si temocapril treatment not reach statistical significance vs x minmul treatment administration temocapril placebo no significant change fast plasma glucose insulin serum level total triglycerides cholesterol lipoprotein cholesterol fraction fibrinogen observe microalbuminuria decrease significantly temocapril treatment vs mg h p not placebo find demonstrate hypertensive patients diabetes mellitus type shortterm treatment temocapril neutral insulin sensitivity lipoprotein metabolism fibrinogen significantly reduce microalbuminuria',\n",
       " 'prospective doubleblind monocenter drug trial primary care patients mild moderate essential hypertension randomize mibefradil mg titrate mg enalapril mg titrate x mg ambulatory h blood pressure measurements abpm echocardiography perform baseline weeks treatment complete data patients analyze mibefradil n titration patients reduce mean h abp mm hg mm hg weeks enalapril n titration six patients reduce baseline abp mm hg mm hg weeks troughtopeak ratios dbp mibefradil enalapril leave ventricular mass lvm decrease g [ mmode modify american society echocardiography ase ] g truncate ellipsoid method weeks response mibefradil p g g mean sd p enalapril mibefradil match enalapril h abp control enalapril reduce lvm significantly weeks p mibefradil not significantly reduce lvm weeks',\n",
       " 'inhibition angiotensinconverting enzyme ace reduce risk cardiovascular problems patients chronic renal failure effect may due part decrease sympathetic nervous activity no direct evidence action available',\n",
       " 'want determine clinical cost manage hypertension follow joint national committee hypertension jnc guidelines include drug therapy cost monitor treat side effect compliance cost switch therapeutic failures',\n",
       " 'medical myths occur many different reason common thread make pathophysiologic sense good example concern use oral cobalamin treat pernicious anemia difficulty absorb vitamin b intrinsic factor not available not make oral replacement impossible dose need higher pathophysiologic concern also key reason physicians avoid use betablockers patients diabetes fear betablockers block adrenergic symptoms patients not know hypoglycemic study address issue appear no real problem increase severe episodes hypoglycemia patients betablockers increase hypoglycemic unawareness several study comment unanticipated symptom increase sweat associate hypoglycemia diabetic patients take betablockers another important concept behind medical myths overreliance case report authoritative text concern depression associate betablocker use grow one widely reference case report subsequent study not show convince evidence strong association betablocker use depression strong position take narcotic use cope early diagnosis acute abdomen probably reason perpetuation myth avoid narcotics pain relief patients undiagnosed acute abdominal condition two study address issue show no problems diagnosis cause provide narcotic pain relief newer therapies usually undergo closer scrutiny accept often include placebocontrolled trials show efficacy medication might not case newer technologies harder evaluate benefit new technology face noncomparable previous technologies catheterization right side heart swanganz catheter technology become widely use outcome study become available multiple report last decade show increase mortality increase utilization resources patients receive catheterization right side heart new drug therapies require randomize data show effect widespread use acceptance occur older therapies widely accept long time might not control trial data behind recommendations use practice pattern become widespread hard change always good ask question ` ` help patient live better longer prescribe therapy myths underscore importance utility outcomebased research help guide physicians practice',\n",
       " 'examine clinical outcomes associate optional beta blockade population patients evidence heart failure myocardial infarction',\n",
       " 'increase evidence important cardiovascular effect aldosterone via classical mineralocorticoid receptors heart administration aldosterone excess salt produce cardiac hypertrophy interstitial cardiac fibrosis rat concomitant administration potassium canrenoate dose modestly lower blood pressure completely block cardiac effect aldosterone present study examine effect leave ventricular hypertrophy add low dose mineralocorticoid receptor antagonist spironolactone mgd angiotensinconverting enzyme inhibitor enalapril maleate patients essential hypertension eighteen untreated patients moderate severe essential hypertension base whoish guidelines participate study subject treat either angiotensinconverting enzyme inhibitor alone group patients men women mean age yr angiotensinconverting enzyme inhibitor plus spironolactone group ii patients men women mean age yr mo leave ventricular mass index various echocardiographic variables mean blood pressure plasma renin activity plasma aldosterone concentration treatment similar two group blood pressure group decrease significantly similarly antihypertensive treatment group mmhg group ii mmhg leave ventricular mass index also decrease significantly group group group ii extent reduction significantly greater spironolactone group group ii p vs group group ii patients spironolactone not cause side effect observation period conclude spironolactone may beneficial effect leave ventricular hypertrophy patients essential hypertension receive angiotensinconverting enzyme inhibitor',\n",
       " 'randomize openlabel clinical trial conduct determine whether mortality readmission quality life differ heart failure patients manage captopril plus diuretics digoxin plus diuretics total heart failure patients new york heart association functional class without atrial fibrillation dyspnea bronchopulmonary origin hypertension not control diuretics randomize digoxin n captopril n treatment follow median years socioeconomic demographic electrocardiographic echocardiographic spirometric chest radiograph data obtain initial examination random sample half patients ergometric echocardiographic holter record obtain entry months patients follow years end point mortality hospitalization cardiac events deterioration quality life worsen functional class need digoxin captopril captopril digoxin group respectively trial terminate prematurely owe difficulty find candidates free angiotensinconverting enzyme ace inhibitor treatment baseline patient characteristics similar group clinical point view month mortality relevantly lower vs respectively among patients treat captopril receive digoxin log rank test p no statistically clinically relevant differences find end point adverse effect result suggest not confirm hypothesis captopril treatment mild moderate heart failure might provide better longterm survival digoxin',\n",
       " 'arterial endothelial dysfunction key early event atherogenesis occur asymptomatic adults type diabetes mellitus dm angiotensin convert enzyme ace inhibitors report reverse microvascular endothelial dysfunction acutely assess longer term effect ace inhibition large vessel endothelial physiology randomize crossover doubleblind control clinical trial',\n",
       " 'convert enzyme inhibition calcium blockade alter large arteries hypertension however heterogeneity response accord site cardiovascular measurements never investigate',\n",
       " 'objective present study determine predictive factor treatment compliance hypertensive patients open largescale multicenter study mild moderate essential hypertensive patients receive trandolapril mg daily days addition usual treatment trandolapril pack electronic pill box register date time open main compliance parameters percentage miss dose percentage delay dose percentage correct dose periods predictive factor poor compliance correct dose periods determine use multivariate stepwise logistic regression analysis two thousand one hundred seventythree patients age years analyze total patients poor compliers patients forget dose patients delay dose rank predictive factor poor compliance age years odds ratio [ ] [ ] p paris area [ ] p smokers [ ] p monotherapy [ ] p baseline diastolic blood pressure mm hg [ ] p therefore conclude young hypertensives large city dwellers smokers likely poor compliers presence characteristics might incite physician either encourage patient compliance prescribe antihypertensive drug effect persist even beyond h',\n",
       " 'ramipril efficacy nephropathy core followup study find mo continue ramipril therapy decrease substantially risk endstage renal failure esrf patients chronic nephropathies urinary protein excretion rate g h study investigate timedependent change gfr patients control subject randomize conventional therapy core period switch ramipril followup study analyse include patients continue ramipril n switch ramipril n least three gfr measurements include baseline whole observation period subgroup patients continue ramipril n switch ramipril n least six gfr measurements include least three core least three followup study ramipril mgd conventional therapy target achieve diastolic bp mm hg main efficacy variables gfr esrf need dialysis analysis intention treat throughout study mean sem rate gfr decline deltagfr significantly lower patients continue ramipril compare switch ramipril versus mlmin per per mo p patients continue ramipril least six gfr measure not control subject deltagfr progressively improve time cohort longest followup decrease mlmin per per mo mo mo rate fold slower compare patients conventional therapy rein core study analyse individual slop find end followup patients continue ramipril therapy positive deltagfr another patients improvement deltagfr ramipril therapy deltagfr significantly improve parallel significant reduction proteinuria change deltagfr p proteinuria p significantly different two group baseline characteristics change systolic diastolic bp h urine urea sodium excretion comparable present result offer evidence chronic nephropathies tendency gfr decline time effectively halt even patients remarkably severe disease',\n",
       " 'nebivolol lipophilic betablocker devoid intrinsic sympathomimetic membrane stabilise activity appear nitric oxidemediated vasodilatory effect nebivolol administer racemic mixture equal proportion lenantiomers drug not significantly influence glucose plasma lipid metabolism appear protective effect leave ventricular function recommend dosage mg daily nebivolol reduce rest diastolic blood pressure effectively standard therapeutic dosages atenolol metoprolol lisinopril nifedipine show comparative trials nebivolol reduce blood pressure significantly enalapril mg daily short not long term although enalapril dose may not optimal nebivolol additive effect combination hydrochlorothiazide stand blood pressure andor mean hour ambulatory blood pressure significantly similarly reduce nebivolol atenolol nifedipine nebivolol tend prevent increase early morning blood pressure better nifedipine overall response rat nebivolol therapy decrease sittingsupine diastolic blood pressure mm hg mm hg fall diastolic blood pressure range weeks treatment comparative study response rat greater nebivolol enalapril metoprolol recipients not significantly different atenolol nifedipine recipients nebivolol mg daily well tolerate patients hypertension adverse events infrequent transient mild moderate report often include headache fatigue paraesthesias dizziness several study report no sign orthostatic hypotension nebivolol comparative trials reveal no significant differences frequency severity adverse events patients receive nebivolol atenolol enalapril placebo however overall incidence adverse events greater nifedipine metoprolol atenolol enalapril not nebivolol recipients report impotence decrease libido therapy',\n",
       " 'compare efficacy indapamide mg daily lowsalt diet mmolday separately combination essential hypertensive patients inadequate bp response perindopril',\n",
       " 'study compare antihypertensive efficacy tolerability combination tablet contain vascularselective calcium antagonist felodipine betaselective adrenergic antagonist metoprolol combination tablet captoprilhydrochlorothiazide randomize doubleblind trial involve patients mild moderate hypertension weeks placebo patients supine diastolic blood pressure mm hg randomize felodipinemetoprolol mg logimax captoprilhydrochlorothiazide mg capozide weeks mandatory dose increase felodipinemetoprolol mg captoprilhydrochlorothiazide mg treatment continue another weeks end study felodipinemetoprolol reduce supine blood pressure significantly captoprilhydrochlorothiazide mean differences change supine systolic diastolic blood pressure treatments weeks mm hg respectively favour felodipinemetoprolol p stand blood pressure also show trend favour felodipinemetoprolol proportion responders similar group treatments well tolerate two patients treat felodipinemetoprolol captoprilhydrochlorothiazide discontinue treatment due adverse events felodipinemetoprolol combination reduce supine blood pressure significantly captoprilhydrochlorothiazide maintain tolerability',\n",
       " 'antihypertensive treatment frequently need type diabetes study measure rat total oxidative nonoxidative glucose disposal glycogen synthesis glycolysis endogenous glucose production lipid oxidation use h euglycemic approximately mmoll hyperinsulinemic approximately pmoll clamp combination dual glucose tracer infusion [ h ] [ uc ] dglucose indirect calorimetry nonobese subject type diabetes subject study twice week runin period week period double blind randomize treatment mgday lacidipine calcium channel blocker n mgday lisinopril angiotensinconverting enzyme inhibitor n antihypertensive treatment result significant increase total glucose disposal insulin clamp well basal insulinstimulated nonoxidative glucose disposal rat contrary oxidative glucose disposal significantly decrease antihypertensive treatment mainly basal state change glucose disposal rat not significantly different subject treat lacidipine treat lisinopril suppression endogenous glucose production insulin clamp significantly greater lacidipine lisinopril result suggest treatment subject type diabetes either lacidipine lisinopril no adverse effect glucose metabolism conversely drug seem improve insulin sensitivity',\n",
       " 'syndrome x define typical angina pectoris positive treadmill exercise test negative intravenous ergonovine test angiographically normal coronary arteries',\n",
       " 'investigate occurrence prognostic significance atrial fibrillationflutter follow acute myocardial infarction',\n",
       " 'investigate influence angiotensin convert enzyme inhibitors beta blockers progression early diabetic glomerulopathy',\n",
       " 'relatively little data available management patients severe uncomplicated hypertension severe hypertension stable hypertensive complications',\n",
       " 'aim study assess effect angiotensinconverting enzyme ace inhibition enalapril forearm endothelial function subject type ii diabetes mellitus',\n",
       " 'hypertensive crisis occur critically elevate blood pressure accompany diastolic pressure greater mm hg presence acute ongoing endorgan damage constitute hypertensive emergency require reduction blood pressure within minutes hours avoid catastrophic outcomes critically elevate blood pressure without endorgan damage know hypertensive urgency generally treat hours closely monitor outpatient set although hypertensive crises relatively rare primary care physicians eventually encounter thus optimal patient outcomes important aware appropriate treatment options well impact potential complications management',\n",
       " 'blood pressure bp reduction compare patients receive angiotensinconverting enzyme inhibitors alone patients receive medications plus statins months dietary intervention although bp similarly reduce week statintreated group greater reduction bp total cholesterol level week suggest synergistic effect cholesterol lower statins angiotensinconverting enzyme inhibitor treatment hypertensive patients',\n",
       " 'study investigate relative value adverse drug events report doctor nurse patients',\n",
       " 'verify efficacy combination captopril mg day losartan mgday early postinfarction phase reperfused anterior acute myocardial infarction',\n",
       " 'organic nitrate widely use treatment chronic heart failure chf no information however available regard effect patients already treat ace inhibitors',\n",
       " 'ace inhibitors may not adequately suppress deleterious level angiotensin ii patients heart failure angiotensin receptor blocker add ace inhibitor may exert additional beneficial effect',\n",
       " 'dry cough troublesome sideeffect associate certain antihypertensive agents act modulate aspects reninangiotensinaldosterone system incidence dry cough associate two therapies novel receptor antagonist telmisartan ace inhibitor lisinopril assess multicentre randomise parallelgroup doubleblind placebocontrolled week study patients mild moderate hypertension previously demonstrate ace inhibitorrelated cough patients receive either telmisartan mg lisinopril mg placebo daily cough incidence measure visit selfadministered symptom assessment questionnaire significantly higher lisinopril telmisartan placebo visual analogue scale demonstrate similar trend cough frequency thus incidence cough telmisartan mg significantly less see lisinopril mg comparable placebo',\n",
       " 'despite prove value reduce morbidity mortality different grade heart failure angiotensin convert enzyme ace inhibitors continue underused one reason clinicians apprehension firstdose hypotension conduct doubleblind randomise placebocontrolled parallel group study investigate effect various ace inhibitors firstdose hypotension eighty unselected patients randomise five treatment group placebo captopril mg enalapril mg perindopril mg lisinopril mg blood pressure measure baseline half hourly two hours hourly three hours drug treatment maximum drop mean arterial pressure mmhg sd placebo perindopril enalapril lisinopril captopril p vs placebo except perindopril perindopril unlike ace inhibitors study not produce firstdose hypotension follow initiation patients congestive heart failure',\n",
       " 'impair fibrinolysis associate thromboembolic complications hypertensive patients report cardiovascular morbidity mortality rat high even lower elevate blood pressure antihypertensive drug aim study assess effect clinically use dosages enalapril nitrendipine fibrinolytic system',\n",
       " 'blood pressure increase soon administration immunosuppressive regimens use cyclosporin characteristic vascular change lead systemic renal vasoconstriction change blood pressure commonly associate disturb circadian regulation may promote rapid development target organ injury include intracranial haemorrhage leave ventricular hypertrophy microangiopathic haemolysis mechanisms underlie disorder complex include alter vascular endothelial function vasodilators prostacyclin nitric oxide suppress whereas vasoconstrictors include endothelin increase change kidney include vasoconstriction reduce glomerular filtration sodium retention effective therapy depend upon rigorous blood pressure control administration vasodilating agents attention potential interactions cyclosporin',\n",
       " 'follow extracorporeal cardiac surgery transient myocardial dysfunction stun cellular damage may develop relation among mechanisms production free radicals fr reperfusion purpose study evaluate whether captopril ctp angiotensin convert enzyme inhibitor thiolic group show useful antioxidant agent vitro vivo study prevent emergence problems use pretreatment within hours patients undergo valvular cardiac surgery',\n",
       " 'present investigation elucidate deleterious effect three prototypical antihypertensive drug namely propranolol clonidine captopril erectile physiology order delineate direct drug effect vascular insufficiency inherent hypertensive state study conduct normotensive animal model adverse effect drug estimate change sexual behaviour intracavernous pressure response electrical stimulation treat rat compare normal agematched control n group copulation study indicate significant impairment sexual function group propranolol clonidine cavernous pressure response nerve stimulation end sixteen weeks reinforce gross compromise sexual function two treat group contrast captopril administration produce marginal alterations responses record result study clearly indicate propranolol clonidine interfere sexual behaviour nerve mediate response erection whereas captopril devoid significant effect parameters may better therapeutic option',\n",
       " 'renal interstitial expansion consider useful marker progression several nephropathies study describe multicenter prospective doubleblind placebocontrolled randomize trial effect perindopril mgd kidney structure function yr type diabetic patients proteinuria range mgd relatively preserve gfr creatinine clearance mlmin patients undergo baseline renal biopsy four not randomize presence nondiabetic nephropathy remain randomize perindopril [ pe ] placebo [ po ] pe po undergo followup biopsy yr bp control equally group throughout proteinuria increase po patients mgd decline pe patients mgd p morphometric analysis perform light microscopy use biocom computer yr mean cortical interstitial fractional volume identical baseline increase significantly po patients versus p unchanged pe patients versus p conclude nondiabetic nephropathy present approximately albuminuric type diabetic patients perindopril prevent interstitial expansion hypertensive patients biopsyproven diabetic glomerulopathy result support role angiotensin ii progression interstitial change type diabetic patients nephropathy',\n",
       " 'purpose study investigate significance possible negative interaction aspirin angiotensinconverting enzyme ace inhibitors',\n",
       " 'purpose study analyze whether longterm treatment nonselective betaadrenergic block agent carvedilol may beneficial effect patients dilate cardiomyopathy dcm poor responders term leave ventricular lv function exercise tolerance chronic treatment selective betablocker metoprolol',\n",
       " 'open randomize hospital study conduct center france compare blood pressure response first h treatment perindopril per mg daily captopril cap mg patients mean age years men echocardiographic leave ventricular systolic dysfunction fractional shorten due ischemia hypertension systolic blood pressure sbp mm hg dose cap induce sharp rapid decrease blood pressure maximum h per decrease gradual maximum h variation less mark however h decrease blood pressure versus baseline similar treatments h period dropouts due mark orthostatic hypotension sbp mm hg fewer per cap case cap group versus six per group p h heart rate lower cap per versus beatsmin respectively p initial therapy stabilize leave ventricular systolic dysfunction first dose per mg induce significantly smaller decrease blood pressure first dose cap mg dropouts due orthostatic hypotension also significantly fewer per cap',\n",
       " 'angiotensin convert enzyme ace inhibition myocardial infarction associate improvement plasma fibrinolytic parameters aim present study determine whether acute ace inhibition angiotensin ii type receptor antagonism similar effect patients heart failure',\n",
       " 'evaluate pharmacokinetic interaction bioequivalence combination formulation angiotensinconverting enzyme inhibitor fosinopril diuretic hydrochlorothiazide hctz',\n",
       " 'objective evaluate safety antihypertensive efficacy sampatrilat novel dual inhibitor angiotensinconverting enzyme ace neutral endopeptidase nep subject poorly responsive ace inhibitor monotherapy ability sampatrilat mg daily n lower blood pressure compare ace inhibitor lisinopril mg daily n use doubleblind randomize parallel group study design day treatment period black hypertensives change systolic sbp diastolic dbp blood pressure determine use repeat ambulatory blood pressure abp monitor sampatrilat lisinopril decrease plasma ace concentrations days decrease plasma ace concentrations ul greater lisinopril compare sampatrilat p therapy lisinopril not sampatrilat increase plasma renin activity lisinopril produce transient decrease mean h abp mm hg days sbp dbp p return pretreatment value days therapy alternatively sampatrilat produce sustain decrease mean abp day treatment period day sbp dbp p day sbp dbp p greater treatment effect dbp lisinopril day p treatmentemergent adverse events note similar treatment group conclude antihypertensive action acenep inhibitor monotherapy black subject offer novel therapeutic approach patients otherwise resistant sustain antihypertensive action ace inhibitor monotherapy',\n",
       " 'endotheliumdependent vasodilation impair patients congestive heart failure vascular endothelium hepatocyte growth factor hgf one potent specific growth factor act protectively endothelial dysfunction hgf production downregulated angiotensin ii ang ii vitro hypothesize hgf production impair result increase ang ii patients congestive heart failure impair production restore angiotensinconverting enzyme inhibitors acei study patients congestive heart failure cause previous anterior myocardial infarction leave ventricular ejection fraction meansd approximately weeks treatment acei blood sample collect measure level hgf ang ii brain natriuretic peptide biochemical marker severity heart failure also study control subject heparin increase hgf production fold however patients heart failure hgf response heparin significantly attenuate fold p vs control therapy acei decrease level ang ii brain natriuretic peptide restore hgf production response heparin fold comparable control response conclusion impair hgf production restore treatment acei probably mechanism ang ii suppression novel effect acei may contribute clinical improvement patients heart failure thereby may important therapeutic implication',\n",
       " 'assess effect longterm angiotensinconverting enzyme ace inhibitor treatment captopril cardiac function acute myocardial infarction ami',\n",
       " 'effect treatment captopril metoprolol heart rate variability hrv investigate patients men women mild moderate symptoms heart failure due idiopathic dilate cardiomyopathy dcm',\n",
       " 'comparisons antihypertensive drug undertake parallel group undertake crossover rotation four main class antihypertensive drug untreated young hypertensive patients assess response rate monotherapy achieve systematic rotation',\n",
       " 'coadministration antihypertensive drug therapy hormonal replacement therapy hrt frequent postmenopausal women not know whether hrt interact concomitant antihypertensive therapy present study design investigate efficacy safety ace inhibitor moexipril comparison placebo hypertensive postmenopausal women hrt week placebo runin phase postmenopausal women years age sit diastolic blood pressure bp mm hg treat hrt randomise week treatment moexipril mg placebo efficacy safety assess measure change sit bp metabolic parameters associate cardiovascular disease include triglycerides total cholesterol hdl ldl total cholesterolhdl ratio glucose adverse events record continuously weeks treatment moexipril mg significantly effective reduce sit systolic diastolic bp baseline placebo mm hg vs mm hg p metabolic parameters not affect treatment moexipril mean level triglycerides total cholesterol hdl ldl total cholesterolhdl ratio glucose remain unchanged throughout study fibrinogen independent cardiovascular risk factor increase placebo mgdl decrease treatment moexipril mgdl difference however not statistically significant moexipril welltolerated postmenopausal women use hrt frequent adverse events include headache cough rhinitis no significant differences number severity adverse events moexipril placebo group study indicate moexipril effective well tolerate treatment hypertensive postmenopausal women safely coadministered hrt',\n",
       " 'determine effective angiotensinconverting enzyme ace inhibitors must prevent diabetic nephropathy warrant early routine therapy pima indians type diabetes mellitus',\n",
       " 'aim study compare efficacy tolerability new angiotensinconverting enzyme ace inhibitor moexipril calcium antagonist nitrendipine postmenopausal women mild moderate hypertension',\n",
       " 'study effect antihypertensive medications autonomic nervous system patients hypertension sleep apnea syndrome use frequency domain measure heart rate blood pressure variabilities',\n",
       " 'captopril inhibitor angiotensinconverting enzyme widely use cardiovascular therapy however patients drug cause allergic side effect fact suggest captopril may release histamine mast cells',\n",
       " 'suggest adverse metabolic effect antihypertensive therapy offset benefit blood pressure reduction also suggest angiotensin convert enzyme ace inhibitors reduce insulin resistance use together thiazide diuretics adverse effect thiazides insulin sensitivity may eliminate examine effect insulin sensitivity captopril either alone combination bendrofluazide hypertensive type diabetic patients',\n",
       " 'nitrate therapy improve hemodynamics patients heart failure chronic effect oral nitrate exercise performance clinical status not well study',\n",
       " 'first dose angiotensinconverting enzyme ace inhibitors may trigger considerable fall blood pressure chronic heart failure response may doserelated determine hemodynamic systemic oxygenation effect lowdose enalaprilat administer intravenous enalaprilat mgkg bolus group b continuous hour infusion group c patients congestive heart failure due ischemic heart disease acute decompensation refractory inotropic vasodilator diuretic therapy hemodynamic systemic oxygenation variables record baseline min min start intervention mean arterial pressure map p mean pulmonary artery pressure mpap p pulmonary artery occlusion pressure paop p oxygen extraction ratio er p decrease regardless enalaprilat application compare group b group c prolong decrease map mpap paop er increase pulmonary artery oxyhemoglobin saturation regard baseline value cardiac index heart rate central venous pressure oxygen consumption index not change low dose intravenous enalaprilat mgkg use safely improve hemodynamics systemic oxygenation congestive heart failure due ischemic heart disease acute refractory decompensation',\n",
       " 'study evaluate efficacy longterm treatment angiotensinconverting enzyme ace inhibitor trandolapril diabetic patients leave ventricular dysfunction acute myocardial infarction ami',\n",
       " 'purpose study determine acute chronic effect cyclooxygenase inhibition aspirin thromboxane receptor blockade ifetroban chronic vasodilating effect enalapril skeletal muscle circulation patients heart failure',\n",
       " 'evaluation losartan elderly elite heart failure study survival benefit primarily reduction sudden deaths observe symptomatic patients treat losartan compare captopril',\n",
       " 'survival benefit use inhibitors angiotensinconverting enzyme ace patients acute myocardial infarction usually present term risk ratios live save per people treat relevant way present extent benefit would term increase life expectancy approach not previously possible limit data longterm outcome aim calculate effect trandolapril life expectancy followup data trandolapril cardiac evaluation trace study',\n",
       " 'outpatients essential hypertension antihypertensive effect troughtopeak ratios oncedaily enalapril lisinopril compare ambulatory blood pressure monitor abpm accord crossover design drug dose titrate thiazide diuretic add necessary attain target office bp less mm hg drug significantly lower bp effect lisinopril greater p day nighttime mean bp fell mm hg respectively mm hg enalapril mm hg lisinopril bp goal reach average dose mg enalapril mg hydrochlorothiazide mg lisinopril combine mg diuretic trough peak ratio value calculate fourier analysis abpm data individual patients independent drug dose combination diuretic result slightly higher trough peak ratios ace inhibitor monotherapy difference not significant median trough peak ratio patients use enalaprilbased therapy take lisinoprilbased treatment n p significant correlation find trough peak ratio change daytime mean arterial pressure map spearman r nighttime map r h abpm perform start h last drug intake ace inhibitors still significant antihypertensive effect p similar drug eleven patients report minor side effect four patients stop aceinhibitor treatment cough data show lisinopril longer duration action enalapril',\n",
       " 'effect new angiotensin receptor antagonist eprosartan mg b enalapril mg u cough blood pressure compare week doubleblind randomise parallelgroup multicentre international study involve patients hypertension uptitration dose base clinic blood pressure measurements first weeks hydrochlorothiazide mgday could add frequency intensity cough assess standardise questionnaire administer clinic visit primary endpoint incidence persistent dry cough not due upper respiratory infection change sit diastolic blood pressure overall incidence cough secondary endpoints first weeks doubleblind therapy enalapril treatment associate fold higher risk definite cough vs p overall cough incidence spontaneous report patients investigator observation also frequent enalapril compare eprosartan agents reduce blood pressure significantly compare baseline although eprosartantreated group slightly higher response rate define sit diastolic blood pressure mm hg least mm hg reduction baseline end titration vs p weeks vs p data suggest unselected hypertensive patients eprosartan associate less cough somewhat higher responder rate enalapril',\n",
       " 'positive history arterial hypertension hbp present many patients acute myocardial infarction ami clinical outcome could greatly improve drug enhance blood pressure control preserve ventricular function aim present study evaluate importance history hbp clinical efficacy early treatment angiotensinconverting enzyme ace inhibitor zofenopril patients anterior ami summarize result posthoc analysis data survival myocardial infarction longterm evaluation smile study randomly evaluate efficacy zofenopril give within h symptom onset patients anterior ami not undergo thrombolysis patients enter study history hbp mean followup time months main outcome measure week combine occurrence death severe congestive heart failure chf year mortality week treatment zofenopril relative risk death severe chf confidence interval [ ci ] p hypertensive group p normotensive patients whereas year risk death ci p ci p respectively week prevalence mildtomoderate chf also significantly reduce zofenopril hypertensive population v p present data suggest treatment zofenopril start within h onset anterior ami could highly beneficial patients history hbp',\n",
       " 'compare two popular strategies intensify treatment hypertension doubleblind randomize prospective parallelgroup partial crossover study weeks placebo runin baseline weeks mg enalapril daily patients randomize weeks treatment either lowdose combination therapy mg enalapril mg felodipine er daily lexxel astra merck inc higher dose monotherapy mg enalapril daily vasotec merck co inc group randomize combination significantly greater reductions sit systolicdiastolic blood pressure bp mm hg compare baseline versus mm hg p well greater percentage patients achieve either diastolic bp mm hg decline least mm hg responders v p patients originally take mg enalapril cross combination therapy weeks bp reduction increase response rate loss significant differences compare treat continuously combination entire weeks greater bplowering efficacy combination independent age gender race no significant differences tolerability regimens data support hypothesis patients not achieve goal bp reduction low dose antihypertensive agent combination two drug complementary mechanisms action effective increase dose first agent',\n",
       " 'ace inhibitors show potentiate effect exogenous bradykinin inhibition breakdown despite little evidence inhibition endogenous bradykinin breakdown actually contribute effect ace inhibitors indeed inhibitors reninangiotensin system angiotensin ii type receptor antagonists no evidence patients heart failure',\n",
       " 'aim study investigate relationships angiotensinconverting enzyme ace activity serum skeletal muscle blood pressure longterm antihypertensive effect fosinopril atenolol examine hypertensive patients randomize receive mg fosinopril mg atenolol daily weeks ace activity measure biopsy specimens skeletal muscle measurements office ambulatory blood pressure serum ace leave ventricular wall thickness also perform investigations perform crosssectional study healthy elderly men muscle ace correlate inversely blood pressure crosssectional analyse populations p atenolol treatment muscle ace activity tend increase p increase correlate inversely change stand systolic diastolic blood pressure r p r p respectively muscle ace also inversely correlate leave ventricular wall thickness two populations pool r p fosinopril group muscle ace activity not different treatment baseline p inverse relationship blood pressure muscle ace level study indicate muscle tissue ace level influence haemodynamic factor humans',\n",
       " 'angiotensinconverting enzyme ace inhibitors widely administer treat numerous medical condition although generally well tolerate associate dry cough lead discontinuation treatment data concern frequency onset clinical effect vary among agents discontinue ace inhibitor not ideal option pharmacologic treatment cough may consider cromolyn baclofen theophylline sulindac local anesthetics',\n",
       " 'report suggest calcium channel blockers may associate increase incidence depression suicide paucity evidence large scale study aim study assess rat depression calcium channel antagonists use data prescription event monitor study',\n",
       " 'previous study base daytime arterial pressure record indicate lifetime treatment captopril exacerbate hypertensive response high nacl diet spontaneously hypertensive rat shr no effect normotensive wistarkyoto wky rat present study use h record methods examine hypothesis normal wake hours rat nighttime hypertensive response high nacl diet exacerbate shr induce wky rat treat lifetime captopril',\n",
       " 'study suggest ace inhibitors antiarrhythmic effect ventricular arrhythmias whether effect atrial fibrillation unknown',\n",
       " 'purpose study assess efficacy tolerability angiotensinconverting enzyme inhibitor moexipril alone combination hydrochlorothiazide versus hydrochlorothiazide monotherapy patients stage ii iii essential hypertension doubleblind randomize multicenter trial evaluate moexipril mg daily hydrochlorothiazide mg daily combinations drug mg moexipril mg hydrochlorothiazide mg moexipril mg hydrochlorothiazide hypertensive patients whose seat diastolic blood pressure bp mm hg primary efficacy variable mean change baseline seat diastolic bp end dose period secondary efficacy measure include change systolic bp stand bp lower dose moexipril hydrochlorothiazide reduce diastolic bp similarly versus mm hg p ns higher dose monotherapeutic regimens moexipril mm hg versus hydrochlorothiazide mm hg p ns combinations moexipril hydrochlorothiazide reduce diastolic bp significantly either monotherapy lower dose mm hg p higher dose mm hg p similar trend observe systolic bp discontinuation rat due adverse events moexipril monotherapy patients patients diuretic combination treatment data demonstrate mg moexipril daily lower bp similarly hydrochlorothiazide patients stage ii iii hypertension also additive effect combine two agents lower bp significantly either monotherapy',\n",
       " 'two weeks washout runin period placebo patients congestive heart failure new york heart association [ nyha ] class ii iii leave ventricular ejection fraction randomly assign treatment period weeks mg quinapril daily mg captopril twice daily end period dose titrate mg quinapril daily mg captopril twice daily basis physician judgment no major adverse reactions blood pressure not mm hg clinical symptoms heart failure significantly relieve drug end week treatment period begin study patients take quinapril patients take captopril nyha functional class iii whereas end trial patients quinapril group p versus quinapril patients captopril group classify nyha class iii drug positive effect echocardiographic parameters statistically significant increase exercise duration treatment group quinapril versus minutes p captopril versus minutes p one patient quinapril group die suddenly study two patients captopril group drop study due persistent dry cough no patient quinapril group report side effect three patients captopril group suffer moderate dry cough one tasteblindness another unstable angina safety test drug confirm laboratory test quinapril effective captopril reduce sign symptoms heart failure improve leave ventricular function exercise capacity side effect',\n",
       " 'study telmisartan new angiotensin receptor antagonist give monotherapy combination hydrochlorothiazide hctz compare lisinopril monotherapy combination hctz week randomize multicenter doubleblind doubledummy parallelgroup dosetitration study patients mildtomoderate essential hypertension mean diastolic blood pressure [ dbp ] mm hg compare efficacy safety telmisartan n lisinopril n dosage could increase telmisartan mg lisinopril mg first monthly visit dbp control mm hg not establish dbp control establish patients enter week maintenance period period dose study drug fix although openlabel hctz mg mg add need regain dbp control end titration period dbp control achieve monotherapy telmisartan lisinopril patients respectively end maintenance period supine dbp control telmisartan lisinopril patients respectively systolic blood pressure dbp reductions mm hg telmisartan mm hg lisinopril treatmentrelated side effect occur fewer telmisartantreated patients lisinopriltreated patients p significantly fewer patients p receive telmisartan experience treatmentrelated cough v cough lead discontinuation significantly less often p telmisartan treatment lisinopril treatment v addition two case angioedema observe lisinopril group selective receptor antagonist telmisartan extremely effective treatment mildtomoderate hypertension monotherapy combination hctz least comparable efficacy lisinopril tolerability profile may offer advantage term reduce incidence adverse events',\n",
       " 'captopril enalapril report influence cognitive function quality life hypertensive patients',\n",
       " 'pulmonary function abnormalities participate cause exercise disability patients congestive heart failure chf impair pulmonary gas transfer one abnormalities angiotensinconverting enzyme ace inhibitors improve diffusion carbon monoxide exercise capacity effect seemingly mediate prostaglandin activation inhibit cyclooxygenase blockade aspirin suggest possibility aspirin may disturb pulmonary function exercise ability chf least patients take ace inhibitors study aim probe hypothesis',\n",
       " 'intrahepatic cholestasis characterize decrease bile flow absence overt bile duct obstruction result accumulation bile constituents liver blood various etiological factor incriminate include drug total parenteral nutrition sepsis pregnancy graftversushost disease systemic disorder sarcoidosis amyloidosis hodgkin disease pathogenesis cholestasis unclear several mechanisms hypothesize without convince evidence play role clinical cholestasis despite uncertainty pathophysiology intrahepatic cholestasis several form therapy employ ursodeoxycholic acid may relieve pruritus lethargy case may modify disease progression cholestasis persist supportive therapy important maintain optimal physical nutritional wellbeing patients advance liver disease associate hepatocellular failure liver transplantation viable option',\n",
       " 'stratum ramipril efficacy nephropathy rein study already show patients chronic nephropathies proteinuria g per h angiotensinconverting enzyme ace inhibition reduce rate decline glomerular filtration halve combine risk double serum creatinine endstage renal failure esrf find control placebo plus conventional antihypertensives rein stratum report h proteinuria g less g per h',\n",
       " 'differences qt dispersion predictor sudden death observe subgroup patients elite heart failure study losartan compare captopril may explain improve survival losartan',\n",
       " 'diagnosis mania geriatric population uncommon however comprise significant healthcare utilization cost requirements expect increase near future project increase geriatric population author review literature pertain geriatric mania discuss epidemiology psychopathology neuropathology differential diagnosis evaluation treatment outcomes literature search perform gratefulmed years secondary tertiarysource followup clear review geriatric mania complex illness many possible etiologies treatments much research need conduct areas review',\n",
       " 'elucidate effect blood pressure blood lipids angiotensin convert enzyme inhibitor captopril betareceptor block agent atenolol give alone combination cholesterol reduce drug betahydroxymethylglutarylcoenzyme reductase inhibitor pravastatin patients also encourage improve lifestyle',\n",
       " 'patients diabetes mellitus increase prevalence hypertension associate cardiovascular disease cvd include coronary cerebrovascular disease risk individual develop cvd much greater diseases coexist magnify frequent association dyslipidemia coagulation platelet endothelial abnormalities metabolic abnormalities frequently associate hypertension insulin resistance enhance coagulation decrease fibrinolytic activity drug treatment hypertension diabetic subject fraught potential difficulties include alter efficacy medications possible side effect worsen glycemic control impairment lipid metabolism hypertension major contributor morbidity mortality diabetes recognize treat early aggressively despite difficulties article review efficacy side effect various class antihypertensive agents patients diabetes mellitus',\n",
       " 'report previously dietary fish oil supplementation retard progression renal disease patients iga nephropathy multicenter placebocontrolled randomize yr clinical trial aim study determine longterm influence fish oil treatment renal progression observations study cohort patients extend beyond yr trial renal function assess serial serum creatinine h urine protein measurements vital endstage renal disease esrd bp status treatment beyond completion yr trial determine trial primary end point increase serum creatinine secondary end point esrd mean followup yr patients fish oil group versus placebo groupreached primary end point p patientseight fish oil group versus placebo groupdeveloped esrd p end yr trial patients fish oil placebo remain risk primary end point also doubleblind part trial end allow physicians stop supplement switch original placeboassigned patients fish oil continue fish oil original fish oilassigned patients significantly greater number nonsupplemented placebo patients develop primary end point p esrd p compare longterm supplement fish oil patients conversely fish oilsupplemented patients stable renal function nonsupplemented patients p intention bp control primarily treat angiotensinconverting enzyme inhibition equal fish oil placebo group proteinuria modestly reduce group conclude early prolong treatment fish oil slow renal progression highrisk patients iga nephropathy',\n",
       " 'fixeddose combination antihypertensive therapy receive interest since publication jncvi report relatively headtohead comparative study fixeddose combinations firstline monotherapies hypertension publish objective study conduct metaanalysis various firstline monotherapies fixeddose combination amlodipinebenazepril result metaanalysis use compare efficacy safety firstline monotherapies amlodipinebenazepril metaanalysis include study include treatment group cohorts study compare nine different monotherapies one combination therapy amlodipinebenazepril study placebocontrolled active treatment control mean absolute decrease supine diastolic blood pressure bp range mm hg verapamil show greatest effect captopril least mm hg mm hg respectively study weight sample size atenolol verapamil lisinopril amlodipinebenazepril show greatest bp effect study weight variance amlodipinebenazepril atenolol show greatest bp effect percentage patients control therapy range lisinopril amlodipinebenazepril show greatest percent control overall incidence adverse effect range lisinopril lowest nifedipine highest incidence overall incidence adverse effect result drug discontinuance range amlodipinebenazepril lowest nifedipine highest incidence result metaanalysis indicate amlodipinebenazepril produce average reductions bp lower average incidence overall side effect lowest incidence adverse effect result drug discontinuance fixeddose combination amlodipinebenazepril achieve goal effective bp lower minimum significant side effect',\n",
       " 'enalapril widely use antihypertensive drug powerful vitro acantholytic effect know potentially induce pemphigus genetically predispose subject action mechanism complex still partially understand describe case yearold man affect intermediary basal cell carcinoma histological examination show suprabasal acantholytic clefts perilesional epidermis surprisingly second biopsy take apparently healthy skin back confirm presence acantholytic change clinical sign pemphigus absent patient history not reveal relevant data mild arterial hypertension treat year mg enalapril take account patient history enalapril longterm administration absence bullous erosive lesions histological find diagnosis make vivo enalaprilinduced acantholysis',\n",
       " 'clinical use ambulatory blood pressure bp monitor require validation prospective outcome study',\n",
       " 'efficacy eprosartan highly selective orallyactive nonbiphenyl nontetrazole type angiotensin ii receptor antagonist compare angiotensinconverting enzyme ace inhibitor enalapril addition hydrochlorothiazide hctz necessary patients severe hypertension sit diastolic blood pressure [ sitdbp ] mmhg mmhg patients n randomize week doubleblind titration phase start oral eprosartan mg total daily dose give b oral enalapril mg total daily dose give dose eprosartan increase mg daily give b enalapril mg daily give weeks sitdbp mmhg blood pressure remain uncontrolled maximum dose eprosartan enalapril week hctz mg add treatment regimen patients whose blood pressure deem medically acceptable investigator week enter week maintenance phase final dose use titration phase primary efficacy measure difference treatments mean reduction baseline sitdbp end study eprosartan enalapril cause similar reduction sitdbp study endpoint mean change sitdbp end study eprosartan group mmhg vs mmhg enalapril group however eprosartan produce significantly greater decrease sit stand systolic blood pressure sitsbp stasbp respectively enalapril mean decrease sitsbp mmhg eprosartan compare mmhg enalapril p mean reduction stasbp mmhg eprosartan compare mmhg enalapril p end study response rate sitdbp mmhg decrease baseline least mmhg eprosartan group enalapril group proportion patients treatment group require addition hctz similar eprosartan well tolerate overall incidence adverse events comparable enalapril group result demonstrate patients severe hypertension eprosartan well tolerate may effective enalapril reduce systolic blood pressure',\n",
       " 'paper report clinical trial tang shen ning [ symbol see text ] tsn treat diabetic nephropathy incipient clinical divide mogensen result show total effective rate treatment group tsn western medicine control group simply western medicine tsn play important roles decrease proteinuria improve renal function',\n",
       " 'acute myocardial infarction ami patients history arterial hypertension ah worse prognosis normotensives whether adverse risk beneficially modulate treatment angiotensinconverting enzyme ace inhibitors unknown evaluate prognostic value antecedent hypertension postami patients give ace inhibitor therapy',\n",
       " 'aetiology cognitive impairment multifactorial however drug important cause delirium dementia several factor may increase risk druginduced cognition disorder elderly include imbalances neurotransmitters e g acetylcholine agerelated alterations pharmacokinetics pharmacodynamics high level medication use nearly drug cause cognitive impairment susceptible individuals however certain class commonly implicate benzodiazepines opioids anticholinergics tricyclic antidepressants probably worst offenders older antihypertensive agents reserpine clonidine negative effect cognition however large clinical trials elderly indicate commonly use agents [ e g thiazide diuretics calcium antagonists amiodipine diltiazem ace inhibitors captopril enalapril betablockers atenolol ] minimal effect cognition newer antidepressants selective serotonin hydroxytryptamine ht reuptake inhibitors ssris reversible inhibitors monoamine oxidase not show negative effect cognition although drug show low risk cause cognition disorder research study risk may increase frail older adults take several medications case review carefully identification druginduced cognitive impairment crucial early detection resolution symptoms preventive strategies direct avoid high risk medications possible appropriately adjust dose base agerelated change close followup may prevent condition',\n",
       " 'describe patient develop nephrotic syndrome months extensive glomerular tubular damage biopsy patient treat diuretics asymptomatic decade despite unremitting proteinuria repeat biopsy years age show remarkable heal histopathological feature consistent ` ` minimal change nephrotic syndrome patient illustrate favorable clinical outcome without specific treatment nephrotic syndrome long duration',\n",
       " 'angiotensinconverting enzyme inhibitors use extensively management hypertension relate cardiovascular condition however treatment approach limit lack specificity continue production angiotensin ii rout antagonism angiotensin ii receptor offer possibility improve control hypertension provide complete blockade reninangiotensin system angiotensinconverting enzyme inhibition without bradykininrelated effect eprosartan nonbiphenyl nontetrazole competitive angiotensin ii receptor antagonist clinically available highly selective receptor subtype clinical trials eprosartan show lower blood pressure effectively oncedaily regimen hypertensive patients recommend dose range mg daily eprosartan effective patients grade hypertension irrespective age sex race furthermore tolerability profile eprosartan comparable placebo no know clinically relevant drugdrug interactions number largescale clinical study currently underway plan determine increase number receptor antagonists may reduce cardiovascular morbidity mortality rat different group hypertensive patients meanwhile current evidence suggest receptor antagonists represent significant new approach cardiovascular therapy merit fuller assessment hypertension cardiovascular diseases',\n",
       " 'previously report chronic treatment angiotensinconverting enzyme inhibitors aceis increase antioxidant defenses mice present study however examine various antioxidant defenses chronic hemodialysis hd patients either treat enalapril mgd least months acei n untreated acei n relationship antioxidant status hd investigate determine oxidative stress markers antioxidant defenses group chronic hd patients n group agematched control n effect single hd session parameters also evaluate hd session prehd hd patients significantly lower level red blood cell rbc glutathione gsh seleniumdependent glutathione peroxidase activity rbcsegpx plasma ubiquinol alphatocopherol control randomly select group patients n single hd session cause additional decrease rbcgsh plasma ubiquinol level plasma thiobarbituric acid reactive substance tbars level significantly greater prehd patients control posthd plasma tbars level similar control value cohort acei hd patients greater prehd rbcgsh content rbcsegpx activity plasma betacarotene concentrations acei patients rbcgsh acei micromolml pack rbcs [ prbcs ] acei micromolml prbcs [ p v acei ] rbcsegpx acei uml prbcs acei uml prbcs [ p v acei ] plasma betacarotene acei micromoll plasma acei micromoll plasma [ p v acei ] result show profound alterations circulate antioxidant systems chronic hd patients additional oxidative stress occur hd procedure addition acei hd patients level several antioxidant defenses greater acei hd patients',\n",
       " 'aldosterone important pathophysiology heart failure doubleblind study enrol patients severe heart failure leave ventricular ejection fraction no percent treat angiotensinconvertingenzyme inhibitor loop diuretic case digoxin total patients randomly assign receive mg spironolactone daily receive placebo primary end point death cause',\n",
       " 'lowdose drug combinations propose international guidelines use patients hypertension fix lowdose combination perindopril mg indapamide mg combine angiotensin convert enzyme ace inhibitor nonthiazide diuretic coadministration perindopril indapamide not clinically significant effect pharmacokinetic profile either agent healthy volunteer experimental model hypertension perindoprilindapamide restore endothelial function improve microvascular density reduce leave ventricular aortic hypertrophy reverse renal endorgan damage daily oral perindopril mgindapamide mg normalise blood pressure bp elderly patients essential hypertension diastolic bp reduce mm hg isolate systolic hypertension systolic bp reduce mm hg approximately year treatment bp normalisation sustain patients throughout study fix lowdose perindoprilindapamide tolerability profile similar placebo clinical trials adverse events mild moderate severity coadministration agents reduce incidence hypokalaemia see indapamide alone',\n",
       " 'investigate effect candesartan angiotensin ii antagonist alone enalapril alone combination exercise tolerance ventricular function quality life qol neurohormone level tolerability congestive heart failure chf',\n",
       " 'ability angiotensin convert enzyme ace inhibitors lower blood pressure may part due formation vasodilatory prostaglandins inhibition prostaglandin synthesis aspirin may therefore theoretically attenuate antihypertensive effect ace inhibitors trial study interaction aspirin asa enalapril ace inhibitor asa losartan angiotensin subtype receptor antagonist seventeen essential hypertensive patients study maintain stable dose either enalapril n losartan n monotherapy weeks throughout study patient receive week course placebo mgday asa mgday asa treatment separate week washout period blood pressure bp serum thromboxane b txb sample obtain end treatment period placebo compare dose asa group enalapril losartan group mean systolic diastolic bp unchanged addition asa concentrations txb suppress group asa study demonstrate mgday asa exert no significant effect bp essential hypertensives take enalapril losartan',\n",
       " 'purpose study test whether shortcourse treatment ace inhibitors may restore endotheliumdependent andor independent vasodilation femoral artery microalbuminuric patients type diabetes normal arterial pressure',\n",
       " 'abnormalities leave ventricular lv diastolic fill stresscorrected midwall shorten mws describe hypertensive patients normal ejection fraction ef however whether stresscorrected mws parallel lv diastolic fill better ef remain uncertain blood pressure body mass index echocardiographic lv mass lv geometry ef stresscorrected mws lv diastolic fill peak e awave velocities ewave deceleration time atrial fill fraction evaluate hypertensive patients lv hypertrophy enrol prospective randomize enalapril study evaluate regression ventricular enlargement study lv structure geometry well lv diastolic fill compare patients reduce ef n normal ef well patients reduce stresscorrected mws n normal stresscorrected mws patients reduce ef higher lv mass eccentric lv geometry higher heart rate normal ef although not differ age blood pressure body mass index lv fill pattern also similar group patients reduce stresscorrected mws higher atrial fill fraction body mass index heart rate lv mass concentric geometry normal stresscorrected mws atrial fill fraction negatively associate stresscorrected mws not ef multivariate model independently age gender heart rate body mass index thus hypertensive patients lv hypertrophy abnormal lv diastolic fill closely relate impair myocardial contractility lv chamber ef',\n",
       " 'drug consider rare cause acute pancreatitis conduct descriptive study assess drug associate acute pancreatitis spontaneous adverse drug reaction report netherlands',\n",
       " 'antihypertensive drug commonly prescribe treatment patients diabetes hypertension however role select agents development hypoglycemia remain controversial main objective study evaluate effect antihypertensive agents risk hypoglycemia diabetic patients receive insulin sulfonylurea therapy match casecontrol study conduct use pennsylvania medicaid data five control subject match sex age no report medical condition hypoglycemia randomly select case patient admit hypoglycemia result total case control sample size able detect difference p primary outcome measure hospitalization hypoglycemia relative risk hypoglycemia estimate use unconditional logistic regression risk hypoglycemia time greater confidence interval [ ci ] insulin versus sulfonylurea users not influence use angiotensinconverting enzyme ace inhibitors overall however use ace inhibitor enalapril associate increase risk hypoglycemia odds ratio ci sulfonylurea users suggest analyze unintended side effect class drug sometimes mask adverse effect individual drug use betablockers not associate increase risk hypoglycemia provide empiric evidence betablockers appropriate treatment persons concomitant diabetes hypertension per capita health care cost approximately time higher patients hospitalize hypoglycemia compare control p hospitalization hypoglycemia expensive may prevent appropriate monitor diabetic patients take select antihypertensive agents enalapril',\n",
       " 'great majority adverse drug reactions doserelated occur patients take standard dose medications facts suggest many patients standard drug dose may excessive principle variability among individuals require tailor dose patient need reassert clinical medicine reduce incidence side effect physicians obtain patients histories drug reactions hand information full range effective drug dose include data low dose gather prerelease postrelease drug study whenever possible manufacturers provide range dose breakable tablets facilitate flexible dose',\n",
       " 'heart failure black associate poorer prognosis white diseases hypertension black show pathophysiological differences respond differently therapies white aim study evaluate clinical characteristics response therapy black compare white patients heart failure',\n",
       " 'chronic heart failure chf increase burden health care pharmacological treatment angiotensinconverting enzyme ace inhibitors beta blockers improve survival reduce hospitalizations patients low leave ventricular ejection fraction lvef despite therapies morbidity mortality remain problematic furthermore patients chf preserve lvef not know treatments benefit group',\n",
       " 'efficacy tolerability safety potent angiotensin ii receptor blocker candesartan cilexetil evaluate adult patients men black severe systemic hypertension background therapy hydrochlorothiazide hctz week multicenter randomize doubleblind placebocontrolled study patients sit diastolic blood pressure bp mm hg placebo runin receive hctz mg daily week sit diastolic bp mm hg hctz runin randomize receive candesartan cilexetil mg daily n placebo n plus hctz mg week doubleblind treatment patients sit diastolic bp mm hg uptitrated candesartan cilexetil mg daily match placebo plus hctz mg require uptitration primary efficacy measurement change trough hours treatment sit diastolic bp end hctz runin doubleblind week mean change systolic diastolic bp significantly greater candesartan cilexetil placebo mm hg versus mm hg p p respectively patients higher sit diastolic bp end hctz runin tend greater decrease bp p patients receive candesartan cilexetil responders diastolic bp mm hg mm hg decrease control diastolic bp mm hg tolerability safety profile similar candesartan placebo group conclusion candesartan cilexetil mg daily effective welltolerated therapy lower bp add hctz mg diverse population patients severe systemic hypertension unite state',\n",
       " 'captoprilinduced bone marrow suppression rare except certain highrisk patient populations severe exfoliative rashes also associate captopril combine presentation toxic epidermal necrolysis agranulocytosis not previously describe report unusual case captoprilinduced toxic epidermal necrolysis agranulocytosis patient no know risk factor bone marrow suppression successfully treat use granulocyte colonystimulating factor gcsf white blood cell wbc count recover within days start therapy case underscore early experience captopril show strong correlation high dose use treat hypertension bone marrow suppression',\n",
       " 'hypertension important risk factor development stroke also risk factor amenable treatment result control trials show reduction relative risk stroke among treat hypertensive patients reduction apply elderly younger patients absolute reductions greater among elderly number patients hypertension need treat prevent stroke lower elderly higher risk stroke reductions relative not absolute risk appear similar isolate systolic hypertension combine systolic diastolic hypertension elderly case antihypertensive treatment secondary prevention stroke less clear result four clinical trials antihypertensive treatment among patients without hypertension history cerebrovascular disease point probable benefit result progress trial elucidate',\n",
       " 'angiotensinconverting enzyme ace inhibitors establish firstline therapy chronic heart failure chf however conflict result exist regard doseeffect relation ace inhibitors',\n",
       " 'large number drug increase number environmental agents reportedly result appearance number autoantibodies many instance appearance range autoimmune clinical syndromes major disorder recognize mark resemblances autoimmune disease systemic lupus erythematosus commonly use term druginduced lupus better term drugrelated lupus considerable interest present time increase number environmental agents two epidemics recent years one spain contaminant rapeseed oil one unite state contaminant ltryptophan cause eosinophilic myositis important physicians others involve health care recognize potential associations diseases unknown cause cause',\n",
       " 'systemic rheumatic symptoms occur widely different frequencies side effect longterm therapy medications currently use symptoms nonspecific subjective protean diagnosis druginduced lupus dil require awareness risk chronic medication however laboratory feature characteristic full recovery discontinue treatment helpful differentiate druginduced spontaneous lupus syndromes druginduced lupus probably mediate reactive drug metabolites not ingest medications susceptibility neutrophilmediated oxidative transformation property ten lupusinducing drug report far mechanisms dil model drug hypersensitivity reactions unsupported experimentally inconsistent feature dil however several new line investigation use mouse model open promise lead origin autoreactive cells disease development dil',\n",
       " 'excessive neurohumoral activity remain major burden circulation patients advance heart failure prostaglandin e pge balance v vasodilator show elicit favorable hemodynamic clinical effect cohort prospective randomize parallel group trial perform evaluate acute intermediate chronic change hemodynamic neurohumoral renal variables response pge dobutamine placebo thirty patients class iii iv heart failure low cardiac index mean lminm two hours oral drug include high dose enalapril include dayinfusion pge ngkgmin range ngkgmin group n dobutamine microgramskgmin range microgramskgmin group b n placebo saline group c n administer via central venous access line stepwise titration intolerable side effect develop pge increase cardiac index occur dobutamine continue dose throughout pge maintain peak dose hemodynamic data collect baseline peak dosages hours days neurohumoral variables plasma norepinephrine big endothelin big et atrial natriuretic peptide anp simultaneously evaluate use ria methods renal plasma flow paraaminohippurate clearance glomerular filtration rate iothalamate clearance measure prior infusions hours days peak dose hours significant drop baseline mean pulmonary artery pressure pulmonary capillary wedge pressure systemic vascular resistance observe accompany rise cardiac output pge dobutamine change maintain days pulmonary vascular resistance level also fell active drug blood pressure not change throughout pge increase heart rate slightly hrs pge dobutamine enhance renal plasma flow days pge decrease glomerular filtration fraction significantly glomerular filtration rate not change either drug pge decrease anp level hrs dobutamine increase big et level peak decrease big et days norepinephrine level unaffected throughout except slight decrease right atrial pressure days placebo not change measure variable significantly take together data suggest treatment pge efficacious lowdose dobutamine improve cardiac performance renal perfusion advance heart failure importance no deleterious neurohumoral counterregulation observe pge',\n",
       " 'patients without significant urologic symptoms microscopic hematuria occasionally detect routine urinalysis present routine screen adults microscopic hematuria dipstick test not recommend intermittent occurrence find low incidence significant associate urologic disease however asymptomatic microscopic hematuria discover cause investigate thorough medical history include review current medications focus physical examination laboratory image study intravenous pyelography renal ultrasonography retrograde pyelography may require determine degree location associate disease process cystourethroscopy perform complete evaluation lower urinary tract microscopic hematuria associate anticoagulation therapy frequently precipitate significant urologic pathology therefore require prompt evaluation',\n",
       " 'sixth report joint national committee prevention detection evaluation treatment high blood pressure jncvi include recommendations assessment overall cardiovascular risk need active antihypertensive drug therapy decision initiate antihypertensive drug therapy make jncvi recommend one three paths choice initial therapy one path patients uncomplicated hypertension another welldefined indications certain drug third path patients various concomitant condition one another drug favorable effect time place newest class antihypertensive drug angiotensin ii receptor antagonists remain uncertain currently consider reasonable alternatives patients compel need angiotensinconverting enzyme ace inhibitor develop cough take medication data ongoing trials become available angiotensin ii receptor antagonists may prove good choice initial therapy many patients favorable side effect profile class drug',\n",
       " 'aim present study assess efficacy tolerability calcium antagonistbetablocker fix combination tablet use firstline antihypertesnive therapy comparison angiotensin convert enzyme inhibitor placebo patients uncomplicated essential hypertension diastolic blood pressure mm hg end week runin period randomly allocate doubleblind week treatment either combination tablet felodipine metoprolol logimax mg daily n enalapril mg daily n placebo n possibility double dose weeks treatment need diastolic blood pressure remain mm hg combine felodipinemetoprolol treatment control blood pressure diastolic mm hg h dose patients weeks compare enalapril placebo dose adjustment require patients receive combination patients allocate placebo enalapriltreated patients overall incidence adverse events felodipinemetoprolol treatment correspond value enalapril placebo respectively withdrawal treatment due adverse events occur patients treat combination patients enalapril patients placebo no significant change patients wellbeing observe either three study group result show fix combination tablet felodipine metoprolol allow normalize blood pressure substantially larger fraction patients enalapril give alone improve efficacy obtain without impair tolerability fixeddose combination felodipine metoprolol therefore may become valuable option initiate antihypertensive treatment',\n",
       " 'nonsteroidal antiinflammatory drug nsaid frequently report interfere blood pressure lower action various antihypertensive medications study women arthritis hypertension receive fosinopril hctz administer sequentially random order ibuprofen sulindac nabumetone month intervene week washout period treatment period washout period subject receive acetaminophen blood pressure end weeks acetaminophen compare blood pressure month treatment nsaid mean blood pressure unchanged nsaid v nabumetone v sulindac v ibuprofen h urinary sodium excretion not significantly different conclude three nsaid not neutralize antihypertensive effect combination fosinopril hctz hence blood pressure lower action combination may not prostaglandin dependent',\n",
       " 'fosinoprilat active product fosinopril eliminate hepatic pathway addition renal pathway share angiotensin convert enzyme inhibitors aceis study aim determine whether impair renal function affect pharmacokinetics pharmacodynamics combination fosinopril hydrochlorothiazide hctz',\n",
       " 'evaluate management patients complain high blood pressure bp cardiological emergency room',\n",
       " 'compare incidence cough two angiotensin convert enzyme ace inhibitors imidapril enalapril comparative crossover study perform patients men females essential renal parenchymal hypertension patients randomly assign one two treatment group group receive imidapril wk period follow enalapril wk period ii group order drug reverse occurrence cough treatment monitor questionnaire case no differences background characteristics two group incidence cough period group initially treat imidapril group ie group initially treat enalapril group ei difference statistically significant p period decrease blood pressure observe group ie group ei patients approximately half patients group ei develop cough period treatment subsequently switch imidapril cough subsequently disappear conclude incidence cough significantly less imidapril enalapril treatment no difference antihypertensive effect two ace inhibitors',\n",
       " 'losartan heart failure elite study recently find patients symptomatic heart failure leave ventricular ejection fraction losartan compare captopril improve survival better tolerability objective study perform economic evaluation losartan versus captopril base result losartan heart failure elite study losartan heart failure elite study multinational doubleblind randomize week study compare safety efficacy losartan captopril angiotensinconverting enzymeinhibitornaive patients years symptomatic heart failure data health care resource utilization collect part trial conduct costeffectiveness analysis estimate lifetime benefit treatment associate cost observe no differences treatments number hospitalizations hospital days emergency room visit per patient trial period estimate total cost losartan usd ci usd usd less per patient captopril time frame also estimate project remain lifetime study population losartan compare captopril would increase survival years undiscounted average cost usd discount per patient cost increase translate costeffectiveness ratio usd per year life gain losartan relative captopril patients symptomatic heart failure losartan compare captopril increase survival better tolerability cost well within range accept costeffective',\n",
       " 'antihypertensive efficacy tolerability profile selective receptor antagonists telmisartan losartan compare placebo week multinational multicentre randomise doubleblind doubledummy parallelgroup study patients mildtomoderate hypertension define clinic diastolic blood pressure dbp mm hg clinic systolic blood pressure sbp mm hg h ambulatory dbp mm hg week singleblind placebo runin eligible patients randomise receive telmisartan mg telmisartan mg losartan mg placebo ambulatory blood pressure monitor abpm weeks doubleblind therapy show active treatments produce significant p reductions baseline h mean sbp dbp compare placebo h period dose reductions sbpdbp telmisartan mg mm hg mg mm hg significantly p greater observe losartan mg mm hg losartan no better placebo also h mean blood pressure telmisartan mg mg significantly p better losartan mg compare losartan telmisartan mg produce significantly p greater reductions sbp dbp monitor periods h period telmisartan mg produce significantly greater reductions sbp dbp nighttime period pm p dbp morning period p treatments comparably well tolerate telmisartan mg mg daily effective well tolerate treatment mildtomoderate hypertension produce sustain h blood pressure control compare favourably losartan',\n",
       " 'report two case hyperkalaemia relate use salt substitute lo salt hypertensive patients treatment ace inhibitors case serum potassium return normal range cessation salt substitute without vigilance contribution salt substitute hyperkalaemia would overlook ace inhibitor erroneously withdraw',\n",
       " 'verapamil well tolerate patients stable unstable angina pectoris well patients threaten infarction no data exist document verapamil inferior betablockers stag coronary heart diseases prethrombolytic era v intervention verapamil not add benefit early phase ami however retrospective analysis suggest hypothesis v verapamil give combination thrombolysis may improve prognosis ongoing study vami trial examine hypothesis give late inhospital phase ami patients without heart failure verapamil significantly reduce mortality morbidity give late inhospital phase patients heart failure verapamil not cause course prognosis deteriorate might even improve patients residual ischaemia especially give combination aceinhibitors plan study davit iii study confirm preliminary data',\n",
       " 'investigate effect enalapril therapy plasma tissue factor tf tissue factor pathway inhibitor tfpi monocyte chemoattractant protein mcp level patients acute myocardial infarction',\n",
       " 'study role depressogenic medication aetiology major depression elderly',\n",
       " 'dayactivity rhythms heart rate blood pressure think mediate mainly sympathetic nervous system may greater amplitudes patients hypertension owe increase daytime largely normal nighttime value druginduced nighttime hypotension patients chronic hypertension associate precipitation cardiac failure fall cerebral flow author examine effect single dose week treatment different class antihypertensive drug ambulatory blood pressure abp patients mild hypertension data assess polynomial analysis harvard graphics single oral dose enalapril mg amlodipine mg carvedilol mg celiprolol mg produce mean reduction hour abp compare placebo respectively mm hg p value enalapril amlodipine carvedilol betweensubject variability contribute significantly overall variability measurements p value versus zero whereas celiprolol not although beta blockers reduce daytime blood pressure similarly ace inhibitor calcium channel blocker not reduce nighttime blood pressure result confirm week crossover trial compare enalapril mg daily celiprolol mg daily group patients author conclude beta blockers produce stable reduction blood pressure patients mild hypertension less affect pressor effect sympathetic nervous system beta blockers unlike ace inhibitors calcium channel blockers not give rise nighttime hypotension category patients selective beta blocker celiprolol may even perform better respect nonselective beta blocker carvedilol',\n",
       " 'angiotensinconverting enzyme ace inhibitors report prevent neointimal formation balloon injury animal model prospective study humans ace inhibitors fail prevent restenosis percutaneous transluminal coronary angioplasty ptca ace genotype assign insertiondeletion id polymorphism know affect potency ace inhibitors several renal diseases author attempt clarify whether effect ace inhibitors restenosis might modify ace genotype total patients randomly prospectively assign control group imidapril group imidapril group patients receive mg imidapril daily start day ptca continue months fortysix control vessels imidapril patients vessels complete study minimal lumen diameter procedure not differ significantly among group three genotypes ii id dd control imidapril group late luminal loss followup period not relate ace genotype control group significantly relate imidapril group ii mm id dd mm p furthermore ii genotype imidapril significantly reduce late loss restenosis rate define frequently use definitions conclusion ace id polymorphism may influence effect ace inhibitors prevent restenosis ptca',\n",
       " 'although angiotensinconverting enzyme inhibitor therapy reduce mortality rat patients congestive heart failure chf may also cause decrease renal function little information available predict patients highest risk complication',\n",
       " 'assess effect months intervention ramipril rest post exercise leave ventricular function patients stable ischaemic heart disease preserve leave ventricular systolic function',\n",
       " 'prevention treatment hypertension remain major challenge clinicians world recently publish sixth report joint national committee prevention detection evaluation treatment high blood pressure jncvi use evidencebased medicine provide guidelines aid clinicians prevention detection treatment high blood pressure include pharmacological approach calcium antagonists use widely treatment hypertension jncvi focus specific situations calcium antagonists could consider prefer treatments large number calcium antagonists available variety pharmacodynamic pharmacokinetic action several sustainedrelease formulations drug also available term blood pressure control calcium antagonists effective antihypertensive treatments betablockers ace inhibitors angiotensin ii receptor blockers black patients dihydropyridine calcium antagonists show reduce morbidity mortality elderly patients isolate systolic hypertension ratelowering calcium antagonists use alternatives betablockers patients coronary artery disease hypertension calcium antagonists use alternatives ace inhibitors patients hypertension concomitant diabetes mellitus andor renal disease dihydropyridine calcium antagonists may useful alternatives ace inhibitors patients hypertension systolic heart failure calcium antagonists appear extremely useful patients cyclosporininduced hypertension patients hypertension concomitant raynaud phenomenon andor migraine ratelowering agents use patients atrial tachyarrhythmias hypertension clinicians aware drugdrug interactions involve calcium antagonists especially recent problems mibefradil although retrospective study cause controversy regard safety calcium antagonists patients hypertension recent prospective study reveal no major safety concern drug',\n",
       " 'trials involve hypertensive non diabetic patients diuretics betablockers prevent stroke without confer protection coronary events death one trial captopril effect comparable diuretics betablockers term overall cardiovascular prevention little less effective prevent stroke trials involve hypertensive subject diuretics betablockers reduce risk stroke coronary events heart failure death one trial diuretic superior betablocker term preventive efficacy adverse effect nitrendipine combination antihypertensive drug prevent stroke one trial trial involve hypertensive diabetic patients captopril atenolol reduce risk stroke heart failure worsen retinal disease without prevent coronary events death two trials coronary events frequent dihydropyridine angiotensincovertingenzyme ace inhibitor one trial diuretic reduce risk relapse stroke even patients without severe hypertension',\n",
       " 'diabetic nephropathy common cause endstage renal disease unite state undertake study assess impact assignment different level blood pressure control course type diabetic nephropathy patients receive angiotensinconverting enzyme ace inhibitor therapy also examine longterm course wellcharacterized cohort patients receive ace inhibitor therapy one hundred twentynine patients type diabetes diabetic nephropathy previously participate angiotensinconverting enzyme inhibition diabetic nephropathy study serum creatinine level less mgdl randomly assign mean arterial blood pressure map goal mm hg less group mm hg group ii patients receive vary dose ramipril primary therapeutic antihypertensive agent patients follow minimum years outcome measure include iothalamate clearance hour creatinine clearance creatinine clearance estimate cockcroft gault formula urinary protein excretion average difference map group mm hg month followup median iothalamate clearance group mlmin baseline mlmin end study compare baseline mlmin final mlmin group ii no statistically significant differences rate decline renal function group significant difference followup total urinary protein excretion group mg h group ii mg h p thirtytwo percent patients achieve final total protein excretion less mg h patients group ii equivalent rat adverse events patients type diabetes mellitus diabetic nephropathy map goal mm hg less optimal renoprotection define include decrease proteinuria combination ace inhibition intensive blood pressure control many patients achieve regression apparent remission clinical evidence diabetic nephropathy',\n",
       " 'renoprotective effect captopril progression diabetic nephropathy demonstrate collaborative study group captopril trial might independent blood pressure angiotensin ii know stimulate prosclerotic cytokine transform growth factorbeta tgfbeta postulate renoprotective effect may due inhibition tgfbeta production tgfbeta level measure serum baseline months patients captopril trial tgfbeta analyse perform available patient sera analysis perform percent change tgfbeta level first months versus percent change glomerular filtration rate gfr subsequent years tgfbeta level increase p placebo group n whereas decrease p captopril group n inverse correlation percent change tgfbeta level first months percent change gfr ensue year period patients placebo r p captopril group r p patients initial gfr mlmin even stronger correlation percent change tgfbeta level percent change gfr placebo n r p captopril group n r p data suggest captopril decrease tgfbeta level diabetic nephropathy change tgfbeta level may predict course diabetic nephropathy',\n",
       " 'adult indonesian outpatients randomise receive either valsartan mg daily captopril mg twice daily weeks main criterion tolerability incidence adverse events primary efficacy variable change mean sit diastolic blood pressure sdbp baseline endpoint no valsartan patients experience dry cough report captopril patients drug reduce mean sdbp ssbp trend favour valsartan percentage valsartan patients whose bp normalise higher captopril patients week week difference statistically significant week p valsartan mg daily effective captopril mg twice daily reduce blood pressure indonesian patients better tolerability profile respect dry cough',\n",
       " 'ace inhibitors important therapeutic agents control hypertension correct pathophysiological derangement improve prognosis many agents may important differences placebo runin double blind crossover study use hour ambulatory blood pressure monitor compare efficacy perindopril mg enalapril mg daily antihypertensive agents patients diastolic blood pressure dbp perindopril placebocorrected peak p reduction blood pressure bp mmhg vs placebocorrected trough mmhg enalapril reduction dbp mmhg p mmhg systolic blood pressure sbp perindopril reduction mmhg p vs mmhg compare enalapril mmhg p vs mmhg placebocorrected troughtopeak ratio sbpdbp perindopril vs enalapril no difference note hour mean bp area curve postdose casual bp measurements perindopril enalapril well tolerate two treatment group similar safety profile perindopril thus predictable sustain blood pressure effect give hour cover patient without excessive peak effect poor trough effect',\n",
       " 'abnormal autonomic nervous system impairment patients acute myocardial infarction ami circadian pattern greatest manifestation morning hours probably play important role pathogenesis cardiac arrhythmias acute ischemic syndromes angiotensinconverting enzyme inhibitors improve autonomic function patients ami circadian pattern effect not study heart rate variabilitynormalized frequency domain index assess days baseline onset uncomplicated ami days therapy quinapril n metoprolol n placebo n solidstate digital holter monitor normal subject n use control quinapril increase parasympathetic decrease sympathetic modulation improve sympathovagal interactions manifest increase normalize highfrequency power hfp decrease normalize lowfrequency power lfp ratio lfphfp entire hour period p maximal effect ratio p p delta ratio respectively metoprolol increase hfp decrease lfp lfphfp ratio mainly noon p delta ratio respectively p heart rate variability index placebo group control remain unchanged days baseline study conclusion quinapril increase parasympathetic decrease sympathetic partially restore sympathovagal interaction patients uncomplicated ami entire hour period peak effect early late morning even hours metoprolol similar effect late morning even hours lower level effect may prove beneficial reduce cardiac arrhythmias acute ischemic syndromes pastami patients',\n",
       " 'oxygen consumption peak exercise peak vo strong independent predictor outcome congestive heart failure chf reninangiotensin system inhibition either ace receptor blockers effective peak vo evaluate whether mechanisms similar categories drug whether combination able produce synergistic effect twenty chf patients randomize receive doubleblind fashion placebo placebo pp enalapril mgday placebo ep losartan mgday placebo lp enalapril losartan el preparations reverse order weeks two patients not complete trial pulmonary function cardiopulmonary exercise test plasma neurohormones quality life assess end treatment compare pp ep lp similarly respectively significantly p augment peak vo enalapril improve lung function reduce slope ventilation vs carbon dioxide production dead space tidal volume ratio increase alveolar membrane conductance tidal volume losartan likely activate exercise muscle perfusion raise delta vodelta work rate measure aerobic work efficiency combination increase peak vo ep p lp p compare runin ep lp significantly reduce plasma norepinephrine pgml pgml aldosterone ngdl ngdl change significantly greater drug combine pgml norepinephrine ngdl aldosterone qualityoflife score not improve significantly treatment step thus lorsartan enalapril similarly increase peak vo chf patients mediators effect least part different therapeutic target may synergistic drug combine',\n",
       " 'perform retrospective cohort study assess relation administration angiotensinconverting enzyme inhibitors duration pleural drainage early postoperative period patients undergo modify fontan operation institution study fail show administration captopril decrease duration pleural drainage patients modify fontan operation',\n",
       " 'efficacy new antihypertensive drug question compare effect conventional newer antihypertensive drug cardiovascular mortality morbidity elderly patients',\n",
       " 'effectiveness well metabolic effect combination diuretics [ hydrochlorothiazide hct vs indapamide ind ] perindopril p patients male female age years mild idiopathic hypertension study follow week washout period week period monotherapy p mgdaily ind mgdaily hct mgdaily add weeks selection diuretic agent random follow week washout period diuretic p give alternative diuretic administer another period weeks p decrease blood pressure level significantly however drug efficacious patients higher plasma renin activity pra combination treatment induce additional decrease blood pressure level mainly patients lower pra combination p hct effective combination p ind addition either hct ind evoke small statistically significant increase serum glucose level fast well g oral glucose challenge however insulin level not change significantly study small not statistically significant change serum electrolytes lipid parameters observe various phase study statistically significant increase serum uric acid notice combination p hct give conclude p small dose effective safe antihypertensive agent pra predictive value determine effectiveness p treatment combination p small dose hct ind efficacious p alone combination treatment adverse effect carbohydrate tolerance not significant change serum electrolyte lipid parameters',\n",
       " 'assess persistence antihypertensive effect aceinhibitor perindopril one miss dose',\n",
       " 'capillary leakage sodiumfluorescein naf skin reflect capillary permeability may marker diabetesassociated microcirculatory abnormalities',\n",
       " 'angiotensinconverting enzyme ace inhibitors generally prescribe physicians dose lower large dose show reduce morbidity mortality patients heart failure unclear however low dose high dose ace inhibitors similar benefit',\n",
       " 'examine effect longterm treatment two dose angiotensin convert enzyme ace inhibitor enalapril various immunological variables patients chronic congestive heart failure chf',\n",
       " 'study design compare different propose methods assess adherence angiotensinconverting enzyme ace inhibitor acei therapy chronic heart failure',\n",
       " 'report case yearold woman angiotensin convert enzyme inhibitorinduced angioedema undergo biopsy hypopharyngeal mass angioedema associate severe transient myocardial dysfunction document echocardiography not anaphylaxis coronary artery disease knowledge first report case transient myocardial dysfunction set angiotensin convert enzyme inhibitorinduced angioedema without anaphylaxis',\n",
       " 'cutaneous manifestations frequently report association drug use aim study analyse skin reactions report spontaneous surveillance systems four italian regions friuli venezia giulia lombardy sicily veneto correlate report estimate drug consumption period pay particular attention reactions antimicrobial agents nonsteroidal antiinflammatory drug nsaids',\n",
       " 'determine pattern presentation risk factor management outcome patients ace inhibitor associate angioedema one british teach hospital',\n",
       " 'angioedema ae associate angiotensinconverting enzyme inhibitors acei rare potentially lifethreatening adverse reaction several study suggest bradykinin bk responsible aceiinduced ae mechanism remain unclear investigate metabolism bk desargbk serum patients history aceiassociated ae control c subject synthetic bk incubate sera various periods time residual bk generate desargbk quantify specific sensitive enzyme immunoassays no significant difference halflife bk desargbk could measure c subject patients ae ae absence acei however analysis accord prolong not desargbk allow new stratification c subject ae patients four subgroups preincubation sera enalaprilat concentration inhibit ace significantly prevent rapid degradation bk desargbk four subgroups presence acei subgroup ae patients ae particularly significant rise desargbk ace inhibit concentration nature acei no significant effect desargbk however test dilution ae sera control c serum show enzyme defect rather circulate inhibitor could responsible abnormal metabolism desargbk ace inhibit conclusion half patients aceiassociated ae present serum enzyme defect involve desargbk metabolism lead accumulation b agonist could responsible least part local inflammatory reaction associate ae',\n",
       " 'enalapril treatment mg every hours patients essential hypertension leave ventricular lv hypertrophy establish normal blood pressure weeks years reduce lv mass index gm normalize lv structure function qt dispersion stepwise reduction enalapril dosage mgd eighth year cause no significant change blood pressure lv structure lv systolic function qt dispersion likewise remain unaltered additional year period mgd regimen conclude hypertensive patients prolong treatment high dose enalapril normalize blood pressure lv structure lv function qt dispersion dose may reduce much fold without detriment cardiovascular control use smaller dose evidently advantageous point view health cost',\n",
       " 'angioedema rare potentially fatal side effect angiotensin convert enzyme ace inhibitors report first time two children systemic lupus erythematosus develop acute angioedema longterm use enalapril prompt recognition appropriate management aceinduced angioedema prevent lifethreatening complications report highlight potential risk angioedema associate use ace inhibitors children patients advise seek medical treatment immediately experience swell face neck tongue especially trouble breathe speak swallow',\n",
       " 'abnormalities fibrinolysis report hypertension angiotensin convert enzyme ace inhibitors show improve alter fibrinolytic balance hypertensive patients not document however whether due decrease angiotensin ii angii generation consequence elevate local level bradykinin accordingly aim study determine effect ace inhibitor perindopril angii receptor antagonist losartan fibrinolytic kinetics examine serum level plasminogen activator inhibitor type pai antigen activity tissue plasminogen activator tpa antigen activity soluble thrombomodulin stm tissue factor pathway inhibitor tfpi reach target blood pressure mm hg hypertensive patients receive perindopril mean age years women men patients receive losartan mean age years women men also compare baseline fibrinolytic activity hypertensive patients normotensive control persons mean age years women men mean basal plasma level pai antigen pai activity stm significantly higher hypertensive patients normal control p value analytes similar group increase plasma level pai antigen pai activity stm reduce patients give perindopril losartan p reductions losartanreceiving group pronounce p no significant effect plasma level tpa antigen tpa activity tfpi patients receive two therapeutic regimens p conclusion chronic hypertension associate hypofibrinolysis beneficial effect ace inhibitors fibrinolysis seem relate blockade angii increase kinin activity not appear play major role',\n",
       " 'hypertension chronic progressive renal disease major clinical problem lead renal function loss study influence ambulatory blood pressure abp effect hypertension therapy renal function patients chronic glomerulonephritis patients subdivide hypertensive normotensive hypotensive accord level abp age hypotensive subject show improvement renal function normotensive subject show slower rate progression renal function loss hypertensives suggest adequate level abp mm hg patients less years old mm hg patients years old mm hg patients years respectively renal protection calcium antagonists associate achieve lower blood pressure level whereas blood pressure level not affect progression renal function patient treat angiotensin convert enzyme ace inhibitor ace inhibitor not calcium antagonists show reduction urinary protein excretion thus mechanisms renal protection different ace inhibitors calcium antagonists',\n",
       " 'compare serum pharmacokinetics fosinoprilat enalaprilat lisinopril days dose fosinopril enalapril lisinopril',\n",
       " 'compare enalapril mg daily mg twice daily term blood pressure reduction patient compliance',\n",
       " 'primary aim perindopril protection recurrent stroke study progress determine effect longterm angiotensin convert enzyme ace inhibitorbased bloodpressurelowering regimen risk stroke among patients history stroke transient ischaemic attack tia secondary aim include investigation effect treatment total cardiovascular events dementia disability',\n",
       " 'antihypertensive drug approve use clinical practice must undergo rigorous clinical test basic pharmacokinetic data usually first obtain healthy normal individuals thereafter patients renal hepatic disease subgroups young elderly acute dose study wide dosage range require prior initiate longerterm study one dosage level select appropriate dose interval establish investigators may proceed study four twelve weeks duration compare new drug placebo standard therapies thiazide diuretic betablocker key element evaluation process assessment drug',\n",
       " 'ramipril efficacy nephropathy study ramipril decrease rate gfr decline deltagfr progression endstage renal disease esrd patients proteinuric chronic nephropathies study investigate whether patients disease outcome response treatment affect gender insertiondeletion id polymorphism angiotensinconverting enzyme ace gene deltagfr versus mlmin per incidence esrd respectively comparable male female patients however compare conventional treatment ramipril decrease deltagfr versus progression esrd versus effectively women men thus relative risk confidence interval [ ci ] events esrd conventional ramipril treatment p women p men genderrelated effect ramipril associate reduction proteinuria versus p still evident even correction potentially confound factor baseline gfr daily sodium intake ramipril dose bp control concomitant treatment diuretics dihydropyridinic calcium channel blockers adjust rr [ ci ] women [ ] p men [ ] p ramipril uniformly decrease deltagfr incidence esrd women either dd ii id genotype men dd genotype no beneficial effect men ii id genotype thus relative risk events esrd conventional ramipriltreated men higher subject dd genotype lower ii id genotype parallel deltagfr events proteinuria decrease women dd ii id genotype men dd genotype not change men ii id genotype note ace genotyperelated effect ramipril still evident even correction potentially confound factor adjust rr [ ci ] dd [ ] p ii id [ ] p thus among patients chronic proteinuric nephropathies men increase risk progression due lower response ace inhibitor treatment ace inhibition uniformly renoprotective women regardless ace polymorphism men dd genotype virtually devoid beneficial effect men ii id genotype information may help guide therapeutic interventions clinical practice interpret result prospective trials chronic renal disease',\n",
       " 'obesity significant risk factor hypertension cardiovascular sequelae hypertension weight loss show effective lower blood pressure overweight individuals purpose study show impact weight loss intervention overall medication requirements obese hypertensive patients substudy hypertension optimal treatment hot study hot study patients body mass index kgm randomize receive either weight loss intervention include dietary counsel group support serve control group patients weight number medication step per hot protocol require achieve target diastolic blood pressure measure months patients weight loss group lose significantly weight control group months v kg [ mean sd ] weight loss group versus control respectively p weight loss group tend regain weight first months study however patients weight loss group use significantly fewer number medication step control group time intervals except months weight loss appear useful tool blood pressure management patients require medication control blood pressure',\n",
       " 'objective study examine influence angiotensin convert enzyme ace inhibition circulatory responses standardize stress test primary mild moderate hypertension patients n receive mg ramipril daily placebo weeks doubleblind crossover design follow months open ramipril treatment mental stress min stroop color word conflict test cold pressor test perform end three study periods noninvasive blood pressure heart rate record ramipril reduce systolic diastolic blood pressure level rest placebo weeks mm hg months laboratory mental stress rest heart rat unchanged ramipril ramipril reduce systolic blood pressure heart rate responses mental stress diastolic blood pressure responses unchanged ramipril reduce cardiac workload systolic blood pressure x heart rate level responses treatment effect months generally greater weeks cold pressor test systolic diastolic blood pressure level lower ramipril responses unchanged heart rate responses however reduce thus ramipril reduce cardiac workload level responses also cold pressor test find show ace inhibitors reduce cardiac workload stressful situations confirm would seem offer advantage treatment hypertension',\n",
       " 'ace genotype ace induce renoprotection chronic proteinuric nephropathies',\n",
       " 'angiotensinconverting enzyme inhibitors acei class antihypertensive agents decrease mortality congestive heart failure establish efficacy treatment hypertension slow establish diabetic nephropathy proteinuriaassociated glomerulonephritides drug not gain wide acceptance treatment hypertension renal transplant recipients rtrs potential decrease renal blood flow glomerular filtration rate associate single kidney concomitant cyclosporine use experimental animal model suggest acei may benefit slow progression chronic renal allograft rejection undertake retrospective chart analysis rtrs institution treat acei angiotensin ii ii antagonist objectives determine safety efficacy side effect profile medications minimum followup period months one hundred seventyseven rtrs prescribe acei ii antagonist fortyseven patients discontinue therapy common cause discontinuation cough patients hyperkalemia patients mean arterial blood pressure followup period lower time initiation acei ii antagonist therapy decrease mm hg mm hg p years treatment serum creatinine concentrations not change throughout followup period nonsustained increase baseline serum potassium meql months p no increase potassium beyond time mean hemoglobin concentration cohort not change rtrs give acei posttransplantation erythrocytosis pte decrease hemoglobin gdl start acei therapy gdl years p acei ii antagonists generally effective antihypertensives safe welltolerated agents cohort rtrs acei also effective treatment pte',\n",
       " 'seek evaluate effect intravenous administration nitric oxide donor substance nitroglycerin ntg metabolic coronaryflow regulation patients coronary artery disease cad patients stable cad measure coronary sinus blood flow myocardial oxygen supply consumption mvo sinus rhythm atrial pace beatsmin sinus rate control infusion ntg microgkgmin ntg microgkgmin study metabolic coronary vasodilation change myocardial oxygen supply relate pacinginduced change mvo use standard regression analysis myocardial oxygen supplyconsumption ratio e slope regression line control characterize physiological metabolic coronary flow regulation compare ratios obtain infusion ntg compare control measurements ntg microgkgmin ntg microgkgmin attenuate pacinginduced increase mvo respectively whereas coronary blood flow pace remain unchanged control normal metabolic coronaryflow regulation result myocardial oxygen supplydemand ratio ci ratio not change ntg microgkgmin ci however ntg microgkgmin ratio significantly increase ci p intravenous administration highdose ntg donor exogenous no blunt pacinginduced increase mvo may increase metabolic coronary vasodilation patients cad',\n",
       " 'background erythroderma protean underlie cause isolate case report suggest association erythroderma human immunodeficiency virus hiv',\n",
       " 'beneficial effect early use angiotensinconverting enzyme inhibitors aceis patients acute myocardial infarction mi well document however effect aceis patients old mi preserve cardiac function not yet study examine effect months enalapril treatment patients previous mi',\n",
       " 'study carry investigate pharmacokinetics zofenopril cas zofenoprilat behaviour angiotensin convert enzyme ace pharmacodynamics follow administration zofenopril calcium single oral dose mg eighteen healthy volunteer open label oneway study carry single centre healthy volunteer volunteer receive oral single mg dose zofenopril calcium follow overnight fast tablet swallow ml water fast continue additional h dose no liquid intake allow h h administration plasma concentrations zofenopril active metabolite zofenoprilat well serum ace activity measure drug intake baseline time sample h period dose lcmsms highly sensitive validate method active moiety concentrations peak plasma concentration reach average h zofenopril h zofenoprilat concentrations decrease reach value close limit quantitation ng ml zofenopril ng ml zofenoprilat h dose complete inhibition ace see first blood sample time h last average h ace activity slowly reactivate enzyme inhibition continue estimate h follow drug administration respectively data complete almost complete enzyme inhibition expect zofenopril give repeat dose regimen',\n",
       " 'determine effect angiotensinconverting enzyme ace inhibition brachial flowmediated vasodilation',\n",
       " 'angiotensinconvertingenzyme inhibitors improve outcome among patients leave ventricular dysfunction whether not heart failure assess role angiotensinconvertingenzyme inhibitor ramipril patients high risk cardiovascular events not leave ventricular dysfunction heart failure',\n",
       " 'observational experimental study suggest amount vitamin e ingest food supplement associate lower risk coronary heart disease atherosclerosis',\n",
       " 'systolic hypertension china systchina collaborative group initiate placebocontrolled systchina trial investigate whether antihypertensive drug treatment could reduce incidence fatal nonfatal stroke older chinese patients isolate systolic hypertension',\n",
       " 'longterm effect angiotensinconverting enzyme inhibition metabolic control hypertensive type diabetic patients',\n",
       " 'angiotensin iconverting enzyme ace inhibitors reduce angiotensin ii formation induce bradykinin accumulation animal study suggest bradykinin may play role effect ace inhibition blood pressure kidney function therefore compare renal hemodynamic effect specific intervention reninangiotensin system blockade angiotensin ii subtype receptor effect ace inhibition',\n",
       " 'patients hypertension increase risk develop heart failure hf mechanisms hypertension lead hf not clarify [ although leave ventricular hypertrophy lvh clearly predictor increase risk hf ] similarly although antihypertensive therapy show reduce risk hf hypertensive patients not know benefit produce currently no clear evidence class antihypertensive agent effective respect theoretical ground betablockers would expect ideal agents prevention hf hypertensive patients addition control blood pressure regression lvh clear benefit morbidity mortality myocardial infarction mi probably play major role development hf hypertensive patients prognosis hf reduction longterm mortality mi demonstrate nonselective betablockers carvedilol nonselective betablocker also ancillary properties include alphareceptor blockade antioxidant effect favourable metabolic profile may appropriate choice prevention hf hypertensive patients reinforce salutary benefit carvedilol reduction morbidity mortality hf',\n",
       " 'study compare effect angiotensin ii receptor antagonist valsartan ace inhibitor enalapril leave ventricular lv diastolic function patients mild moderate essential hypertension no evidence lv hypertrophy echocardiography',\n",
       " 'understand cardiac drug interactions concurrent psychotropic prescriptions essential practice cardiologist primary care physician well psychiatrist explosive use new drug psychiatry cardiology without widespread knowledge potential interactions increase tendency toward polypharmacy use psychotropic medications cardiologists primary care physicians care cardiac patients growth age population present major challenge practitioner finally need modelsparadigms predict potential drug interactions e g cytochrome p schema paper describe method identify understand codify interactions psychotropic cardiac drug systematic approach update key database specific cardiacpsychotropic drug interactions specifically paper detail interactions address level clinical significance describe potential mechanism interactions offer recommendations clinician since majority original clinical trials either cardiac medications psychotropic drug not include study compare two drug domains contemporaneously interactions often become know combine use clinical arena use patient ` ` guinea pig subsequent report',\n",
       " 'week openlabel study compare efficacy safety oncedaily telmisartan either alone combination hydrochlorothiazide hctz amlodipine similar enalapril regimen patients severe hypertension clinically relevant reductions supine systolic blood pressuredbp observe telmisartan mmhg enalapril mmhg monotherapy incremental reductions see uptitration monotherapy telmisartan enalapril mmhg addition hctz telmisartan enalapril mmhg amlodipine telmisartan enalapril weeks treatment supine dbp control achieve patients telmisartan enalapril regimens respectively treatment regimens well tolerate telmisartan new angiotensin receptor blocker safe effective drug use combination treatment patients severe hypertension prove least effective enalapril combination',\n",
       " 'doubleblind placebocontrolled multicenter study involve center different brazilian regions perform evaluate antihypertensive efficacy tolerability trandolapril angiotensin convert enzyme inhibitor treatment mildtomoderate systemic arterial hypertension',\n",
       " 'use angiotensinconverting enzyme ace inhibitors link decrease risk develop cancer longerterm use calcium channel blockers ccbs associate increase risk develop cancer general breast cancer particular',\n",
       " 'smell taste disorder common general population loss smell occur frequently although disorder substantial impact quality life may represent significant underlie disease often overlook medical community patients may difficulty recognize smell versus taste dysfunction frequently confuse concepts ` ` flavor ` ` taste common cause smell disturbance nasal sinus disease upper respiratory infection head trauma frequent cause taste disturbance include oral infections oral appliances e g dentures dental procedures bell palsy medications interfere smell taste review patients report dysfunction addition advance age associate natural impairment smell taste ability focus history physical examination nose mouth usually sufficient screen underlie pathology compute tomographic scan magnetic resonance image affect areas well commercially available standardize test may useful select patients cause olfactory dysfunction amenable treatment include obstruct polyps mass treat excision inflammation treat steroids enhancement food flavor appearance improve quality life patients irreversible dysfunction',\n",
       " 'treat hypertensive subject may remain five time likely die cardiac cerebrovascular diseases normotensive subject equivalent rest blood pressure bp level research evidence suggest exercise bp better predictor endorgan damage mortality rest bp data centre show significant proportion treat hypertensives uncontrolled bp min dundee step test prognostic usefulness exercise bp yet translate clinical practice lack suitable technique dundee step test evaluate ascot angloscandinavian cardiac outcome trial study year followup multicentre multinational trial compare effect newer amlodipine perindopril older bendroflumethiazide atenolol antihypertensive agents stratify accord cholesterol level cardiac outcome value dundee step test prove may adopt routine clinical practice assessment exercise bp may result improve management hypertension subsequent reduction morbidity mortality publication study protocol mean statement ongoing research may stimulate interest among interest area research journal human hypertension',\n",
       " 'diabetes mellitus strong risk factor cardiovascular renal disease investigate whether angiotensinconvertingenzyme ace inhibitor ramipril lower risk patients diabetes',\n",
       " 'patients rib disease rd form multiple epiphysal dystrophy hypertension frequent often severe accompany relevant cardiac dysfunction',\n",
       " 'purpose study compare effect different antihypertensive agents calcium antagonists angiotensinconverting enzyme ace inhibitors betablockers diuretic agents endothelial function',\n",
       " 'describe case syndrome inappropriate antidiuretic hormone secretion siadh associate lisinopril therapy',\n",
       " 'remain uncertain whether angiotensin convert enzyme ace inhibitors benefit heart failure patients reninangiotensinaldosterone system raas activation',\n",
       " 'study conduct determine whether culture human coronary artery aorta vascular smooth muscle vsm cells express nuclear transcription factor peroxisome proliferatoractivated receptorgamma ppargamma whether thiazolidinedione troglitazone ligand ppargamma would inhibit cfos expression cells whether troglitazone would inhibit proliferation migration induce cells mitogenic growth factor use immunoblotting reversetranscriptase polymerase chain reaction rtpcr techniques show human aorta coronary artery vsm cell line express ppargamma protein mrna ppargamma isoforms ppargamma ppargamma immunocytochemical stain localize ppargamma protein primarily within nucleus troglitazone inhibit basic fibroblast growth factor plateletderived growth factorbb induce dna synthesis dosedependent manner downregulated growthfactorinduced expression cfos troglitazone also inhibit migration coronary artery vsm cells along plateletderived growth factorbb concentration gradient find demonstrate first time expression nuclear localization ppargamma human coronary artery aorta vsm cells data also suggest downregulation cfos expression growthfactorinduced proliferation migration vsm may part mediate activation ppargamma receptor',\n",
       " 'several experimental clinical study indicate renin system may play pivotal role progress renal disease combination angiotensinconverting enzyme inhibitor angiotensin receptor blocker could provide higher degree blockade reninangiotensin system either agent alone enhance suppression might benefit patients exhibit progressive decline renal function chronic renal disease',\n",
       " 'calcium channel blockers ccbs blunt postural skin vasoconstriction autoregulatory mechanism minimize gravitational increase capillary pressure avoid fluid extravasation stand evaluate doseresponse relation pharmacological interference dependent edema frequent side effect ccbs antihypertensive treatment skin blood flow laser doppler flowmetry dorsum foot supine limb passively place cm heart level leg weight archimedes principle measure baseline increase dose dihydropyridine amlodipine mg uid weeks drug withdrawal hypertensive men angiotensinconverting enzyme inhibitors may attenuate ankle swell ccbs parameters evaluate accord similar design amlodipine mg uid enalapril mg uid combine n control effect enalapril monotherapy mg uid weeks evaluate third series patients n amlodipine mg uid increase leg weight without modify postural vasoconstriction percent skin blood flow decrease horizontal dependent position indicate extravascular fluid shift independent postural skin vasoconstriction mg uid however amlodipine blunt postural vasoconstriction increase leg weight suggest skin blood flow autoregulation limit additional fluid transfer parameters normalize drug withdrawal enalapril per se not affect cutaneous vasomotion leg weight reduce amount dependent fluid extravasation ccb despite persistent antagonism postural vasoconstrictor responses',\n",
       " 'hypertensive patients autosomal dominant polycystic kidney disease adpkd faster progression endstage renal disease esrd normotensive counterparts aim prospective randomize study compare effect calcium channel blocker amlodipine angiotensinconverting enzyme inhibitor enalapril firstline therapy blood pressure renal function urinary albumin excretion hypertensive patients adpkd twentyfour patients adpkd hypertension creatinine clearances ccrs greater mlmin include study twelve patients receive amlodipine mean dose mgd patients receive enalapril mean dose mgd patients follow years baseline mean arterial pressure mm hg amlodipine group mm hg enalapril group decrease significantly year followup amlodipine mm hg p enalapril mm hg p remain stable year amlodipine mm hg p versus baseline enalapril mm hg p versus baseline ccrs mlmin amlodipine group mlmin enalapril group remain stable year followup decrease significantly year group amlodipine mlmin p versus year baseline enalapril mlmin p versus year p versus baseline no significant change thereafter no change observe urinary albumincreatinine ratio amlodipine group baseline mgg year mgg year mgg whereas decrease significantly enalapril group year baseline mgg year mgg p remain stable end study year mgg investigators conclude blood pressure similar group enalapril significant effect sustain decrease urinary albumin excretion year followup although proteinuria consider surrogate renal disease progression study necessary confirm hypothesis adpkd years no differences renal function observe enalapril amlodipine group comparison patients adpkd uncontrolled hypertension effective control blood pressure undertake present study delay onset esrd approximately years',\n",
       " 'study compare valsartan mg mg captopril mg placebo plasma lipids normotensive treat hypertensive patients type ii diabetes microalbuminuria one hundred twentytwo adult outpatients randomise receive either valsartan mg mg captopril mg placebo days change baseline endpoint plasma lipid parameters measure primary criterion tolerability incidence adverse events treatment group show minor change lipid parameters triglyceride increase valsartan mg placebo total cholesterol decrease valsartan mg group show increase mmoll decrease total cholesterol p apolipoprotein b p apolipoprotein p significant comparison mg valsartan captopril valsartan mg mg not cause deleterious change diabetic lipid profile unlike captopril not associate dry cough',\n",
       " 'information clinical pharmacokinetic study angiotensinconverting enzyme inhibitors aceis come subject mostly male caucasian use aceis extend populations worldwide significant differences chinese general male caucasians demonstrate pharmacokineticsdynamics drug class could implications use aceis chinese population include significant chinesecaucasian genetic variation reninangiotensin system base insertiondeletion od polymorphism ace gene genetic determination plasma ace activity chinese population genetic factor involve disease substrate may also influence response treatment oral iv pharmacokinetic data various study chinese caucasian subject available cilazapril fosinopril perindopril pharmacodynamic data available eight different aceis base data differences among pharmacokinetics aceis chinese caucasians aceis show good blood pressure lower efficacy chinese benazepril enalapril fosinopril spirapril perhaps less blood pressure lower cilazapril relatively shorterterm effect cilazapril perindopril compare caucasions chinese experience cough aceis captopril enalapril caucasians data suggest fosinopril may not induce cough many subject aceis seem true chinese well mechanism currently unknown could involve fosinopril dual elimination pathway hepatic renal pharmacokinetic data also support use fosinopril congestive heart failure elimination pathways may impair conclusion ethnic differences chinese caucasians respect ace agt gene polymorphism might expect differentially affect action aceis two ethnic group not fact effect rather differences among aceis appear important journal human hypertension',\n",
       " 'effect glucose metabolism betablocker atenolol angiotensinconverting enzyme ace inhibitor trandolapril investigate randomise doubleblind parallel group study patients primary hypertension twentysix patients treat mg atenolol patients mg trandolapril intravenous glucose tolerance test euglycaemic hyperinsulinaemic clamp serum lipid measurements perform weeks active treatment weeks insulin sensitivity reduce atenolol remain unchanged trandolapril treatment p difference treatments ancova effect triglycerides vs highdensity lipoprotein cholesterol vs also differ significantly atenolol trandolapril result weeks similar glucose tolerance not affect either drug atenolol reduce diastolic blood pressure dbp better trandolapril mm hg vs mm hg supine dbp weeks p difference effect insulin sensitivity drug correspond baseline value insulin sensitivity persist weeks treatment choice antihypertensive treatment could influence risk diabetes associate treat hypertension journal human hypertension',\n",
       " 'blockade reninangiotensin system begin way study pathogenesis cardiovascular disease specific pharmacological probe oral activity achieve shorten original peptide structure transform probe therapeutic agents angiotensinconverting enzyme ace inhibitors however ace nonspecific target block reninangiotensin enzymatic cascade availability orally active drug turn ace inhibition therapeutic breakthrough specific blockade always seem desirable goal achieve orally active angiotensin ii receptor antagonists six market development new class drug equal efficacy ace inhibitors least hypertensive patients trials underway demonstrate whether angiotensin ii receptor antagonists prevent targetorgan damage reduce cardiovascular morbidity mortality compound might one day replace ace inhibitors',\n",
       " 'angiotensinconverting enzyme ace inhibitor therapy early mortality benefit unselected patients acute myocardial infarction ami however effect ace inhibition myocardial fatty acid metabolism patient population not study test hypothesis ace inhibitor therapy improve myocardial fatty acid metabolism decrease mortality rate patients ami',\n",
       " 'objective compare compliance hypertensive patients treat captopril twice daily trandolapril daily week placebo period hypertensive patients diastolic bp mm hg randomly allocate trandolapril mg daily captopril mg twice daily months trandolapril captopril pack electronic pillboxes equip microprocessor record date time open mems patients compliance assess standard pillcount electronic monitor blood pressure measure use validate semiautomatic device end placebo period treatment period one hundred sixtytwo patients enter study compliance data evaluable patients captopril group trandolapril group treatment group comparable baseline except age p use electronic pillbox overall compliance trandolapril group captopril group p percentage miss dose trandolapril group captopril group p percentage delay dose trandolapril group captopril group p percentage correct dose periods ie period one correct record open trandolapril group captopril group p result unchanged adjust age end study patients trandolapril group captopril group ns blood pressure normalize systolic bp diastolic bp mm hg month study electronic pillbox allow refine analysis compliance hypertensive patients patients compliance daily trandolapril higher twice daily captopril betweengroup difference mainly explain increase delay dose twice daily group',\n",
       " 'aim study evaluate occurrence dry cough treatment candesartan cilexetil enalapril placebo patients hypertension history angiotensin convert enzyme ace inhibitorrelated cough patients confirm cough enalapril mg challenge period follow no cough placebo dechallenge period randomize weeks doubleblind treatment candesartan cilexetil mg n enalapril mg n placebo n incidence severity dry cough evaluate symptom assessment questionnaire frequency dry cough visual analog scale possible impact quality life minor symptom evaluation mse profile percentage patients cough significantly lower candesartan cilexetil enalapril p not differ candesartan cilexetil placebo p patients cough less frequently less severe cough candesartan cilexetil enalapril similarly candesartan cilexetil placebo change mse profile minor although candesartan cilexetil better score contentment placebo p also tend associate better sleep enalapril p hypertensive patients aceinhibitorinduced cough incidence frequency severity dry cough significantly lower candesartan cilexetil enalapril no different find placebo',\n",
       " 'establish reliability ease use cambridge neuropsychological test automate battery cantab assess change cognitive function induce antihypertensive drug',\n",
       " 'compare antihypertensive effect combination therapy versus single drug regimen schedule dosetitration switch different drug class type diabetic hypertensive patients inadequate blood pressure bp control monotherapy',\n",
       " 'although angiotensinconverting enzyme inhibitors recommend first line therapy patients chronic heart failure target dose prove effective major morbidity mortality trials e g captopril mg b generally not use daily practice belgium',\n",
       " 'adverse drug reactions adrs lead cause morbidity mortality highest incidence occur patients age older prescribe lowest effective dose medications older patients help avoid adrs minimize bothersome side effect increase rat compliance many drug clinical experience publish study demonstrate effectiveness dose substantially lower recommend standard reference article examine problem adrs older patients discuss pharmacokinetic data regard older versus younger adults provide effective lower dose many common drug',\n",
       " 'yearold man transurethral resection prostate perform spinal anaesthesia develop profound bradycardia hypotension disturbance consciousness transfer recovery room initial treatment atropine produce rapid improvement cardiovascular cerebral function hypotensive episode without bradycardia occur approximately h later respond rapidly methoxamine patient make full recovery overnight stay high dependency unit possible mechanisms event discuss proposal concomitant administration captopril relative unavailability angiotensin ii may significantly contribute problem',\n",
       " 'cardiologists generalists report diverge term selfreported use angiotensinconverting enzyme ace inhibitors information actual use ace inhibitors lack order assess ace inhibitor use patients heart failure teach hospital differences specialties study patients western infirmary glasgow april october echocardiogram show moderate severe leave ventricular systolic dysfunction n find patients ace inhibitor try find intolerant not try contraindication not try despite no contraindication treatment dose use major survival study patients patients treat cardiologist ace inhibitor vs p fewer try find intolerant vs fewer never try vs p irrespective whether contraindication vs p not vs dose use major survival study vs p conclude despite improvements time ace inhibitors still underused sometimes without good reason also differences use ace inhibitors cardiologists generalists may affect outcome could affect resource utilisation',\n",
       " 'compare safety tolerability antihypertensive efficacy valsartan enalapril different altitudes',\n",
       " 'present analysis examine prognostic implications moderate renal insufficiency patients asymptomatic symptomatic leave ventricular systolic dysfunction',\n",
       " 'betablocker therapy show improve cardiac function prognosis patients idiopathic dilate cardiomyopathy dcm however whether betablockers reduce severe ventricular arrhythmias sudden cardiac death not clarify present study design investigate effect betablockers nonsustained ventricular tachycardia vt sudden cardiac death patients dcm sixtyfive patients dcm treat diuretics digitalis angiotensinconverting enzyme inhibitors assign receive betablockers n not n mean followup months echocardiographic indices cardiac function incidence nonsustained vt holter monitor electrocardiograms sudden cardiac death rate compare group comparable improvement cardiac function echocardiograms find treatment group patient group treat betablockers show significant reduction prevalence vt p development new episodes vt vs compare group without betablockers sudden cardiac death rate not differ group result present study suggest betablockers effective reduce severe ventricular arrhythmias patients dcm',\n",
       " 'medications use treat cardiovascular diseases congestive heart failure high blood pressure arrhythmia prescribe extensively western countries however taste complaints common side effect many cardiovascular medications although clinical observations helpful determine potential taste problems medication experimental study necessary obtain quantitative data taste study perform nine cardiovascular medications labetalol hcl captopril diltiazem hcl enalapril maleate hydrochlorothiazide propranolol hcl mexiletine hcl procainamide hcl propafenone hcl apply tongue human volunteer measure direct effect drug taste receptors medications apply topically tongue surface young elderly subject mimic situation drug secrete saliva detection thresholds range mm propafenone mm procainamide detection thresholds healthy elderly subject not significantly differ young control compound test predominantly bitter taste qualities well addition topical application medications tongue affect taste one taste stimuli medications differ pattern taste effect exhibit mechanism taste effect not fully know result study suggest one route may due medications effect peripheral taste receptors',\n",
       " 'arterial pressure increase age common chronic disease elderly men women alike present arterial hypertension consider social disease pose great health economic social problems',\n",
       " 'contrastinduced nephrotoxicity important cause hospitalacquired acute renal insufficiency different modalities use prevent contrast inducednephrotoxicity namely saline infusion mannitol furosemide calcium channel blockers atrial natriuretic factor dopamine infusion variable success possible role medullary ischaemia mediate renin angiotensin system genesis contrastinduced nephrotoxicity prompt us investigate role captopril sulfhydryl group contain angiotensinconverting enzyme inhibitor prevention seventyone patients diabetes mellitus undergo coronary angiography include study patients randomise receive captopril receive drug dose mg thrice day three days start one hour prior angiography patients control group undergo angiography routine manner without receive captopril follow angiography patients control group develop significant increase serum creatinine blood urea nitrogen level compare receive captopril contrastinduced nephrotoxicity e rise mgdl serum creatinine develop percent control group administration captopril reduce risk development contrastinduced nephrotoxicity percent glomerular filtration rate measure tc dtpa renal scan prior hours follow angiography demonstrate mean fall mlmin control group captopril group mean increase mlmin glomerular filtration rate conclude abnormalities renal perfusion possibly mediate renin angiotensin system responsible development contrastinduced nephrotoxicity administration angiotensinconverting enzyme inhibitor captopril offer protection development contrastinduced nephrotoxicity',\n",
       " 'diabetes mellitus common patients hypertension greatly increase risk cardiovascular disease include myocardial infarction stroke peripheral vascular disease ` ` pharmacologic therapy patients hypertension diabetes surround controversy concern metabolic effect several antihypertensive agents well concern safety calcium antagonists objective review reevaluate management diabetic patients hypertension light latest clinical trials also review importance intensive blood pressure control patients',\n",
       " 'reduce action reninangiotensinaldosterone system angiotensinconverting enzyme inhibitors aceis slow nephropathy progression patients without diabetes post hoc analyse many aceibased clinical trials demonstrate greatest slow renal disease progression patients greatest degree renal insufficiency study initiation however many physicians fail use aceis angiotensin receptor blockers patients renal insufficiency fear either serum creatinine potassium level rise',\n",
       " 'establish optimal dose perindoprilindapamide combination perind treatment mild moderate hypertension',\n",
       " 'determine longterm efficacy safety fix verylowdose tablet combine onehalf standard dose perindopril onequarter standard dose indapamide firstline treatment elderly patients',\n",
       " 'numerous drug acutely ill expose place patients significant risk develop druginduced thrombocytopenia patients tend preexist hemostatic defect place additional risk complications result druginduced thrombocytopenia clinical challenge provide rapid identification removal offend agent clinically significant bleed case heparin thrombosis result druginduced thrombocytopenic disorder classify three mechanisms bone marrow suppression immunemediated destruction platelet aggregation clinical characteristics preliminary laboratory find drug history specific mechanisms assist clinicians rapidly isolate causative drug',\n",
       " 'prognostic significance pathological q wave appear acute phase myocardial infarction not determine investigate whether new q wave present electrocardiogram patients acute stsegment elevation independently associate worse outcome first myocardial infarction',\n",
       " 'study perform assess effect treatment ramipril incidence cardiac events invasive revascularization patients asymptomatic moderate leave ventricular dysfunction',\n",
       " 'stroke incidence mortality rat higher southeastern region unite state call ` ` stroke belt compare response antihypertensive medication use patients different us regions',\n",
       " 'druginduced injury oesophagus common cause oesophageal complaints pillinduced oesophagitis associate ingestion certain drug account many case erosive oesophagitis date drug report induce oesophageal disorder antibacterials doxycycline tetracycline clindamycin offend agents case commonly prescribe drug cause oesophageal injury include aspirin acetylsalicylic acid potassium chloride ferrous sulfate quinidine alprenolol various steroidal nonsteroidal antiinflammatory agents however many physicians even patients not aware problem capsule tablets commonly delay passage oesophagus highly caustic coat direct medication injury poor oesophageal clearance pills lead acute inflammation oesophageal damage occur caustic content drug remain oesophagus long enough produce mucosal lesions take medications bedtime without fluids common cause oesophagitis possibility drugrelated damage suspect case oesophagitis chest pain dysphagia history gastrointestinal endoscopy confirm diagnosis treatment supportive although acid reduction use frequently adjunct review reflect current state knowledge field',\n",
       " 'clinical trials show beneficial effect angiotensinconverting enzyme ace inhibitors delay progression diabetic renal disease less evidence primary clinical trials nondiabetic renal disease perform update metaanalysis determine efficacy ace inhibitors slow progression renal disease broad range functional renal impairment include publish unpublished randomize placebocontrolled parallel trials least year followup available january june nine trials subject diabetic nephropathy microalbuminuria relative risk develop macroalbuminuria confidence interval [ ci ] individuals treat ace inhibitor compare placebo seven trials subject overt proteinuria renal insufficiency variety cause diabetes nondiabetes relative risk double serum creatinine concentration develop endstage renal disease ci individuals treat ace inhibitor compare placebo treatment individuals chronic renal insufficiency ace inhibitors delay progression disease compare placebo across spectrum disease cause renal dysfunction',\n",
       " 'many patients congestive heart failure not receive benefit angiotensinconverting enzyme ace inhibitors intolerance seek determine tolerability angiotensin ii receptor blocker candesartan cilexetil among patients consider intolerant ace inhibitors',\n",
       " 'angiotensinconverting enzyme ace inhibitors prolong life lower progression heart failure decrease need hospitalizations patients myocardial infarctions still unclear whether effect could also achieve block angiotensin ii atii type receptor',\n",
       " 'aim study examine effect trandolapril long act angiotensin convert enzyme ace inhibitor high tissue uptake insulin sensitivity lipid concentrations hypertensive patients type diabetes mellitus',\n",
       " 'betablocker therapy show improve leave ventricular lv ejection fraction reduce lv volumes patients heart failure cause ischemic heart disease however possible mechanisms improvement effect treatment regional wall motion not establish substudy australianew zealand trial carvedilol patients heart failure cause ischemic heart disease effect treatment lv regional wall motion assess use dimensional echocardiography',\n",
       " 'echocardiographic substudy vasodilatorheart failure trial iii vheft iii aim determine felodipine treatment patients heart failure take angiotensinconverting enzyme inhibitor favorable effect leave ventricular lv structure function earlier vheft trials show hydralazineisosorbide dinitrate improve ejection fraction ef survival whereas enalapril achieve greater survival smaller increase ef would combination potent vasodilator enalapril produce greater improvements function survival',\n",
       " 'heart failure therapy angiotensinconverting enzyme ace inhibitors may not optimal owe persistent level angiotensin ii occur incomplete blockade alternate pathways benefit add irbesartan angiotensin receptor antagonist conventional therapy include ace inhibitors examine multicentre randomise doubleblind placebocontrolled study patients heart failure new york heart association functional class ii iii leave ventricular ejection fraction lvef receive stable dose ace inhibitors diuretics throughout study irbesartan titrate tolerate mg daily patients exercise tolerance time ett lvef clinical status assess baseline weeks compare placebo irbesartan combination conventional therapy include ace inhibitors produce favourable trend ett lvef well tolerate patients mild moderate heart failure',\n",
       " 'nonsteroidal antiinflammatory drug nsaids widely prescribe unite state treat pain reduce inflammation chronic inflammatory disorder rheumatoid arthritis osteoarthritis approximately older americans take nsaids chronic nsaid use carry risk peptic ulcer gastrointestinal disturbances article review diagnosis medicationinduced ulcers base clinical presentation laboratory test endoscopic find assist clinician early diagnosis appropriate therapy risk factor nsaidinduced ulcers include old age poor medical status prior ulcer alcoholism smoke high nsaid dosage prolong nsaid use concomitant use drug gastric irritants alendronate bone resorption inhibitor prescribe osteoporosis appropriate treatment options patients medicationinduced ulcers include dosage reduction medication substitution medication withdrawal antiulcer therapy discontinuation gastrotoxic drug',\n",
       " 'nephropathy complication diabetes mellitus affect women reproductive years article review effect treatment main factor associate short longterm complications pregnant women diabetic nephropathy tight glycemic control adequate treatment elevate blood pressure renal function early pregnancy significant predictors maternal perinatal outcomes contemporary methods perinatal care adequate treatment blood pressure allow fetal survival rat furthermore pregnancy per se not appear worsen natural progression endstage renal disease women renal insufficiency however patients moderate severe renal impairment may experience acceleration renal disease',\n",
       " 'several large scale clinical trials show early ace inhibitor treatment patients acute myocardial infarction reduce day mortality shortterm evidence benefit risk appear consistent among trials scarce data available respect longterm effect shortterm treatments study show early reduction mortality rate observe among patients treat captopril persist years suggest benefit achieve acute phase not lose even long period time',\n",
       " 'inappropriate use antihypertensive medications may cause hypotensive responses associate organ failure describe patient develop nonocclusive splanchnic ischemia lead death follow administration enalapril treat postoperative hypertension mechanisms consequences refractory hypotension induce angiotensinconverting enzyme inhibitors discuss',\n",
       " 'angiotensinconverting enzyme ace inhibitors standard therapy congestive cardiac failure ace inhibitors use worldwide usually safe relatively side effect hypotension develop first dose captopril lead symptomatic renal hypoperfusion subsequent acute renal failure arf case yearold patient congestive heart failure develop acute renal failure follow first dose captopril describe require hemodialysis weeks improvement renal function urinary output renal biopsy confirm presence acute tubular necrosis reversibility captoprilinduced arf confirm patient make uneventful recovery immunoallergic mechanism not think responsible adverse effect advise caution exert give ace inhibitors elderly patients congestive heart failure particularly diuretics routine biochemical monitor suggest captopril therapy',\n",
       " 'study assess oncedaily od sustainedrelease sr diltiazem alone combination ramipril essential hypertension fifty patients supine diastolic blood pressure dbp mm hg enter active treatment phase study weeks placebo runin sustainedrelease diltiazem mg od administer weeks optimally titrate week intervals sr diltiazem mg od sr diltiazem mg ramipril mg od achieve supine dbp mm hg weeks diltiazem monotherapy sr diltiazem mg mg od mean supine dbp reduce mm hg mm hg p mean supine heart rate reduce bpm bpm p diltiazem monotherapy reduce supine dbp mm hg patients combination therapy sr diltiazem mg ramipril mg od receive nonresponders diltiazem monotherapy reduce supine dbp mm hg patients sinus bradycardia observe one patient sustainedrelease diltiazem alone combination ramipril reduce blood pressure dose relate manner well tolerate',\n",
       " 'heart outcomes prevention evaluation hope study find ace inhibitor ramipril lower risk atherosclerotic disease events death patients without heart failure know atherosclerosis diabetes plus least one cardiovascular risk factor benefit independent ramipril effect blood pressure additional benefit reduce risk diabetic nephropathy diabetic patients lower likelihood newly diagnose diabetes hand vitamin e dose duration study iuday years not lower risk significantly',\n",
       " 'study examine effect angiotensinconverting enzyme inhibition administer dose no effect systemic blood pressure albuminuric action atrial natriuretic peptide anp',\n",
       " 'rilmenidine innovative antihypertensive agent bind specifically imidazoline receptors antihypertensive efficacy rilmenidine treat type diabetics demonstrate associate good clinical laboratory tolerance',\n",
       " 'predictive value digoxin furosemide treatment identify patients receive treatment congestive heart failure chf use angiotensinconvertingenzyme ace inhibitors population ability pharmacist outreach program address underutilization ace inhibitors study physicians ownermanagers community pharmacies newfoundland avalon peninsula ask participate study pharmacists agree participate ask list patients participate physicians prescriptions furosemide digoxin without ace inhibitor angiotensin iireceptor inhibitor ace inhibitor physicians visit pharmacist ask whether patients receive digoxin furosemide treat chf identify case chf among patients receive ace inhibitor interventiongroup physicians receive academic detail use dosage ace inhibitors angiotensin iireceptor inhibitors chf group reinterviewed three months establish change therapy occur patient discuss first visit positive predictive value digoxin furosemide treatment identify patients receive treatment chf seventysix percent patients identify physicians chf patients take digoxin furosemide treat ace inhibitor thirtysix percent patients treat ace inhibitor chf receive target dosage four physicians state outreach visit influence prescribe no significant difference ace inhibitor prescribe intervention control group pharmacist outreach program involve use prescription record academic detail not affect prescribe dosages ace inhibitors demonstrate value quality assurance tool',\n",
       " 'hypertension associate significantly increase risk morbidity mortality diuretics betablockers show reduce risk longterm clinical trials whether newer antihypertensive agents reduce incidence cardiovascular disease cvd unknown',\n",
       " 'currently no objective practical guide intensity drug treatment individuals heart failure hypothesise pharmacotherapy guide plasma concentrations cardiac peptide aminoterminal brain natriuretic peptide nbnp would produce superior outcome empirical trialbased therapy dictate clinical acumen',\n",
       " 'chronic renal failure crf irreversible deterioration renal function gradually progress end stage renal disease esrd chief cause crf include obstructive uropathy primary glomerular diseases reflux nephropathy hypoplastic dysplastic kidneys progressive hyperperfusion hyperfiltration cause increase glomerular injury renal damage symptoms crf usually see gfr normal children severe crf often suffer failure thrive growth retardation acidosis anemia renal osteodystrophy management crf aim retard progression renal damage treatment complications relate renal dysfunction measure suggest retard progression include protein restriction strict control hypertension use angiotensin convert enzyme inhibitors control hyperlipidemia appropriate amount protein calories recommend prevent growth failure nutritional supplement often require availability recombinant erythropoietin calcitriol human growth hormone significantly improve management patients esrd supervene renal replacement therapy form chronic peritoneal hemodialysis transplantation necessary',\n",
       " 'animal study demonstrate interaction within striatum angiotensin dopaminergic systems rat angiotensin convert enzyme ace inhibitor perindopril cross blood brain barrier increase striatal dopamine synthesis release humans angiotensin type receptors find dopaminergic neurons substantia nigra striatum parkinson disease mark reduction receptors associate nigrostriatal dopaminergic neuron loss',\n",
       " 'study effect daily administration mg fosinopril blood pressure response mental physical stress evaluate mild moderate essential hypertension total patients women men mild moderate essential hypertension enrol study treatment mgday fosinopril treatment months systolic diastolic blood pressure heart rate record rest perform mental arithmetic test addition exercise stress test bruce protocol perform treatment systolic diastolic blood pressure heart rate record rest peak exercise statistical analysis use pair ttest mental arithmetic test systolic diastolic blood pressure significantly reduce p p respectively months fosinopril treatment systolic diastolic blood pressure also significantly reduce exercise stress test p p treatment heart rate not change either mental arithmetic exercise test result daily mg fosinopril may effective reduce blood pressure not rest also stressful situations',\n",
       " 'angiotensinconverting enzyme inhibitors acei block degradation bradykinin bradykinin stimulate prostacyclin synthesis therefore set determine whether effect ace inhibitors prostaglandin production essential hypertensive patients class effect dependent ace inhibitor structure addition study whether hypertensives show impair capacity synthesize vasodilator prostaglandins address question compare effect captopril sulfhydrylcontaining inhibitor enalapril ramipril carboxylcontaining inhibitors fosinopril phosphorylcontaining inhibitor blood pressure urinary excretion ketoprostaglandin pg falpha breakdown product prostacyclin mildtomoderate essential hypertensive subject weeks administration acei also study prostacyclin excretion normotensive healthy control level urinary ketopgfalpha pgml measure specific radioimmunoassay hypertensive subject show lower excretion ketopgfalpha normotensive control vs pgml p acei induce significant decrease map increase rate excretion prostacyclin metabolite c pgml p e pgml p r pgml p f pgml p hypertensives n decrease blood pressure correlate negatively rise ketopgfalpha excretion r p data suggest impair prostacyclin biosynthesis hypertensive patients could account haemodynamic change lead hypertensive state moreover hypotensive mechanisms acei may mediate increase prostacyclin production effect seem classdependent',\n",
       " 'losartan orally active nonpeptide selective angiotensin subtype receptor antagonist provide specific complete blockade action angiotensin ii renin ace inhibitors short term weeks duration clinical trials show losartan effective lower blood pressure bp [ cause decrease bp mm hg ] elderly patients hypertension recommend dosages captopril atenolol enalapril felodipine nifedipine patients isolate systolic hypertension ish efficacy losartan similar atenolol addition hydrochlorothiazide losartan therapy provide greater antihypertensive efficacy equivalent see captopril plus hydrochlorothiazide preliminary evidence also indicate losartan therapy contribute regression leave ventricular hypertrophy associate chronic hypertension exercise capacity increase losartan patients either asymptomatic symptomatic heart failure result losartan heart failure survival elite ii evaluation losartan elderly ii study indicate no statistically significant difference losartan captopril reduce overall deaths reduce sudden cardiac death andor resuscitate cardiac arrest patients heart failure elite ii little conclusive long term mortality morbidity data exist losartan additional long term trials evaluate survival benefit losartan elderly patients hypertension renal disease acute myocardial infarction currently progress elderly patients hypertension incidence treatmentrelated adverse events associate daily losartan alone combination hydrochlorothiazide [ ] similar felodipine nifedipine however losartan tend better tolerate captopril vs losartan also better tolerate atenolol patients ish vs patients heart failure renal tolerability losartan similar captopril losartan associate lower withdrawal rate adverse events no dosage adjustment require elderly patients mild moderate renal dysfunction risk firstdose hypotension low',\n",
       " 'compare candesartan cilexetil lisinopril fix combination hydrochlorothiazide respect antihypertensive efficacy tolerability',\n",
       " 'determine accuracy captopril renography cr gadoliniumenhanced breathhold magnetic resonance mr angiography diagnosis renal artery stenosis ras',\n",
       " 'aim investigation determine whether presence additional risk factor type hypertension diastolic isolate systolic influence blood pressure bp response treatment international nifedipine gits study intervention goal hypertension treatment insight study doubleblinded outcome comparison calcium channel blockade diuretics highrisk patients age years dynamic randomization nifedipine daily hydrochlorothiazideamiloride perform ensure approximately equal number patients group major cardiovascular risk factor patients isolate systolic hypertension also separately randomize atenolol enalapril mandatory secondline drug patients complete week titration bp fell mm hg meansd receive placebo mm hg twentysix percent patients require drug require drug patients diabetes resistant treatment require second third drug frequently patients without diabetes achieve marginally highest final bp risk group mm hg age smoke gender hypercholesterolemia leave ventricular hypertrophy exist atherosclerosis little mm hg no influence bp end titration except smoke slightly reduce initial response either systolic diastolic bp patients isolate systolic hypertension slightly responsive average treatment find suggest patients high absolute risk cardiovascular complications hypertension risk factor not prevent recommend bp target achieve',\n",
       " 'different spectral methodologies heart rate variability recently show provide qualitative result context passive tilt test however impact method use normalize power units longterm ecg monitor still debate autoregressive fast fourier transform fft spectral approach apply assess circadian modulation effect betablocker administration mild hypertensive patients undergo continuous ambulatory ecg record n years men spectral analysis apply minute sequence spectral parameters representative circadian period hour day night calculate baseline record fft spectral method provide smaller estimate total low frequency power contrary low highfrequency components systematically larger fft circadian variations favor increase overall nocturnal variability reduce low frequency normalize power spectral methods chronic oral administration betablocker induce increase spectral components except unchanged lowfrequency normalize power independently spectral approach spite quantitative differences qualitative assessment circadian pattern betablockade effect autoregressive fftbased spectral analyse equivalent lowfrequency component heart rate variability not consider reliable direct marker sympathetic activity longterm ambulatory ecg record',\n",
       " 'undertake prospective systematic overview base data individual patients five longterm randomise trials assess inhibitors angiotensinconverting enzyme ace patients leftventricular dysfunction heart failure',\n",
       " 'elite study show association angiotensin ii antagonist losartan unexpected survival benefit elderly heartfailure patients compare captopril angiotensinconvertingenzyme ace inhibitor elite ii losartan heart failure survival study confirm whether losartan superior captopril improve survival better tolerate',\n",
       " 'objective study compare effect angiotensin ii ang ii antagonist losartan angiotensinconverting enzyme inhibitor acei enalapril haemorheology twentynine patients renal parenchymal disease hypertension enrol prospective open parallel study involve day washout period follow day treatment period patients allocate randomly receive either losartan mgday n enalapril mgday n achieve blood pressure control mm hg blood pressure haemorheology profile plasma fibrinogen concentration measure washout phase days treatment data analyse use anova repeat measure twentyseven patients complete study treatment losartan enalapril associate significant decrease p relative high shear rate whole blood viscosity indicate increase blood cell deformability patients take losartan increase blood cell deformability not result decrease mean whole blood viscosity due concomitant significant increase mean plasma viscosity p contrast improve cell deformability patients treat enalapril result small statistically insignificant decrease mean whole blood viscosity p mean change mpa sec mechanism increase blood cell deformability rise plasma viscosity associate losartan remain unclear possible unproven improvement intrinsic blood cell rheology losartan enalapril may result change cation transport systems andor consequence protective antioxidant properties drug metabolites',\n",
       " 'assess antihypertensive efficacy angiotensinconverting enzyme ace inhibitor perindopril elderly patients years age supine diastolic blood pressure bp mm hg end week placebo washout period treat perindopril mgdaily vs placebo use multicentre randomise doubleblind parallel group design patients enter complete weeks doubleblind therapy average age years supine stand bp end placebo runin period vs mm hg bps measure morning h previous day dose ie end dose interval placebo group supine stand diastolic bp decrease mm hg systolic bp mm hg perindoprilgroup diastolic bp decrease mm hg systolic bp mm hg p vs placebo data indicate substantial placebo response particularly systolic bp older hypertensives indicate importance parallel placebogroup assess extent actual drug effect perindopril cause additional decrease diastolic bp mm hg systolic bp mm hg extent drugeffect may less older vs middleaged hypertensives',\n",
       " 'numerous falsenegative result photopatch test seldom relevant systemic druginduced photosensitivity falsenegative photopatch test result attribute inability drug penetrate epidermis order enhance penetration test drug epidermis author propose breach cutaneous barrier perform prospective study compare photopatch photoscratch test fifteen patients present systemic druginduced photosensitivity prove favourable outcome discontinue drug test drug photopatch photoscratch test perform twothirds patients negative photopatch photoscratch test suspect drug photopatch photoscratch test positive relevant respectively patients photoscratch test induce falsepositive result due irritation confirm control subject study prove photoscratch test not change sensitivity phototesting',\n",
       " 'angiotensin convert enzyme ace inhibitors dihydropyridine calcium antagonists well establish widely use monotherapy patients mild moderate essential hypertension earlier study combine short act drug class require multiple dose associate poor compliance availability longer act compound allow daily administration avoid inconvenience multiple daily dose decide perform randomise double blind crossover study long act calcium channel blocker amlodipine long act ace inhibitor lisinopril give either alone combination essential hypertension twenty four patients diastolic blood pressure dbp mm hg receive amlodipine mg mg lisinopril mg mg combination per prior randomisation schedule supine stand blood pressure heart rate record weekly intervals higher dose drug individually combination use target supine dbp mm hg not achieve significant additional blood pressure lower effect combination compare either amlodipine lisinopril alone five mg amlodipine mg lisinopril monotherapy achieve target blood pressure patients respectively combination mg amlodipine mg lisinopril produce much significant lower blood pressure higher percentage patients individual low dose',\n",
       " 'report medical literature suggest effect blood pressure bp calcium channel blockers ccbs angiotensinconverting enzyme ace inhibitors additive report provide neither definition additive necessary information determine whether effect additive review medical literature effect combination therapy define additive sum mean reductions bp follow monotherapy ccb ace inhibitor not significantly different mean reduction bp combination therapy review generally show combination therapy effective treatment either monotherapy alone base mean decrease either diastolic systolic bp study provide no clear evidence effect combination therapy either additive less additive',\n",
       " 'patients age years older essential hypertension treat angiotensinconverting enzyme inhibitor acei delapril adecut longacting calcium ca antagonist manidipine calslot years incidences cardiovascular events well drugrelated side effect compare two group investigate whether class antihypertensive drug beneficial elderly hypertensive patients no significant differences characteristics patients two intervention group except slightly lower blood pressure p caantagonist group initiation study no significant differences total death two group cardiovascular events fatal nonfatal note patients patientyears acei group patients patientyears caantagonist group no significant difference find two group correlation cardiovascular incidence blood pressure attain treatment show jshaped phenomenon suggest excessive reduction less mm hg systolic blood pressure sbp unnecessary may harmful certain case side effect frequent acei group caantagonist group p cough major adverse event occur patients acei group conclusion study indicate acei delapril caantagonist manidipine equally beneficial reduce cardiovascular morbidity mortality elderly hypertensive patients however tolerability acei lower due adverse event cough',\n",
       " 'aim large randomize doubleblind parallelgroup study hypertensive women compare antihypertensive efficacy effect subjective symptoms quality life new angiotensin ii type receptor blocker candesartan cilexetil angiotensinconverting enzyme inhibitor enalapril diuretic hydrochlorothiazide hctz women age years seat diastolic blood pressure dbp mm hg randomize candesartan cilexetil mg n enalapril mg n hctz mg n weeks higher dose use dbp greater mm hg weeks candesartan cilexetil lower seat blood pressure mm hg weeks treatment respectively reduction greater p enalapril mm hg hctz mm hg proportion patients control dbp mm hg weeks treatment candesartan cilexetil enalapril hctz respectively patients experience less dry cough p candesartan cilexetil hctz enalapril no treatment differences find incidence dizziness quality life well maintain group compare candesartan cilexetil enalapril hctz increase uric acid decrease serum potassium p conclusion candesartan cilexetil reduce blood pressure effectively better tolerate enalapril hctz women mild moderate hypertension',\n",
       " 'use placebo clinical trials vigorously debate placebo control may useful disease state stage stage hypertension define sixth report joint national committee detection evaluation treatment high blood pressure jnc vi response rat placebo high close response rat effective therapies establish interventions significant adverse effect',\n",
       " 'mechanism angiotensinconverting enzyme inhibitors reduce mortality rat disease progression patients heart failure likely mediate part prevention adverse ventricular remodel study examine effect angiotensinconverting enzyme inhibitor captopril angiotensin ii type receptor antagonist losartan ventricular volumes function elderly patients heart failure reduce leave ventricular ejection fraction',\n",
       " 'hypertension constitute major cardiovascular risk factor high prevalence elderly reduce elevate blood pressure show significant benefit decrease incidence cardiovascular cerebrovascular disease patient population elderly patients likely comorbid disorder dyslipidaemia diabetes renal disease atherosclerosis males benign prostatic hyperplasia bph therefore choose antihypertensive agent elderly patients particularly important ensure treatment not exacerbate comorbid condition not interact deleteriously concurrent medication patient take alpha adrenoceptor antagonist doxazosin show effective welltolerated antihypertensive therapy elderly male patients not exacerbate case improve common disorder doxazosin show effective reduce symptoms bph elderly patients whose blood pressure well control concomitant antihypertensive medication addition improvements symptoms bph well reductions blood pressure observe elderly men mildtomoderate hypertension doxazosin show positive effect lipid profile glycaemic control make attractive choice therapy elderly patients hypertension diabetes dyslipidaemia addition doxazosin administer daily either morning even may aid compliance important consideration elderly',\n",
       " 'effective treatment hypertension extremely important consideration patients endstage renal disease esrd virtually drug class possible exception diuretics use treat hypertension patient esrd despite wide range treatment options drug interrupt reninangiotensin axis generally suggest agents choice population even though evidence support preferential use quite scanty ace inhibitors recently angiotensin antagonists drug class commonly employ alter reninangiotensin axis activity therefore produce blood pressure control ace inhibitor use patients esrd sometimes prove exact proposition ace inhibitors variably dialyse compound catopril enalapril lisinopril perindopril undergo substantial crossdialyser clearance standard dialysis session phenomenon make selection dose time administration ace inhibitor complex issue patients esrd furthermore ace inhibitors recognise range nonpressor effect pertinent patients esrd effect include ability decrease thirst drive decrease erythropoiesis addition ace inhibitors unique adverse effect profile case use patients without renal failure use ace inhibitors patients esrd accompany cough less frequently angioneurotic oedema esrd population ace inhibitor use also accompany socalled anaphylactoid dialyser reactions angiotensin antagonists similar ace inhibitors mechanism blood pressure lower angiotensin antagonists not dialysable therefore distinguish number ace inhibitors addition adverse effect profile angiotensin antagonists remarkably bland cough angioneurotic oedema rarely ever occur patients esrd angiotensin antagonists also not associate anaphylactoid dialyser reactions occur ace inhibitors nonpressor effect angiotensin antagonists influence thirst drive erythropoiesis not explore nearly depth ace inhibitors although ace inhibitors not compare directly angiotensin antagonists patients esrd angiotensin antagonists possess number pharmacokinetic adverse effect characteristics would favour use population',\n",
       " 'recent study show diabetic hypertensive patients administration angiotensinconverting enzyme ace inhibitors calcium antagonists effectively lower blood pressure bp prevent diabetesrelated cardiovascular complications no adverse metabolic effect seek assess antihypertensive metabolic effect new dihydropyridine calcium antagonist manidipine patients diabetes mellitus essential hypertension compare ace inhibitor enalapril e weeks placebo men age range years hypertensives type ii diabetes mellitus randomize mg e mg od weeks end placebo period activetreatment phase bp measure mercury sphygmomanometer office h ambulatory monitor abp record analyze obtain h day midnight night midnight average systolic diastolic bp heart rate hr value homogeneity antihypertensive effect h assess smoothness index [ si e ratio average hourly bp change treatment correspond standard deviation higher si uniform bp control treatment h ] sbp dbp significantly p similarly reduce mm hg n e mm hg n percentage patients whose dbp reduce mm hg e value indicate optimal dbp goal diabetic hypertensives similar e reduction h bp also similar n e n drug systolic mm hg diastolic ns vs e antihypertensive effect distribute similar homogeneous fashion throughout dose interval show similar si value sbp dbp e sbp dbp ns vs e hr unchanged either treatment markers glucose lipid metabolism renal function not significantly modify treatment e diabetic hypertensives effective metabolically neutral aceinhibitor e',\n",
       " 'study design assess antihypertensive effect combine angiotensinconverting enzyme ace inhibition angiotensin ii type receptor antagonism patients essential hypertension twenty patients uncontrolled ambulatory diastolic blood pressure bp weeks ace inhibitor monotherapy benazepril mg randomize receive doubleblind valsartan mg antagonist match placebo weeks continue receive background benazepril patients cross alternative regimen second week period h ambulatory bp monitor final day benazepril monotherapy period final day doubleblind treatment period valsartan add benazepril produce significant antihypertensive effect benefit placebo mm hg systolicdiastolic average awake ambulatory bp p mm hg asleep bp p mm hg average h ambulatory bp p pulse rate unaffected plasma active renin higher benazeprilvalsartan combination compare benazeprilplacebo p no change routine biochemical variables valsartan add benazepril six patients report mild dizziness fatigue three also placebo data suggest hypertensive patients uncontrolled ace inhibitor addition antagonist provide powerful safe antihypertensive drug combination',\n",
       " 'recommendation firstline therapy hypertension remain beta blocker diuretic give low dosage target blood pressure less mm hg achieve percent patients treat monotherapy two agents different pharmacologic class often need achieve adequate blood pressure control singledose combination antihypertension therapy important option combine efficacy blood pressure reduction low side effect profile convenient oncedaily dose enhance compliance combination antihypertensives include combine agents follow pharmacologic class diuretics potassiumsparing diuretics beta blockers diuretics angiotensinconverting enzyme ace inhibitors diuretics angiotensinii antagonists diuretics calcium channel blockers ace inhibitors',\n",
       " 'local pulse pressure pp independent determinant carotid artery wall thickness stronger mean blood pressure bp present study design assess whether betaadrenoceptor antagonistbased ace inhibitorbased treatment able reduce carotid artery wall hypertrophy reduction carotid pp rather lower mean bp whether influence local pp reduction could also detect site muscular artery radial artery',\n",
       " 'seek determine whether clinical effect early angiotensinconverting enzyme ace inhibitor acei treatment acute myocardial infarction mi influence concomitant use aspirin asa',\n",
       " 'octapeptide angiotensin ii major effector reninangiotensinaldosterone system angiotensin ii cause variety potentially noxious biological effect vasoconstriction rise blood pressure release aldosterone enhancement effect catecholamines vascular myocardial hypertrophy include remodel heart myocardial infarction noxious effect angiotensin ii mediate angiotensin ii receptors receptors subtype functional effect receptors characterize mean biochemical techniques far not clearly identify stimulation receptor mean angiotensin ii assume counteract vascularmyocardial remodel possibly induce vasodilation accordingly receptors believe provoke opposite effect draw attention fetal tissue contain high density receptors lower significantly birth identification analysis receptors greatly stimulate development nonpeptidergic receptor antagonists losartan prototype far unclear whether receptors activate hypertensive disease survey make hemodynamic effect receptor antagonists interaction receptors probably important role sympathetic nervous system involve antihypertensive action receptor antagonists',\n",
       " 'angiotensinconverting enzyme ace inhibitors increasingly use firstline therapy hypertension type diabetes mellitus widely believe improve insulin sensitivity however evidence latter effect not stand close scrutiny assess effect ace inhibitor trandolapril patients mean sd age yr mildtomoderate essential hypertension initial blood pressure mm hg obesity body mass index kgm impair glucose intolerance n type diabetes n doubleblind placebocontrolled crossover design patients undergo three h euglycemic hyperinsulinemic clamp study soluble insulin mukg x min week placebo runin end two week periods treatment mg trandolapril placebo week washout mean sd not change trandolapril placebo runin mgkg x min placebo mgkg x min trandolapril mgkg x min p confidence intervals trandolapril vs placebo power exclude increase conclusion trandolapril no clinically relevant effect patients hypertension type diabetes previous report improve ace inhibitor treatment may attributable suboptimal study design andor use surrogate measure',\n",
       " 'ramipril efficacy nephropathy rein study find angiotensinconverting enzyme ace inhibitors effectively decrease proteinuria glomerular filtration rate gfr decline deltagfr incidence endstage renal disease esrd patients proteinuric chronic nephropathies study prospectively investigate main clinical determinants progression response treatment patients enrol rein study mean deltagfr [ sem ] versus mlmin mo p incidence esrd p twice patients proteinuria g h greater protein compare protein less g h relative risk [ rr ] confidence interval [ ci ] well patients hypertension compare normotension mean deltagfr versus mlmin mon p esrd versus p rr ci hypertension study entry p greater mean blood pressure followup p urinary protein excretion rate p independent predictors faster deltagfr deltagfr approximately twofold faster patients type diabetes primary glomerular disease p include immunoglobulin [ iga ] nephropathy p nephrosclerosis p adult polycystic kidney disease apkd chronic interstitial nephritis p diabetes study entry p greater mean blood pressure p urinary protein excretion rate p followup independent predictors faster deltagfr correction baseline covariates diabetes also associate increase risk progression esrd rr ci p multivariate analyse ramipril significantly decrease deltagfr regression coefficient [ sem ] p esrd rr ci p patients baseline proteinuria g h greater protein renoprotective effect increase increase level proteinuria ramipril decrease deltagfr similar extent normotensive hypertensive patients versus significantly limit esrd hypertensive patients rr ci p deltagfr decrease primary glomerular disease p iga nephropathy nephrosclerosis not improve type diabetes apkd interstitial nephritis multivariate analyse ramipril significantly slow deltagfr p progression esrd rr ci p patients without diabetes not patients diabetes tend faster deltagfr ramipril therapy summary patients proteinuria g h greater protein preexist hypertension type diabetes faster progressors greater blood pressure degree proteinuria strongest determinants faster gfr decline renoprotective effect ramipril similar patients normotension hypertension hypertensive patients proteinuria g h greater protein primary glomerular disease nephrosclerosis gain ace inhibitor treatment study period proteinuria less g h protein type diabetes polycystic kidney disease not benefit treatment appreciable extent',\n",
       " 'prevalence hypertension extremely high endstage renal disease probable contributor epidemic cardiovascular disease endstage renal disease however paucity prospective randomize clinical trials make difficult precisely define treatment strategies therefore present time guidelines develop national kidney foundation cardiovascular disease task force follow',\n",
       " 'earlier large multicentre trials hypertensive patients address question whether mild moderate hypertension treat whether similar approach would effective elderly hypertensive patients isolate systolic hypertension research focus recent trials shift rather whether patients treat trials hypertension optimal treatment study attempt discern optimal target longterm blood pressure control although unsuccessful primary aim establish safety aggressive blood pressure lower diastolic target less mmhg well safety efficacy calcium entry blocker first line antihypertensive approach captopril prevention project study swedish trial old patients hypertension trial focus whether might specific antiatherosclerotic advantage newer agents angiotensin convert enzyme inhibitors calcium entry blockers conventional therapy comparison study beta blockers diuretics similar efficacy cardiovascular outcomes appear emerge major class drug degree blood pressure lower prime importance cardiovascular disease prevention',\n",
       " 'ace inhibitor lisinopril lysine derivative enalaprilat active metabolite enalapril patients heart failure maximum pharmacodynamic effect produce hours administration drug persist hours high dose mg administer daily lisinopril assessment treatment lisinopril survival atlas study demonstrate clinically important advantage low dose mg administer daily drug treatment congestive heart failure high dose lisinopril effective low dose reduce risk major clinical events patients heart failure treat months compare recipients low dose receive high dose lisinopril lower risk allcause mortality p lower risk death hospitalisation reason p fewer hospitalisations heart failure p benefit associate significant cost save short term generally weeks duration randomise doubleblind parallelgroup multicentre clinical trials lisinopril significantly effective placebo least effective captopril enalapril digoxin irbesartan improve symptomatic endpoints clinical status patients heart failure lisinopril generally well tolerate patients heart failure control clinical trials common adverse events occur recipients drug dizziness headache hypotension diarrhoea overall adverse event profile patients treat high low dose lisinopril atlas study similar however high dose lisinopril use atlas study associate higher incidence adverse events importantly hypotension worsen renal function nevertheless events generally well manage alter dose lisinopril concomitant medications furthermore despite higher incidence adverse events high dose lisinopril frequency treatment discontinuations adverse events high low dose group',\n",
       " 'study carry evaluate influence antihypertensive treatment combine low dose enalapril plus isradipine mg daily compare either drug higher dose level mg daily doubleblind threeway crossover study balance latin square design subject mean age years essential hypertension leave ventricular mass function evaluate mb mode echocardiography renal function glomerular filtration rate gfr serum h urinary na k washout period weeks treatment',\n",
       " 'evaluate clinical efficacy safety new antihypertensive drug combination trandolaprilverapamil compare monotherapy verapamil trandolapril patients mild moderate primary hypertension',\n",
       " 'study cognition prognosis elderly scope multicentre prospective randomize doubleblind parallelgroup study primary objective scope assess effect angiotensin ii type receptor blocker candesartan cilexetil mg daily major cardiovascular events elderly patients years age mild hypertension dbp andor sbp mmhg secondary objectives study test hypothesis antihypertensive therapy prevent cognitive decline measure mini mental state examination mmse dementia assess effect therapy total mortality myocardial infarction mi stroke renal function hospitalization total patients participate countries recruit randomization phase scope exceed target population mean age patients enrolment years ratio male female patients approximately patients already treat antihypertensive agent enrolment majority patients educate least primary school level randomization mean sit blood pressure value sbp mmhg dbp mmhg mean mmse score previous cardiovascular disease study population include myocardial infarction stroke atrial fibrillation men often women history previous mi stroke atrial fibrillation greater percentage men smokers vs women attend university vs women randomize patients years age age group smoke less common vs yearolds fewer attend university vs yearolds incidence mi similar age group however stroke atrial fibrillation occur approximately twice frequently older patients patients mean age baseline similar participate countries countries show approximate ratio male female patients also little intercountry variation term mean sbp dbp mmse score however considerable regional variation percentage patients therapy prior enrolment',\n",
       " 'efficacy aceinhibitor therapy well document treatment chronic heart failure pharmacological mechanisms aceinhibition angiotensin ii atreceptorantagonists differ additional positive effect concern leave ventricular function expect combine class drug',\n",
       " 'great deal research demonstrate benefit treat patients chronic heart failure angiotensin convert enzyme ace inhibitors rather less research actual uptake treatment general practice particular methods might improve uptake',\n",
       " 'summary report presentation make american college cardiology th scientific sessions anaheim march study particular interest heart failure physicians review optimechf outcomes prospective trial intravenous milrinone exacerbations chronic heart failure optimechf randomisedcontrolled trial compare h infusion milrinone standard therapy patients recruit year period patients exclude investigator believe clinical condition mandate inotropic therapy patients randomise within h admission acute exacerbation chronic heart failure receive milrinone placebo infision h patients diabetics receive angiotensin convert enzyme inhibitor already betablocker atrial fibrillation no significant difference two group length hospital stay index admission subsequent readmissions days hospital follow days subjective clinical assessment score also no different average admission rate next year one per patient group however significant increase incidence sustain hypotension milrinone group account increase adverse event rat active therapy day mortality group previous trials oral formulation milrinone clearly demonstrate lack benefit milrinone either acute exacerbations stable severe chronic heart failure [ packer carver jr rodeheffer rj et al effect oral milrinone mortality severe chronic heart failure n engl j med ] medium size study milrinone patients milder severities heart failure also suggest adverse impact prognosis presence absence digoxin [ dibianco r shabetai r kostuk w moran j schlant rc wright r comparison oral milrinone digoxin combination treatment patients chronic heart failure n engl j med ] whether milrinone even role management haemodyamic crisis require inotropic therapy must also question',\n",
       " 'assess prevalence renal artery stenosis ras subject type diabetes coexistent hypertension use magnetic resonance angiography mra renal arteries assess clinical biochemical predictors ras assess hemodynamic significance ras use captopril test measure response plasma renin activity single oral dose captopril',\n",
       " 'investigate influence insertiondeletion polymorphism ace gene progression early diabetic glomerulopathy patients without antihypertensive treatment aht',\n",
       " 'antihypertensive lipidlowering treatment prevent heart attack trial allhat large randomize doubleblind study compare four antihypertensive agents chlorthalidone doxazosin amlodipine lisinopril hypertensive patients older years doxazosin arm terminate early trial safety monitor board note twofold higher incidence congestive heart failure patients receive doxazosin receive chlorthalidone vs years p',\n",
       " 'enalapril longacting inhibitor angiotensinconverting enzyme give years seven children alport syndrome five patients classical xlinked form disease two siblings autosomal recessive variant age years enalapril start patients haematuria proteinuria creatinine clearance mlmin per one patient hypertensive start dose enalapril mgkg body weight per day increase progressively accord individual clinical tolerance median dose mgkg months respectively median value mean blood pressure mmhg start mmhg months median daily proteinuria decrease mgkg mgkg months mgkg months mgkg months mgkg months serum creatinine increase time median mgdl baseline mgdl months concomitantly decrease gfr mlmin per months increase mlmin per months analysis individual data show three pattern no response n temporary response n sustain response n',\n",
       " 'clinical proteinuria risk factor endstage renal disease cardiovascular disease prevalence clinical proteinuria correlate predictive value effect ace inhibitors prevent clinical proteinuria diabetic nondiabetic patients leave ventricular lv dysfunction unknown',\n",
       " 'antihypertensive medication dose typically increase within several weeks initiation therapy inadequate blood pressure bp control andor adverse effect',\n",
       " 'fluoroquinolones generally well tolerate clinically useful antimicrobials paper highlight rare potentially serious adverse effect involve kidney antimicrobials long know cause various form nephrotoxicity occur allergic interstitial nephritis granulomatous interstitial nephritis necrotising vasculitis allergic tubular nephritis tubular necrosis medline search may ciprofloxacin norfloxacin levofloxacin ofloxacin trovafloxacin enoxacin sparfloxacin grepafloxacin gatifloxacin clinafloxacin moxifloxacin conduct ascertain incidence feature fluoroquinolone nephrotoxicity unfortunately data primarily consist case report temporally relate events incidence adverse effect hard estimate cause may multifactorial use ciprofloxacin appear increase risk may due longer widespread use compare newer agents',\n",
       " 'objective randomise open active control crossover study evaluate effect fix combination verapamil srtrandolapril compare captoprilhydrochlorothiazide serum lipids lipoproteins metabolic electrolyte parameters patients essential hypertension another objective assess efficacy safety combinations one hundred hypertensives systolic blood pressure mm hg diastolic blood pressure mm hg evaluate weeks receive fix combination verapamil sr mg trandolapril mg vt captopril mghydro chlorothiazide mg ch give daily lipids lipoproteins assess duplicate consecutive days study complete patients no statistically significant difference two combine regimens respect lowdensity lipoprotein ldl cholesterol intentiontotreat population measure end treatment period mmoll vt mmoll ch no differences find lipid parameters like total cholesterol triglycerides apolipoproteins b lp highdensity lipoprotein hdl cholesterol significantly higher vt vs p serum potassium decline uric acid glucose increase ch conclusion no significant differences find ldlcholesterol lipid parameters exception hdlcholesterol significantly higher vt serum potassium decline uric acid glucose increase ch significantly fix combinations well tolerate incidence adverse events higher ch fix combinations significantly lower bp journal human hypertension',\n",
       " 'blood pressure bp find vary examiners example often higher measure physician nurse whether location physicianmeasured bp also source variation however not study hence find interest find location use examination significance',\n",
       " 'negatively charge membrane know evoke anaphylactoid reactions without concomitant ace inhibition underlie reason mainly induction bradykinin release due negatively charge membrane reduce degradation bradykinin due ace inhibition complication report repeatedly anaphylactoid reactions still occur clinical practice recently treat two patients suffer anaphylactoid reactions extracorporal therapy membrane simultaneous ace inhibition first incident occur patient hemodialysis second patient continuous venovenous hemofiltration anaphylactoid reaction induce membrane continuous extracorporal treatment combination ace inhibition not report far report intend serve reminder potentially lethal combination membranes ace inhibitor treatment avoid',\n",
       " 'study use hour ambulatory blood pressure bp monitor author assess potential bp control use hydrochlorothiazide hctz mg daily give monotherapy months black south african patients mild moderate hypertension mean day diastolic blood pressure [ dbp ] mmhg uncontrolled patients receive fix combination quinaprilhctz mg dose titration monthly intervals bp control not achieve day dbp mmhg overall profound sustain bp reduction observe end study hour bp decrease mmhg p end study vs baseline mean day bp decrease mmhg p end study vs baseline overall control mean day dbp mmhg response decrease day dbp mmhg rat respectively end study patients remain treatment hctz initial patients control hctz months patients remain control months patient months contrast quinaprilhctz combinations maintain antihypertensive effect months significant number patients require highest dose combination mg daily conclusion lowdose hctz not recommend monotherapy black patients mild moderate hypertension due fact bplowering effect attenuate already months treatment patients require addition ace inhibitor',\n",
       " 'compare effect enalapril longacting nifedipine orthostatic hypotension older patients',\n",
       " 'assess whether ace inhibitors superior alternative agents prevention cardiovascular events patients hypertension type diabetes',\n",
       " 'study examine whether longterm therapy angiotensinconverting enzyme ace inhibitor reduce excessive increase leave ventricular lv mass well volume grow children aortic regurgitation mitral regurgitation',\n",
       " 'describe result systematic treatment program modify renal cardiovascular disease aboriginal community whose rat renal failure cardiovascular deaths among highest australia',\n",
       " 'hypertension lead chronic disease south africa significant mortality result condition stroke ischaemic heart disease hypertension play major role objective study evaluate evidence clinically effective costeffective treatment hypertension give clinician decide administer receptor blocker',\n",
       " 'angiotensin ii atii receptor antagonists review research focus block reninangiotensin system ras lead discovery angiotensinconvertingenzyme ace inhibitors effective treatment hypertension associate high frequency cough adverse effect atiireceptor antagonists develop agents would completely block ras thus decrease adverse effect see ace inhibitors atiireceptor antagonists include losartan valsartan irbesartan candesartan eprosartan telmisartan tasosartan several clinical trials demonstrate atiireceptor antagonists effective calciumchannel blockers betablockers ace inhibitors treatment hypertension induce fewer adverse effect adverse effect atiireceptor antagonists dizziness headache upperrespiratorytract infection cough gastrointestinal disturbances occur rate placebo [ correct ] available atiireceptor antagonists seem equally effective reduce systolic diastolic blood pressure comparable cost currently atiireceptor antagonists use either monotherapy patients not tolerate ace inhibitors combination antihypertensive agents angiotensin iireceptor antagonists well tolerate effective ace inhibitors decrease blood pressure',\n",
       " 'previously report hyperglycemia healthy human subject increase renal vasodilator response angiotensinconverting enzyme inhibitor captopril observation raise intrigue possibilities relevant pathogenesis nephropathy patients diabetes mellitus ascertain whether effect captopril indeed mediate reduction angiotensin ii ang ii formation perform another study ang ii antagonist eprosartan use place captopril nine healthy subject study high sodium balance ie sodium intake mmold first day subject receive mg eprosartan orally renal plasma flow rpf glomerular filtration rate gfr measure glucose infuse intravenously second third study days increase plasma glucose level threshold glycosuria approximately mmoll eprosartan dose mg placebo administer randomly second third study day hour initiation glucose infusion rpf increase ml min p response sustain moderate hyperglycemia increase ml min p eprosartan administer hyperglycemia eprosartan conversely not affect rpf gfr normoglycemic subject gfr not affect either hyperglycemia eprosartan neither plasma renin activity plasma ang ii concentration change hyperglycemia suggest hormonal responses responsible enhance renal vasodilator response eprosartan occur within kidney enhancement renal vasodilator effect eprosartan hyperglycemia consistent activation intrarenal reninangiotensin system',\n",
       " 'compare regression leave ventricular hypertrophy patients moderate hypertension treat enalapril losartan combination two drug lower dose',\n",
       " 'heart failure symptom complex vary etiology associate substantial mortality approximately million americans disease new case diagnose year despite better understand pathophysiology therapeutic options remain suboptimal syndrome remain associate high rat hospitalization loss economic productivity management traditionally include vasodilators diuretics digoxin focus control symptoms improve ejection fraction exercise capacity drug therapy focus improve survival reduction health care cost relate hospitalizations drug prove benefit reduce morbidity mortality angiotensinconverting enzyme inhibitors betablockers combination hydralazine plus nitrate diuretics digoxin dihydropyridine calcium channel blockers phosphodiesterase inhibitors catecholamine infusions amiodarone leave ventricular assist devices transplantation also options',\n",
       " 'investigate whether prevention remodel would translate stable electrophysiological profile investigators randomize patients treatment angiotensinconverting enzyme ace inhibition placebo months myocardial infarction program electrical stimulation reveal no significant differences inducibility monomorphic sustain ventricular tachycardia vt whereas ventricular fibrillation vf tend lower aceinhibitor group effective refractory periods consistently longer dispersion refractoriness significantly shorter aceinhibitor group investigators conclude small patient group ace inhibition may mildly add stable electrophysiological profile',\n",
       " 'objective compare three different methods blood pressure measurement result control study aim compare antihypertensive effect trandolapril losartan two hundred twentynine hypertensive patients randomize doubleblind parallel group study week placebo period receive either mg trandolapril mg losartan daily weeks end placebo active treatment periods three methods blood pressure measurement use office blood pressure three consecutive measurements b home self blood pressure measurements sbpm consist three consecutive measurements perform home morning even consecutive days c ambulatory blood pressure measurements abpm h bp record three measurements per hour patients perform least valid sbpm measurements placebo treatment periods whereas perform good quality h abpm record periods p one hundredforty patients perform three methods measurement well baseline treatment agreement office measurements abpm sbpm weak conversely good agreement abpm sbpm mean difference sbpdbp abpm sbpm baseline end treatment period correlation sbpm abpm express r coefficient p value follow baseline active treatment hourly h reproducibility blood pressure response quantify standard deviation bp response compare office blood pressure global hourly sbpm responses exhibit lower standard deviation hourly reproducibility sbpm response mm hg mm hg lower hourly reproducibility abpm response mm hg mm hg conclusion sbpm easier perform abpm good agreement two methods whereas concordance sbpm abpm office measurements weak hourly reproducibility sbpm response better reproducibility hourly abpm office bp response sbpm seem appropriate method evaluate residual antihypertensive effect',\n",
       " 'approximately patients heal myocardial infarction develop asymptomatic progressive leave ventricular lv dilation remodel increase risk progression symptomatic congestive heart failure premature death goal study test whether quinapril may interrupt process analyze potential mechanisms patients average infarct age months asymptomatic progressive lv dilation randomize prospective doubleblind study placebo quinapril baseline mean sem ejection fraction reduce enddiastolic volume gate singlephoton emission compute tomography increase mlm placebo n quinapril n respectively progressive dilation continue patients take placebo months mlm months mlm change baseline p vs baseline p vs months not quinapril months mlm months mlm [ p ] vs placebo wedge pressure bicycle exercise similar baseline months tend lower quinapril mm hg placebo mm hg p thus quinapril prevent progression asymptomatic lv dilation remodel remote myocardial infarction possibly due attenuation exerciseinduced increase lv fill pressure',\n",
       " 'noninsulindependent diabetes hypertension microalbuminuria proteinuria cardiovascular events ramipril diabhycar study randomize prospective doubleblind placebocontrolled multicenter international trial ace inhibitor ramipril mgday patients type ii diabetes micro macroalbuminuria main outcome study time first occurrence either death cardiovascular origin include sudden death nonfatal myocardial infarction stroke congestive heart failure requirement hemodialysis renal transplantation study launch france early participation general practitioners extend countries due difficulties recruitment since years begin trial observe event rate much less anticipate decide increase recruitment followup duration include congestive heart failure definition main outcome keep study power satisfactory level recruitment end april randomize patients follow early discontinuation efficacy another study ramipril high cardiovascular risk patients heart outcomes prevention evaluation study hope second interim analysis diabhycar perform early instead patients present main outcome data safety monitor board recommend study continue followup plan end march',\n",
       " 'longterm effect angiotensinconverting enzyme inhibitors angiotensin ii receptor blockers ambulatory blood pressure cardiac performance never examine comparatively',\n",
       " 'efficacy tolerability losartan mghydrochlorothiazide hctz mg enalapril mghctz mg compare doubleblind randomize trial hypertensive patients inadequately control experience side effect prior therapy patients moderate severe hypertension currently treat least two singleagent drug exclude angiotensinconverting enzyme inhibitors sit diastolic blood pressure dbp mm hg least one undesirable drugrelated symptom randomize oncedaily treatment one combinations weeks losartanhctz lower sit dbp prior therapy baseline mm hg sit systolic blood pressure mm hg similar reductions occur enalaprilhctz trough sit dbp reduce normal level mm hg patients switch losartan combination treat enalapril combination combination associate improve tolerability compare prior therapy although fewer patients report undesirable symptoms weeks losartanhctz improvement prior therapy occurrence cough significantly greater losartanhctz p enalaprilhctz not losartanhctz increase serum uric acid level week conclusion combination losartan mghctz mg offer beneficial therapeutic option patients history moderate severe hypertension whose blood pressure not adequately control exhibit side effect two singleagent antihypertensive drug population switch prior antihypertensive therapies daily losartan mghctz mg improve blood pressure control reduce side effect',\n",
       " 'objectives study compare effect angiotensin ii receptor blocker losartan angiotensinconverting enzyme inhibitor enalapril albuminuria renal function relationship clinic ambulatory blood pressure abp hypertensive type diabetic subject early nephropathy tolerability agents effect metabolic profile also evaluate',\n",
       " 'cardiac complications main cause death renal transplantation rt leave ventricular hypertrophy lvh may play important role patients unfavorable genotype angiotensinconverting enzyme ace gene associate cardiovascular disease include lvh ace inhibitors aceis reduce lvh little know effect aceis lvh rt patients different insertiondeletion id genotypes ace gene',\n",
       " 'usefulness ambulatory blood pressure monitor abpm vs casual blood pressure measurement physicians practice pm routine management patients hypertension concern total mortality morbidity compare prospective randomise open multicentre study year followup study perform general practitioners offices germany total patients essential hypertension include cardio cerebrovascular events total mortalitymorbidity drugsaving effect hypertensives treat accord two different methods blood pressure measurement primary secondary endpoints study total patients group abpm n group pm n prematurely discontinue study reason discontinuation patients group group reach main endpoint total mortalitymorbidity cardio cerebrovascular events study difference statistically significant p favour group cardio cerebrovascular events also occur lower number patients n group compare group n difference however not significant p difference direct drugsaving effect could not observe two group initially screen patients detect abpm white coat hypertension thus patients not receive antihypertensive treatment',\n",
       " 'since pharmacotherapy portal hypertension always subject wide interest decide study effect different angiotensinconverting enzyme inhibitors endoscopic sclerotherapy portal hemodynamics patients portal hypertension bleed esophageal varices',\n",
       " 'effect see clinical trials may not translate actual practice situations examine persistence blood pressure effect months clinical trial treatment hypotensive agents',\n",
       " 'eprosartan potent selective angiotensin ii subtype receptor antagonist result large n randomise doubleblind study patients mild moderate severe hypertension demonstrate antihypertensive efficacy eprosartan usually mgday single daily dose divide dose significantly greater placebo least good enalapril placebocontrolled trials eprosartan achieve mean reductions baseline trough sit systolic blood pressure mm hg diastolic blood pressure mm hg response rat associate daily administration eprosartan mg approximately double placebo overall eprosartan well tolerate similar tolerability profile placebo comparative trials incidence persistent dry cough evaluate primary endpoint enalapril severalfold likely induce adverse event eprosartan difference statistically significant regardless study population definition cough conclusion angiotensin ii receptor antagonist eprosartan well tolerate effective antihypertensive agent administer twice daily without regard meals eprosartan low potential serious adverse events drug not associate clinically significant drug interactions unlike ace inhibitors enalapril eprosartan not high propensity cause persistent nonproductive cough thus eprosartan represent useful therapeutic option management patients hypertension',\n",
       " 'sudden unexpected death frequently occur chronic heart failure importance acute coronary events trigger sudden death sd unclear',\n",
       " 'primary objective study investigate effect angiotensinconverting enzyme ace inhibitor ramipril carotid atherosclerosis patients coronary cerebrovascular peripheral vascular disease',\n",
       " 'selfmatched control study aim compare efficiency two different regimens active treatment aspirin low mg daily versus intermediate mg daily dose abolish angiotensinconverting enzyme inhibitor acei induced cough dry bothersome cough common adverse class effect angiotensinconverting enzyme inhibitors prostaglandins pg pinpoint play lead role genesis aceiassociated cough role different dose commonly use pg inhibitoraspirinin acei cough modification not yet elucidate consecutive aceitreated patients identify nonsmoking aceirelated coughers patients lung disease nonsteroidal antiinflammatory drug nsaid treatment not agree participate study exclude remain acei coughers eight men six women mean age years treatment discontinue dry cough completely disappear return patients within week acei reintroduction end rechallenge period patients start low dose aspirin week switch thereafter intermediate dose aspirin additional week visit cough severity cs frequency cf score register low dose aspirin ineffective suppress aceiinduced cough whereas intermediate dose completely abolish cough five patients reduce cough one patient cs cf decrease respectively p p overall intermediate dose aspirin beneficially modify cough score patients enable nine continue acei treatment aspirin not influence blood pressure control either hypertensives postinfarction patients conclude intermediate not low dose aspirin probably suppress aceiinduced cough find propose new alternative therapeutic approach patients aceirelated cough especially acei treatment seem essential',\n",
       " 'prevalence chronic heart failure chf rise increase age years age years age major cause morbidity mortality older people recent european guidelines point major deficiency knowledge treat diastolic chronic heart failure lack information treatment heart failure elderly general',\n",
       " 'serial echocardiographic investigations carry patients idiopathic dilate cardiomyopathy evaluate treatment effect leave ventricular lv performance therapy either metoprolol captopril thirtytwo patients males females mild moderate symptoms heart failure nyha iiiii mean age years include investigation patients investigate doppler echocardiography treatment months treatment either metoprolol captopril month withdrawal treatment intra interinvestigator reproducibility acceptable coefficient variation less lv dimension reduction lv dimension see treatment group metoprolol group also increase lv stroke volume fractional shorten noninvasive data accordance invasive measurements stroke volume lv fill pressure patients idiopathic dilate cardiomyopathy mild moderate symptoms heart failure echocardiography seem sufficiently reproducible use determination treatment effect longitudinal heart failure study metoprolol captopril well tolerate favourable effect lv performance',\n",
       " 'receptor antagonists differ angiotensin convert enzyme inhibitors achieve complete blockade angiotensin ii action not affect bradykinin metabolism little information whether cause clinically significant differences haemodynamics neurohormones exercise tolerance heart failure',\n",
       " 'compare effect exercise capacity neutral endopeptidase inhibitor candoxatril angiotensin convert enzyme inhibitor captopril patients mild moderate heart failure',\n",
       " 'beneficial effect ace inhibitors mortality establish series trials however clinical practice ace inhibitors commonly administer dose much lower show effective landmark trials',\n",
       " 'firstdose hypotension refer observe reduction blood pressure administration first dose ace inhibitors patients congestive heart failure',\n",
       " 'early sign renal dysfunction glycogen storage disease type ia gsd ia glomerular hyperfiltration proteinuria nonrandomized study effect captopril improvement proteinuria gsd ia patients microalbuminuria investigate positive effect show insulindependent diabetes mellitus patients microalbuminuria define albumincreatinine ratio mgmmol spot urine nineteen patients microalbuminuria patients receive captopril dose mgkg per day microalbuminuria evaluate periodically followup period captopriltreated patients one lose followup remain patients urinary albumin excretion normalize patients decrease least another patients months treatment one patient oldest not benefit untreated patients two patients decrease microalbuminuria patients microalbuminuria significantly higher blood lactate p plasma triglyceride p concentrations significantly lower blood bicarbonate concentration p patients without additionally patients microalbuminuria diagnose earlier without microalbuminuria p patients microalbuminuria severe clinical laboratory find without microalbuminuria captopril dose mgkg per day seem effective least gsd ia patients microalbuminuria',\n",
       " 'hypertensive heart disease no data available repair coronary resistance vessels patients longterm ace inhibitor treatment fourteen patients essential hypertension study coronary flow reserve transvenous endomyocardial biopsy months antihypertensive treatment perindopril mgd mean mgd leave ventricular muscle mass index decrease gm p maximal coronary blood flow increase ml min g p minimal coronary vascular resistance diminish mm hg min g ml p consequently coronary reserve increase p structural analysis reveal regression periarteriolar collagen area microm p total interstitial collagen volume density vv vv p whereas arteriolar wall area slightly not significantly reduce longterm therapy ace inhibitor perindopril induce structural repair coronary arterioles mainly characterize regression periarteriolar fibrosis associate mark improvement coronary reserve find indicate beneficial reparative effect ace inhibition coronary microcirculation hypertensive heart disease',\n",
       " 'additive hemodynamic effect combine blockade reninangiotensin system angiotensin convert enzyme inhibitor angiotensin ii antagonist observe sodiumdepleted normotensive volunteer patients congestive heart failure',\n",
       " 'importance criterion quality life qol compliance antihypertensive drug lead us study qol hypertensives receive mg new formulation prazosin sustain release compare subject treat convert enzyme inhibitor enalapril mg doubleblind randomize trial qol assess mean item selfadministered questionnaire improve significantly prazosin weeks trial intention treat analysis global score qol increase p covariance analysis show improvement obtain early th week similar favourable evolution observe anxiety retardation anhedonia components compute questionnaire no significant difference qol evolution find prazosin enalapril treatments prove equivalent respect efficacy bloodpressure value tolerance estimate number dropouts sideeffects result confirm benefit qol hypertensive patients new formulation prazosin',\n",
       " 'block formation angiotensin ii convert enzyme inhibitors establish intervention kidney disease advent antagonists angiotensin ii receptor increase options inhibit reninangiotensinaldosterone system adults angiotensin ii antagonists antihypertensive antiproteinuric effect similar convert enzyme inhibitors adverse effect profile similar placebo children no information available angiotensin ii antagonists total children age years chronic kidney disease receive angiotensin ii antagonist irbesartan give daily hypertension n overt proteinuria n n last followup months start irbesartan median dosage mgkg body weight daily arterial pressure significantly reduce systolic value [ ] diastolic value [ ] mmhg median interquartile range nine patients proteinuria urinary albumincreatinine ratio significantly decrease [ ] mgmmol frequency report adverse events similar irbesartan',\n",
       " 'aim assess patients congestive heart failure whether dual inhibition neutral endopeptidase angiotensinconverting enzyme ace vasopeptidase inhibitor omapatrilat better ace inhibition alone lisinopril functional capacity clinical outcome',\n",
       " 'efficacy antihypertensive drug newer diuretics betablockers not establish compare effect calciumchannel blocker nifedipine daily diuretic combination coamilozide cardiovascular mortality morbidity highrisk patients hypertension',\n",
       " 'goal present study assess effect antihypertensive therapy clinic cbp ambulatory abp blood pressure ecg voltages incidence stroke cardiovascular events older patients sustain nonsustained systolic hypertension',\n",
       " 'study describe rationale design baseline characteristics trial determine whether treatment fosinopril mgday andor pravastatin mg day prevent cardiovascular renal disease nonhypertensive rr mm hg not use antihypertensive medication nonhypercholesterolemic total cholesterol mmoll case previous myocardial infarction not use lipid lower medication men women persistent microalbuminuria urinary albumin excretion mgl early morning spot urine mghour least two hour urine collections prevention renal vascular endstage disease intervention trial singlecenter doubleblind randomize placebocontrolled trial x factorial design randomize subject monitor minimum years maximum years primary efficacy parameter define combine incidence allcause mortality hospital admission document nonfatal myocardial infarction myocardial ischemia heart failure peripheral vascular disease cerebrovascular accident andor endstage renal disease',\n",
       " 'unlike angiotensin convert enzyme inhibitors acei longterm study show calcium antagonists retard progression renal dysfunction aim prospectively compare effect amlodipine acei enalapril renal function hypertensive patients renal impairment due chronic glomerulonephritis essential hypertension total hypertensive patients serum creatinine cr mgdl randomly allocate treatment either drug year period patients treat acei drop due adverse events whereas patients amlodipine drop data patients available analysis year followup reductions blood pressure comparable amlodipine mm hg acei group serum cr increase sd mgdl amlodipine n difference equivalent acei n creatinine clearance ccr moderate dysfunction group basal cr mgdl change mlmin not significant amlodipine change similar note acei annual decline ccr amlodipine mlminyear acei mlminyear comparable tend smaller annual decline glomerular filtration rate report modification diet renal disease study mlminyear serum potassium increase significantly p meql acei group year prospective study demonstrate effect amlodipine renal function likely acei furthermore amlodipine better tolerate acei hypertensive patients renal dysfunction',\n",
       " 'multicenter study evaluate efficacy candesartan cilexetil angiotensin ii type receptor antagonist use alone combination amlodipine combination amlodipine hydrochlorothiazide treatment patients moderatetosevere essential hypertension week singleblind placebo runin period patients enter week openlabel dosetitration period candesartan cilexetil dose increase mg daily amlodipine mg daily hydrochlorothiazide mg daily additional medication also add sequentially necessary patients enter final week parallelgroup doubleblind randomize placebocontrolled withdrawal period candesartan alone total patients recruit week runin period placebo tablets mean sit blood pressure bp mm hg end week dosetitrationmaintenance period mean sit bp fell mm hg patients randomize placebo candesartan withdraw highly significant increase mean systolicdiastolic bp mm hg compare patients continue candesartan ancova p conclusion candesartan cilexetil effective bplowering drug use alone combination amlodipine amlodipine plus hydrochlorothiazide treatment moderatetosevere essential hypertension drug well tolerate throughout investigation period',\n",
       " 'nsaids know attenuate effect antihypertensive medications not know whether new class angiotensin ii receptor antagonists similarly affect conduct multicenter study assess effect indomethacin antihypertensive effect losartan captopril weeks placebo washout hypertensive patients receive weeks active antihypertensive therapy either mg losartan daily n mg captopril twice daily week increase mg twice daily weeks n follow week concomitant therapy indomethacin mg daily primary outcome measure change mean hour ambulatory diastolic blood pressure addition indomethacin captopril losartan significantly lower ambulatory diastolic blood pressure losartan mm hg p captopril mm hg p weeks therapy indomethacin significantly attenuate hour ambulatory diastolic blood pressure losartan mm hg p captopril mm hg p also attenuate effect captopril trough sit diastolic blood pressure change daytime diastolic blood pressure pm similar hour response group nighttime diastolic blood pressure pm significantly attenuate captopriltreated patients mm hg p losartan unaffected mm hg thus concurrent treatment indomethacin similarly attenuate hour antihypertensive response losartan captopril',\n",
       " 'local pulse pressure pp independent determinant carotid artery wall thickness stronger mean bp present study design assess whether betaadrenoceptor antagonist ace inhibitorbased treatment able reduce carotid artery wall hypertrophy reduction carotid pp rather lower mean bp whether influence local pp reduction could also detect site muscular artery radial artery',\n",
       " 'compare antihypertensive therapeutic strategies efficacy whether physicians aware not calculate cardiovascular risk years obtain framingham equation also possible evaluate concordance general physicians estimation cardiovascular risk calculate percentage',\n",
       " 'arterial hypertension leave ventricular hypertrophy lvh include myocyte hypertrophy fibrosis lead lv diastolic dysfunction finally heart failure spontaneously hypertensive rat myocardial fibrosis regress lv diastolic function improve treatment angiotensinconverting enzyme inhibitor lisinopril whether hold true patients hypertensive heart disease address prospective randomize doubleblind trial',\n",
       " 'prescribe medications overthecounter drug nutritional supplement use many patients although products well tolerate druginduced hyperkalemia may develop patients underlie renal impairment abnormalities potassium handle druginduced hyperkalemia often occur impair renal potassium excretion however disturb cellular uptake potassium load well excessive ingestion infusion potassiumcontaining substances may also occur physicians must aware medications precipitate hyperkalemia drug induce alterations potassium homeostasis patient characteristics increase risk hyperkalemia',\n",
       " 'effect chronic captopril therapy serum angiotensin convert enzyme ace study patients essential hypertension patients assess serum ace level serially every week weeks thirty healthy individuals serve control basal serum ace level among hypertensives ul find significantly higher p control ul one week start captopril therapy serum ace level fell almost half basal value p however thereafter rise level higher basal level even though blood pressure remain well control study suggest besides action ace captopril may lower blood pressure mechanisms well',\n",
       " 'fifteen patients idiopathic nephrotic syndrome fail respond weeks corticosteroid therapy form material study males females age range years three patients hypertension histological lesions focal segmental glomerulosclerosis fsgs membranous glomerulonephritis mesangial proliferative glomerulonephritis membranoproliferative glomerulonephritis patients proteinuria range g mday serum albumin range gdl serum creatinine elevate mgdl case discontinue steroids enalapril start dose mgday increase mgday every days till maximum tolerate dose not exceed mgday proteinuria serum albumin serum creatinine estimations every weeks six months every three months thereafter patients follow months proteinuria decrease g mday patients g mday patients weeks no significant decrease proteinuria patients two case fsgs one membranoproliferative glomerulonephritis oedema hypoalbuminaemia hypercholesterolaemia return normal patients decrease proteinuria no correlation histological lesion response enalapril no rise serum creatinine level baseline patients except cough one patient no significant side effect observe conclude enalapril effective reduce proteinuria thereby morbidity steroid resistant nephrotic syndrome irrespective underlie pathology',\n",
       " 'compare efficacy combination enalaprilatlabetalol enalaprilatnicardipine prevent emergence postcraniotomy hypertension prospective randomize open label clinical trial design compare incidence breakthrough hypertension systolic blood pressure [ sbp ] mm hg adverse effect hypotension tachycardia bradycardia two drug combinations secondarily effect drug sbp mean blood pressure diastolic blood pressure evaluate course study fortytwo patients receive enalaprilat mg iv dural closure follow either multidose nicardipine mg iv labetalol mg iv maintain sbp mm hg sbp similarly control group marginally smaller incidence failures adverse effect labetalol blood pressure profile similar group',\n",
       " 'question whether patients posterior infarctions pmi comparable benefit aceinhibitor therapy anterior infarction ami still open study undertake investigate different influence ace inhibitors remodel leave ventricle ami pmi patients pt female years randomize receive either mgday captopril c mgday fosinopril f begin day acute myocardial infarction pt ami pt pmi infarct size determine creatine kinase integral method pt examine cine magnetic resonance image weeks infarction determine leave ventricular enddiastolic lvedvi endsystolic lvesvi volume index ejection fraction ef infarction weight iw leave ventricular muscle mass mm systolic wall thicken swt motility mot vital myocardium clinical behavior accord guidelines new york heart association nyha result compare sample v without ace inhibitor therapy females males years ami pmi no significant differences c f without aceinhibition therapy lvedvi increase ami pmi p aceinhibition ami pmi p lvesvi increase v ami pmi p aceinhibitor find increase ami pmi p ef decrease without aceinhibitor ami pmi p aceinhibition increase ami pmi respectively n nyha get better group ami pmi without aceinhibitor n ami pmi aceinhibitor p ig increase ami pmi v p ami pmi c f p mm get bigger v ami pmi p aceinhibitor ami pmi p swd increase ami pmi v p ami pmi c f p mot decrease ami pmi without aceinhibition p increase ami pmi aceinhibitor n differences v aceinhibitor group significant even patients pmi clearly benefit aceinhibitor therapy less ami captopril fosinopril show no different effect myocardial infarction',\n",
       " 'base epidemiologic facts elevate cardiovascular mortality renal allograft recipients echocardiographic year followup hypertensive renal allograft recipients conduct study provide evidence contrast atenolol quinapril independent blood pressure reduction reduce leave ventricular hypertrophy improve leave ventricular diastolic function population',\n",
       " 'endothelial dysfunction early event atherosclerotic disease precede clinical manifestations complications noninvasive assessment endothelial function patients risk factor undergo clinical treatment important medical advance set alter endothelial function patients coronary hypercholesterolemia modifications treatment enalapril simvastatin either separately combination assess brachial artery randomize doubleblind period crossover study',\n",
       " 'objective study evaluate tolerability novel dual acenep inhibitor za oral administration rise single dose healthy volunteer study also preliminarily investigation za pharmacodynamics pd pharmacokinetics pk',\n",
       " 'series study conduct healthy young males healthy elderly males females evaluate pharmacokinetic profile telmisartan addition two phaseii clinical trials assess pharmacokinetics safety telmisartan mildtomoderate hypertensive patients telmisartan give single oral mg intravenous mg dose young males another multipledose study telmisartan mg administer orally daily days healthy young male subject elderly subject receive oral telmisartan mg daily days telmisartan dose mg take daily mildtomoderate hypertensive patients days additionally oral telmisartan mg administer daily days hypertensive subject follow oral dose median time maximum plasma telmisartan concentration h maximum plasma concentrations increase disproportionately dose contrast plasma concentrations directly relate intravenous dose steady state observe days oncedaily administration no clinically relevant accumulation days plasma concentrationtime profile similar study group characterize fast absorption rapid biexponential decline peak plasma concentration prolong terminal elimination phase h healthy hypertensive subject telmisartan well tolerate low incidence drugrelated adverse events frequent event headache also occur placebotreated control subject no change heart rate electrocardiograms clinical chemistry detect follow receipt telmisartan study thus show high systemic level telmisartan well tolerate attain healthy adults age hypertensive subject long terminal elimination halflife make telmisartan suitable oncedaily dose contribute sustain efficacy full h dose interval',\n",
       " 'compare antihypertensive efficacy tolerability telmisartan mg valsartan mg throughout h dose interval',\n",
       " 'prospective multicenter study include patients refer difficulttotreat hypertension analysis possible secondary hypertension standardize selection protocol base sharply define drugresistant hypertension renal function impairment angiotensinconverting enzyme inhibition patients undergo renal scintigraphy captoprilrenin challenge test set clinical characteristics also record sensitivity specificity renal scintigraphy diagnose renal artery stenosis captoprilrenin test depend criterion use clinical characteristics use construct clinical prediction rule renal artery stenosis sensitivity specificity cutoff level predict probability however prediction rule sensitivity could reach perform arteriography patients predict probability stenosis result considerable reduction number arteriograms make diagnostic strategy advocate start drugresistant hypertension continue renal arteriography patients increase probability stenosis patients atherosclerotic renal artery stenosis randomize balloon angioplasty n versus antihypertensive medication n three months randomization patients medication group undergo balloon angioplasty second instance intentiontotreat analysis no difference blood pressure find group months months followup although small medicationsparing effect balloon angioplasty lack beneficial effect balloon angioplasty compare medication could not attribute high stenosis recurrence rate angioplasty fact inclusion criterion set stenosis level patients relatively mild stenosis also include renal function angioplasty slightly better angioplasty group medication group improvement renal scintigram occur often angioplasty apart treatment patients specific characteristics present therapeutic approach start extend antihypertensive drug therapy control blood pressure blood pressure not control renal function deteriorate balloon angioplasty stent placement indicate',\n",
       " 'longterm multicenter randomize doubleblind placebocontrolled x factorial angiographic trial evaluate effect cholesterol lower angiotensinconverting enzyme inhibition coronary atherosclerosis normocholesterolemic patients',\n",
       " 'glucose insulin level associate leave ventricular mass lvm insulinresistant individuals antihypertensive drug different effect glucose insulin metabolism gim lvm evaluate whether effect antihypertensive therapy lvm associate effect gim compare effect atenolol perindopril parameters group insulinresistant obese hypertensives',\n",
       " 'usefulness treatment angiotensinconverting enzymeinhibitor aceinhibitor normotensive patients type diabetes controversial investigate whether aceinhibition improve endothelial function patients compare responses healthy subject',\n",
       " 'describe case yearold woman present two episodes abdominal pain vomit diarrhea abdominal compute tomographic scan episode demonstrate edema small bowel review patient history reveal start treatment lisinopril hypertension month first episode prescribe dose increase hours presentation angiotensinconverting enzyme ace inhibitorassociated angioedema suspect medication discontinue patient remain symptomfree not take ace inhibitor year review literature reveal nine similar case case include occur women angioedema small bowel associate ace inhibitors rare often not recognize surgical exploration angioedema gastrointestinal tract consider symptomatic patients take ace inhibitors',\n",
       " 'inhibition reninangiotensin system know raise serum potassium [ k ] level patients renal insufficiency diabetes no study evaluate comparative effect angiotensinconverting enzyme ace inhibitor versus angiotensin receptor blocker arb change serum [ k ] people renal insufficiency',\n",
       " 'effect enalapril low prednisone dose urinary protein electrophoretic pattern study pediatric patients glomerular diseases steroidresistant nephrotic syndrome enalapril administer dose mgkg per day months prednisone introduce months later patients dose mgm alternate days urine protein electrophoretic pattern show reduction total protein albumin respectively enalapril total urinary protein decrease gm per day p mark change pattern nonselective urinary protein loss albuminselective proteinuria observe mean total plasma proteins increase gdl p four patients become free proteinuria months enalapril start remain free proteinuria months followup patients persistent albuminuria gm per day selective urinary electrophoretic pattern no additional decrease observe steroids introduce clinical improvement edema observe children three patients develop transient acute renal failure course infectious disease develop peritonitis pneumopathy patients withdrawal enalapril necessary complete recovery renal function observe four patients hypertensive admission achieve normal blood pressure month enalapril start no episodes systemic arterial hypotension see creatinine clearance serum potassium show no statistically significant change',\n",
       " 'around elderly population suffer arterial hypertension effective antihypertensive treatment therefore require calcium antagonists use treat hypertension owe mechanism action provoke systemic well coronary vasodilatation study author aim evaluate activity tolerability diltiazem compare ramipril group elderly patients suffer essential arterial hypertension',\n",
       " 'heart failure increasingly common costly chronic disorder rise prevalence least populations age years mortality rat poor common solid cancers high health care utilisation cost despite increase evidence support range effective interventions predominantly therapeutic remain significant degrees physician underperformance term heart failure diagnosis management early management heart failure largely confine symptomatic relief patients well establish heart failure fluid overload introduction angiotensinconverting enzyme ace inhibitors provide first treatments beneficially alter prognosis patients common expression heart failure namely establish systolic dysfunction whether symptomatic asymptomatic evidence extend benefit delay progression heart failure reduce hospitalisation much understand pathophysiology heart failure stem study recent data clarify limit role digoxin important benefit betablockade aldosterone blockers adjuvants ace inhibition emerge evidence angiotensin ii antagonists contrast positive find reliable data europe north america reveal significant underperformance primary care hospital physicians heart failure diagnosis management evidence underuse underdosing evidencebased therapies limit qualitative data suggest reason underperformance complex relate lack access objective test ventricular function exaggerate concern treatment risk sideeffects heart failure represent complex cluster aetiologies risk not easy correctly identify even specialist settings since powerful evidence heart failure modify improve explicit guidance need suspect patients refer confirmation diagnosis advice appropriate treatment regimes patients handle mainly within primary care enhance access objective noninvasive test improve diagnostic reliability stratify patients evidencebased therapies current evidence suggest north america europe today primary care physicians underperform management patients heart failure often owe factor outside immediate control',\n",
       " 'survivors acute myocardial infarction mi complicate heart failure andor result leave ventricular dysfunction heighten risk subsequent death major nonfatal cardiovascular events inhibition reninangiotensin system angiotensinconverting enzyme inhibitor consistently demonstrate result reductions risk approximately development angiotensin ii receptor blockers offer new specific theoretically complete pharmacologic mode inhibit adverse influence angiotensin ii',\n",
       " 'second swedish trial old patients hypertension stophypertension conduct compare effect ` ` newer antihypertensive therapies angiotensin convert enzyme [ ace ] inhibitors calcium antagonists establish therapies betablockers diuretics cardiovascular mortality morbidity elderly hypertensive patients total patients randomize receive conventional treatment ace inhibitors calcium antagonists follow mean years primary endpoint combination fatal stroke fatal myocardial infarction fatal cardiovascular disease secondary endpoints combination fatal nonfatal stroke myocardial infarction cardiovascular mortality three treatments produce similar reductions supine systolic blood pressure no significant differences risk cardiovascular events patients receive conventional therapy receive newer therapies three treatments well tolerate stophypertension result thus add extensive literature show benefit blood pressure reduction elderly hypertensive patients moreover consistent current management guidelines emphasise importance achieve blood pressure reduction prevention cardiovascular events',\n",
       " 'hypertension management guidelines issue world health organization international society hypertension emphasize importance blood pressure reduction prevention cardiovascular events furthermore conclude benefit treatment due blood pressure lower per se rather specific antihypertensive therapy result second swedish trial old patients hypertension stophypertension consistent recommendations since trial angiotensin convert enzyme ace inhibitors calcium antagonists reduce blood pressure extent conventional therapy betablockers diuretics elderly hypertensive patients three treatments produce similar reductions risk cardiovascular events furthermore first subgroup analysis cardiovascular mortality show three treatments seem equally effective diabetic patients stophypertension data therefore fully consistent hypertension management guidelines underline advantage offer older newer antihypertensive therapies',\n",
       " 'shortacting calcium entry blockers use primarily slowrelease form furthermore study antihypertensive efficacy drug negatively influence enrol patients not hypertensive accord ambulatory blood pressure bp measurement thus randomize doubleblind multicenter parallelgroup study conduct compare effect nifedipine gits gastrointestinal therapeutic system enalapril',\n",
       " 'vascular remodel occur skeletal muscle patients severe congestive heart failure chf remodel mediate part increase activity reninangiotensin system animal model suggest vasculature angiotensin ii receptor type atr expression may upregulated pathological state associate vascular remodel therapeutic effect atr antagonist may therefore part due increase plasma angiotensin ii level stimulate atr however whether atr express skeletal muscle vasculature patients severe chf unknown',\n",
       " 'compare efficacy indapamide sustain release sr mg enalapril mg reduce leave ventricular mass index lvmi hypertensive patients leave ventricular hypertrophy lvh',\n",
       " 'estimate cost consequences diagnose symptomatic heart failure leave ventricular systolic dysfunction initiate angiotensin convert enzyme inhibitors primary care',\n",
       " 'present study perform evaluate preadmission history presentation initial treatment longterm mortality patients myocardial infarction diabetes',\n",
       " 'analysis design determine whether chronic heart failure patients high cardiovascular risk benefit extent highdose lisinopril whole atlas population',\n",
       " 'angiotensinconverting enzyme ace inhibitors know cause potentially fatal peripheral angioedema patients ace inhibitors may also cause isolate visceral angioedema rarely report complication article describe patients experience complication patients come medical attention episodes recurrent abdominal symptoms occur take ace inhibitors hypertension patient undergo surgical procedures symptoms persist surgery ultimately relieve cessation ace inhibitors case call attention may underappreciated cause abdominal pain patients present emergency departments',\n",
       " 'first dose hypotension administration angiotensinconverting enzyme inhibitor patients acute myocardial infarction one important adverse events type treatment no information first dose hypotension angiotensin type receptor blocker type patient',\n",
       " 'arthritis hypertension frequent comorbidities elderly hypertensive population nonsteroidal antiinflammatory drug often use relieve pain arthritic patients side effect sodium retention consequent elevation blood pressure bp effect dihydropyridine calcium block drug relatively independent sodium intake whereas angiotensinconverting enzyme ace inhibitors effect blunt highsodium diet study compare effect indomethacin placebo elderly patients essential hypertension control amlodipine enalapril indomethacin mg twice daily placebo administer weeks doubleblind crossover study patients control amlodipine enalapril response assess ambulatory bp measurement indomethacin raise bp lower pulse rat patients take enalapril little effect patients receive amlodipine difference cause indomethacin two group mm hg increase bp beatsmin fall pulse people take enalapril addition indomethacin patients take either drug cause rise weight fall plasma renin postulate effect due inhibition prostaglandin synthesis cause sodium retention patients take amlodipine fall plasma renin ameliorate effect sodium retention bp patients take enalapril plasma renin fall not translate effect blockage convert enzyme thus full effect sodium retention bp express patients treat indomethacin fewer patients may respond ace inhibitors however major problem patient intermittently take indomethacin nonsteroidal antiinflammatory drug person treat ace inhibitor cause bp go control patients amlodipine would appear prefer choice enalapril',\n",
       " 'large multicenter study test antihypertensive effect isradipine dihydropyridine calcium channel blocker enalapril angiotensinconverting enzyme inhibitor saltsensitive hypertensive patients low high salt intake diet week weeks ad lib salt diet patients sit diastolic blood pressure sdbp mm hg qualify enter week weeks placebo runin low salt diet mmol naday high salt mmol naday add placebo treatment weeks weeks patients demonstrate increase sdbp mm hg low high salt diet consider salt sensitive randomize week weeks doubleblind treatment period either isradipine mg twice day enalapril mg twice day placebo enter week weeks placebo washout phase low salt diet mmol naday week low salt diet continue patients restart doubleblind treatment weeks weeks study complete patients screen randomize doubleblind treatment phase complete study isradipine enalapril decrease sit systolic blood pressure ssbp sdbp high salt diet similar degree whereas enalapril cause greater reduction ssbp sdbp isradipine low salt diet mm hg v mm hg mean sem respectively p within drug effect isradipine blood pressure bp higher high low salt diet v mm hg ssbp v mm hg sdbp p enalapril exert similar effect diet salt restriction lower ssbp sdbp lowest bp achieve drug salt restriction phase',\n",
       " 'present study examine effect forearm endothelial function angiotensin ii type receptor antagonist losartan subject noninsulindependent diabetes mellitus niddm',\n",
       " 'aim study assess effect year captopril therapy initiate days mean h begin ami exercise performance myocardial ischemia cycle ergometer test pts first document qwave ami age l years qualify study pts randomly include captopril group control group group pts inferior ami accordingly normal lv function ef echo prevail study captopril therapy initiate dose mg every hours dose mg administer ist iind day mg iii day mg iv day exercise cycle ergometer test ext perform every pt day months ami ext begin w power increase minute intervals w fatigue typical cause termination test captopril group duration ext lengthen significantly comparison initial test day vs min p vs min p months vs min p control group exercise time longer months compare initial examination accordingly vs min p however differences regard time captopril control group not significant consecutive control stag final result test positive negative doubtful not differ significantly group consecutive examination stag captopril administer year period ami slightly improve physical work capacity accelerate improvement no effect ischemia estimate cycle ergometer test result may depend inclusion study predominantly pts normal lv function interior mi',\n",
       " 'reninangiotensinaldosterone system actively participate derangement renal function since early stag heart failure hf diminish capacity excrete sodium secondary increase proximal tubular reabsorption loss renal functional reserve two relevant initial alterations renal function angiotensin ii prove act directly meanwhile octapeptide contribute maintain glomerular filtration rate gfr within normal limit efferent arteriole vasoconstriction administration angiotensin convert enzyme inhibitors acei angiotensin receptor antagonists ara may thus accompany functional fall parameter advance age higher initial serum creatinine history hypertension diabetes atrial fibrillation predict onset gfr impairment associate blockade reninangiotensin system concomitant administration betablockers may help protect renal function preliminary data indicate combination acei ara not accompany higher renal risk good prognostic effect aldosterone antagonists hf not seem relate intrarenal effect compound exception prevent potassium loss hypokalemia systematic therapeutic use drug provide beneficial renal effect treat arterial hypertension myocardial ischemia may contribute delay prevent development hf',\n",
       " 'present multicenter study design evaluate whether patients essential hypertension derive equal benefit use combination therapy calcium antagonist angiotensinconverting enzyme ace inhibitor double dose calcium antagonist week washout week singleblind placebo runin period total patients treat either nifedipine mg study amlodipine mg study daily weeks patients whose diastolic blood pressure remain mm hg randomize weeks doubleblind therapy amlodipine mgbenazepril mg amlodipine mg benazepril mg nifedipine mg nifedipine mg study amlodipine mgbenazepril mg amlodipine mgbenazepril mg amlodipine mg amlodipine mg study dose calcium antagonistace inhibitor combination therapy lower diastolic pressure much high dose significantly better lower dose calcium antagonist monotherapy either nifedipine amlodipine however patients nifedipine highdose monotherapy group amlodipine highdose monotherapy group present form edema contrast incidence edema similar patients treat combination therapy lowdose calcium antagonists thus combination therapy calcium antagonist ace inhibitor provide blood pressure control equal highdose calcium antagonist monotherapy significantly fewer dosedependent adverse experience vasodilatory edema inc',\n",
       " 'evaluate effect angiotensinconverting enzyme inhibition quinapril cardiopulmonary baroreflex sensitivity patients uncomplicated myocardial infarction quinapril group patients placebo group patients days onset myocardial infarction study indicate quinapril improve cardiopulmonary baroreflex thus reduce sympathetic outflow patients acute myocardial infarction',\n",
       " 'urinary podocyte postulate marker estimation severity active glomerular injury predictor disease progression children glomerulonephritis nondihydropyridine calcium antagonist include verapamil reduce proteinuria extent similar angiotensinconverting enzyme inhibitor acei include trandolapril greater extent antihypertensives angiotensin ang ii receptor antagonists include candesartan cilexetil show potent longterm preventive effect progression renal injury aim present study assess whether verapamil trandolapril candesartan cilexetil affect proteinuria urinary podocytes patients iga nephropathy thirtytwo normotensive patients age years biopsyproven iga nephropathy nonnephrotic proteinuria gday normal renal function creatinine clearance mlmin study twenty patients diffuse mesangial proliferative glomerulonephritis noniga pgn healthy control also include study number urinary podocytes patients advance iga nephropathy n significantly higher patients disease mild stage n p patients noniga pgn p urinary podocytes not detect healthy control patients iga nephropathy randomly divide four treatment group treat verapamil mgday n treat trandolapril mgday n treat candesartan cilexetil mgday n give placebo n treatment continue months antiproteinuric response trandolapril group similar candesartan cilexetil group vs action trandolapril candesartan cilexetil greater verapamil p reduction number urinary podocytes baseline significantly greater patients treat trandolapril candesartan cilexetil patients treat verapamil p however no difference patients treat trandolapril treat candesartan cilexetil proteinuria urinary podocytes unaffected placebo group data suggest urinary podocytes may marker disease activity adult patients iga nephropathy trandolapril candesartan cilexetil effective verapamil reduce number podocytes',\n",
       " 'inhibition angiotensinconverting enzyme ace exert renoprotective effect adult patients chronic kidney disease evaluate prospectively change blood pressure bp protein excretion renal function administration longacting ace inhibitor ramipril monotherapy months moderately hypertensive children age years various nephropathies four patients initially decrease glomerular filtration rate gfr mlmin bp evaluate ambulatory h monitor weeks treatment oral ramipril mgm daily mean value systolic diastolic h ambulatory bp fell mmhg nine patients eight patients dose double end study systolic bp th percentile diastolic bp patients initially reduce nocturnal dip increase significantly patients increase albumin excretion median gg creatinine respond ramipril median reduction range whilst albuminuria increase median gfr well preserve no adverse effect drug note study demonstrate ramipril efficacious antihypertensive agent children renal hypertension well tolerate even mild renal insufficiency addition drug persistent antiproteinuric action half patients contribute conserve renal function',\n",
       " 'ischaemic degenerative brain diseases major health problem lead devastate loss autonomy hypertension show carry increase risk not cerebrovascular morbidity mortality also cognitive impairment dementia although diastolic blood pressure consider important risk factor clear isolate systolic hypertension elevate pulse pressure also play important role development brain complications therefore treatment condition must urgently become widespread tool prevention randomise placebocontrolled trials complete last years show reduction fatal andor nonfatal stroke recent trials isolate systolic hypertension older patients benefit even greater higher risk populations new class drug particular calciumchannels blockers angiotensinconverting enzyme inhibitors show effective originally use diuretics betablockers active treatment systeur trial base nitrendipine first step possibly associate enalapril andor hydrochlorthiazide reduce not stroke cardiovascular complications also incidence dementia include alzheimer disease important find must confirm trials specifically focus prevention dementia addition importance pulse pressure risk factor underline need new drug could increase aortic distensibility decrease systolic blood pressure without greatly reduce diastolic pressure improve management hypertension offer new opportunities reduce agerelated disease older people promote healthy age',\n",
       " 'nonimmediate cutaneous reactions drug skin organ frequently involve cells may play relevant role cells relate skin immune responses express cutaneous lymphocyteassociated antigen cla skinhoming receptor',\n",
       " 'yearold woman develop pemphigus foliaceus fosinopril angiotensinconverting enzyme inhibitor ace inhibitor years antiintercellular cement substance antibodies positive titre die admission unrelated illness yearold man develop pemphigus vulgaris months treatment quinapril months develop pemphigus man continue prednisone azathioprine speculate case aceinhibitorrelated pemphigus review aceinhibitorrelated pemphigus',\n",
       " 'editor associate editors please readership opportunity benefit series contributions dr john rutherford address current issue pharmacology therapeutics pertinent coronary artery disease please also dr rutherford provide authoritative perspectives topics immediate interest regular basis',\n",
       " 'blockade reninangiotensinaldosterone system raas prefer mechanism action control hypertension select group patients include diabetic nephropathy heart failure currently class drug work block raas albeit differ mechanisms angiotensinconverting enzyme ace inhibitors angiotensin ii angiotensin type receptor blockers arbs',\n",
       " 'assess compare effect candesartan lisinopril blood pressure urinary albumin excretion patients microalbuminuria hypertension type diabetes',\n",
       " 'survival benefit betablocker treatment patients heart failure establish recent trials yet impact betablockers add high dose angiotensin convert enzyme inhibitors not report',\n",
       " 'valsartan heart failure trial valheft first largescale randomize multinational clinical study assess efficacy safety valsartan angiotensin ii receptor blocker add conventional therapy include angiotensinconverting enzyme inhibitors heart failure patients total patients ejection fraction randomize either valsartan titrate mg b placebo',\n",
       " 'costeffectiveness analysis high low dose angiotensinconverting enzyme ace inhibitor lisinopril treatment chronic heart failure',\n",
       " 'postulate angiotensinconverting enzyme inhibitorangiotensin receptor antagonist aceiatra may decrease proteinuria patients glomerulonephritis action glomerular basement membrane therefore study relationship response patients iga nephritis igan aceiatra therapy decrease proteinuria effect selectivity index si patients',\n",
       " 'demonstrate previously inhibition angiotensinconverting enzyme ace enalapril angiotensin ii blockade losartan improve acetylcholinedependent endothelial function resistance vessels patients type ii diabetes therefore interest examine effect losartan conduit vessel function group influence losartan mg daily weeks endotheliumdependent independent vasodilator function determine subject type ii diabetes use randomize doubleblind placebocontrolled crossover protocol conduit vessel endothelial function assess use highresolution ultrasound brachial artery response reactive hyperaemia flowmediated dilation fmd glyceryl trinitrate gtn use nonendotheliumdependent dilator losartan administration significantly increase fmd response means e vessel diameter p pair ttest no effect losartan endotheliumindependent responses gtn consistent previous find resistance vessels administration mg losartan daily improve nomediated dilation conduit vessels subject type ii diabetes together find ace inhibition angiotensin ii blockade improve resistance vessel function group likely least beneficial effect mediate angiotensin iitype receptor pathway type receptor antagonist seem reasonable alternative ace inhibitor maintain conduit vessel endothelial function type ii diabetic subject',\n",
       " 'investigate whether angiotensinconverting enzyme ace inhibitor increase production nitric oxide no exhale air normotensive hypertensive subject study normotensive male subject receive single oral dose enalapril mg nitrendipine mg crossover manner exhale air collect baseline hours administration drug study normotensive subject men women hypertensive subject men women receive single oral dose enalapril mg exhale air collect baseline hours administration drug study enalapril significantly increase no release rate lung normotensive subject pmols baseline versus pmols hours p nitrendipine not change no release rate study enalapril significantly increase release no lung normotensive subject pmols baseline versus pmols hours p not hypertensive subject ace inhibition increase no production lung normotensive subject not hypertensive patients reduction angiotensin ii production andor accumulation bradykinin pulmonary tissue may responsible increase no production components lung pulmonary vascular endothelium bronchial epithelial cells macrophages nasopharyngeal cells neurons however effect ace inhibition no production lung differ hypertensive subject normotensive subject',\n",
       " 'myocardial blood flow mbf abnormalities present early stage dilate cardiomyopathy dcm attribute coronary microvascular abnormalities favorable effect verapamil coronary microcirculation might indicate use early stage dcm assess safety longterm combination therapy verapamil enalapril effect leave ventricular function myocardial perfusion compare enalapril alone patients dcm men women mean age years without overt heart failure nyha class iii baseline months randomize treatment either enalapril mg nine patients group enalapril mg verapamil mg nine patients group leave ventricular function assess rest handgrip bicycle exercise equilibrium radionuclide angiography mean mbf measure rest dipyridamole positron emission tomography pet nammonia flow tracer baseline two group reduce leave ventricular ejection fraction rest impair isometric exercise increase peak bicycle exercise mbf similarly reduce two group rest dipyridamole treatment no adverse events occur either group months no significant difference main study variables either two group within group treatment longterm combination therapy verapamil enalapril safe patients dcm without overt heart failure despite no favorable effect myocardial perfusion combine treatment prevent deterioration leave ventricular function similarly enalapril alone',\n",
       " 'study perform compare assessments druginduced liver injury obtain methods council international organizations medical sciences cioms scale recently validate maria victorino v clinical scale case submit registry hepatotoxicity total case hepatotoxicity report structure report form evaluate independent experts use multiple drug rat generate probability diagnosis classify definitive probable possible unlikely exclude evaluate consistency weight kappa statistical test absolute agreement scale observe case weight kappa disagreement level case level case best correlation scale obtain druginduced liver injury involve suggest immunoallergic mechanism disagreement level less case compare case involve presume idiosyncratic metabolic mechanism lowest agreement observe case evidence cholestasis no agreement find case fulminant hepatitis death cioms scale show better discriminative power produce assessments closer specialists performance v scale poor reactions long latency periods e amoxycillinclavulanic acid evolution chronicity withdrawal cholestatic pattern death',\n",
       " 'seek investigate effect angiotensinconverting enzyme ace inhibition h myocardial infarction mi leave ventricular lv dilation patients receive thrombolysis',\n",
       " 'seek prospectively randomly compare survival clinical hemodynamic variables patients congestive heart failure chf treat standard versus high dose enalapril',\n",
       " 'compare longterm effect kidney function longacting calcium antagonist nisoldipine versus longacting ace inhibitor lisinopril hypertensive type diabetic patients diabetic nephropathy',\n",
       " 'assess low mg andor standard mg dose ace inhibitor ramipril could prevent progression microalbuminuria incipient diabetic nephropathy normotensive type diabetic patients',\n",
       " 'lercanidipine vasoselective dihydropyridine calcium antagonist cause systemic vasodilation block influx calcium ions ltype calcium channel cell membranes highly lipophilic drug slower onset longer duration action number calcium antagonists preclinical evidence suggest lercanidipine antiatherogenic potential may also protect endorgan damage well control clinical study daily administration lercanidipine mg effectively reduce blood pressure bp compare placebo patients mild moderate hypertension without affect heart rate response rate percentage patients diastolic bp mm hg reduce mm hg baseline range lercanidipine mgday lercanidipine mgday drug long duration action clinical measurements diastolic bp yield troughpeak ratio lercanidipine dosages study comparative trials either publish full abstract find lercanidipine mg daily weeks least effective atenolol mg daily candesartan cilexetil mgday captopril mg twice daily enalapril mgday hydrochlorothiazide mg daily irbesartan mgday slow release nifedipine mg twice daily patients mild moderate hypertension addition lercanidipine mgday effective amlodipine mgday lercanidipine effective treatment elderly patients age years mild moderate essential hypertension isolate systolic hypertension addition monotherapy lercanidipine mgday show efficacy patients severe hypertension addon therapy help control bp large proportion patients severe hypertension not respond sufficiently betablockers diuretics ace inhibitors unpublished data indicate drug reduce blood pressure patients type noninsulindependent diabetes mellitus without adversely affect glucose homeostasis lercanidipine well tolerate clinical trials treatmentrelated adverse events typical dihydropyridine calcium antagonists namely headache flush dizziness ankle oedema',\n",
       " 'several observational study individual randomise trials hypertension suggest compare drug calcium antagonists may associate higher risk coronary events despite similar bloodpressure control aim metaanalysis compare effect calcium antagonists antihypertensive drug major cardiovascular events',\n",
       " 'programme overviews randomise trials establish investigate effect angiotensinconvertingenzyme ace inhibitors calcium antagonists bloodpressurelowering drug mortality major cardiovascular morbidity several populations patients separate overviews trials compare active treatment regimens placebo trials compare intensive less intensive bloodpressurelowering strategies trials compare treatment regimens base different drug class',\n",
       " 'study investigate whether drug therapyinduced reduction nocturnal blood pressure bp associate decrease sleep apnea activity two polysomnographies hospitalize male hypertensive obstructive sleep apnea patients analyze doubleblind randomize parallelgroup trial angiotensinconverting enzyme inhibitor cilazapril c mg daily placebo p blood pressure measure mean intraarterial catheter compare p c lower mean arterial bp nonrapid eye movement nrem mm hg p rem sleep mm hg p respiratory disturbance index eventsh sleep nh p apnea index ai nh p nrem sleep lower c lesser extent p nh p nh p respectively effect ai hypopnea index hi rem sleep not significant c ns respectively p ns respectively significant linear correlation change rem systolic bp change rem ai r p mean bp change correlate negatively change hi p nrem sleep no significant correlation change bp treatment effect sleep apnea activity blood pressure reduction shortterm antihypertensive treatment not affect sleep disorder breathe nrem sleep reduce bp associate weak reduction ai slight increase hi rem sleep appear elevate bp contribute marginally sleep apnea severity hypertensive patients obstructive sleep apnea',\n",
       " 'many investigators report angiotensinconverting enzyme ace inhibitors antiproteinuric effect retard progression renal impairment diabetic patients hand effect ace inhibitors not well establish patients essential hypertension study conduct prospectively evaluate whether ace inhibitor temocapril could modify urinary microalbumin excretion rate uae hypertensive outpatients no sign renal impairment compare longterm effect temocapril diuretic uae hypertensive patients treat diuretic trichlormethiazide enrol prospective study normal serum creatinine level no overt proteinuria month screen period urinary microalbumintourinarycreatinine ratio mg albuminmmol cr use estimate uae patients visit hospital monthly determine blood pressure bp uae baseline observation treatment diuretic subject randomly divide two group group diuretic switch temocapril mg daily months group b subject continue receive diuretic additional months seventysix outpatients men women mean age years essential hypertension enter study effect temocapril bp appear clinically similar trichlormethiazide use temocapril significantly decrease uae group n uae decrease significantly p baseline value mg albuminmmol cr mg albuminmmol cr th th month temocapril therapy respectively contrast group b n uae unchanged baseline mg albuminmmol cr months months result indicate longterm therapy temocapril may superior reduce uae diuretic therapy patients essential hypertension no sign renal impairment',\n",
       " 'patients type diabetes mellitus hypertension think high risk cardiovascular diseases recent guidelines treatment hypertension jnc vi whoish guidelines recommend antihypertensive agents strated low mmhg blood pressure lower less mmhg study design clarify well extent blood pressure bp control japanese hypertensive patients without type diabetes mellitus interview two hundred physicians randomly sellected among members japanese society hypertension jsh n japanese diabetes society jds n obtain information regard five recent case hypertension n total recent case hypertension without diabetes n total achieve bp mmhg nondiabetic diabetic hypertensives percentage patients whose bp less mmhg nondiabetics diabetics average number hypotensive agents use nondiabetics diabetics physicians prescribe ace inhibitors alphablockers diabetics nondiabetics although caantagonists administer patients irrespective whether not diabetes contrast fewer betablockers diuretics administer diabetics result suggest although japanese physicians consider effect hypotensive agents metabolism renal function treat diabetic hypertensives achieve blood pressure hypertensives without diabetes insufficient one ten patients blood pressure less mmhg even among diabetics improve blood pressure control therefore need treat high risk group patients diabetes mellitus',\n",
       " 'present study design evaluate effect ace inhibitor lisinopril calcium antagonist nitrendipine urinary albumin excretion uae renal function mild moderate essential hypertensive patients microalbuminuria week drugfree period patients randomly divide two group first group group n receive lisinopril mg daily weeks follow nitrendipine mg daily another weeks second group group n receive nitrendipine mg daily weeks follow lisinopril mg daily another weeks mean blood pressure mbp significantly decrease similar manner group uae significantly decrease weeks treatment lisinopril group weeks subsequent treatment lisinopril group hand uae not alter treatment nitrendipine change uae significantly correlate change mbp weeks treatment nitrendipine not weeks treatment lisinopril no significant change creatinine clearance urinary excretion sodium urinary nacetylbetadglucosaminide observe treatment either group result suggest lisinopril not nitrendipine reduce uae essential hypertensive patients microalbuminuria independently effective antihypertensive properties',\n",
       " 'measure healthrelated qualityoflife hrqol elderly symptomatic heart failure patients follow treatment angiotensin ii receptor antagonist losartan vs angiotensinconvertingenzyme ace inhibitor captopril',\n",
       " 'objectives predict longterm cost efficacy angiotensinconverting enzyme ramipril patients nondiabetic chronic nephropathies',\n",
       " 'understand pathophysiology heart failure advance last decade result new therapeutic advance convince data exist angiotensinconverting enzyme ace inhibition adrenergic blockade important therapies capacity improve survival lower morbidity higher dose ace inhibitors betablockers appear provide additional benefit aldosterone antagonist spironolactone use severe heart failure provide additional survival advantage add standard triple therapy angiotensin receptor blockers not show superior ace inhibitors role heart failure treatment require investigation no trial data support use inotropic agents calcium channel blockers heart failure number new therapeutic agents include vasopressin antagonists tumor necrosis factoralpha receptor antibody phase ii iii clinical trials prove beneficial may provide new treatment options patients heart failure nevertheless current challenge increase use prove therapies namely ace inhibitors betablockers improve outcomes rapidly grow population patients congestive heart failure',\n",
       " 'determine efficacy angiotensin convert enzyme inhibitor prophylaxis migraine',\n",
       " 'report present yearold man treat hypertension angiotensinconvertingenzyme ace inhibitor enalapril years continuous treatment present jaundice progressive liver failure continue despite withdrawal medication patient take no medication know cause acute liver failure could exclude indicate druginduced liver damage longterm treatment enalapril analysis liver biopsies reveal pathomorphological pattern comparable observe severe halothane hepatitis serological study include tcell stimulation enalapril broad spectrum test autoimmunity include autoantibodies calreticulin major ca zn bind protein endoplasmic reticulum suggest involve pathogenesis halothane hepatitis negative thus mechanism enalaprilinduced liver injury remain obscure liver failure progress finally lead orthotopic liver transplantation knowledge longest duration chronic treatment ace inhibitor liver failure occur addition liver failure progress despite withdrawal medication conclude even longterm treatment ace inhibitor liver failure may induce therefore regular monitor liver enzymes consider',\n",
       " 'adverse drug reactions account hospital admissions prevent administration otherwise effective therapeutic agent hypersensitivity immunemediated reactions although less common tend proportionately serious convince evidence implicate immune system pathogenesis hypersensitivity reactions understand way immune system recognise drug base hapten hypothesis onset hypersensitivity involve drug bioactivation covalent bind proteins follow uptake antigen process cell proliferation central hypothesis critical role drug metabolism balance metabolic bioactivation detoxification one important component individual susceptibility purpose review classify drug hypersensitivity reactions term clinical presentation also consider recent advance understand chemical biochemical particular cellular immunological mechanisms hypersensitivity follow topics review drug disposition cellular metabolism ii mechanisms antigen process presentation iii role cytokines costimulatory molecules induction maintenance polarise immune response iv application hapten hypothesis danger hypothesis serial trigger model drug hypersensitivity greater understand mechanism hypersensitivity may identify novel therapeutic strategies help combat one severe form adverse reactions drug',\n",
       " 'purpose study investigate effect angiotensinconverting enzyme inhibitor perindopril mean arterial blood pressure mabp cerebral blood flow cbf glomerular filtration rate hypertensive stroke patients moderate severe internal carotid artery ica disease ica occlusion',\n",
       " 'secondary hyperkalaemic paralysis rare condition often mimic guillainbarr syndrome case report hyperkalaemia cause renal failure trauma drug presentation muscle weakness case hyperkalaemic paralysis cause angiotensin convert enzyme inhibitor report',\n",
       " 'angiotensinconverting enzyme inhibitors improve longterm survival patients leave ventricular dysfunction myocardial infarction mechanism action not entirely clear neurohormonal effect may important respect well early hemodynamic unload induce drug primary objective assess effect trandolapril plasma level atrial natriuretic peptide secondary objective assess effect trandolapril select neurohormones vasoactive peptides enzymes may important development leave ventricular remodel heart failure follow acute myocardial infarction total patients acute myocardial infarction wall motion index segment echocardiographic model randomize double blind treatment trandolapril placebo within days onset infarction blind treatment discontinue days index infarction venous blood sample collect rest randomization day treatment discontinue end study no differences plasma level atrial natriuretic peptide two treatment group angiotensinconverting enzyme activity suppress plasma renin activity higher trandolapril group no differences plasma level nterminal proatrial natriuretic peptide brain natriuretic peptide aldosterone noradrenaline adrenaline vasopressin big endothelin neuropeptide find two treatment group positive correlations several markers neurohormonal activation baseline variables express leave ventricular dysfunction clinical heart failure neurohormonal activation relate leave ventricular dysfunction effect weeks angiotensinconverting enzyme inhibition neurohormonal activation not predict already establish beneficial longterm effect myocardial infarction thus early modulation circulatory neurohormone level may not major mechanism efficacy angiotensinconverting enzyme inhibitors patients select plasma hormone markers may still use identify patients might get greatest benefit treatment',\n",
       " 'antihypertensive lipid lower treatment prevent heart attack trial allhat randomize practicebased trial sponsor national heart lung blood institute nhlbi doubleblind activecontrolled component allhat design determine whether rate primary outcomea composite fatal coronary heart disease nonfatal myocardial infarctiondiffers diuretic chlorthalidone treatment three class antihypertensive drug calcium antagonist amlodipine angiotensinconverting enzyme inhibitor lisinopril alphaadrenergic blocker doxazosin highrisk hypertensive persons age years older addition allhat participants mild moderate hypercholesterolemia also enrol randomize openlabel trial design determine whether lower serum ldl cholesterol hmg coa reductase inhibitor pravastatin reduce allcause mortality compare control group receive ` ` usual care january independent data review committee recommend discontinue doxazosin treatment arm nhlbi director promptly accept recommendation article discuss step involve orderly closeout one arm allhat dissemination trial result step include provisional preparations actual decision process establish timetable form transition committee prepare materials instructions inform trial officer coordinators active clinics satellite locations institutional review board patients general public report detail trial result monitor closeout process control clin trials',\n",
       " 'flowdependent endotheliummediated vasodilation fdd activity extracellular superoxide dismutase ecsod major antioxidative enzyme arterial wall severely impair patients coronary artery disease cad hypothesize ace inhibitor acei angiotensin ii type receptor antagonist increase bioavailability nitric oxide no reduce oxidative stress vessel wall possibly increase ecsod activity',\n",
       " 'betablockers ace inhibitors reduce early mortality either one start first hours myocardial infarction mi consider close correlation morphological change prognosis aim investigate whether benefit betablockers ace inhibitors might reside similar protective effect infarct size ventricular volume',\n",
       " 'increase leave ventricular lv wall stress myocardial infarction mi implicate lv remodel however relationship lv wall stress lv remodel incompletely define',\n",
       " 'incidence chronic heart failure increase correspond increase morbidity mortality make substantial financial impact society improve therapy heart failure result significant prolongation survival decrease number hospitalizations enhance quality life many patients reasonably expect therefore adherence rational medical regimen patients might decrease cost well management patients severe heart failure begin identify etiology educate patients families angiotensinconverting enzyme inhibitors cornerstone therapy diagnostic test perform establish etiology extent myocardial dysfunction cardiac transplantation therapeutic option limit number patients surgical medical therapies view mainstay treatment strategy',\n",
       " 'hypertension play critical role cause high rate cardiovascular events patients diabetes mellitus large trials show lower blood pressure patient diabetes hypertension profoundly favorable effect review discuss recent trials answer question low patients blood pressure go agents use achieve goal national institute health guidelines publish sixth report joint national committee prevention detection evaluation treatment high blood pressure call blood pressure goal mmhg patients diabetes base data recent trials even lower blood pressure mmhg patients diabetes hypertension appear appropriate observational study show lowest cardiovascular event rate observe patients diabetes whose systolic blood pressure mmhg thus goal blood pressure patients diabetes hypertension may need revise lower mmhg patients overt proteinuria gd mean arterial pressure mmhg recommend available evidence justify use angiotensinconverting enzyme ace inhibitors firstline agents angiotensin receptor blockers patients intolerant ace inhibitors blood pressure goal lower patients diabetes hypertensive patients require use multiple agents diuretics longacting calcium channel blockers logical second choices synergistic blood pressure reduction effect observe ace inhibitors alphablockers use caution however patients renal disease loop diuretics may require reduce sodium volume overload improve blood pressure control',\n",
       " 'treatment angiotensinconverting enzyme ace inhibitors reduce mortality morbidity patients chronic heart failure chf affect patients not receive agents treat dose lower find efficacious trials primarily concern safety tolerability agents especially recommend dose present study examine safety tolerability high compare lowdose lisinopril chf',\n",
       " 'increase physical activity associate reduce risk cardiovascular disease general population data limit role among persons type diabetes mellitus',\n",
       " 'study whether angiotensinconverting enzyme inhibition quinapril treatment prevent instent restenosis successful implantation palmazschatz stents intravascular ultrasound study not quantitative coronary angiography analysis reveal quinapril treatment significantly prevent loss minimal lumen crosssectional area lumen volume stents addition reduce increase intimal hyperplasia volume',\n",
       " 'activation reninangiotensinaldosterone system oxidative modification ldl cholesterol play important roles atherosclerosis study evaluate carotid ultrasound change patients treat ramipril vitamin e secure substudy heart outcomes prevention evaluation hope trial prospective doubleblind x factorial design trial evaluate effect longterm treatment angiotensinconverting enzyme inhibitor ramipril vitamin e atherosclerosis progression highrisk patients',\n",
       " 'modulation biotransformation genetic traits may important determine environmentallyinduced nephrotoxicity conduct casecontrol study investigate role occupational hydrocarbon exposure along polymorphisms genes cod nacetyltransferase nat glutathione stransferase mu gstmu development idiopathic membranous glomerulonephritis imgn patients n biopsyproven imgn match healthy control age gender geographical area lifetime hydrocarbon exposure assess validate questionnaire polymorphisms nat gstmu genes gstm define use polymerase chain reaction whitecell dna peripheral blood exposure hydrocarbons significantly greater patients imgn control meansem hydrocarbon exposure score vs p nat acetylator status identical patients control fast slow acetylators group gstmu present patients control occupational exposure hydrocarbons remain likely factor pathogenesis work require identify genetic polymorphisms modulate risk imgn',\n",
       " 'diabetic nephropathy one lead cause endstage renal disease examine whether ace inhibitor treatment may nephroprotective effect normotensive insulindependent diabetic patients without microalbuminuria normal glomerular filtration rate gfr whether effect associate ace genotype prospective doubleblind randomize study normotensive patients type diabetes mellitus normal serum creatinine no microalbuminuria treat either placebo perindopril ace inhibitor urine albuminecreatinine ratio acr mean blood pressure mbp index glomerular filtration rate gfr base screatinine determine ace genotype determine electrophoresis acr higher placebo group perindopril group months continue increase study period months observation acr placebo group mgmmol mgmmol aceinhibitortreated group p mannwhitney test treatment significant increase acr placebo group p wilcoxon match pair test observe no differences group regard mbp gfr nephroprotective effect ace inhibitor treatment not associate ace genotype ii id dd',\n",
       " 'recent evidence aldosterone aldo exert profibrotic effect act via mineralcorticoid receptors cardiovascular tissue partial aldosterone escape aceinhibition treatment occur',\n",
       " 'compare effect maximal exercise tolerance weeks four dosages telmisartan mg daily specific angiotensin ii receptor antagonist continuation angiotensin convert enzyme inhibitor enalapril patients stable mildtomoderate congestive heart failure nyha class ii iii leave ventricular ejection fraction',\n",
       " 'study conduct healthy male volunteer evaluate absorption metabolic pattern mode elimination telmisartan nonpeptide angiotensin ii receptor antagonist [ c ] telmisartan administer orally solution single mg dose subject subject receive shortterm intravenous infusion [ c ] telmisartan mg measurement total c radioactivity plasma show absorb follow oral administration maximum plasma concentration observe hour absolute bioavailability average total radioactivity plasma reflect parent compound remainder total radioactivity could ascribe glucuronide conjugate telmisartan represent metabolite man telmisartan bind plasma protein mainly albumin alphaacid glycoprotein telmisartan reversibly distribute erythrocytes administer dose excrete within hours excretion balance complete hours dose radioactivity almost exclusively excrete via feces urinary excretion account dose irrespective route administration small fraction excrete urine glucuronide conjugate telmisartan predominant although telmisartan glucuronide detect plasma unchanged drug identify feces no change vital sign electrocardiogram clinical laboratory test detect follow telmisartan administration adverse events predominantly unrelated treatment mild intensity infrequent one subject faint another occasion report faintness events probably due antihypertensive action intravenous study medication',\n",
       " 'openlabel crossover study two objectives compare steadystate pharmacokinetics highdose telmisartan without coadministered highdose hydrochlorothiazide compare steadystate pharmacokinetics hydrochlorothiazide without coadministered telmisartan total healthy males females nonchildbearing potential receive follow oral oncedaily medications days telmisartan mg hydrochlorothiazide mg telmisartan mg plus hydrochlorothiazide mg medication periods day washout blood collect intervals hours respectively end day dose period determination plasma telmisartan hydrochlorothiazide concentrations highperformance liquid chromatography predose blood sample also collect days tolerability singleagent combination medication monitor hydrochlorothiazide telmisartan give alone combination no appreciable differences trough plasma concentrations days thus day agents achieve steady state mean value primary end point cmax auc secondary end point cmin telmisartan hyrochlorothiazide unaffected administer simultaneously moreover concurrent telmisartan no effect urinary excretion hydrochlorothiazide transient lightheadedness associate postural hypotension common adverse event absence significant effect pharmacokinetics either hydrochlorothiazide telmisartan show no dose adjustment require two agents give concurrently management hypertension',\n",
       " 'effect multipledose telmisartan steadystate pharmacodynamics pharmacokinetics warfarin assess healthy young males openlabel singleperiod study conduct days subject receive load dose oral oncedaily warfarin days individually adjust days andor attain stable predose prothrombin time value inrpre end medication phase day days medication phase subject receive oral oncedaily telmisartan mg addition individualize oral dose oncedaily warfarin days medication phase oral oncedaily warfarin administer alone individualize dose steadystate condition inrpre remain unchanged medication phase difference phase confidence interval [ ci ] phase ci mean trough plasma warfarin concentrations cpre stable medication warfarin alone show small although statistically significant decrease combinedmedication phase point estimate ratio phase phase ci decrease cpre not result decrease anticoagulation suggest extent pharmacokinetic interaction telmisartan warfarin limit since telmisartan no effect inrpre concomitant medication well tolerate no evidence clinically relevant interaction telmisartan warfarin',\n",
       " 'two openlabel twoway crossover study perform assess pharmacokinetic interaction telmisartan either acetaminophen ibuprofen healthy male adult volunteer n receive single oral dose acetaminophen g alone oral telmisartan mg one study oral ibuprofen mg three time daily without oral oncedaily telmisartan mg give days study conduct males females study washout period days single combination medication administration primary end point cmax auc compare combination acetaminophen ibuprofen telmisartan singleagent medication acetaminophen ibuprofen pharmacokinetic drug interaction assess analysis variance anova calculation confidence intervals ci treatment ratios use logtransformed parameters bioequivalence e lack interaction conclude ci ratios cmax auc within acceptance limit geometric mean cmax value acetaminophen r ibuprofen enantiomers similar without telmisartan coadministration microgramsml vs microgramsml microgramsml vs microgramsml microgramsml vs microgramsml respectively value r well ibuprofen bioequivalent geometric mean auc value acetaminophen r ibuprofen also bioequivalent without telmisartan distribution elimination parameters acetaminophen ibuprofen comparable presence absence telmisartan concomitant singleagent medications well tolerate conclusion long halflife excellent safety profile telmisartan unaffected concurrent acetaminophen ibuprofen medication thus oncedaily dose telmisartan maintain may help optimize patient compliance patients may selfadminister concomitant acetaminophen ibuprofen',\n",
       " 'openlabel crossover study perform establish evidence interaction telmisartan angiotensin ii antagonist amlodipine class ii dihydropyridine calcium channel antagonist basis pharmacokinetics safety twoway crossover trial healthy caucasian males randomize receive daily days oral amlodipine mg without oral telmisartan mg washout period days subject switch medication regimen geometric mean primary pharmacokinetic parameters steady state day amlodipine give alone follow maximum plasma concentration cmax ngml area plasma concentrationtime curve auc ng hml renal clearance mlmin total amlodipine dose excrete concomitant telmisartan give respective value ngml ng hml mlmin total amlodipine dose excrete renally limit confidence intervals cis ratios steadystate parameters cmax auc within predefined reference range bioequivalence high intersubject variability urinary amlodipine excretion result bioequivalence not demonstrate renal clearance adverse effect mild moderate intensity transient whether amlodipine give alone telmisartan vital sign except blood pressure clinical laboratory value unaffected either medication find study show concomitant telmisartan amlodipine may administer no clinically significant variation primary pharmacokinetic parameters amlodipine presence telmisartan safety combination comparable amlodipine alone',\n",
       " 'pharmacokinetics safety telmisartan assess subject hepatic impairment singlecenter openlabel study single oral dose telmisartan mg mg separate washout period days give hepatically impair subject healthy subject hepatically impair subject receive oral dose single v infusion telmisartan mg later administer oral dose pharmacokinetic profile telmisartan characterize rapid absorption disposition kinetics slow terminal elimination phase mean halflives hours maximum plasma concentration area telmisartan plasma concentrationtime curve aucinfinity increase hepatically impair subject compare healthy volunteer fold fold respectively telmisartan mg fold fold respectively telmisartan mg maximum plasma concentrations aucinfinity v infusion markedly elevate compare value obtain study conduct healthy volunteer hepatic impairment result apparent increase absolute bioavailability telmisartan total clearance follow oral v administration significantly reduce compare healthy volunteer plasma protein bind telmisartan hepatically impair healthy subject not change compare healthy subject oral v telmisartan well tolerate hepatically impair healthy headache common potentially telmisartanrelated adverse event change vital sign clinical laboratory parameters transient no clinical relevance good tolerability telmisartan hepatically impair patients demonstrate study prove sustain blood pressure control hypertensive patients increase exposure patients hepatic dysfunction suggest effective treatment hypertensive patients impair hepatic function would achieve even lowest dose telmisartan available increase bioavailability telmisartan suggest lower dose telmisartan consider drug administer patients hepatic impairment',\n",
       " 'pharmacokinetics oral telmisartan mg evaluate subject severe renal insufficiency dialyse hemodialysis compare observe healthy male subject dialyse dialysis plasma concentrationtime curve subject renal insufficiency lower healthy subject mean plasma protein bind telmisartan healthy subject compare mean value dialyse dialysis small amount telmisartan remove dialysis single dose telmisartan mg well tolerate subject severe renal insufficiency administer either dialyse dialysis no clinically relevant change vital sign detect conclusion maximum plasma concentrations telmisartan areas plasma concentrationtime curve subject severe renal insufficiency markedly reduce compare healthy subject fraction telmisartan not bind plasma proteins increase approximately twofold change pharmacokinetic profile subject renal insufficiency not affect safety profile telmisartan well tolerate subject',\n",
       " 'randomize doubleblind doubledummy placebocontrolled parallelgroup study evaluate doseresponse relationship telmisartan patients mild moderate hypertension diastolic blood pressure [ dbp ] mmhg day placebo runin period patients randomize days oncedaily doubleblind doubledummy treatment telmisartan mg enalapril mg placebo blood pressure bp manually record hours first dose hours baseline day day day doubleblind treatment pharmacokinetic pharmacodynamic parameters assess telmisartan plasma concentrations dose telmisartan enalapril significantly reduce bp compare placebo p mean se reductions supine dbp days treatment range mmhg mmhg telmisartan group mmhg enalapril mmhg placebo mean se reductions supine systolic blood pressure sbp mmhg mmhg telmisartan versus mmhg enalapril placebo increase supine sbp mmhg bp reductions weeks treatment telmisartan no different achieve enalapril no significant linear trend bp reduction evident among telmisartan dose reductions sbp dbp maintain hour period day treatment not affect supine heart rate troughpeak dbp ratios telmisartan dose versus enalapril high interpatient variability telmisartan plasma concentrations observe example mean sd value cmax ngml telmisartan mg ngml telmisartan mg ngml telmisartan mg plasma concentrationeffect analyse indicate antihypertensive effect telmisartan mg plateau region concentrationresponse curve active treatments well tolerate tolerability profile similar placebo telmisartan not produce clinically relevant firstdose effect data confirm antihypertensive efficacy placebolike tolerability telmisartan',\n",
       " 'hydrochlorothiazide hctz commonly use treat black patients hypertension avoid metabolic disturbances associate highdose hctz blood pressure control may achieve combine low dose another antihypertensive',\n",
       " 'epidemiologic evidence suggest elevate heart rate hr adverse independent prognostic factor arterial hypertension cardiovascular diseases although diltiazem characterize hrlowering calcium antagonist no study quantify magnitude hr change patients angina hypertension',\n",
       " 'premenopause period precede actual menopause decrease ovarian hormones present lead cardiovascular diseases arterial hypertension acute myocardial infarction cerebrovascular diseases',\n",
       " 'critically review study compare angiotensin ii agii receptor antagonists placebo angiotensinconverting enzyme ace inhibitors patients congestive heart failure chf',\n",
       " 'hypertension high prevalence among elderly patients randomise trials already demonstrate treat healthy older persons hypertension highly efficacious nevertheless question arise one hand generalizability trial result particularly older persons serious medical comorbidities poor functional status not clear hand different antihypertensive drug show effective drug patient even data randomise intervention trials show treatment affect cardiovascular morbidity mortality miss ace inhibitors use decade treat high blood pressure younger population captopril prevention project show no differences ace inhibitors conventional antihypertensive treatment diuretics betablocker concern primary endpoints myocardial infarction stroke cardiovascular death stop study also confirm result elderly patients treat elderly patients one must aware physiological change age comorbidities significance among patient group decline renal function admissions uraemia relate use ace inhibitors still commonplace although many case preventable monitor renal function guidelines still miss concern comorbidities ace inhibitors benefit compare antihypertensive drug especially case heart failure diabetes coronary heart disease',\n",
       " 'insulinmediated vasodilation show impair hypertension aggravate dietary sodium restriction whether vascular insulin resistance set could improve antihypertensive therapy unknown therefore determine effect therapy angiotensinconverting enzyme inhibitor vascular sensitivity insulin hypertensive subject feed sodiumrestricted diet',\n",
       " 'plaque hypertension lipid lower italian study phyllis first study patients hypertension diastolic blood pressure dbp mmhg systolic blood pressure sbp mmhg moderate hypercholesterolaemia ldlcholesterol mmoll mgdl initial carotid artery alterations maximum intimamedia thickness imt tmax mm primary objective phyllis investigate whether patients administration angiotensin convert enzyme inhibitor fosinopril statin pravastatin effective administration diuretic lipidlowering diet retard regress alterations carotid imt study progress baseline data report clarify association various risk factor carotid imt mediumhigh risk hypertensive patients',\n",
       " 'aim study describe renal function renal hemodynamics water sodium handle relation cardiovascular structural change population essential hypertensive patients antihypertensive treatment glomerular filtration rate renal plasma flow measure constant infusion technique reference substances use [ ] iodohippurate hippuran [ ] iothalamate lithium clearance method use measure renal water sodium handle microalbuminuria measure subcutaneous gluteal biopsy take media thickness lumen diameter ratio small resistance vessels determine leave ventricular mass index determine echocardiography thirtyseven patients newly diagnose poorly control essential hypertension randomize treatment regimens base upon either isradipine perindopril hydrochlorothiazideamiloride atenolol hydralazine add secondary tertiary drug respectively need normalization diastolic blood pressure investigations perform months normalization blood pressure renal function untreated hypertensive patients characterize increase renal vascular resistance decrease renal blood flow normal glomerular filtration fraction normal serum creatinine no association find peripheral resistance vessel structure subcutaneous vessels renal hemodynamic parameters patients severe leave ventricular hypertrophy leave ventricular mass g lower glomerular filtration fraction greater renal vascular resistance lower renal blood flow increase microalbuminuria comparison patients less pronounce cardiac change year treatment profound effect heart vessel structure renal hemodynamics unchanged patients receive antihypertensive treatment regimens base ace inhibitor perindopril caantagonist isradipine whereas renal plasma flow reduce glomerular filtration rate preserve filtration fraction significantly increase treat regimen base diuretics serum creatinine concentration decrease former group whereas unchanged latter two significantly detrimental effect uric acid homeostasis find patients treat regimen base diuretics',\n",
       " 'introduction generalization h ambulatory blood pressure bp monitor show clinical relevance home bp aim study assess validity homemeasured bp monitor control patients arterial hypertension homogeneous treatment additional objective establish degree office bp control obtain prospective longitudinal observational multicenter study cohort patients sex age years essential hypertension receive fix combination enalaprilhctz mg hypertensive agent least weeks previously office bp average three measurements home bp semiautomated device omron hem cp use patients measure bp twice day consecutive days average differences two measure methods low significant mmhg systolic bp sbp p mmhg diastolic bp dbp p pearson regression coefficient office home value highly significant p sbp dbp heart rate home bp measurement highly reproducible show high withinclass correlation coefficient individual measurements first day compare second confidence interval ci p sbp dbp ci p percentage patients strict office dbp sbp control mmhg dbp control mmhg conclusion espada study application home bp measurement valid reproducible show high correlation office bp',\n",
       " 'compare effect calcium antagonist amlodipine angiotensin convert enzyme inhibitor lisinopril leave ventricular mass diastolic function elderly previously untreated hypertensives',\n",
       " 'asthma recognize inflammatory disease inhale corticosteroids mainstay treatment patients persistent disease recently no inhale corticosteroid approve unite state children age years younger no practical dosage form available infants young children unable use metereddose inhalers effectively budesonide inhalation suspension bis glucocorticoid high topical low systemic activity children age months years bis improve asthma symptoms lung function decrease need breakthrough bronchodilators longterm followup study children conclude bis well tolerate little no effect growth hypothalamicpituitaryadrenal axis function thus valuable therapeutic alternative systemic corticosteroid therapy infants young children',\n",
       " 'seek study effect angiotensinconverting enzyme inhibition exerciseinduced myocardial ischemia',\n",
       " 'persistent dry cough occasional clinically important adverse reaction angiotensin iconverting enzyme ace inhibitors acei report incidence variable cough occur certain individuals unclear insertiondeletion id polymorphism ace gene associate serum ace activity previously show susceptibility cough induce acei associate polymorphism patients genotype ii susceptible cough patients genotypes order confirm extend previous observation conduct randomize placebocontrolled doubleblind crossover study healthy volunteer genotype ii genotype dd cough threshold determine concentration inhale capsaicin cause two cough usage acei cilazapril weeks change cough threshold subject genotype ii [ nm meansd nm ] significantly differ subject genotype dd nm nm skin responses intradermal bradykinin substrate ace tussigenic significantly increase subject genotype ii vs cm p not subject genotype dd vs cm n usage cilazapril contrast skin responses intradermal substance p not change subject either genotype find provide evidence link aceiinduced cough id polymorphism ace gene suggest aceis induce cough modulate tissue level bradykinin',\n",
       " 'verapamil sr mg plus trandolapril mg potent antihypertensive combination efficacy safety treatment not study fully hypertensive patients metabolic disorder enrol patients mild moderate hypertension least one follow disorder diabetes mellitus hypercholesterolaemia mild renal failure sit systolic pressure diastolic blood pressure significantly decrease weeks treatment blood pressure inadequately control patients progressive decrease blood glucose total cholesterol lowdensity lipoprotein triglyceride level observe study no significant change blood urea nitrogen creatinine transaminase level p significant decrease microalbuminuria level no significant change glycosylated haemoglobin level diabetic patients verapamil sr plus trandolapril effective drug combination treatment hypertension may use safely patients diabetes mellitus hyperlipidaemia mild renal failure',\n",
       " 'compare nonblind randomise parallel study efficiency quadropril amlodipine treatment mild moderate arterial hypertension',\n",
       " 'previously report beneficial effect pentoxifylline xanthinederived agent know inhibit production tumor necrosis factoralpha patients idiopathic dilate cardiomyopathy treat diuretics digoxin ace inhibitors since large clinical trials show important clinical benefit betablockers population therefore design present study establish whether patients heart failure already receive treatment ace inhibitors betablockers addition pentoxifylline would additive beneficial effect',\n",
       " 'one arguments put forward primary use betablockers concern adverse metabolic effect unfavorable effect lipids insulin sensitivity another lessappreciated potential drawback propensity cause weight gain patients evaluable prospective randomize control trials last months body weight higher betablocker control group end study median difference body weight kg range kg regression analysis suggest betablockers associate initial weight gain first months thereafter no weight gain compare control apparent no relationship demographic characteristics change body weight base observations firstline use betablockers obese hypertensive patients review obesity management overweight hypertensive patients may difficult face betablocker treatment',\n",
       " 'quo vadis study design explore whether year angiotensinconverting enzyme inhibition quinapril mgday would decrease ischemia patients undergo coronary artery bypass graft cabg patients n schedule cabg randomize weeks surgery study medication use randomization year cabg exercise test perform randomization exercise test repeat year cabg patients undergo hour holter monitor clinical ischemic events record define death revascularization myocardial infarction recurrence angina pectoris ischemic stroke transient ischemic attack baseline characteristics similar group total exercise time increase overall second year cabg placebo second quinapril second p patients ischemic stsegment change randomization patients ischemic stsegment change year cabg placebo quinapril p holter monitor number patients experience episodes ischemia equal group treatment quinapril significantly reduce clinical ischemic events cabg patients placebo versus patients quinapril hazard ratio confidence interval p longterm quinapril treatment significantly reduce clinical ischemic events within year cabg although ischemia exercise test holter monitor unchanged',\n",
       " 'mechanisms action omapatrilat agent inhibit neutral endopeptidase angiotensinconverting enzyme arterial function patients heart failure not previously report fortyeight patients new york heart association functional class ii iii leave ventricular ejection fraction sinus rhythm randomize doseranging mg study omapatrilat weeks measurements obtain baseline weeks decrease systolic vs mm hg p mean arterial vs mm hg p pressure see weeks therapy higher dose ventriculararterial couple improve doserelated decrease augmentation index vs p no change rest forearm blood flow group however maximum forearm vasodilator response reactive hyperemia increase highdose group compare control group vs p omapatrilat induce increase postdose plasma atrial natriuretic peptide level vs pmoll p highdose group consistent endopeptidase inhibition omapatrilat show beneficial change ventricularvascular couple arterial function heart failure',\n",
       " 'light recent randomize control trials chronic heart failure commonly assume treatment angiotensinreceptor blocker arb equivalent treatment angiotensinconverting enzyme ace inhibitor perform impute placebo analysis use previous placeboace inhibitor trials current ace inhibitorarb comparison study show arbs may not even superior placebos let alone ace inhibitor',\n",
       " 'purpose study effect atrial natriuretic peptide anp cardiorenal function use manage patients heart failure receive angiotensinconverting enzyme inhibitor acei acute saline solution load',\n",
       " 'principles manage type diabetes mellitus elderly no different younger patients priorities therapeutic strategies need cautiously individualise objectives treatment improve glycaemic control stepwise approach involve nonpharmacological methods include diet exercise pharmacological therapy include mixtures oral antihyperglycaemic agents alone combination insulin although goals treatment may elderly younger patients certain aspects type diabetes elderly require special consideration treatment decisions influence age life expectancy comorbid condition severity vascular complications adherence dietary therapy physical activity medication regimens may compromise comorbid condition psychosocial limitations druginduced hypoglycaemia main consideration serious potential complication addition long term macrovascular microvascular complications type diabetes source significant morbidity mortality indeed vascular neuropathic complications already present time diagnosis significant number patients impact improve diabetes control depend age life expectancy patient agerelated change pharmacokinetics potential adverse effect drug interactions also consider choose appropriate pharmacological therapy general conservative stepwise approach treatment elderly patient type diabetes suggest treatment may initiate monotherapy follow early intervention combination oral agents include sulphonylurea foundation insulin secretagogue addition supplemental insulin sensitiser insulin therapy eventually require significant hyperglycaemia [ glycosylated haemoglobin hbac ] persist despite oral combination therapy combination therapy even insulin longacting sulphonylurea glimepiride effective strategy improve hyperglycaemia elderly patient type diabetes polypharmacy oral agents unsuccessful addition regimen simple follow patient may not able adhere complicate insulin regimen hyperglycaemia elderly manage well practical intervention straightforward treatment plan enhance compliance optimal glycaemic control possible every patient treatment individualise however strict glycaemic control may not achievable patients even desirable many elderly patients',\n",
       " 'insulin resistance hyperinsulinaemia presume participate pathogenesis essential hypertension eh insulin resistance characterise impair insulinmediated glucose uptake participation reninangiotensin system development hyperinsulinaemia eh patients not unanimously prove present study aim asses influence antihypertensive therapy angiotensin convert enzyme inhibitor acei enalapril mgday male patients angiotensin ii receptor blocker ii rb losartan mgday male patients respectively insulin sensitivity patients eh hours euglycaemic clamp test constant infusion insulin mummin perform twice weeks therapy acei ii rb respectively control group cg consist healthy males clamp test perform serum insulin concentration estimate radioimmunoassay glucose disposal rate mvalue mgkgmin tissue insulin sensitivity mi value mgkgmin per mul calculate subject cg patients eh antihypertensive therapy acei ii rb respectively cg mvalue tissue insulin sensitivity mi significantly higher eh treatment acei mvalue mi ii rb mvalue mi respectively acei therapy follow significant increase mi value contrast acei treatment ii rb not influence neither mi value respectively contrast ii rb acei show beneficial effect insulin sensitivity eh patients effect not seem mediate influence receptor',\n",
       " 'pharmacogenomics term recently coin embody concept individualize rational drug selection base genotype particular patient customization drug therapy offer potential optimal safety efficacy individual patient process contrast current prescribe practice use medications show safe effective patient populations base anecdotal experience within patient populations medications vary efficacy among individual patients importantly medication safe effective one patient may ineffective even harmful another underlie many phenotypic differences genotypic variants polymorphisms key enzymes proteins affect safety efficacy drug individual patient understand polymorphisms potential enhance patient care allow physicians customize selection medication meet individual patient need pharmacogenomics may also lead improve compliance shorter time optimal disease management thereby reduce morbidity mortality significant cost save could result reductions polypharmacy well fewer physician encounter hospitalizations exacerbations underlie illness adverse drug reactions',\n",
       " 'objective study compare antihypertensive efficacy tolerability candesartan cilexetil cc enalapril e placebo p hypertensives clinic ambulatory blood pressure bp',\n",
       " 'hypertensive rat environmental stress cause sodium retention exaggerate increase renal sympathetic nerve activity modulate angiotensin ii test whether similar effect observe humans normotensive subject half family history hypertension subject mild essential hypertension urinary sodium excretion renal hemodynamics examine rest mental stress treat either placebo ace inhibition doubleblind randomize crossover design despite mark increase glomerular filtration rate response mental stress deltaglomerular filtration rate mlmin normotensives without versus mlmin normotensives family history versus mlmin patients mild essential hypertension p increase urinary sodium excretion blunt patients mild essential hypertension deltaurinary sodium excretion mmolmin versus mmolmin versus mmolmin p ace inhibition correct natriuretic response mental stress subject mild essential hypertension deltaurinary sodium excretion mmolmin placebo versus mmolmin ace inhibition p thus ace inhibition urinary sodium excretion increase similarly group conclusion impair sodium excretion occur mental stress human essential hypertension not subject positive family history hypertension abnormality sodium handle activation sympathetic nervous system appear mediate angiotensin ii',\n",
       " 'aim present study evaluate possible interaction chronic aspirin therapy angiotensinconverting enzyme inhibitor acei leave ventricular ejection fraction lvef patients survive acute myocardial infarction ami fortytwo patients reduce lvef recruit warfarin aspirin reinfarction study warisii randomize open study compare enteric coat aspirin mgd warfarin inr combination aspirin mgd warfarin inr mortality reinfarction stroke ami lvef relevant biochemical measurements perform discharge months overall lvef increase study period median p no difference patients aspirin warfarin regard main end point lvef furthermore neither endothelin anp show significant differences treatment group possible interaction acei aspirin might theoretically lead reduce level renin activity patients aspirin not find intergroup difference conclusion not find evidence interaction acei lowdose aspirin',\n",
       " 'despite grow body data demonstrate benefit multidisciplinary care heart failure persistently high rat readmission especially within first month discharge continue document',\n",
       " 'paper report international comparison characteristics treatment health outcomes chronic heart failure chf patients discharge acute hospital care australia scotland baseline characteristics treatment chf patients recruit randomise study nonpharmacological intervention australia chf patients concurrently recruit similar study scotland compare subsequent health outcomes include survival readmission within months discharge patients receive usual postdischarge care australia n scotland n also compare individuals countries predominantly old frail significant comorbidity likely complicate treatment similar proportion australian scottish patients prescribe either high vs medium vs dose angiotensinconverting enzyme inhibitor proportionately australian patients prescribe longacting nitrate digoxin andor betablocker months postdischarge ci australian ci scottish patients assign usual care remain eventfree ns similarly vs require unplanned readmission ns vs australian scottish patients respectively die ns australian scottish patients accumulate median vs days respectively hospitalisationpatientmonth ns multivariate analysis include country origin unplanned readmission death independently correlate severe renal impairment adjust odds ratio p previous hospitalisation chf p longer index hospitalisation days p greater comorbidity incremental unit charlson index p health outcomes among predominantly old frail chf patients appear independent healthcare system patient manage likely dependent syndrome',\n",
       " 'inpatients computer monitor use improve detection adverse drug events ades however similar program not available outpatients',\n",
       " 'major change treatment heart failure occur last fifty years dramatic effect morbidity mortality two hundred years pass since demonstration benefit digitalis heart failure development potent loop diuretics observation vasodilators could improve cardiac function mortality lead investigation angiotensin convert enzyme inhibitors acei although agents significant vasodilator properties major benefit appear relate ability effect remodel fail leave ventricle recent randomize clinical trials demonstrate beta adrenergic block agents provide incremental effect mortality morbidity add therapy acei although agents improve outlook heart failure patient little effect improvement leave ventricular function future research must direct methods deal issue either change contractile properties cardiomyocyte pharmacologic electrical therapy transplant functional cells increase number function contractile units',\n",
       " 'comparative antihypertensive efficacy tolerability angiotensin ii receptor blocker candesartan cilexetil calcium channel blocker amlodipine evaluate week multicenter doubleblind randomize parallelgroup forcedtitration study adult patients women black mild hypertension stage follow week placebo runin period patients sit diastolic blood pressure bp mm hg receive candesartan cilexetil mg n amlodipine mg n daily weeks doubleblind treatment patients uptitrated candesartan cilexetil mg amlodipine mg daily no significant differences candesartan cilexetil amlodipine regimens reduce bp mean systolic bpdiastolic bp reductions mm hg versus mm hg respectively p overall patients candesartan cilexetil amlodipine control diastolic bp mm hg total patients candesartan cilexetil discontinue treatment compare patients amlodipine include versus adverse events versus peripheral edema respectively peripheral edema prespecified primary tolerability end point occur significantly greater frequency patients amlodipine mild moderate severe versus patients candesartan cilexetil mild moderate p candesartan cilexetil amlodipine highly effective control bp patients mild hypertension candesartan cilexetil offer significant tolerability advantage respect less risk develop peripheral edema',\n",
       " 'optimaal study multicenter doubleblind randomize parallel trial highrisk patients treat early acute myocardial infarction compare treatment angiotensinconverting enzyme inhibitor captopril selective angiotensin ii antagonist losartan survival morbidity total patients heart failure acute phase new qwave anterior infarction reinfarction recruit study describe baseline data initial course cohort compare data patient management across countries',\n",
       " 'patients reduce leave ventricular function ventricular enlargement myocardial infarction significantly greater risk congestive heart failure death nevertheless recovery ventricular function occur significant proportion patients myocardial infarction modern reperfusion strategies associate increase recovery function',\n",
       " 'recent evidence suggest via mineralocorticoid receptors present cardiovascular tissue aldosterone exert profibrotic effect partial aldosterone escape occur aceinhibitor treatment',\n",
       " 'assess perceptions us department veterans affairs va physicians regard effect national formulary nf patient care access drug physician workload resident train approximately year implement',\n",
       " 'patients renal disease use angiotensinconverting enzyme ace inhibitors think improve renal function whereas others use lead worsen many question remain categories patients benefit ace inhibitor use',\n",
       " 'study design identify potential specialtyrelated differences epidemiology clinical profile management outcome patients hospitalize congestive heart failure departments cardiology internal medicine',\n",
       " 'one third patients chronic heart failure electrocardiographic evidence major intraventricular conduction delay may worsen leave ventricular systolic dysfunction asynchronous ventricular contraction uncontrolled study suggest multisite biventricular pace improve hemodynamics wellbeing reduce ventricular asynchrony assess clinical efficacy safety new therapy',\n",
       " 'assess agreement leave ventricular lv volumes ejection fraction ef determine twodimensional echocardiography echo cineangiography postinfarction patients',\n",
       " 'asymptomatic leave ventricular dysfunction treat early stage continuum chronic heart failure author present clinical trial data current management angiotensinconverting enzyme inhibitors betablockers base issue surround screen also discuss',\n",
       " 'advance knowledge develop cardiovascular system compensatory physiologic change occur infants congenital heart disease lead new approach management cardiac failure arrhythmias information pharmacologic effect pharmacokinetics pharmacodynamics newer agents use management congenital heart disease lead appropriate use medications prolong survival improve outcomes',\n",
       " 'compliance problems common cause inadequate treatment hypertension patients quit treatment within year doserelated adverse drug events ades frequently cause compliance problems many ades occur initial dose antihypertensive drug thus establish tenet initiate antihypertensive therapy low dose avoid ades diminish patients quality life reduce compliance however lowest effective dose antihypertensive drug',\n",
       " 'ventricular arrhythmias consider relate leave ventricular lv dysfunction ace inhibitors though improve lv function beneficial role exerciseinduced ventricular arrhythmias not establish study effect ace inhibitors exercise capacity visavis role exerciseinduced ventricular arrhythmias patients congestive heart failure chf various etiologies nyha class ii iii subject prospective randomise control trial control group comprise patients receive conventional treatment digitalis diuretics test group give enalaprilcaptopril addition tolerate follow months exercise test treadmill monitor clinical biochemical parameters begin end study case ventricular arrhythmias observe exercise postexercise minutes analyse use lown grade frequency severity ventricular arrhythmia mean exercise duration show significant improvement ace inhibitor compare control group p however no significant change grade arrhythmia serum electrolytes biochemical parameter within normal range conclude effect ace inhibitor improve functional capacity chf independent effect exerciseinduced ventricular arrhythmias',\n",
       " 'study effect losartan potassium treatment mild moderate hypertension compare efficacy adverse effect profile enalaparil maleate',\n",
       " 'fifty newly diagnose nonsmoker patients suffer mild moderate hypertension diastolic bp mmhg randomly select not respiratory systemic diseases may affect pulmonary function subject thorough interrogation clinical examination twenty five normal age sex match healthy volunteer serve control patients control subject ventilatory pulmonary function test vpft computerize spirometer hypertensive patients put oral enalapril dose titrate maintain mg daily twenty percent total hypertensive patients report mild moderate dry cough frequently observe among females significant decline observe mef mef vital capacity value p days enalapril therapy two vpft parameters show significantly higher decline among patients develop cough compare patients not develop cough decline vpft parameters directly relate dose enalapril',\n",
       " 'benazepril hydrochloride new nonsulfhydryl ace inhibitor acei study titrate dose mg mg day weeks mild moderate adult hypertensive patients sit diastolic blood pressure sdbp mm hg predrug sdbp mean se mm hg show significant reduction mm hg end treatment bp control sdbp mm hg patients drop least mm hg pretreatment sdbp value note patients common adverse reaction cough patients clinically significant change laboratory evaluations not see patient study show benazepril dose range mg per day effective agent treatment mild moderate hypertension',\n",
       " 'angiotensinconverting enzyme ace inhibitors show value treatment postinfarction remodel question whether substances greater tissue affinity associate advantage acute chronic course however still unclear',\n",
       " 'dihydropyridine nondihydropyridine calcium channel blockers ccb differ pharmacologic characteristics clinical study distinguish effect ccb monotherapy conduct comprehensive comparison two ccb patients moderate severe hypertension thirty patients pretreatment diastolic blood pressure mm hg randomly assign either nifedipinegits verapamilsr dose titration achieve diastolic blood pressure mm hg decrease mm hg weeks clinic blood pressure bp h ambulatory bp exercise bp leave ventricular mass systolic diastolic function echocardiography coronary flow reserve splitdose thallium image adenosine assess baseline end titration months months treatment plasma renin activity atrial natriuretic peptide norepinephrine epinephrine assay drug cause similar reductions clinic h ambulatory bp similar reductions leave ventricular mass index compare nifedipinegits verapamilsr produce significantly lower rest peak exercise heart rate nifedipinegits elicit lower peak exercise systolic bp end titration nifedipinegits produce lower plasma atrial natriuretic peptide level no longer apparent months plasma norepinephrine lower verapamilsr also end titration months not months plasma epinephrine plasma renin activity unchanged either drug no difference systolic diastolic leave ventricular function coronary flow reserve two treatments daily nifedipinegits verapamilsr equally effective reduction arterial pressure moderate severe hypertension differences hemodynamic profile neurohormonal responses consistent preclinical pharmacologic characteristics clinical implications similarities differences remain fully evaluate outcome study',\n",
       " 'objective study determine common group antihypertensive drug effective lower systolic blood pressure sbp elderly patients previously untreated hypertension percentage patients control single sequential monotherapy subject recruit patients attend outpatient clinics enter study sbp mm hg three visit patients give low high dose main class drug placebo month study balance randomize crossover design five periods placebo angiotensin convert enzyme inhibitors betablocking drug calciumblocking drug thiazide diuretics blood pressure bp measure h previous dose questionnaire side effect administer visit seventyfour patients enter study betablockers could not use patients asthma bronchospasm two placebo periods patients p betablockers calciumblocking drug diuretic patients ace inhibitors not progress higher dose side effect decrease sbp compare randomize placebo calciumblocking drug mm hg diuretic mm hg ace inhibitors mm hg betablockers mm hg blood pressure decrease correlate placebo bp p r correct placebo target sbp mm hg reach patients monotherapy sequential monotherapy achieve target angiotensin convert enzyme inhibitors calciumblocking drug diuretics no side effect placebo patients betablockers side effect wellbeing score reduce diuretics calciumblocking drug effective elderly patients lower sbp pressure betablockers relatively ineffective frequently contraindicate side effect monotherapy achieve control small number patients elderly people essential hypertension therapy institute diuretics calciumblocking drug combination therapy usually require achieve goal',\n",
       " 'angiotensin convert enzyme inhibitors acei effective antiproteinuric agents use firstline drug diabetic nondiabetic proteinuric nephropathies role calcium channel blockers ccb much controversial diabetic patients verapamil diltiazem seem effective dihydropyridines reduce urinary protein excretion additive effect acei little available chronic treatment nondiabetic nephropathies nondihydropyridine ccbs test whether combination verapamil mg amlodipine mg trandolapril mg reduce urinary protein excretion trandolapril mg alone plan prospective randomize doubleblind multicenter trial secondary aim evaluate effect treatments selectivity proteinuria check safety consecutive patients age years nondiabetic proteinuria g h plasma creatinine mgdl creatinine clearance mlmin ask participate fourweek runin previous antihypertensive therapy withdraw single dose trandolapril mg give day open condition four weeks end period patients randomly assign receive day double blind fashion either trandolapril mg verapamil mg [ plus placebo ] trandolapril mg plus amlodipine mg monitor one two five eight months',\n",
       " 'prevent subclinical organ damage currently major issue management patients essential hypertension antihypertensive drug act different pathophysiological mechanisms might confer specific target organ protection beyond already provide blood pressure lower effect',\n",
       " 'investigate hypothesis abnormalities hemorheological fibrinogen plasma viscosity endothelial von willebrand factor [ vwf ] platelet soluble pselectin function would exist patients chronic heart failure chf sinus rhythm conduct crosssectional study patients stable chf median ejection fraction also hypothesize ace inhibitors betablockers would beneficially affect measure indices',\n",
       " 'extensive data many randomise control trials show benefit treat hypertension target blood pressure bp antihypertensive management systolic mmhg diastolic mmhg minimal no drug sideeffects however lesser reduction elicit benefit although not optimal reduction bp elderly severe hypertension achieve gradually months stricter bp control require patients endorgan damage coexist risk factor comorbidity e g diabetes mellitus coexistent risk factor also control',\n",
       " 'outcome trials provide information renal function older hypertensive patients diuretics betablockers mostly use firstline drug longterm renal effect calciumchannel blockers remain unclear',\n",
       " 'hypertension major problem throughout develop world although current antihypertensive treatment regimens reduce morbidity mortality patients often noncompliant medications may not completely normalize blood pressure result current therapy frequently not prevent reverse cardiovascular remodel often occur blood pressure chronically elevate blockade reninangiotensin system ras effective control hypertension treat congestive heart failure angiotensinconverting enzyme ace inhibitors angiotensin receptor blockers arbs inhibit activity ras two class antihypertensive medications different mechanisms action different pharmacologic profile angiotensinconverting enzyme inhibitors block single pathway production angiotensin ii ang ii addition angiotensin not substrate ace ace inhibitors also block degradation bradykinin may potential benefit cardiovascular disease bradykinin however presume cause cough associate ace inhibitor therapy data clinical trials ace inhibitors serve support involvement ras development cardiovascular disease angiotensin receptor blockers act distally ras block ang ii type receptor selectively thus arbs specific agents avoid many side effect experimental clinical trials document efficacy arbs preserve targetorgan function reverse cardiovascular remodel instance maximal benefit may obtain ang ii blockade use arbs ace inhibitors review describe clinical trials document efficacy arbs protect myocardium blood vessels renal vasculature',\n",
       " 'treatment diabetic nephropathy ace inhibitor therapy reduce albumin excretion slow rate decline glomerular filtration rate gfr study design investigate whether effect lay amelioration underlie glomerular structural abnormalities total type diabetic patients albuminuria blood pressure bp mmhg randomize receive mg enalapril daily mg nifedipine retard twice daily placebo multicenter doubleblind study years duration renal biopsy perform baseline followup tissue analyze standard morphometric methods bp gfr albumin excretion rate aer hbac measure every months enalapril lower aer months p however reduction not sustain years no significant effect nifedipine placebo aer gfr decrease similar average rate ml x min x year ci three group bp hbac unchanged throughout study group baseline nearly biopsies show classic appearances diabetic glomerulopathy no detectable effect enalapril compare either nifedipine placebo renal structure years however find patients increase aer establish glomerulopathy progressive average decline gfr ml x min x year absence overt hypertension baseline aer appear predictive subsequent mesangial volume fraction r p small cohort nonhypertensive patients study years disease evolution appear unaffected treatment either enalapril nifedipine',\n",
       " 'report case fosinoprilinduced prolong cholestatic jaundice pruritus yearold man no previous hepatobiliary disease present asthenia jaundice itch weeks start fosinopril therapy drug take patient not consider probable cause diagnostic evaluation show no biliary obstruction possible cause intrahepatic cholestasis exclude liver biopsy show cholestasis without bile duct damage disease run severe course months hospitalization prolong itch months eventually control oral naltrexone jaundice subside months anicteric cholestasis persist months similar occurrences report inhibitors angiotensinconverting enzyme mostly captopril first case important adverse reaction fosinopril',\n",
       " 'main objective calm candesartan lisinopril microalbuminuria study assess effect dual blockade reninangiotensin system use angiotensin convert enzyme inhibitor acei angiotensin ii type receptor blocker patients type diabetes high blood pressure microalbuminuria study include patients randomize receive candesartan mg lisinopril mg weeks follow weeks monotherapy combination treatment main outcomes reduction microalbuminuria blood pressure three treatments effective dual blockade respectively mmhg mmhg effective reduce microalbuminuria systolic diastolic blood pressure no comparison make ` ` new association frequently use biotherapy e acei plus thiazidic diuretic therefore usefulness regular practice still determine',\n",
       " 'adverse drug events ades major cause morbidity mortality even minor ades may adversely affect patients compliance treatment ades doserelated phenomena adjust drug dosages account individual patients need tolerances fundamental good therapeutics',\n",
       " 'thiazides recommend initiate antihypertensive drug treatment black subject',\n",
       " 'possible vasodilator therapy may retard leave ventricular lv dilatation functional deterioration chronic mitral regurgitation mr study objectives evaluate comparatively efficacy nicorandil new balance vasodilator enalapril therapy lv volume mass function mildly symptomatic chronic rheumatic severe mr',\n",
       " 'objectives seek assess effect ramipril leave ventricular lv volumes clinical significance thereof patients moderate lv dysfunction no clinical heart failure undergo invasive revascularization chronic stable angina',\n",
       " 'comparison treatment cost cost effectiveness perform retrospectively use patientlevel data randomize control oneyear clinical trial amlodipine enalapril treatment mildtomoderate hypertension unit cost amlodipine enalapril apply daily dosages individual patients calculate total cost average cost per patient treatment group clinical trial intenttotreat basis efficacy rat use calculate average treatment cost per success blood pressure control although not statistically significant amlodipine treatment result higher efficacy vs enalapril average cost per amlodipinetreated patient consistently lower enalapriltreated patient week treatment amlodipine result average cost per success per patient compare per enalapriltreated patient sensitivity analysis reveal treatment mildtomoderate hypertension week treatment period amlodipine would remain less costly enalapril decrease cost enalapril would remain cost effective decrease cost enalapril',\n",
       " 'number trials metaanalyses demonstrate clear benefit blood pressure bp reduction patients age years regard reduction stroke cardiovascular events however variety study suggest positive relationship bp cardiovascular mortality weaken indeed reverse elderly intervention trials date either exclude not recruit sufficient patients age years determine whether significant benefit treatment age group metaanalysis intervention trials recruit patients age years suggest benefit term stroke reduction also raise possibility increase total mortality benefit risk ratio therefore need clearly establish recommendations make treat elderly patients hypertension hypertension elderly trial hyvet pilot recruit patients age years show feasibility perform trial age group prospective randomise open blind endpoints probe design main trial additional pharmaceutical sponsorship run doubleblind trial therefore main trial randomise doubleblind placebocontrolled trial design assess benefit treat elderly patients hypertension compare placebo low dose diuretic indapamide sustain release mg daily additional ace inhibitor perindopril therapy require pilot trial primary endpoint stroke events fatal nonfatal trial design determine whether not difference occur placebo active treatment main objective achieve power level significance secondary outcome measure include total mortality cardiovascular mortality cardiac mortality stroke mortality skeletal fracture patients age years recruit follow average years entry bp criteria months singleblind placebo runin period sustain sit systolic bp sbp mm hg diastolic bp mm hg stand sbp must mm hg trial carry accordance principles good clinical practice describe detail protocol main trial discuss reason change pilot use drug regimen bp criteria use trial',\n",
       " 'cardiovascular risk associate early renal insufficiency unknown clinicians often reluctant use angiotensinconverting enzyme inhibitors patients renal insufficiency',\n",
       " 'examine relation serum creatinine uric acid mortality cardiovascular disease older age years chinese patients isolate systolic hypertension systolicdiastolic blood pressure mm hg use cox regression correlate outcome baseline serum creatinine uric acid measure respectively patients enrol placebocontrolled systolic hypertension china systchina',\n",
       " 'hypertension htn major risk factor cardiovascular disease cvd set diabetes no consensus best treat hypertension among diabetes describe characteristics cohort hypertensive adults diabetes part large prospective blood pressure study study help clarify treatment htn set diabetes',\n",
       " 'primary objective randomise placebo control doubleblind crossover study evaluate compare longer term effect angiotensin ii type receptor antagonist losartan convert enzyme inhibitor enalapril h ambulatory blood pressure bp week placebo runin period nine patients essential hypertension enter doubleblind phase study consist three week periods patients treat placebo enalapril mg losartan mg losartan enalapril take reduce ambulatory bp throughout h period average night time bp reduce mm hg placebo mm hg enalapril mm hg losartan daytime bp average mm hg placebo significantly lower enalapril mm hg losartan treatment mm hg clinic bp measure hours drug intake reduce extent drug losartaninduced bp change significantly relate obtain enalapril r ambulatory bp monitor repeat weeks combine therapy six patients bp lower effect combination not significantly better achieve enalapril alone conclusion losartan mg enalapril mg lower bp approximately extent except pronounce effect enalapril daytime ambulatory bp current study not provide convince evidence addition losartan enalapril dose use reduce bp',\n",
       " 'randomize doubleblind placebocontrolled clinical trial show elderly hypertensive men study uncomplicated beneficial response either fosinopril verapamil welltolerated reduction systolic blood pressure sbp diastolic blood pressure drp no significant adverse drug events sit sbp sit dbp significantly lower fosinopril verapamil sr reduction sbp dbp elderly hypertensives show beneficial find take importance consider choice medication antihypertensive therapy elderly increase norepinephrine fosinopriltreated patients may explain patients treat longterm angiotensinconverting enzyme inhibitors alone combination diuretics rarely complain orthostatic symptoms',\n",
       " 'evaluate use computer program identify adverse drug events ades ambulatory set evaluate relative contribution four computer search methods identify ades include diagnosis cod allergy rule computer event monitor rule text search',\n",
       " 'persistent activation reninangiotensinaldosteronesystem raas know occur patients chronic heart failure chf despite treatment angiotensinconverting enzyme inhibitor ace therapy add ace inhibitors angiotensin ii type antagonists may allow complete blockade raas preserve beneficial effect bradykinin accumulation not see receptor blockade alone',\n",
       " 'objective analysis assess costeffectiveness achieve tight control versus less tight control blood pressure define uk prospective diabetics study type ii diabetic patients uk italy effect include doxazosin tight control combination therapy analyse give doxazosin positive impact lipid level addition antihypertensive effect hypothesise treatment include doxazosin reduce incidence macrovascular complications country markov model construct simulate macrovascular outcomes patients various drug combinations transitional probabilities base risk rat present ukpds risk rat adjust age cohort lipidlowering properties doxazosin use framingham risk equations incremental costeffectiveness ratios range pound pound us per lifeyear save uk l million us per lifeyear save italy doxazosin costeffective agent include combination therapy treatment hypertension diabetic populations uk italy',\n",
       " 'aim study compare efficacy angiotensinconverting enzyme inhibitor dihydropyridine calcium channel blocker prevent progression macroalbuminuria andor decline renal function normotensive patients type diabetes microalbuminuria fortytwo patients randomize treatment either perindopril slowrelease nifedipine placebo first months drug dosage titrate achieve decrease diastolic blood pressure least mm hg thirtythree patients minimum months data patients follow beyond months mean months patients study every months end treatment period remain normotensive discontinue therapy follow additional months baseline geometric mean albumin excretion rat aers follow perindopril microgmin nifedipine microgmin placebo microgmin first years perindopriltreated none placebo nifedipinetreated patients revert normoalbuminuria p median aers years treatment group microgmin perindopril microgmin nifedipine microgmin placebo patients p patients years followup median aers decrease first year stabilize perindopril group increase nifedipine group placebo group p first year increase progressively patients significant decline glomerular filtration rate nifedipine group mlmin not two group perindopril mlmin placebo mlmin p end study cessation treatment months associate double aers perindopriltreated group no change two group p conclusion longterm perindopril therapy effective nifedipine placebo delay progression diabetic nephropathy reduce aer normoalbuminuric range microgmin normotensive patients type diabetes microalbuminuria',\n",
       " 'evaluate effect acute blood pressure reduction endotheliumdependent vasodilation peripheral circulation essential hypertensive patients',\n",
       " 'objective study evaluate hemodynamic clinical effect fosinopril patients heart failure prospective multicenter doubleblind randomize parallelgroup study patients years age receive diuretics systolic blood pressure sbp mm hg new york heart association nyha functional class iiiv leave ventricular ejection fraction pulmonary capillary wedge pressure pcwp mm hg cardiac index ci lminm eligible total patients randomize single doubleblind oral dose placebo fosinopril mg hemodynamic monitor perform hours postdose patients sbp mm hg rerandomized weeks doubleblind fosinopril mg daily hemodynamic monitor repeat last visit begin hours postdose trough continue hours thereafter significant decrease preload pcwp afterload mean arterial blood pressure [ mabp ] systemic vascular resistance [ svr ] evident hours single dose fosinopril mg continue hours postdose pcwp svr hours postdose mabp p v placebo baseline sustain decrease pcwp mabp svr heart rate increase ci stroke volume index observe weeks treatment fosinopril mg daily p v mg group pcwp mabp time point p v baseline parameters time point doserelated trend toward reduce supplemental diuretic use p reduce symptoms dyspnea p observe mg mg fosinopril dose group daily administration fosinopril mg safe well tolerate provide sustain beneficial hemodynamic effect improve leave ventricular performance reduce symptoms dyspnea result reduce need supplemental diuretic therapy',\n",
       " 'patients chronic heart failure chf increase risk sudden death increase risk associate increase qt dispersion qtd reflection heterogeneity ventricular repolarization angiotensinconverting enzyme ace inhibitors report decrease heart size well decrease morbidity mortality moderatetosevere chf aim study determine ace therapy associate decrease qtd marker increase electrical instability ninetyseven patients evaluate normalize qtd months ace therapy decrease reduction dispersions qtd also decrease p qtc dispersions decrease p months ace inhibitor therapy heart rate slow significantly rr intervals ace negative correlation ejection fraction qtd r p study also find no correlation ace level percent convert enzyme inhibition qtd effect ace therapy appear early term repolarization change reduction qtd may explain reduce sudden death mortality patients heart failure treat ace inhibitor therapy',\n",
       " 'geriatric population account unite state population consume prescription medications polypharmacy patient noncompliance often encounter care patients issue along variety agerelated physiologic change presence multiple medical illnesses place elderly increase risk adverse drug reactions especially worrisome use longacting benzodiazepines anticholinergic medications population problem adverse drug reactions common clinical problem great public concern number older persons unite state continue grow response variety proactive measure develop measure include development consensus criteria inappropriate medications federal government regulation expansion role clinical pharmacists computerassisted prescribe protocols',\n",
       " 'evaluate ability antihypertensive therapy improve arterial stiffness assess aortic pulse wave velocity pwv large population hypertensive patients',\n",
       " 'beneficial effect spironolactone additive ace inhibitors among patients heart failure andor hypertension however essential identify patients prone develop serious hyperkalemia combine treatment evaluate associate morbidity mortality',\n",
       " 'extensive animal study grow number human clinical trials definitively demonstrate central role reninangiotensinaldosterone system expression modulation cardiovascular disease contrast original hypothesis benefit angiotensin antagonism not emanate antihypertensive effect alone subsequent extensive investigations angiotensin blockade suggest benefit approach may also result pharmacologic alteration endothelial cell function ensue change biology vasculature recent availability direct antagonists angiotensin receptor introduce element doubt realm clinical decision make receptor antagonists widely study convertingenzyme inhibitors share many endpoint attribute nevertheless partially overlap mechanisms action two class angiotensin antagonists confer distinct pharmacologic properties include side effect profile mechanisms action theoretic salutary effect upon expression cardiovascular disease current review attempt contrast biology angiotensin convertingenzyme inhibition angiotensin ii receptor antagonism discussion differential effect drug class endothelial cell function modulation vascular disease utilize provide theoretic framework clinical decision make therapeutics',\n",
       " 'determine antihypertensive efficacy effect duration safety angiotensin ii type receptor blocker candesartan cilexetil angiotensin convert enzyme inhibitor enalapril daily patients mild moderate hypertension',\n",
       " 'black patients heart failure poorer prognosis white patients difference not adequately explain whether racial differences response drug treatment contribute differences outcome unclear address issue pool analyze data study leave ventricular dysfunction solvd prevention treatment trials two large randomize trials compare enalapril placebo patients leave ventricular dysfunction',\n",
       " 'study design investigate effect delapril ace inhibitor manidipine long action calcium antagonist persistent microalbuminuria normotensive type diabetic patients sixty type diabetic patients randomize take delapril mgday manidipine mgday weeks open label design twenty eight thirty subject delapril group twenty nine thirty manidipine group complete study urine albumin excretion measure urinary albumin creatinine ratio decrease significantly group mgg mgg delapril manidipine group respectively p pair ttest systolic diastolic blood pressure not significantly change treatment delapril group significantly decrease manidipine group mmhg p student pair ttest weeks treatment two patients delapril group one patient manidipine group convert normoalbuminuria urinary albumin creatinine ratio mgg one patient group progress overt nephropathy urinary albumin creatinine ratio mgg no significant change fast plasma glucose hbac serum fructosamine creatinine potassium lipid profile weeks treatment group two case delapril group withdraw study intolerable cough one case manidipine group intolerable dizziness headache conclusion delapril manidipine effective reduction microalbuminuria normotensive type diabetic patients persistent microalbuminuria',\n",
       " 'purpose study evaluate prospective doubleblind placebocontrolled study effect longterm year lisinopril treatment cardiovascular endorgan damage patients previously untreated isolate systolic hypertension ish patients ish derive population screen program endorgan damage measurements initially months treatment include measurements aortic distensibility echocardiographic leave ventricular mass index lvmi diastolic function blood pressure measure office ambulatory measurements subject ish select screen lisinopril complete study accord protocol office blood pressure decrease group ambulatory result significantly decrease lisinopriltreatment aortic distensibility increase significantly lisinopril oppose decrease placebotreated subject main effect increase distensibility occur months whereas ambulatory blood pressure change mainly first months treatment lvmi decrease treatment group significantly higher reduction lisinopriltreated subject leave ventricular diastolic function show no significant change either group vascular pathophysiologic alterations isha decrease aortic distensibilitycan improve longterm lisinopril treatment whereas value deteriorate placebotreated subject result one first study include subject previously untreated ish indicate lisinopril treatment might favorably influence cardiovascular risk ish',\n",
       " 'myocardial infarction stroke heart failure endstage renal disease link inadequate control blood pressure despite overwhelm evidence uncontrolled hypertension responsible sizeable number adverse healthrelated outcomes control disease remain considerably suboptimal available data demonstrate order achieve adequate blood pressure control large number patients require therapy one medication fix dose combination antihypertensive therapy many advantage treatment options positive effect blood pressure control rat adherence adverse effect cost identify amlodipinebenazepril lotrel novartis fix dose combination product indicate treatment hypertension although not currently recommend firstline therapy study confirm combination longacting calcium antagonist angiotensinconverting enzyme ace inhibitor possess substantial blood pressure lower capabilities whereas adverse events tend become frequent increase dose antihypertensive monotherapy rate adverse events attribute amlodipinebenazepril clinical trials often correlate rat ascribe placebo amlodipinebenazepril capable sustain blood pressure control h period appear minimally affect occasional dose omission unlike older calcium antagonists amlodipine unlikely cause alterations myocardial contractility additionally amlodipinebenazepril combination product cost less therapy administer individual components therefore reasonable consider therapy amlodipinebenazepril appropriate patients adequate trial antihypertensive monotherapy',\n",
       " 'short review present historical perspective treatment hypertension highlight current issue look possible future antihypertensive therapy distribution blood pressure within population adopt continuous albeit somewhat skew distribution constitute hypertension conventionally disease define level blood pressure mmhg accept arbitrary definition infer approximately one quarter adult population us hypertensive [ ] significant implications term impact upon public health know treatment hypertension prevent serious consequences cardiovascular disease stroke myocardial infarction mi heart failure renal disease thus important raise blood pressure detect effectively lower level blood pressure reduce conventionally level mmhg use define normotension indications certain circumstances not target question also arise whether matter blood pressure treat choice agent may ultimately depend upon presence concomitant condition risk factor recent trial evidence conclude therapy select treat raise blood pressure take account overall cardiovascular risk profile patient [ ]',\n",
       " 'set soar popularity postmarketing study calcium channel blockers come suggest increase variety major adverse end point evidence however largely observational largescale trials capable address concern want clinical trials support safety efficacy longacting dihydropyridines patients uncomplicated diabetic hypertension although conventional therapies latter case angiotensinconverting enzyme inhibitors superior proof benefit contrast shortacting dihydropyridines avoid acute coronary syndromes betablockers remain treatment choice evidence nondihydropyridines remain inconclusive stable angina call betablockers firstline therapy nondihydropyridines secondline therapy whereas ventricular dysfunction safety data nondihydropyridines lack initial report cancer bleed suicide contradict subsequent data make associations uncertain unlikely remain question await completion ongoing trials better define indications agents',\n",
       " 'dd genotype angiotensini convert enzyme ace deletion allele polymorphism possible genetic risk factor restenosis coronary stent implantation aim establish whether not blockade ace high dose ace inhibitors could reduce risk angiographic restenosis',\n",
       " 'study whether administration mg ramipril daily compare placebo treatment reduce urinary albumin excretion rate uaer normotensive patients type diabetes',\n",
       " 'angiotensinconverting enzyme inhibitors improve endothelial function inhibit experimental atherogenesis decrease ischemic events quinapril ischemic event trial design test hypothesis quinapril mgday would reduce ischemic events occurrence cardiac death resuscitate cardiac arrest nonfatal myocardial infarction coronary artery bypass graft coronary angioplasty hospitalization angina pectoris angiographic progression coronary artery disease patients without systolic leave ventricular dysfunction total patients randomize quinapril mgday placebo follow mean months incidence ischemic events similar group rr confidence interval p also no significant difference incidence patients angiographic progression coronary disease p rate development new coronary lesions also similar group p however difference incidence angioplasty new previously unintervened vessels p quinapril well tolerate patients angioplasty normal leave ventricular function quinapril mg not significantly affect overall frequency clinical outcomes progression coronary atherosclerosis however absence demonstrable effect quinapril may due several limitations study design',\n",
       " 'antihypertensive treatment presently recommend type diabetic patients microalbuminuria longterm effect angiotensin convert enzymes ace inhibitor acei treatment exercise urinary albumin excretion euae exercise blood pressure ebp type diabetic patients low grade microalbuminuria not well document addition possible predictive effect baseline euae progression overnight uae remain clarify',\n",
       " 'study effect acei type diabetic patients early microalbuminuria regard uae ii h ambp include effect diurnal bp variation iii renal haemodynamics',\n",
       " 'hypertension find among young women treatment aim decrease cardiovascular risk magnitude less dependent absolute level blood pressure bp associate cardiovascular risk factor hypertensionrelated target organ damage andor concomitant disease lifestyle modifications recommend hypertensive individuals threshold bp antihypertensive therapy initiate base absolute cardiovascular risk young women low risk not need antihypertensive therapy antihypertensive agents appear equally efficacious choice depend personal preference social circumstances agent effect cardiovascular risk factor target organ damage andor concomitant disease although agents appropriate tolerate well young women another consideration remain pregnancy unplanned clinician must aware woman method contraception potential antihypertensive agent cause birth defect follow inadvertent exposure early pregnancy conversely oral contraceptive effective well tolerate woman bp become mildly elevate continue contraceptive initiate antihypertensive treatment may not contraindicate especially ability plan pregnancy important e g type diabetes mellitus no commonly use antihypertensive know teratogenic although ace inhibitors angiotensin receptor antagonists discontinue antihypertensive drug continue pregnancy anticipate benefit outweigh potential reproductive risk hypertensive disorder pregnancy complicate pregnancies lead cause maternal perinatal mortality morbidity treatment aim improve pregnancy outcome consensus severe maternal hypertension systolic bp mm hg andor diastolic bp mm hg treat immediately avoid maternal stroke death possibly eclampsia parenteral hydralazine may associate higher risk maternal hypotension intravenous labetalol neonatal bradycardia no consensus whether mildtomoderate hypertension pregnancy treat risk transient severe hypertension antenatal hospitalisation proteinuria delivery neonatal respiratory distress syndrome may decrease therapy intrauterine fetal growth may also impair particularly atenolol methyldopa betablockers use extensively report bias uncertainty outcomes define warrant cautious interpretation find preclude treatment recommendations',\n",
       " 'impair erectile function men component dysmetabolic syndrome high blood pressure well sequela antihypertensive therapy prospective interventional study men uncontrolled hypertension blood pressure mm hg use survey instrument assay sexual dysfunction therapy losartan',\n",
       " 'test hypothesis hypercoagulable state hypertension significantly alter antihypertensive therapy conduct pilot prospective randomise doubleblind trial untreated hypertensive patients males mean age years treat either enalapril mg per day losartan mg per day weeks thrombogenicity assess measurement plasma fibrinogen soluble pselectin index platelet activation plasminogen activator inhibitor pai index fibrinolysis von willebrand factor index endothelial dysfunction baseline von willebrand factor alone significantly higher untreated hypertensive patients compare control p follow weeks treatment enalapril mean dose mgday losartan mean dose mgday significant reduction mean blood pressure mmhg baseline mmhg posttreatment p however no statistically significant change level haemostatic markers von willebrand factor fibrinogen spsel pai pilot study confirm previous observations endothelial dysfunction hypertensives however plasma fibrinogen indices platelet activation fibrinolysis endothelial dysfunction not significantly affect antihypertensive treatment enalapril losartan despite satisfactory blood pressure control',\n",
       " 'prevalence chronic renal disease increase worldwide chronic nephropathies lack specific treatment progress relentlessly endstage renal disease however research animals people help understand mechanisms progression indicate possible preventive methods notion renoprotection develop combine approach renal diseases main measure pharmacological control blood pressure reduction proteinuria lower blood lipids smoke cessation tight glucose control diabetes also form part multimodal protocol management renal patients available treatments dialysis postpone many patients chronic nephropathies real goal less dialysisin word remission disease regression structural damage kidney experimental clinical data lend support notion less dialysis maybe none patients least possible',\n",
       " 'prolong angiotensinconverting enzyme ace inhibitor therapy lead angiotensin ang accumulation may ` ` escape ace inhibition generate ang ii stimulate ang ii subtype receptor exert deleterious renal effect patients chronic renal diseases test hypothesis losartan therapy add background chronic months maximal ace inhibitor therapy lisinopril mg q result additional ang ii antagonism patients proteinuric chronic renal failure hypertension',\n",
       " 'acute renal failure well recognize complication use angiotensinconverting enzyme inhibitors patients severe bilateral renovascular disease yearold woman present acute pulmonary edema intractable hypertension history lower limb claudication addition lisinopril antihypertensive regimen result within h development acute renal failure remit cessation drug find heavily calcify occlusion aortic arch another occlusion aorta renal arteries angiography doppler ultrasonography show normal renal arteries first report case angiotensinconverting enzyme inhibitorinduced renal failure occur patient atherosclerotic occlusion aorta literature suprarenal aortic occlusion review determine manner presentation prevalent risk factor physical find typify unique clinical entity',\n",
       " 'pharmacological treatment hypertension show reduce risk stroke coronary events heart failure progression renal disease however rat successful blood pressure control remain low among treat patients antihypertensive medication represent large increase proportion healthcare expenditure many countries several influential pharmacoeconomic analyse confirm cost effectiveness conventional antihypertensive treatments usually involve monotherapy diuretics betablockers compare alternative strategies recent research show considerable proportion total cost antihypertensive treatment general practice due factor inadequate blood pressure control poor compliance therapy discontinuation switch therapies factor operate much lesser extent wellconducted clinical trials not fully incorporate economic study novel strategies particularly low dose combinations antihypertensive agents may offer advantage term efficacy reduce adverse effect improve compliance treatment therefore need comprehensive pharmacoeconomic analyse novel strategies take additional factor account study available wider use low dose combination therapy novel strategies not hold back basis earlier economic study not include relevant considerations',\n",
       " 'purpose study compare safety tolerability recommend initial dose fosinopril fos captopril cap diuretictreated salt deplete ` ` high risk patients congestive heart failure thirty patients randomize double blind fashion receive single dose either fos mg cap mg placebo cap produce significant early brief fall bp firstdose hypotensive response fos not differ significantly placebo baseline plasma angiotensin convert enzyme ace activity similar group cap show acute significant fall plasma ace activity whereas fos placebo not change ace activity no correlation mean arterial pressure percentile change mean arterial pressure plasma ace activity also no correlation find high low ace activity level first dose hypotension practical importance result patients congestive heart failure fos cap different effect bp first dose effect may dependent plasma ace activity level fos produce ace inhibition bp change similar placebo safer choice treatment congestive heart failure',\n",
       " 'investigate frequency general practitioner awareness patients chronic heart failure chf evaluate cardiac algorithm document cardiac investigations perform establish diagnosis',\n",
       " 'incidence endstage renal disease due hypertension increase recent decades optimal strategy treatment hypertension prevent renal failure unknown especially among african americans',\n",
       " 'multicentre randomize doubleblind study compare antihypertensive efficacy safety oral oncedaily imidapril mg hydrochlorothiazide mg elderly patients mildtomoderate essential hypertension weeks treatment significant reduction mean sit diastolic blood pressure mmhg mmhg imidapril group n mmhg mmhg hydrochlorothiazide group n intenttotreat population correspond reductions sit systolic blood pressure stand blood pressure least one adverse event report patients imidapril group patients hydrochlorothiazide group imidapril mg effective well tolerate hydrochlorothiazide treatment mildtomoderate hypertension elderly patients',\n",
       " 'treatment hypertension patients chronic renal failure show postpone decline renal function treatment ace inhibitor show superior conventional antihypertensive treatment not know ace inhibitor compare treatment calcium channel blocker treatment combination drug aim study evaluate rate decline gfr patients chronic renal failure hypertension treat isradipine spirapril monotherapy combination',\n",
       " 'isolate systolic hypertension affect people older years elderly systolic hypertension major modifiable cardiovascular risk factor systolic blood pressure associate higher risk adverse outcome whereas diastolic blood pressure inversely correlate total mortality independent systolic blood pressure highlight role pulse pressure risk factor three placebocontrolled outcome trials antihypertensive drug treatment older patients isolate systolic hypertension publish systolic hypertension elderly program shep systolic hypertension europe systeur trial systolic hypertension china systchina trial three trials demonstrate benefit antihypertensive drug treatment metaanalysis perform pool patients three trials subset patients isolate systolic hypertension five trials elderly antihypertensive treatment base calciumchannel blocker may provide additional benefit diabetic patients prevention dementia renal dysfunction pool result older patients isolate systolic hypertension prove antihypertensive drug treatment justify repeat clinic measurements systolic blood pressure mmhg higher',\n",
       " 'perindopril erbumine perindopril prodrug ester perindoprilat angiotensin convert enzyme ace inhibitor perindopril mg daily significantly reduce supine systolic blood pressure sbp diastolic blood pressure dbp baseline value hypertensive patients reductions maintain least hours evidence troughpeak ratios vascular abnormalities associate hypertension improve normalise perindopril treatment perindopril mg daily significantly decrease carotidfemoral aortic pulse wave velocity pwv improve arterial compliance reduce leave ventricular mass index patients recent cerebral ischaemia andor stroke preserve cerebral blood flow despite significantly reduce sbp dbp research need establish significance promise result show reductions aortic pwv associate reduce mortality patients endstage renal failure third receive perindopril response rat number patients supine dbp mm hg significantly higher perindopril mg daily captopril mg twice daily randomise doubleblind trials clinical trials antihypertensive effect perindopril similar ace inhibitors include enalapril calciumchannel antagonists combination treatment perindopril antihypertensive agent another treatment class provide additional benefit either firstline treatment patients fail respond monotherapy perindopril monotherapy also effective elderly patients hypertension concomitant disease perindopril similar adverse event profile ace inhibitors cough common event report treatment also common adverse event responsible treatment withdrawal',\n",
       " 'test primary hypothesis newer antihypertensive treatment regimen calcium channel blocker angiotensin convert enzyme inhibitor effective older regimen betablocker diuretic primary prevention coronary heart disease chd test second primary hypothesis statin compare placebo protect chd endpoints hypertensive subject total cholesterol mmoll',\n",
       " 'aim study evaluate antihypertensive efficacy tolerability lowdose combination angiotensinconverting enzyme inhibitor perindopril mg plus diuretic indapamide mg pi compare angiotensin ii antagonist losartan mg l treatment essential hypertension patients n randomise doubleblind allocate receive either pi l daily period weeks responder normalisation rat two group compare chi test ambulatory blood pressure monitor result compare use onetailed student ttest normalisation rat significantly greater pi group l group p responder rat significantly higher pi group l group p average blood pressure reductions ssbp pil mmhg ci sdbp pil mmhg ci average nighttime sbp decrease abpm significantly greater pi group p tolerability comparable two group term emergent adverse events relate treatment pi patients l patients laboratory evaluations not show significant variations conclude lowdose pi combination significantly higher responder normalisation rat l study also confirm good tolerability treatments',\n",
       " 'cigarette smoke pernicious risk factor pathogenesis coronary artery disease endothelial dysfunction important antecedent event process important cigarette smoke directly toxic endothelial cells inhibitors angiotensinconverting enzyme ace show improve endothelial function diabetes hypercholesterolaemia promise option smokers treat subject age years means weeks mg lisinopril randomize control trial endothelial function assess measurement forearm blood flow responses intraarterial infusions endothelialdependent independent vasodilators endothelialdependent vasoconstrictor [ acetylcholine sodium nitroprusside monomethyllarginine lnmma respectively ] use venous occlusion plethysmography lisinopril significantly increase forearm blood flow response acetylcholine [ lisinopril means e placebo p confidence intervals ci ] value give ratios flow infuse arm control arm no effect response sodium nitroprusside lisinopril placebo p ci vasoconstrictor response lnmma demonstrate significant improvement lisinopril placebo p ci conclusion result indicate ace inhibition improve endothelial function cigarette smokers show lisinopril improve receptormediated tonic no release mechanism could either lisinopril limit angiotensin iiinduced production superoxide radicals would normally inactivate no lisinopril may increase bradykininmediated no release',\n",
       " 'largescale week openlabel clinical experience trial evaluate efficacy angiotensin ii receptor subtype blocker candesartan cilexetil mg daily either alone addon therapy hypertensive patients study population female african american mean age years include patients essential hypertension hbp patients isolate systolic hypertension ish patients either untreated uncontrolled hypertension systolic blood pressure [ sbp ] mm hg diastolic blood pressure [ dbp ] mm hg inclusive baseline despite variety antihypertensive medications include diuretics calcium antagonists angiotensin convert enzyme ace inhibitors alpha betablockers either singly combination mean baseline blood pressure hbp group mm hg candesartan cilexetil monotherapy hbp patients reduce mean sbpdbp mm hg addon therapy hbp patients various background therapies candesartan cilexetil consistently reduce mean sbpdbp irrespective background therapy diuretics mm hg calcium antagonists mm hg betablockers mm hg ace inhibitors mm hg alphablockers mm hg mean baseline blood pressure ish group mm hg candesartan cilexetil monotherapy ish patients reduce sbpdbp mm hg addon therapy ish patients various background therapies candesartan cilexetil consistently reduce mean sbpdbp irrespective background therapy diuretics mm hg calcium antagonists mm hg betablockers mm hg ace inhibitors mm hg alphablockers mm hg blood pressure lower effect candesartan cilexetil addon therapy see regardless age sex race overall patients withdraw adverse events commonly headache dizziness orthostatic hypotension infrequent candesartan cilexetil alone candesartan cilexetil addon therapy thus candesartan cilexetil either alone addon therapy highly effective control systolic diastolic hypertension regardless demographic background use typical clinical practice settings',\n",
       " 'common carotid artery intimamedia thickness imt progression compare years treatment nifedipine diuretic',\n",
       " 'role reninangiotensinaldosterone system pathogenesis hypertensive disease long recognize interruption cascade angiotensinconverting enzymei beneficial management hypertension recently new class drug angiotensin receptor blockers emerge enlarge antihypertensive armamentarium since elderly patients prone adverse drug reactions paper review several trials short duration efficacy safety angiotensin receptor blockers geriatric population mild moderate hypertension study establish drug welltolerated safe instance efficacious class antihypertensive medications combination therapy angiotensin receptor blockers hydrochlorothiazide additive without significant effect safety profile',\n",
       " 'week multicenter doubleblind randomize parallelgroup forcedtitration study conduct evaluate antihypertensive efficacy candesartan vs losartan hypertensive patients diastolic blood pressure mm hg sit throughout u eligible patients randomize candesartan cilexetil mg daily losartan mg daily two weeks follow randomization patients double respective dose angiotensin receptor blockers additional weeks week candesartan cilexetil lower trough systolicdiastolic blood pressure significantly greater amount losartan mm hg candesartan cilexetil vs mm hg losartan p less period candesartan cilexetil also lower peak blood pressure significantly greater amount losartan mm hg candesartan cilexetil vs mm hg losartan p less statistically significantly p less higher proportion responders control patients candesartan cilexetil group respectively losartan group respectively treatment regimens well tolerate candesartan cilexetil group losartan group withdraw adverse events conclusion forcedtitration study confirm candesartan cilexetil effective losartan lower blood pressure administer daily maximum dose drug well tolerate c le jacq',\n",
       " 'choose initial antihypertensive drug uncomplicated hypertensive patient important frequent event primary care physician patients first experience antihypertensive drug therapy likely affect longterm perception hypertension treatment choice make basis sound scientific data patient perspective need drug take day prove efficacy hypertension control cardiovascular morbidity mortality reduction side effect possible lowdose thiazide diuretics meet description although need monitor electrolytes may make less ideal angiotensin ii receptor antagonist class sideeffects similar placebo control trials attractive patient perspective although outcome trial data not yet exist prove hypertension treatment angiotensin ii receptor antagonists reduce cardiovascular events angiotensinconverting enzyme inhibitors angiotensin ii receptor antagonists low sideeffect profile unique effect vascular remodel attractive second choices combine diuretic need although lowdose diureticbeta blocker combinations also show lower blood pressure minimal side effect present ensure adequate longterm hypertension control important aspect hypertensive care antihypertensive drug physician choose greatly affect hypertensive patient ability achieve maintain longterm blood pressure control c le jacq communications inc',\n",
       " 'hypertensive crisis affect upward americans year although incidence hypertensive crisis low affect fewer hypertensive adults million adult americans suffer hypertension presentation patient severe hypertension emergency room demand immediate evaluation prompt recognition hypertensive emergency urgency prompt institution appropriate therapeutic measure prevent progression targetorgan damage avoid catastrophic event hypertensive emergencies severe elevations blood pressure complicate evidence progressive targetorgan dysfunction coronary ischemia disorder cerebral function cerebrovascular event pulmonary edema renal failure although therapy parenteral antihypertensive agents may initiate emergency department patients warrant prompt admission intensive care unit continuous monitor blood pressure assure therapy',\n",
       " 'new york heart association nyha class treadmill exercise test variables widely use estimate prognosis measure outcomes treatment patients heart failure not take patients perceptions account',\n",
       " 'purpose study assess whether longterm years inhibition angiotensinconverting enzyme ace protect kidney function normotensive type diabetic patients diabetic nephropathy',\n",
       " 'report two case undergo surgery median sternotomy ace inhibitors [ correct ] preoperatively patients develop persistent dry cough postoperatively result sternal wind dehiscence no clinical bacteriological evidence sternal wind infection although one patient overweight moderately impair leave ventricular function no associate risk factor patients undergo rewire sternum type ii receptors inhibitor introduce postrewiring cure persistent dry cough patients enjoy good quality life year months years postrewiring sternum',\n",
       " 'randomize doubleblind placebocontrolled study treatment last weeks withdrawal last weeks try determine whether stop nitrate effect leftventricular endsystolic volume patients heart failure chronically treat captopril diuretics',\n",
       " 'study design mainly establish rat response valsartan mg daily qd valsartan mg qd give nonresponders mg qd well determine safety valsartan blood pressure control achieve use valsartan period h use ambulatory blood pressure monitor abpm devices',\n",
       " 'mild moderate hypertension still remain poorly control relate multiple factor include low antihypertensive efficacy single drug therapies reluctance primary care physicians modifytitrate initially choose therapy obtain target blood pressure poor compliance medication several guidelines treatment high blood pressure include combination therapy low dose drug one strategies initial management mildmoderate arterial hypertension evidence discuss article point superior control blood pressure combinations low dose drug compare monotherapy regular dose superior effectiveness combine therapy relate better antihypertensive efficacy higher response rat low range dose result complementary mechanisms antihypertensive effect better tolerance result lower rate adverse effect low dose range improve compliance better tolerance simple drug regimen lower cost whether increase use fix low dose combination therapies would translate better control arterial hypertension population thereby reduction cardiovascularcerebrovascular morbidity mortality cause hypertension remain assess',\n",
       " 'bamidipine antihypertensive drug belong dihydropyridine dhp group calcium antagonists available modifiedrelease formulation gradual onset action effective single daily oral dose mg bamidipine selective action cardiovascular calcium antagonist receptors antihypertensive action relate reduction peripheral vascular resistance secondary vasodilatory action clinical antihypertensive efficacy barnidipine similar dhp calcium antagonists nitrendipine amlodipine antihypertensives belong drug class atenolol enalapril barnidipine find efficacious well tolerate hydrochlorothiazide management hypertension elderly patients barnidipine generally well tolerate dhp calcium antagonists vasodilator adverse events headache flush peripheral oedema account adverse events report use usually transient oedema less frequent amlodipine nitrendipine use not associate reflex tachycardia',\n",
       " 'cardiac remodel case hypertension induce hypertrophy myocytes elevate collagen content subsequently impair diastolic fill leave ventricle purpose prospective study evaluate change leave ventricular lv myocardial mass well diastolic fill properties hypertensive patients treat ace inhibitor fosinopril sixteen hypertensive patients echocardiographically document lv hypertrophy diastolic dysfunction receive fosinopril mg daily measurements lv myocardial mass properties diastolic fill peak fill fraction pff peak fill rate pfr perform prior medication well months therapy use cine magnetic resonance image mri ten healthy subject serve control group lv myocardial mass gm decrease continuously within months followup vs vs gm p extent regression correlate severity lv hypertrophy baseline r p early diastolic fill increase significantly within months therapy pff vs p pfr mlsecond vs p cine mri use assess time course pharmacological effect cardiac remodel course hypertension ace inhibitor therapy result significant reduction lv mass within months accompany normalization diastolic fill complete months',\n",
       " 'determine whether circulate plasma vascular endothelial growth factor vegf elevate presence diabetic microvascular complications whether impact angiotensinconverting enzyme ace inhibitors complications account change circulate vegf',\n",
       " 'whether angiotensinconverting enzyme ace inhibitors clinically significant antiatherogenic effect humans remain unproven undertake prospective randomize clinical trial patients noninsulindependent diabetes mellitus niddm examine efficacy ace inhibition enalapril prevent intimamedia im thicken carotid wall measure ultrasonographically',\n",
       " 'paper review effect medical treatment renal function patients congestive heart failure examine data largescale heart failure study angiotensinconverting enzyme inhibitors angiotensin receptor blockers calcium channel blockers betareceptor blockers aldosterone antagonist vasopeptidase inhibitor renal outcome report almost study angiotensinconverting enzyme inhibitors despite concern renal adverse events drug class seem safe patients congestive heart failure contrast not find report renal function patients treat betareceptor blockers congestive heart failure',\n",
       " 'et selective dual et ab receptor antagonists favourable short longerterm haemodynamic action patients acute chronic heart failure effect neurohumoral measure not yet fully determine two moderately large mediumduration study examine effect dual et ab receptor antagonists clinical status reach conflict conclusions one large scale longterm morbidity mortality evaluation underway bosentan',\n",
       " 'examine efficacy ace inhibitors treatment nondiabetic renal disease',\n",
       " 'compare relationships plasma concentrations c perindoprilat active metabolite angiotensin iconverting enzyme inhibitor acei perindopril effect e induce plasma convert enzyme activity pcea brachial vascular resistance bvr healthy volunteer hv congestive heart failure chf patients single oral dose perindopril',\n",
       " 'week multicentre sit us doubleblind randomise parallel group force titration study compare antihypertensive efficacy candesartan cilexetil losartan total patients essential hypertension diastolic blood pressure mm hg randomise initially candesartan cilexetil mg daily losartan mg daily weeks randomise treatment dose candesartan cilexetil losartan double mg mg daily continue respectively weeks week candesartan cilexetil lower blood pressure bp h trough h peak h post dose significantly greater extent p losartan candesartan cilexetil lower trough bp mm hg peak bp mm hg h bp mm hg compare reduction trough bp mm hg peak bp mm hg h bp mm hg losartan responder control rat numerically higher candesartan cilexetil group differences not reach statistical significance responder rat candesartan cilexetil group losartan group control rat candesartan cilexetil group losartan group overall treatment regimens well tolerate total patients withdraw study due adverse event include nine candesartan cilexetil group six losartan group conclusion force titration study confirm candesartan cilexetil effective lower bp losartan compare daily maximum dose',\n",
       " 'compare efficacy tolerability safety oncedaily therapy amlodipine mgbenazepril mg vs amlodipine mg benazepril mg placebo',\n",
       " 'ramipril efficacy nephropathy rein trial ramipril significantly lower rate reach combine endpoint double baseline serum creatinine level endstage renal failure esrf',\n",
       " 'leave ventricular hypertrophy lvh hypertensive subject associate increase prevalence ventricular arrhythmias evaluate effect antihypertensive treatment cardiac arrhythmias ca transient episodes myocardial ischemia temi study hypertensive patients lvh divide four group randomly treat enalapril hydrochlorothiazide hctz atenolol verapamil srv months office blood pressure office heart rate value record basal condition months treatment patients undergo echocardiography electrocardiographic holter monitor stress test drug significantly lower blood pressure whereas leave ventricular mass index reduce atenolol enalapril srv not hctz treatment induce significant reduction number patients supraventricular arrhythmias v p v exclude patients treat hctz p number patients ventricular arrhythmias also reduce v consider group p v exclude patients treat hctz p number temi holter monitor significantly decrease p patients p exclude patients treat hctz group irrespective treatment reduction blood pressure heart rate systolic blood pressureheart rate product measure exercise stress test observe present study show hypertensive patients lvh antihypertensive treatment atenolol enalapril srv reduce lvh decrease prevalence ca temi treatment hctz month study not alter lvh not appear reduce ca temi',\n",
       " 'previous clinical trials demonstrate important influence ethnicity dietary salt antihypertensive efficacy drug block renin angiotensin system angiotensin ii receptor blockers new therapeutic entity not widely study african american hypertensives either alone combination therapies diuretics angiotensin convert enzyme inhibitors perform pilot prospective open label randomize design clinical trial evaluate effect angiotensin ii receptor blocker valsartan mg day systolic diastolic blood pressure hypertensive african americans n low salt meq naday weeks diet supplement meq na weeks evaluation continue na supplementation patients randomize valsartan mgday n addition hydrochlorothiazide hctz mgday n benazepril mgday valsartan mgday additional weeks valsartan mgday lower blood pressure significantly african american patients low salt mm hg p high salt diet mm hg p high salt diet attenuate antihypertensive effect slightly mm hg p not significant compare efficacy three randomize therapeutic regimens na supplement valsartan mghctz mg effective therapy incremental reduction blood pressure mm hg p compare valsartan mgday alone double dose valsartan mg incrementally lower blood pressure mm hg p not significant least effective approach add benazepril mgday valsartan mgday no incremental reduction systolic blood pressure diastolic blood pressure reduction mm hg p not significant conclude open label pilot study antihypertensive activity valsartan not significantly attenuate supplement salt diet hypertensive african americans moreover add low dose hctz appear effective strategy enhance antihypertensive activity angiotensin ii receptor blocker contrast either double dose add angiotensin convert enzyme inhibitor',\n",
       " 'test hypothesis antihypertensive response angiotensin convert enzyme ace inhibition predict response angiotensin ii type receptor atr antagonism hypertensive patients randomize receive lisinopril mg losartan mg weeks patients crossedover alternative treatment second week period twentyfourhour ambulatory bp abp measure randomization final day period agreement abp response two drug assess use follow approach subject classify responders nonresponders use threshold arbitrary level response abp fall mm hg systolic mm hg diastolic median abp response achieve drug disagreement two drug respondersnonresponders classification express proportion subject whose abp respond one drug lisinopril effective losartan reduce abp mean difference mm hg systolicdiastolic p disagreement antihypertensive response two drug find subject systolicdiastolic abp use arbitrary response criterion use median response criterion significant correlations find responses lisinopril losartan r systolicdiastolic p conclude one third hypertensive subject bp response ace inhibition fail predict response atr antagonism vice versa data suggest differences two drug class not theoretical also practical significance',\n",
       " 'fix lowdose combination ace inhibitor perindopril nonthiazide diuretic indapamide evaluate management patients mild moderate hypertension combination therapy aim improve overall therapeutic efficacy minimise adverse effect welldesigned multicentre clinical trials perindoprilindapamide dose range mgday significantly effective placebo achieve adequate blood pressure bp control similar reduction supine bp observe combine perindoprilindapamide mgday compare losartan mgday atenolol mgday similar reductions hour ambulatory bp also see perindoprilindapamide mgday irbesartan mgday however response normalisation rat significantly higher combination therapy losartan irbesartan monotherapy combine perindoprilindapamide mgday therapy effectively reduce bp elderly patients age years significantly greater extent either atenolol mgday placebo supine bp also normalise approximately twothirds patients small noncomparative trial patients hypertension renal impairment lowdose perindoprilindapamide mgday well tolerate clinical trials common adverse events headache cough hypokalaemia associate use diuretics occur higher incidence combine perindoprilindapamide mgday therapy either atenolol mgday placebo perindoprilindapamide mgday show efficacy well design comparative trials atenolol losartan irbesartan include elderly patients patients renal impairment study compare dosage perindopril indapamide combination therapies would beneficial allow place perindoprilindapamide accurately determine fixedlow dose combination perindoprilindapamide provide promise well tolerate treatment option management patients mild moderate hypertension',\n",
       " 'angiotensinconverting enzyme ace inhibitors among firstchoice drug treat hypertension congestive heart disease report however drug could induce chronic cough airway hyperresponsiveness aim work assess pig effect bradykinin tachykinins citricacidinduced cough ace inhibitor pretreatment cough induce challenge pig aerosol citric acid min cough count train observer min animals undergo two cough induction test two days apart days first take control drug inject intravenously min second challenge control group no difference observe days ace inhibitor enalapril microgkg cause cough frequency increase significantly contrast doserelated decrease observe hoe icatibant bradykinin b receptor antagonist mgkg drug administer simultaneously microgkg enalapril mgkg hoe significant increase observe compare control value obtain day enalapril combine three tachykinin receptor antagonists sr nk receptor antagonist sr nk receptor antagonist sr nk receptor antagonist significant decrease observe compare control value obtain day percentage variation also significantly different compare observe enalapril group dose data suggest aceinhibitorinduced enhancement cough reflex mainly due tachykinins not bradykinin pig model bradykinin however play major role cough induce citric acid alone',\n",
       " 'eosinophilic gastroenteritis rare disorder unknown etiology describe case yearold woman chronic diarrhea eosinophilia small bowel biopsy reveal eosinophils large cluster lamina propria focal infiltration epithelium patient diarrhea eosinophilia start shortly enalapril prescribe patient instruct stop take drug diarrhea promptly cease blood eosinophil level return normal first report case eosinophilic gastroenteritis associate angiotensinconverting enzyme inhibitor eosinophilic gastroenteritis entertain differential diagnosis patients take angiotensinconverting enzyme inhibitors develop diarrhea gastrointestinal symptoms',\n",
       " 'cardiovascular disease dominant cause death renal transplant recipients leave ventricular hypertrophy lvh know risk factor renal transplantation persistent hypertension important determinant evolution lvh aim present study compare effect angiotensin convert enzyme ace inhibitor lisinopril calcium channel blocker ccb control release nifedipine treatment posttransplant hypertension focus change lvh',\n",
       " 'liquid oral medicine form significant proportion medicine use population whole either prescribe counter active agent well ingredients pose threat oral health',\n",
       " 'goal investigate effect antihypertensive drug juxtaglomerular apparatus jga young type diabetic patients microalbuminuria',\n",
       " 'compare net cost tight blood pressure control policy angiotensin convert enzyme inhibitor captopril beta blocker atenolol patients type diabetes',\n",
       " 'nonpeptide orally active angiotensin ii type receptor antagonists specific mean presently available block reninangiotensin enzymatic cascade six drug already license europe unite state treatment high blood pressure additional candidates pipeline world health organisation also recently endorse use condition inasmuch receptor antagonists prove equal angiotensin convert enzyme inhibitors respect antihypertensive efficacy demonstrate better safety profile class drug may consider qualitative improvement treatment essential hypertension interestingly six agents market diverge considerably respect pharmacokinetic pharmacodynamic properties although not certain whether differences clinically relevant considerable number large multicentre trials progress ascertain possible longerterm organoprotective effect substances cardiovascular morbidity mortality noteworthy safety record date simple onceaday dosage regimen receptor antagonists potential improve compliance patients chronic hypertension',\n",
       " 'week doubleblind parallelgroup comparative trial adult patients mildtomoderate hypertension randomly allocate receive imidapril captopril initially dose mg day mg twice daily respectively weeks therapy dose drug increase twice diastolic blood pressure dbp remain mm hg treatments effectively lower dbp comparable manner mean change baseline dbp weeks mm hg imidapril mm hg captopril p responder rat patients receive active treatment least weeks imidapril captopril p treatments well tolerate adverse drug reactions observe imidapril group captopril group p cough frequent side effect report imidapril group captopril group result indicate imidapril effective captopril treatment hypertension imidapril produce less adverse effect compare captopril',\n",
       " 'substantial evidence support role natriuretic peptides major defence mechanism excess salt water retention high blood pressure considerable interest therapeutic potential natriuretic peptide system several approach explore include use native peptides development natriuretic peptides mimetics targetting endogenous clearance natriuretic peptides anp bnp administration may valuable circumstances however limitations use peptides especially longterm treatment well apparent view considerable effort devote development orally active agents enhance endogenous natriuretic peptides inhibition breakdown neutral endopeptidase research lead vasopeptidase inhibitors dual inhibitors endopeptidase angiotensin convert enzyme agents clearly provide novel approach enhance endogenous natriuretic peptide function background reduce angiotensin ii activity may lead important advance treatment hypertension condition associate overt salt water overload',\n",
       " 'trials patients leave ventricular dysfunction heart failure ace inhibitor use unexpectedly associate reduce myocardial infarction mi use heart outcomes prevention evaluation hope trial data test prospectively whether ramipril ace inhibitor could reduce coronary events revascularization procedures among patients normal leave ventricular function',\n",
       " 'effect quinapril nifedipine platelet aggregation vascular endothelial function coagulation system activity compare parallelgroup investigatorblind study carry patients mild moderate hypertension no diseases receive medication might affect platelet function vascular endothelium coagulation forty patients two group patients control subject recruit patients randomise receive either quinapril nifedipine retard dose escalate control hypertension platelet aggregation study assess serially betathromboglobulin angiotensinconverting enzyme ace von willebrand factor vwf coagulation factor viiic xii fibrinogen measure begin end week period blood pressure adequately control patients group platelet function impair certain parameters slope reaction adp collagen maximum aggregation collagen patient group compare control treatment improve patients quinapril not nifedipine likewise betathromboglobulin higher patient group fell significantly quinapril group not nifedipine measurements endothelial function coagulation normal treatment show no alteration study except expect fall plasma ace quinapril group result indicate ace inhibitor quinapril beneficial effect platelet function unlike calcium channel blocker nifedipine',\n",
       " 'potential risk factor preventability druginduced threats life study case report adverse drug events ades publish clinalert source information druginduced life threats patient drug event variables identify causality predictability preventability case assess data enter relational database analysis data indicate druginduced life threats seventyfour percent case assess definite probable patients receive usual belowusual dosages case patients tend middleaged moderately ill drug categories frequently associate life threats antimicrobials centralnervoussystem agents plasma drug level monitor perform case occur case event type distribute adverse drug reactions allergic reactions drug interactions medication errors commercial reference classify almost half drug interactions associate life threat pose minimal no potential risk patient half lifethreatening events judge preventable half could prevent pharmacist litigation report case druginduced threats life judgments settlements average million review publish case report ades yield information possible risk factor druginduced life threats events may preventable',\n",
       " 'summary analysis three descriptive study significant adverse drug events ades conduct case report ades publish clinalert source information ades include druginduced deaths disabilities threats life result three study compare recommendations make year period significant ades report result death permanent disability life threats event type distribute adverse drug reactions allergic drug reactions medication errors drug interactions drug interactions classify highest significance one drug information reference drug interactions unclassified typically patients years old relatively healthy moderately ill receive usual dosages however patients druginduced permanent disability less years old drug could monitor blood level test monitor drug categories commonly involve ades centralnervoussystem agents antimicrobials antineoplastics cardiovascular agents nervous hematopoietic cardiovascular respiratory systems affect faulty prescribe common reason medication error wrong dosage common type error lawsuit report case overall case judge preventable could prevent pharmacist litigation report case settlements judgments average million summary analysis publish case report ades yield information possible risk factor drugrelated deaths disabilities life threats events may preventable',\n",
       " 'angiotensinconverting enzyme inhibitors angiotensin ii receptor subtype antagonists prove effective well tolerate antihypertensive agents also exhibit unique cardioprotective renoprotective properties patients comorbid condition congestive heart failure proteinuria renal insufficiency benefit observe dramatically diabetic persons although inconclusive result limit number clinical trials support notion additive antihypertensive cardioprotective renoprotective effect may obtain combine use angiotensinconverting enzyme inhibitors angiotensin ii receptor subtype antagonists patients study need confirm find preliminary study define clearly subsets patients might derive greatest benefit angiotensinconverting enzyme inhibitorangiotensin ii receptor subtype antagonist combination therapy',\n",
       " 'large artery properties constitute important component leave ventricular afterload hypertension present study examine whether properties particularly responsive angiotensin convert enzyme inhibitor therapy prospective randomize week study previously treat hypertensive subject usual treatment uc replace perindopril p therapy large artery properties assess central arterial pressure augmentation determine applanation tonometry radial artery transfer function baseline augmentation index ai pressure ap mm hg relate body size heart rate gender addition ap relate age systolic blood pressure bp weeks treatment ap decrease significantly perindopril uc group whereas ai decrease significantly treat perindopril decrease ap mm hg v mm hg ai v week week greater perindopriltreated group differences group fail reach statistical significance p respectively change ai week treatment period dependent initial heart rate p systolic bp p weight p sex p not treatment group p al weeks negatively correlate heart rate regression slop association virtually identical perindopril uc group perindopril treatment produce greater decrease ai continuation previous therapy largely explain hemodynamic change rather direct arterial effect',\n",
       " 'uncontrolled hypertension lead increase risk cardiovascular disease stroke hypertensive patients concomitant type diabetes even greater risk cardiovascular complications also highrisk patient population increase risk renal disease ultimately renal failure prospective morbidity mortality trials demonstrate tight blood pressure control improve cardiovascular prognosis provide target organ protection current treatment guidelines recommend target blood pressure mm hg patients hypertension diabetes angiotensin ii aii major component reninangiotensin system play essential role pathophysiology hypertension diabetesrelated renal disease currently treatment choice hypertensive patients diabetes angiotensinconverting enzyme ace inhibition data limit patients type diabetes although ace inhibition clearly mechanism block aii formation inhibition site may not complete alternate pathways exist aii formation thus interrupt reninangiotensin system aii receptor antagonists theoretically provide advantage ace inhibitors directly inhibit aii bind receptor subtype objectives review provide overview associate risk cardiovascular complications concomitant hypertension diabetes demonstrate cardiovascular benefit effective blood pressure control patient population review current treatment guidelines manage highrisk hypertensive patients discuss major ongoing clinical study aii receptor antagonists patients concomitant hypertension type diabetes renal disease c le jacq communications inc',\n",
       " 'september national institute diabetes digestive kidney diseases national institute health call early halt amlodipine arm african american study kidney disease hypertension aask trial careful deliberation independent data safety monitor board interim analysis aask years reveal renoprotective effect angiotensinconverting enzyme inhibitor ramipril compare dihydropyridine calcium channel blocker dhpccb amlodipine patients mild moderate renal insufficiency differential effect independent blood pressure bp level reach evident proteinuric patients suggestive patients baseline proteinuria mgd not conclusive aask trial data suggest dhpccbs use cautiously presence mild moderate renal insufficiency judgment reserve use ccbs verapamil diltiazem since fundamentally different ccbs potential different impact hypertensive nephrosclerosis blind observation period aask complete end september time additional clinically useful information expect become available c le jacq communications inc',\n",
       " 'aim prospective randomize study compare safety efficacy enalapril e losartan l treatment posttransplantation erythrocytosis effect ace genotype response therapy',\n",
       " 'combination perindopril mg indapamide mg approve secondline treatment hypertension failure perindopril alone combination low dose angiotensinconvertingenzyme inhibitor mg perindopril diuretic mg indapamide promote firstline treatment hypertension clinical file preparations limit strict minimum dosefinding study show perindopril mg indapamide mg dose combination offer best riskbenefit ratio comparison combinations contain perindopril dose indapamide dose doubleblind trial suggest antihypertensive activity perindopril mg indapamide mg combination equivalent captopril mg hydrochlorothiazide mg enalapril mg hydrochlorothiazide mg combinations safety profile three combinations mg perindopril combination not compare perindopril monotherapy usual dose mg indapamide monotherapy mean dose mg two combinations costlier competitors',\n",
       " 'international expert group ignore grind rule govern clinical assessment clinical trial data take stance favour drug manufacturers',\n",
       " 'multicentre doubleblind trial patients mild moderate essential hypertension randomize amlodipine enalapril monotherapy week period placebo dose amlodipine mg daily enalapril mg daily titrate achieve office blood pressure mm hg weeks therapy drug similarly effective lower blood pressure goal blood pressure achieve patients treat amlodipine enalapril also degree reduction blood pressure similar group compare initial value systolicdiastolic blood pressure decrease mm hg amlodipine group mm hg subject receive enalapril however adverse effect especially dry cough frequent enalapriltreated patients amlodipine enalapril provide significant blood pressure reduction stage iii hypertension tolerance shortterm therapy good group however number adverse events significantly lower amlodipinetreated patients',\n",
       " 'recent study show steroids improve renal survival reduce proteinuria iga nephropathy igan patients moderate urinary protein excretion normal renal function however effect seem diminish time moreover demonstrate longterm use ramipril reduce risk endstage renal disease proteinuric diabetic nondiabetic chronic nephropathies plan longterm unblinded prospective centrally randomize control multicentric trial assess whether combine treatment steroids ramipril superior ramipril alone patients progressive igan disease minimum patients biopsyproven igan grade g g daily proteinuria g creatinine clearance mlmin enrol year recruitment period patients allocate randomly receive sixmonth course oral prednisone mgkgday months taper mgkgday every month plus ramipril mgday one month increase mgday every month achieve maintain blood pressure less mm hg andor reduce daily proteinuria g less least experimental group ramipril alone control group ramipril administer whole year followup period group primary endpoint renal survival estimate increase baseline serum creatinine secondary endpoints urinary protein cytokine excretion sideeffects analyse intention treat p take significant',\n",
       " 'chronic hypertension occur pregnant women rat vary accord population study criteria use confirm diagnosis complication may result significant maternal fetal neonatal morbidity mortality confusion terminology criteria use diagnose complication well benefit potential harm treatment pregnancy purpose document review effect chronic hypertension pregnancy clarify terminology criteria use define diagnose pregnancy review available evidence treatment options',\n",
       " 'dry cough common limit factor ace inhibitor acei use generation no proinflammatory substance bronchial epithelial cells increase acei use randomize doubleblind placebocontrolled trial test hypothesis supplement iron inhibitor no synthase may reduce cough associate acei use subject patients develop aceiinduced cough week observation period randomize daily morning dose either mg ferrous sulfate tablet placebo treatment period weeks subject request fill cough diary score daily severity cough scale mean daily cough score last week observation treatment period compare change blood cell count serum iron ferritin concentration periods evaluate mean daily cough score observation treatment periods respectively iron group respectively placebo group show significant reduction cough score iron supplementation p not placebo three subject iron group show almost complete cough abolition no significant change laboratory data observe either group conclusion iron supplementation successfully decrease aceiinduced cough effect may relate decrease no generation associate inhibition no synthase activity bronchial epithelial cells',\n",
       " 'congestive heart failure characterize sympathetic activation couple baroreflex impairment whether alterations affect clonidine unknown normotensive patients age years meansem affect congestive heart failure new york heart association functional class ii iii treat furosemide enalapril measure mean arterial pressure heart rate venous plasma norepinephrine muscle sympathetic nerve traffic microneurography rest baroreceptor stimulation deactivation cause stepwise intravenous infusions phenylephrine nitroprusside respectively measurements repeat month administration transdermal clonidine patch patients placebo patients accord doubleblind randomize sequence clonidine cause slight nonsignificant reduction mean arterial pressure heart rate without affect exercise capacity echocardiographically determine leave ventricular ejection fraction contrast plasma norepinephrine sympathetic nerve traffic significantly reduce respectively p reduction couple no change cardiac sympathetic baroreflex responses transdermal placebo administration month period not affect abovementioned variables thus congestive heart failure patients undergo conventional drug treatment chronic clonidine administration exert mark sympathoinhibitory effect without adversely affect cardiac function clinical state whether lead therapeutic benefit remain test',\n",
       " 'examine geographic variations intimeii randomize doubleblind trial compare alteplase lanoteplase myocardial infarction',\n",
       " 'hypertension patients diabetes mellitus type ii not adequately control angiotensinconverting enzyme inhibitors acei betablocker frequently add secondline therapy recently large randomize trials demonstrate beneficial effect secondgeneration dihydropyridine calciumchannel blockers patients compound increasingly use replace betablockers withdrawal betablockers may influence diabetic control may cause rebound hypertension rebound hypertension betablocker withdrawal may not occur betablocker replace calciumchannel blocker calciumchannel blocker influence vascular resistance vr blood pressure differently betablocker thirtyfour patients diabetes mellitus type ii rest diastolic blood pressure mm hg despite enalapril mg daily equipotent dosages acei least months treat open label sequential comparison acei combination betablocker metoprolol mg months subsequently months acei combination dihydropyridine calciumchannel blocker lercanidipine mg daily weeks patients diastolic blood pressure mm hg titrate mg metoprolol mg lercanidipine daily patients examine every weeks trial weeks receive lercanidipine addition blood pressure measurements vr measure iridium strain gauge plethysmography express units unit mm hgml blood ml tissue per minute two patients not complete protocol noncompliance lercanidipine treatment first weeks treatment data include analysis no rebound hypertension days changeover therapies observe mean arterial pressure [ map ] not significantly different point withdrawal betablockers however heart rate rise beatsmin p months lercanidipine map fell mm hg p compare point withdrawal betablocker vascular resistance fell units p glucosylated hemoglobin hbac rise p body weight rise kg p multiple regression analysis reveal significant associations decrease vr increase hbalc decrease map partial dependence variables one another hypertensive patients diabetes type ii replacement acei metoprolol acei lercanidipine not appreciably influence metabolic control not cause rebound hypertension lercanidipine effective metoprolol secondline antihypertensive drug patients least two mechanisms may involve withdrawal pressor effect betablocker calciumchannelmediated vasodilation',\n",
       " 'transtubular potassium gradient ttkg consider reflect mainly aldosterone bioactivity regard kaliuretic response determine ttkg aldosterone serum concentrations patients severe druginduced hyperkalemia dih',\n",
       " 'independent prognostic value elevate jugular venous pressure third heart sound patients heart failure not well establish',\n",
       " 'angiotensinconverting enzyme ace inhibitors reduce urine protein excretion slow progression renal disease beneficial effect slow progression renal disease greater patients higher urine protein excretion onset treatment hypothesize greater beneficial effect ace inhibitors progression renal disease patients higher baseline level proteinuria due greater antiproteinuric effect patients',\n",
       " 'nacetylserylaspartyllysylproline acsdkp physiological inhibitor hematopoiesis maintain stable level normal plasma degradation vivo vitro angiotensinconverting enzyme ace account high plasma concentrations acsdkp patients treat ace inhibitors ace inhibitors induce anemia patients measure plasma acsdkp concentrations patients chronic renal failure hemodialysis hd nondialysis nd patients administer ace inhibitors study relationships acsdkp level hematologic parameters recombinant human erythropoietin rhuepo requirements patients acsdkp level significantly greater hd pmolml nd pmolml patients not administer ace inhibitors control pmolml patients treatment ace inhibitors significantly increase level fourfold hd sessions significantly decrease acsdkp concentrations reduce predialysis vitro halflife acsdkp minutes value minutes not significantly different control nd patients hd patients treat ace inhibitors acsdkp level greater pmolml greatest concentration find nd hd patients group patients weekly dose rhuepo correlate acsdkp level result show renal function essential maintain stable acsdkp plasma level high level acsdkp act uremic toxin cause partial resistance erythropoietin inhibit erythropoiesis',\n",
       " 'several years stress smoke increase alcohol use weight gain accompany hypertension young man ominous family history aid shortterm drug therapy change ways reduce blood pressure long term',\n",
       " 'cutaneous drug reactions frequently occur adverse reactions drug among hospitalize patients incidence reactions range frequency cutaneous reactions specific drug may exceed reactions may range mildly discomforting lifethreatening antiinfective anticonvulsant agents among drug commonly associate adverse reactions skin describe illustrate clinical morphology common cutaneous drug reactions well drug commonly precipitate specific reactions vary nature reactions occur even specific agents indicate multiplicity mechanisms available whereby cutaneous drug reactions may initiate although variety term propose categorize cutaneous drug reactions propose reactions best define base upon mechanisms know review assess current knowledge four categories cutaneous drug reactions immediatetype immunemediated reactions delayedtype immunemediated reactions photosensitivity reactions autoimmune syndromes moreover describe evidence viral infection important predispose factor development cutaneous drug reactions upon drug administration finally review current knowledge type mechanisms cutaneous drug reactions several categories drug',\n",
       " 'consider renovascular hypertension ht newly diagnose hypertension present feature atypical essential hypertension resistant hypertension associate risk factor atheroma angiotensinconverting enzyme ace inhibitor angiotensiniireceptor antagonist therapy associate increase plasma creatinine level atheromatous renovascular ht often manage medically include intensive correction cardiovascular risk factor ace inhibitors probably secondline antihypertensives patients unilateral renal artery stenosis two kidneys firstline antihypertensives diuretics betablockers calciumchannel blockers bilateral renal artery stenosis unilateral stenosis patient one kidney absolute contraindication ace inhibition',\n",
       " 'endotheliumdependentnitric oxide no mediated vasodilation impair hypertensive individuals asymmetric dimethylarginine adma endogenous inhibitor no synthase synthesize many type cells include vascular endothelial cells serum level adma elevate patients essential hypertension mechanism increase unknown therefore present study examine whether reninangiotensin system ras involve patients essential hypertension [ systolic blood pressure bp mmhg andor diastolic bp mmhg ] randomize angiotensinconverting enzyme ace inhibitor treatment group perindopril mgday weeks n angiotensin ii type receptor antagonist treatment group losartan mgday weeks n betablocker treatment group bisoprolol mgday weeks n treatment bp serum concentration adma plasma concentration von willebrand factor vwf biological marker endothelial injury measure perindopril losartan bisoprolol decrease bp similar extent either perindopril losartan not bisoprolol significantly decrease serum adma plasma vwf find suggest ras may contribute mechanism increase serum adma well endothelial injury observe hypertensive patients vasculoprotective action ace inhibitors receptor antagonists may explain least part amelioration endothelial injury decrease serum adma concentration',\n",
       " 'prospective randomise crossover study compare effect ace inhibitor temocapril calcium channel blocker ccb amlodipine ambulatory blood pressure asymptomatic elderly hypertensive patients mean age years study perform crossover fashion week placebo period weeks treatment temocapril amlodipine hypertensive patients three patients side effect patients whose office bps not achieve target bps exclude remain analyse study consist dippers night time reduction systolic bp sbp nondippers reduction baseline no significant differences office h daytime bps two group dippers nondippers though office bps daytime bps successfully control level treatments dip group antihypertensive effect stronger ccb ace inhibitor night time morning especially nondippers conclude even though office bps control successfully almost level possibility longacting drug differential antihypertensive effect night time morning bps among hypertensive patients different night time bp dip statuses',\n",
       " 'prospective randomize enalapril study evaluate regression ventricular enlargement preserve study design test whether enalapril achieve greater leave ventricular lv mass reduction nifedipine gastrointestinal treatment system prognostically meaningful degree population basis gm',\n",
       " 'omapatrilat novel vasopeptidase inhibitor highly potent selective inhibitor neutral endopeptidase angiotensinconverting enzyme therapeutic potential investigate treatment hypertension heart failure present study safety tolerability hemodynamic effect single oral dose omapatrilat mg compare placebo patients heart failure patients heart failure new york heart association functional class ii iv rest leave ventricular ejection fraction enrol doubleblind placebocontrolled sequentialpanel study single dose omapatrilat mg follow hemodynamic assessment hours hours dose mg dose omapatrilat compare placebo reduce mean pulmonary capillary wedge pressure approximately mm hg mm hg baseline mm hg mg omapatrilat dose maintain effect compare placebo approximately mm hg reduction mean pulmonary capillary wedge pressure hours omapatrilat improve additional hemodynamic parameters include cardiac index systemic vascular resistance stroke volume index mean arterial pressure additionally hours dose omapatrilat mg trend peak increase baseline plasma atrial natriuretic peptide twofold cyclic guanosine monophosphate nearly twofold observe moreover omapatrilat well tolerate thus omapatrilat administer orally patients heart failure safe well tolerate result improve hemodynamic performance',\n",
       " 'unknown whether either angiotensiniireceptor blocker irbesartan calciumchannel blocker amlodipine slow progression nephropathy patients type diabetes independently capacity lower systemic blood pressure',\n",
       " 'diabetic nephropathy lead cause endstage renal disease interruption reninangiotensin system slow progression renal disease patients type diabetes similar data not available patients type common form diabetes assess role angiotensiniireceptor antagonist losartan patients type diabetes nephropathy',\n",
       " 'clinical case publish literature show angiotensinconverting enzyme ace inhibitor administration may cause acute pancreatitis work author report case patient affect hypertension upon admission author start antihypertensive therapy use captopril cause important amylase lipase rise within days aceinhibitor therapy stop rapid decrease serum enzyme observe within days high level serum amylase lipase link neutrophilia not associate relevant symptomatic find feature pancreatopathy absence usual condition may cause pancreatitis biliary stasis hypercalcemia alcohol abuse rapid decrease serum enzyme level drug suspension suggest aceinhibitorinduced pancreatitis first clinical report aceinhibitorinduced pancreatitis captopril administration find hospitalization drug suspension probably prevent complications case report suggest aceinhibitor administration start serum amylase lipase monitor order prevent acute pancreatitis without wait clinical evidence pancreatopathy',\n",
       " 'data patients receive antihypertensive therapy collect general practitioners gps campania italy determine prescription different antihypertensive class use drug concomitant diseases investigate main factor influence antihypertensive choice document treatment outcome assess adverse drug reactions adrs gp complete data card consultation produce antihypertensive prescription card collect frequently use antihypertensives angiotensinconverting enzyme inhibitors calcium antagonists beta blockers angiotensin iireceptor blockers alpha blockers patients blood pressure reduce not reach normotensive level choice antihypertensive treatment influence international guidelines clinical diagnosis concomitant diseases cost compliance factor adrs often cough edema headache tachycardia occur patients',\n",
       " 'multicenter randomize doubleblind parallel group study undertake determine effectiveness select antihypertensives doxazosin amlodipine enalapril bendrofluazide maintain hour control blood pressure bp predictive value ambulatory bp versus clinic c bp measurements method detect patients hypertension also evaluate total patients screen diagnose mild moderately hypertensive clinic diastolic bp mm hg mm hg patients coronary heart disease risk factor antihypertensives equally effective control bp h show hour abp measurements incidence adverse events similar treatment group headache common event report patients clinically relevant reduction total cholesterol doxazosin mgdl amlodipine mgdl treatment group comparison enalapril bendrofluazide result abp measurements suggest antihypertensives study effective firstline therapy regulation hypertension abp reproducible measure abp may also useful identify patients various type high bp instance white coat hypertension enable accurate screen diagnosis',\n",
       " 'handle increase complexity congestive heart failure chf care several new model care patients chf develop replace traditional strategies undertake study evaluate potential benefit implement chf disease management program tertiary care center particularly term betablocker use cost health care system',\n",
       " 'ldlcholesterol particles hypertensive patients exhibit enhance susceptibility vitro oxidation abnormality think increase cardiovascular risk test whether blood pressure bp normalization reverse abnormality',\n",
       " 'ace inhibitor anthracycline aaa study randomize doubleblind control clinical trial compare enalapril placebo determine whether treatment slow progression cardiac decline patients screen positive anthracycline cardiotoxicity',\n",
       " 'purpose evaluate reliability validity responsiveness minute walk test mwt patients heart failure hf enrol randomize evaluation strategies leave ventricular dysfunction resolvd pilot study',\n",
       " 'study evaluate independent combine effect captopril carvedilol leave ventricular remodel chronic heart failure although angiotensinconverting enzyme inhibitors bblockers know attenuate remodel process chronic heart failure direct comparison agents not perform',\n",
       " 'electrocardiographic markers leave ventricular hypertrophy lvh predict poor prognosis determine whether ace inhibitor ramipril prevent development cause regression ecglvh whether change associate improve prognosis independent blood pressure reduction',\n",
       " 'forty children hypertension age months years receive mgkg enalapril single daily dose enalapril administer orally novel extemporaneous suspension children younger years age tablets older children firstdose steadystate pharmacokinetics estimate children age months months years years years maximum serum concentrations enalapril occur approximately hour administration serum concentrations enalaprilat active metabolite enalapril peak hours first dose hours multiple dose area concentration versus time curve auc adjust body surface area not differ age group base comparison firstdose steadystate aucs accumulation enalaprilat children range fold children age years mean urinary recovery total enalaprilat range children age years children age years urinary recovery children age years mean percentage conversion enalapril enalaprilat range children age months children age years median effective halflife accumulation range hours children age years hours children age years two serious adverse events neither attribute enalapril result discontinuation study drug extemporaneous suspension use study tolerate well pharmacokinetics enalapril enalaprilat hypertensive children age months years normal renal function appear similar previously observe healthy adults',\n",
       " 'purpose study calculate improvement life expectancy treat patients leave ventricular dysfunction myocardial infarction ace inhibitor life expectancy estimate median lifetime follow trace study prolong median lifetime could calculate treatment group median lifetime reach placebo group years trandolapril group median lifetime increase months conclude increase lifetime treatment patients leave ventricular dysfunction myocardial infarction substantial',\n",
       " 'aim study compare effect trandolapril losartan plasminogen activator inhibitor type pai level insulin sensitivity hypertensive postmenopausal women study hypertensive diastolic blood pressure mm hg postmenopausal women age years not take hormone replacement therapy diabetic obese smoke patients exclude week placebo period randomize receive mg oral trandolapril n mg oral losartan n weeks accord doubleblind parallel group design end placebo active treatment periods blood pressure bp measure plasma sample draw evaluate pai antigen level insulin sensitivity assess trandolapril losartan reduce systolic bp mean mm hg mm hg respectively p v placebo diastolic bp mean mm hg mm hg respectively p v placebo no difference two treatments pai antigen level significantly decrease trandolapril ngdl ngdl p not losartan ngdl ngdl pnot significant glucose infusion rate significantly increase trandolapril mgminkg mgminkg p not significantly modify losartan mgminkg mgminkg p not significant trandolapril group pai decrease correlate glucose infusion rate increase r p result provide evidence different effect angiotensin convert enzyme inhibitors antagonists fibrinolysis suggest pai decrease induce angiotensin convert enzyme inhibitors relate action insulin sensitivity not dependent angiotensin ii antagonism rather mechanisms remain see whether find apply patient populations postmenopausal women',\n",
       " 'effect antihypertensive treatment large arteries may influence type drug concomitant risk factor blood cholesterol explore possibilities investigate common carotid artery subject low cholesterol subject high cholesterol essential hypertension randomly allocate months treatment nitrendipine mgd trandolapril mgd carotid parameters determine record instantaneous pressure applanation tonometry diameter echotracking device model pressurediameter loop obtain peterson modulus stiffness index measure isobaric compliances wall viscosity effect drug carotid parameters not differ except systolic diastolic diameters p increase insignificantly nitrendipine decrease p trandolapril blood cholesterol status not influence carotid effect trandolapril whereas patients low high cholesterol treat nitrendipine exhibit significant differences drug effect systolic pulse pressure p decrease patients low cholesterol p p not high cholesterol b diastolic diameter p increase insignificantly patients low cholesterol unchanged high cholesterol c wall viscosity p decrease patients low cholesterol p increase insignificantly high cholesterol also wall viscosity change nitrendipine positively relate baseline blood cholesterol r p thus nitrendipine trandolapril show noteworthy differences effect carotid artery particular respect status blood cholesterol differences confirm larger study',\n",
       " 'study evaluate longterm effect angiotensinconverting enzyme inhibitor enalapril angiotensin ii type receptor antagonist losartan angiotensinconverting enzyme activity lymphocytes plasma patients essential hypertension study randomize placebocontrolled doubleblind crossover design nine patients sit blood pressure mm hg mm hg end week placebo runin period enter doubleblind phase study consist three week periods patients treat placebo enalapril mg daily losartan mg daily angiotensinconverting enzyme activity lymphocytes measure activity degradation substrate hippurylhisleu appearance dipeptide hisleu quantify spectrofluorometrically enalapril not losartan suppress p angiotensinconverting enzyme activity plasma whereas stimulate p angiotensinconverting enzyme activity circulate lymphocytes data document induction angiotensinconverting enzyme human lymphocytes longterm treatment angiotensinconverting enzyme inhibitor enalapril angiotensin ii receptor type antagonism losartan no effect plasma lymphocytic angiotensinconverting enzyme',\n",
       " 'doubleblind multicenter trial compare antihypertensive efficacy tolerability impact quality life manidipine amlodipine patients mildtomoderate essential hypertension patients randomly assign weeks oncedaily manidipine mg amlodipine mg patients not respond treatment weeks also give enalapril mg study duration main efficacy end point equivalence sit systolic sisbp diastolic sidbp blood pressure reduction two drug weeks per protocol analysis intentiontotreat itt analysis perform patients least one efficacy determination treatment quality life assess ` ` subjective symptoms assessment profile ssap ` ` general wellbeing schedule gwbs weeks treatment sisbp reduction weeks equivalent manidipine mm hg n amlodipine mm hg n correspond figure sidbp mm hg manidipine mm hg amlodipine larger itt population sidbp similarly significantly reduce manidipine mm hg n amlodipine mm hg n similar result observe sisbp stand sbp dbp neither drug change sit stand heart rate compare baseline ssap score improve manidipine not amlodipine gwbs total partial score increase manidipine amlodipine safety profile favor manidipine associate significantly less ankle edema amlodipine study show first time longterm treatment longacting calcium channel blocker manidipine effective treatment amlodipine better tolerability profile induce greater improvement quality life amlodipine',\n",
       " 'blood pressure determinant risk stroke among hypertensive nonhypertensive individuals cerebrovascular disease however uncertainty efficacy safety bloodpressurelowering treatments many patients perindopril protection recurrent stroke study progress design determine effect bloodpressurelowering regimen hypertensive nonhypertensive patients history stroke transient ischaemic attack',\n",
       " 'losartan show increase urinary uric acid excretion hence lower serum uric acid level purpose present study evaluate effect losartan serum uric acid hypertensive patients hyperuricemia gout compare effect losartan irbesartan another angiotensin ii receptor antagonist evaluate whether losartan mg b greater impact serum uric acid level losartan mg day',\n",
       " 'investigate random comparison capacity angiotensin convert enzyme inhibitor fosinopril longacting dihydropiridine nifedipine gits modify decay renal function patients primary renal disease exhibit progressive increase serum creatinine previous years',\n",
       " 'determine quality life qol mild hypertensive patients treat captopril compare placebo',\n",
       " 'unique find hope heart outcomes prevention evaluation study strongly support extend use angiotensinconverting enzyme ace inhibitor ramipril preventive agent patients high risk cardiovascular events normal leave ventricular function addition ramipril provide significant benefit diabetic patients find impact ramipril use primary care ace inhibitors currently underprescribed patients reflect inclusion criteria hope study consider suitable candidates longterm ramipril therapy addition exist drug regimen screen include control kidney function serum creatinine particularly within first two weeks treatment addition regular monitor serum potassium however hope study show ramipril well tolerate high dose long treatment period effectiveness therapy also regularly review dose adjustments make necessary concern remain referral specialist cardiologist diabetologist may ultimately necessary',\n",
       " 'patients type ii noninsulindependent diabetes mellitus increase risk macrovascular microvascular disease reduce control raise blood pressure hypertensive patients intensive glycaemic control also show reduce microvascular disease effect macrovascular disease remain uncertain study examine hypotheses lower blood pressure ace inhibitordiuretic combination intensively control gylcaemia sulphonylureabased regimen highrisk patients type ii diabetes hypertensive nonhypertensive reduce incidence macrovascular microvascular disease',\n",
       " 'type diabetes grow clinical public health problem preventive efforts relate lifestyle modification not always successful therefore alternative prevention strategies need study',\n",
       " 'hypertension one important risk factor ischaemic heart disease stroke aim study assess antihypertensive effect angiotensine convert enzyme inhibitor perindopril versus beta blocker acebutolol hypertensive patients double blind placebo control study perform group patients males females mean age years newly diagnose previously not treat mild moderate hypertension patient washout period two weeks give placebo randomize active treatment perindopril mgday acebutolol mgday weeks follow drug cross match one week wash period blood pressure bp mercury sphygmomanometer measure three time weeks placebo treatment weeks perindopril weeks acebutolol treatment perindopril acebutolol prove effective monotherapy hypertension weeks treatment observe bp systolic diastolic normalization patients systolic bp normalization perindopril treatment',\n",
       " 'study prospectively systematically explore factor acutely precipitate exacerbation congestive heart failure chf patients leave ventricular dysfunction knowledge factor important design measure prevent deterioration clinical status objective study prospectively describe precipitants associate exacerbation chf status patients enrol randomize evaluation strategies leave ventricular dysfunction pilot study',\n",
       " 'conventionally angiotensinconverting enzyme ace inhibitors contraindicate patients aortic stenosis abundant evidence available show angiotensin ii central role development leave ventricular hypertrophy lvh myocardial contractile failure diastolic dysfunction response pressure overload animal model ace inhibitors show attenuate pathological responses humans no evidence available however uncontrolled study show agents not tolerate associate acute improvements haemodynamics diastolic function study merit assess possible role ace inhibitors aortic stenosis valve replacement potential benefit may include prevention lvh improve diastolic function reduction arrhythmias preservation leave ventricular function',\n",
       " 'renal artery stenosis among common curable cause hypertension definitive diagnosis make renal angiography invasive costly procedure prevalence renal artery stenosis less nonselected hypertensive patients higher hypertension resistant drug',\n",
       " 'present study evaluate effect nonevaluative social support intervention pet ownership blood pressure response mental stress ace inhibitor therapy fortyeight hypertensive individuals participate experiment home physician office participants randomize experimental group assignment pet ownership addition lisinopril mgd control group lisinopril mgd study day blood pressure heart rate plasma renin activity record baseline mental stressor serial subtraction speech drug therapy mean responses mental stress not differ significantly experimental control group heart rate [ sd ] versus [ ] bpm systolic blood pressure [ ] versus [ ] mm hg diastolic blood pressure [ ] versus [ ] mm hg plasma renin activity [ ] versus [ ] ng ml h lisinopril therapy lower rest blood pressure approximately mm hg group responses mental stress significantly lower among pet owners relative receive lisinopril p heart rate [ ] versus [ ] bpm systolic blood pressure [ ] versus [ ] mm hg diastolic blood pressure [ ] versus [ ] mm hg plasma renin activity [ ] versus [ ] ng ml h conclude ace inhibitor therapy alone lower rest blood pressure whereas increase social support pet ownership lower blood pressure response mental stress',\n",
       " 'international guidelines recommend antihypertensive drug therapy normalize not diastolic dbp also systolic blood pressure sbp therapeutic trials base cardiovascular mortality recently show sbp reduction require normalization large artery stiffness wave reflections aim present study compare antihypertensive effect verylowdose combination indapamide mg perindopril mg perind betablocking agent atenolol mg determine whether perind decrease sbp pulse pressure pp atenolol whether decrease predominantly due reduction aortic pulse wave velocity pwv automatic measurements reduction wave reflections pulse wave analysis applanation tonometry doubleblind randomize study patients essential hypertension follow months dbp reduction perind decrease brachial sbp mm hg confidence interval pp confidence interval significantly atenolol difference significantly pronounce carotid artery brachial artery whereas antihypertensive agents decrease pwv similar degree perind significantly attenuate carotid wave reflections result selective decrease sbp pp verylowdose combination perind normalize sbp pp arterial function significantly larger extent atenolol hemodynamic profile know improve survival hypertensive populations high cardiovascular risk',\n",
       " 'pulse pressure strongly associate cardiovascular outcomes especially myocardial infarction heart failure systolic diastolic mean arterial pressure variety populations little know however comparative effect various class antihypertensive agents pulse pressure retrospective analyse veterans affairs singledrug therapy hypertension study compare change pulse pressure class antihypertensive agents men diastolic blood pressure mm hg placebo randomize receive hydrochlorothiazide atenolol captopril clonidine diltiazem prazosin placebo drug dose titrate achieve goal diastolic blood pressure mm hg week medication titration phase pulse pressure change placebo subtract assess baseline end month titration year maintenance mean baseline systolic diastolic pulse pressure mm hg respectively reductions pulse pressure titration greater p clonidine mm hg hydrochlorothiazide mm hg captopril mm hg diltiazem mm hg atenolol mm hg reduction prazosin mm hg similar clonidine year pulse pressure reduce significantly p hydrochlorothiazide mm hg captopril atenolol mm hg clonidine mm hg diltiazem mm hg prazosin mm hg intermediate data show class antihypertensive agents differ ability reduce pulse pressure whether differences affect rat cardiovascular events remain determine',\n",
       " 'increase intimamedia thickness common carotid artery predict increase risk myocardial infarction stroke preliminary evidence suggest decrease blood pressure bp associate diminish wall thickness not know class antihypertensive agents similar protective effect doubleblind parallelgroup clinical trial previously untreated patients hypertension allocate randomly year treatment either amlodipine mg daily lisinopril mg daily doxazosin bendrofluazide add require achieve bp control months treatment clinic bp ambulatory bp cardiac mass reduce similarly two treatment regimens common carotid artery intimamedia thickness decrease mm confidence intervals mm amlodipinetreated group decrease mm mm lisinopriltreated group p difference treatments common carotid artery lumen diameter decline significantly patients treat lisinopril [ amlodipine mm mm lisinopril mm mm p ] intimamedia area decline similarly two treatment group [ amlodipine mm mm lisinopril mm mm not significant ] result confirm decrease bp cause regression structural change carotid artery hypertensive patients nature structural regression differ markedly two treatment regimens spite similar decrease bp calcium channel blocker induce greater regression common carotid artery intimamedia thickness angiotensinconverting enzyme inhibitor however carotid artery wall mass indicate intimamedia area reduce similar extent two treatments remain establish whether differences confer prognostic advantage',\n",
       " 'describe estimate incidence preventability postdischarge adverse drug reactions adrs detect primary care france',\n",
       " 'adverse drug reactions noncompliance important cause admissions elderly medical clinics contribution adverse drug reactions noncompliance admission medical emergency department analyse',\n",
       " 'aim open multicentric study investigate efficacy safety addition angiotensin convert enzyme ace inhibitor benazepril mgday diuretic hydrochlorothiazide mgday weeks patients mild moderate essential hypertension treat weeks angiotensin ii antagonist valsartan mgday still diastolic blood pressure bp mmhg medication give alone',\n",
       " 'two elderly patients treat captopril leave ventricular dysfunction diabetes develop severe cholestatic jaundice no alternative explanation could find jaundice resolve completely discontinuation drug review literature identify highly similar distinctive clinical pattern another case report suggest hepatotoxicity wellestablished yet rare adverse effect captopril however common use drug together severity liver injury may cause call high index suspicion increase awareness phenomenon',\n",
       " 'whether antihypertensive drug offer cardiovascular protection beyond blood pressure lower not establish aim investigate whether pharmacological properties antihypertensive drug reduction systolic pressure account cardiovascular outcome hypertensive highrisk patients',\n",
       " 'examine effect lowdose losartan angiotensin ii antagonist persistent microalbuminuria normotensive type diabetes mellitus subject type diabetes randomly assign two month treatment periods either losartan mgday enalapril mgday singleblind crossover design urinary albumin excretion uae blood pressure lipids glycemia hbac serum potassium creatinine clearance measure treatment period uaes similarly reduce treatments median uae decrease range mgday p enalapril decrease mgday p losartan systolic diastolic blood pressure also decrease significantly p whereas serum level potassium increase p treatments level serum hbac mean fast glucose total cholesterol triglycerides ldl cholesterol hdl cholesterol creatinine clearances not significantly p change either enalapril losartan treatment no significant differences find effect enalapril losartan conclusion losartan treatment reduce microalbuminuria effectively enalapril normotensive type diabetic patients',\n",
       " 'main purpose study compare efficacy tolerability influence quality life qol nifedipine gastrointestinal therapeutic system ni mg day vs amlodipine mg day elderly patients mildmoderate hypertension',\n",
       " 'examine effect ace inhibition glomerular structure type diabetic patients nephropathy',\n",
       " 'every new drug potential cause cutaneous adverse drug reactions usually clinical pattern well know describe association drug new entities however describe frequently article review several',\n",
       " 'vasopeptidase inhibitors new class cardiovascular drug simultaneously inhibit neutral endopeptidase angiotensinconverting enzyme ace increase availability peptides vasodilatory vascular effect also inhibit production angiotensin ii animal model vasopeptidase inhibitors decrease blood pressure low medium high renin form hypertension also appear confer benefit model heart failure ischaemic heart disease study human hypertension show agents effective decrease blood pressure regardless race age experience omapatrilat clinically advance drug show effective currently available ace inhibitors widely use antihypertensive agents study omapatrilat congestive heart failure show beneficial effect haemodynamics symptoms vasopeptidase inhibitors appear safety profile similar ace inhibitors though frequency sideeffects angiooedema cough remain establish large trials clinical endpoints already progress need establish place class drug beside establish therapies condition hypertension heart failure ischaemic heart disease nephropathy',\n",
       " 'hypertension important cardiovascular risk factor goal pharmacologic treatment reduce morbidity mortality treatment usually initiate low dose single agent titrate higher dose require many patients require addition second agent achieve satisfactory blood pressure control aim study assess doseresponse relationship nitrendipine enalapril alone fix combination treatment mild moderate hypertension total patients enrol multicenter randomize doubleblind factorialdesign parallelgroup clinical trial compare placebo nitrendipine mg enalapril mg alone combination singleblind week placebo runin period patients whose diastolic blood pressure range mm hg randomly assign treatment group combination nitrendipine enalapril particularly regimens include nitrendipine mg enalapril mg significantly superior monotherapies mean diastolic blood pressure reductions baseline last visit mm hg respectively response surface analysis provide evidence combinations optimal term antihypertensive efficacy treatments well tolerate incidence adverse events not differ significantly group summary antihypertensive efficacy combination find superior monotherapies dose dose combination achieve greatest blood pressure reduction nitrendipine mg enalapril mg',\n",
       " 'use angiotensinconverting enzyme ace inhibitors angiotensin receptor antagonists aldosterone antagonists important beneficial effect progression renal disease associate glomerular interstitial fibrosis especially adverse side effect eg hyperkalemia minimize appear chronic renal insufficiency proteinuria may well cardiovascular risk factor excite note recent large scale epidemiologic study heart outcomes prevention evaluation [ hope ] show cardioprotective renoprotective effect ace inhibition appear paradoxic renoprotective effect clearly evident diabetes mellitus plasma renin activity may suppress even set appear activation renal angiotensin system inhibitions intrarenal systems involve renoprotective effect agents recent study identify nearly components need generate angiotensin ii renal luminal compartment suggest may direct effect receptors nacl transport distal nephron possibility components intraluminal reninangiotensin system may acutely regulate variations dietary salt intake provide opportunity better understand normal maintenance salt balance whether not inhibition pathways involve renoprotective effect ace inhibitors angiotensin receptor antagonists important issue address',\n",
       " 'adverse drug reactions significant cause morbidity mortality although many adverse drug reactions consider nonpreventable recent developments suggest reactions may avoid individualization drug therapies base genetic information application know pharmacogenomics',\n",
       " 'purpose study change vasoconstrictive neurohormones nterminal proatrial natriuretic peptide ntproanp brain natriuretic peptide bnp relationship leave ventricular lv remodel soon anterior myocardial infarction mi',\n",
       " 'clinical trial mainly involve patients coronary heart disease ramipril reduce mortality vitamin e no preventive effect',\n",
       " 'antihypertensive efficacy tolerability novel angiotensinii aii receptor blocker candesartan cilexetil prototype aii receptor blocker losartan compare week multicenter doubleblind randomize parallelgroup titrationtoeffect study adults women black systemic hypertension sit diastolic blood pressure [ dbp ] mmhg inclusive patients mean trough hours dose sit dbp mmhg higher weeks daily administration candesartan mg losartan mg dose titrate candesartan mg losartan mg daily candesartan regimen significantly effective losartan regimen reduce trough sit dbp week mmhg versus mmhg candesartan also produce numerically greater reductions secondary blood pressure parameters include sit systolic blood pressure sbp trough stand dbp sbp peak hours dose sit stand dbp sbp responder rat sit dbp mmhg reduction blood pressure mmhg control rat sit dbp mmhg higher candesartan versus versus respectively total patients take candesartan take losartan discontinue prematurely adverse events lack efficacy',\n",
       " 'aim study compare mechanical intrinsic effect angiotensin convert enzyme inhibitor vs betablocker brachial arterial compliance double blind study essential hypertensive patients treat months either ramipril mg daily n age males atenolol mg daily n age males blood pressure bp brachial artery diameter brachialradial pulse wave velocity pwv effective compliance ceff measure end study isobaric evaluation ciso perform entire population study average mean bp mmhg ramipril significantly reduce bp mmhg mmhg p without affect heart rate hr vs bpm addition significantly improve pwv p arterial compliance p relate pressure independent effect p atenolol also induce reduction bp mmhg p hr bpm p similar way pwv p ceff p significantly improve without significant change ciso suggest blood pressure reduction responsible compliance improvement conclusion suggest atenolol induce hemodynamic change mediate mainly bp reduction contrast improve brachial buffer function observe ramipril involve not hemodynamic change also change mediate mechanisms modification wall structure',\n",
       " 'skin disorder common adverse reactions attribute drug skin disorder imitate induce aggravate drug help keep uptodate latest skin reactions occur new establish drug section journal bring information select adverse drug reaction alert service reactions weekly follow case report select latest publish world dermatology literature claim first report verify search adisbase proprietary database adis international auckland new zealand medline case report assess seriousness use fda medwatch definition serious patient outcome death lifethreatening hospitalization disability congenital anomaly require intervention prevent permanent impairment damage',\n",
       " 'skin test drug value investigate patients develop cutaneous adverse drug reactions cadr specificity relevance remain determine falsepositive result skin test happen not compare result control subject perform intradermal test idt determine lowest concentrations induce falsepositive result many drug include betalactam antibiotics cephalosporins antibiotics nonsteroidal antiinflammatory drug drug commercialize form contain sodium lauryl sulfate induce irritation patch test patch test colchicine pet cytotec pill contain misoprostol pet respectively negative control develop falsepositive result lastly positive result patch test drug relate contact allergy one components commercialize form drug without relevance investigation cadr observe case iodine avocado oil',\n",
       " 'captopril prevention project cappp evaluate effect ace inhibitorbased therapeutic regimen cardiovascular mortality morbidity hypertension one plan subanalysis cappp evaluate outcome diabetic patient group',\n",
       " 'rapidly accumulate clinical data repeatedly demonstrate not critical importance even small increase blood pressure pathophysiologic factor development cardiovascular disease particularly individuals diabetes mellitus also therapeutic necessity aggressive blood pressure reduction achievement progressively lower blood pressure target reduce cardiovascular event rat jnc vi define optimal blood pressure mm hg stage hypertension mm hg target blood pressure mm hg patients diabetes mm hg patients hypertensive renal disease proteinuria gm hours achieve target pressure increasingly difficult particularly diabetic patients chronic renal disease require complex multidrug antihypertensive regimens review attempt provide suggestions construct antihypertensive regimens provide considerations appropriate use diuretics effective drug combinations factor potentially contribute drug resistant hypertension include problems failure maximize drug dose suboptimal diuretic use noncompliance possible confound effect concomitant medications nonsteroidal antiinflammatory drug decongestants issue underlie drugresistant hypertension list together strategies overcome problem',\n",
       " 'determine drug prescription pattern extent conformity world health organizationinternational society hypertension whoish guidelines diabetic hypertension',\n",
       " 'menopause consequences hypertension women change risk myocardial infarction stroke rise steeply rise blame part loss estrogen onset menopausal metabolic syndrome endothelial dysfunction hyperlipidemia insulin resistance derangement coagulation hypertensive menopausal women not optimum treatment poorer prognoses men age antihypertensive management therefore merit special attention hormone replacement aspirin prophylaxis lipidlowering drug place antihypertensive drug choose not worsen metabolic syndrome angiotensinii convert enzyme ace inhibitors therefore among firstline drug drug specifically aim menopausal hypertension review',\n",
       " 'aspirin asa angiotensinconverting enzyme inhibitor acei therapy reduce mortality administer early onset myocardial infarction asa antagonize effect acei therapy inhibit synthesis vasodilating prostaglandins however evidence effect large control trials contradictory author analyze database patients gruppo italiano per lo studio della sopravvivenza nellinfarto miocardio gissi trial patients allocate either receive lisinopril not receive lisinopril within hours onset symptoms myocardial infarction aim study verify possible negative interaction asa acei lisinopril postacute phase acute myocardial infarction analyzable patients receive asa entry overall lisinopril reduce day mortality patients receive asa mortality reduce lisinopril patients not receive asa difference proportional reductions mortality correspond fact mark lisinopril effect see patients higher baseline risk across study subgroups one coincide noasa group analysis inhospital incidence major clinical events not reveal potentially negative interaction asa lisinopril find obtain analysis reinfarction days interaction asa lisinopril also test multivariate analysis adjust confound variables entry interaction test not statistically significant serum creatinine level days significantly higher lisinopril group control group systolic diastolic blood pressure lisinopril group significantly lower control days effect lisinopril creatinine blood pressure not differ asa noasa group asa not decrease mortality benefit early lisinopril myocardial infarction increase risk major adverse events lisinopril safe effective give early onset myocardial infarction regardless concomitant administration asa start early continue week period',\n",
       " 'assess efficacy tolerability angiotensinii receptor blocker candesartan cilexetil association black cardiologists abc coordinate week multicenter doubleblind placebocontrolled clinical trial black adults sit diastolic blood pressure dbp mmhg inclusive goal abc trial address previous report suggest drug block reninangiotensinaldosterone system may not effective control bp hypertensive black individuals patients randomize receive candesartan cilexetil mg n placebo n daily week singleblind placebo runin period candesartan cilexetil placebo dose double trough hours dose sit dbp mmhg higher weeks dbp mmhg higher week hydrochlorothiazide mg add placebo candesartan cilexetil mg candesartan cilexetil significantly effective placebo reduce trough sit systolic bp sbp dbp week mmhg versus mmhg week mmhg versus mmhg hydrochlorothiazide add patients candesartan cilexetil placebo group respectively control responder rat consistently higher candesartan cilexetil treatment group weeks discontinuation adverse event rat similar two group candesartan cilexetil daily effective reduce bp substantial proportion exclusively black hypertensive population combination candesartan cilexetil plus hydrochlorothiazide demonstrate additional efficacy maintain excellent tolerability profile',\n",
       " 'tolerability important consideration evaluate new antihypertensive agent assess informally conventional patient interview formally use validate healthrelated quality life hrql measure assess patient perception agent tolerability hrql secondary end point week multicenter doubleblind randomize placebocontrolled study efficacy tolerability candesartan cilexetil black patients systemic hypertension hrql evaluate use generic medical outcomes study item short form sf population conditionspecific vital sign quality life questionnaire vsqlq data gather via facetoface interview screen baseline weeks patients randomize evaluable hrql analysis clinical result report companion article find candesartan cilexetil initiate mg daily titrate mg daily need subsequent addition hydrochlorothiazide mg need effective lower diastolic systolic blood pressure well tolerate base office interview analyse patients perceptions tolerability find hrql maintain week study period no significant differences treatment placebo group end doubleblind treatment result indicate hrql black patients systemic hypertension maintain treatment candesartan cilexetil',\n",
       " 'post hoc secondary analysis ramipril efficacy nephropathy rein trial angiotensinconverting enzyme ace inhibition riskbenefit profile assess patients nondiabetic proteinuric chronic nephropathies different degrees renal insufficiency rate gfr decline delta gfr incidence endstage renal disease esrd ramipril nonace inhibitor treatment compare within three tertiles basal gfr delta gfr comparable three tertiles whereas incidence esrd higher lowest tertile middle highest tertiles ramipril decrease delta gfr incidence esrd p p lowest middle highest tertiles respectively delta gfr reduction predict basal systolic p diastolic p mean p bp proteinuria p not basal gfr p esrd risk reduction predict basal proteinuria p gfr p strongly dependent treatment duration p adverse events comparable among three tertiles within tertile two treatment group thus disease progression response ace inhibition not depend severity renal insufficiency risk esrd absolute number events save ace inhibition highest patients lowest gfr however renoprotection maximize ace inhibition start earlier longlasting treatment may result gfr stabilization definitive prevention esrd',\n",
       " 'present yearold male moderate chronic renal insufficiency diabetic nephropathy develop severe metabolic acidosis life threaten hyperkalemia treatment regular dose trimethoprimsulfamethoxazole tmpsmz urinary tract infection metabolic acidosis hyperkalemia resolve upon appropriate medical intervention discontinuation tmpsmz hyperkalemia commonly report high dose tmpsmz severe metabolic acidosis quite uncommon regular dose tmpsmz emphasize patients renal tubular acidosis rta renal insufficiency aldosterone deficiency old age reduce renal mass function angiotensin convert enzyme ace inhibitor therapy high risk develop severe potentially life threaten complications',\n",
       " 'calcium channel blockers angiotensin convert enzymeinhibitors commonly use treatment hypertensive renal transplant recipients purpose study investigate response rate treatment differ drug set single centre prospective randomise doubleblinded comparative study address efficacy control release nifedipine lisinopril treatment hypertension diastolic blood pressure mmhg cyclosporin csa treated renal transplant recipients perform recipients randomise receive either lisinopril mg daily control release nifedipine mg daily dose double indication number responders diastolic blood pressure mmhg monotherapy address early posttransplant phase first months late posttransplant phase months renal transplantation patient population one hundred fiftyfour patients nifedipine lisinopril untreated hypertension diastolic blood pressure mmhg randomise within wk renal transplantation one hundred twentythree patients nifedipine lisinopril complete study fourteen nifedipinetreated recipients respond early late postoperative phase months renal transplantation eleven lisinopriltreated recipients respond early late posttransplant phase nonresponders average kg heavier early phase yr treatment p yr older responders p conclusion result indicate control release nifedipine lisinopril equally efficient treatment posttransplant hypertension monotherapy drug show ` ` response rate depend time interval transplantation',\n",
       " 'antihypertensive lipidlowering treatment prevent heart attack trial allhat practicebased randomize multicenter clinical trial highrisk hypertensive patients age years older patients also lipidlowering trial component purpose antihypertensive component determine whether occurrence fatal coronary heart disease andor nonfatal myocardial infarction differ patients randomize diuretic chlorthalidone randomize either calcium antagonist amlodipine angiotensinconverting enzyme inhibitor lisinopril alphaadrenergic blocker doxazosin therapy doxazosin arm discontinue purpose lipidlowering component determine whether lower lowdensity lipoprotein cholesterol hydroxymethylglutaryl coenzyme reductase inhibitor pravastatin moderately hypercholesterolemic patients reduce allcause mortality compare control group receive ` ` usual care allhat recruit patients variety practice settings february january sit pay randomizations pay complete followup visit document study events communication monitor facilitate nine regional coordinator team recognize outset patient recruitment would large task number participants need ambitious nature goal recruitment africanamericans knowledge many investigators limit experience recruit participants clinical trials multiple adjustments initial allhat overall recruitment plan facilitate achievement sample size goals components trial experience obtain large trial valuable plan implementation successful recruitment future trials',\n",
       " 'treatment posttransplant hypertension still matter debate calcium antagonists may ameliorate renal side effect cyclosporin angiotensin convert enzyme ace inhibitors may effective sustain renal function native chronic renal disease prospectively compare effect control release nifedipine lisinopril longterm renal function hypertensive kidney transplant patients treat cyclosporin',\n",
       " 'omapatrilat vasopeptidase inhibitor simultaneously inhibit neutral endopeptidase ace efficacy hormonal profile omapatrilat lisinopril compare saltsensitive hypertensive patients enrollment antihypertensive medications withdraw patients receive singleblind placebo day saltsensitivity determinations make saltsensitive hypertensive patients return within days baseline evaluations ambulatory diastolic blood pressure ambulatory systolic blood pressure atrial natriuretic peptide saltsensitive hypertensive patients randomize receive doubleblind omapatrilat n lisinopril n initial dose mg week increase mg respectively additional weeks ambulatory blood pressure urinary atrial natriuretic peptide assess study termination omapatrilat lisinopril significantly reduce mean hour ambulatory diastolic systolic blood pressure however omapatrilat produce significantly greater reductions mean hour ambulatory diastolic blood pressure p ambulatory systolic blood pressure p ambulatory mean arterial pressure p compare value lisinopril drug potently inhibit ace hours omapatrilat significantly p increase urinary excretion atrial natriuretic peptide hour fold hour fold intervals lisinopril produce no change omapatrilat significantly p increase urinary excretion cgmp hour intervals compare lisinopril neither drug diuretic natriuretic kaliuretic effect conclusion saltsensitive hypertensive patients omapatrilat demonstrate hormonal profile vasopeptidase inhibitor lower ambulatory diastolic systolic blood pressure lisinopril',\n",
       " 'reduce conduit arteries flowdependent dilatation alter compliance describe heart failure however role shear stress relation endothelial dysfunction mechanics effect chronic ace inhibition relationship not investigate present study design evaluate heart failure patients relationship flowdependent dilatation radial artery mechanics know shear stress level assess effect chronic ace inhibition sixteen stable congestive heart failure patients never treat ace inhibitors participate study arterial pressure cardiac output bioimpedance radial artery diameter echo track flow doppler total blood viscosity mean artery wall shear stress assess gradual increase forearm blood flow response gradual distal hand skin heat crosssectional radial artery compliance distensibility index calculate degrees c degrees c degrees c endotheliumindependent vasodilatation evaluate use glyceryl trinitrate parameters assess hours last administration perindopril mg daily placebo month doubleblind randomize study treatment no difference group parameters chronic ace inhibition systolic arterial pressure decrease baseline mm hg p heat increase diameter response shear stress higher ace inhibition placebo timetreatment interaction p moreover contrast placebo shear stress significant increase compliance x x kpa p distensibility x x kpa p heat ace inhibition effect glyceryl trinitrate not change present study demonstrate chronic administration ace inhibitor perindopril increase magnitude flowdependent dilatation restore flowdependent increase compliance distensibility radial artery evaluate stable shear stress addition decrease baseline systolic arterial pressure ace inhibitor suggest associate increase distensibility proximal elastic conduit arteries',\n",
       " 'congestive heart failure chf associate impair flowmediated vasodilation reflect impair endothelial function limit information available however whether extent impairment improve pharmacological nonpharmacological treatment measure radial artery diameter blood flow echotracking doppler device baseline minutes hand ischemia increase diameter no secretion mediate increase flow shear stress data collect chf patients new york heart association class iii standard treatment diuretic digitalis enalapril mgd chf severity assess cardiopulmonary stress test age sexmatched control chf patients randomize maintain months standard treatment n b treatment double ace inhibitor dose n c standard treatment angiotensin ii antagonist losartan mgd n standard treatment bicycle train minutes time week n baseline radial artery diameter flow similar chf patients control chf patients modest although significant impairment flow increase strike impairment diameter increase follow minutes ischemia months baseline diameter flow remain unaltered group minutes ischemia radial artery flow diameter increase group standard treatment whereas group increase significantly p diameter markedly b c greater vasodilatation induce trinitroglycerin similar chf control subject not affect treatments chf radial artery show mark reduction flowmediated vasodilation reflect impairment endothelial function impairment markedly improve treatments effectively block reninangiotensin system either ace ace plus angiotensin receptor level case also nonpharmacological treatment chf',\n",
       " 'aortic compliance decrease patients endstage renal disease malfunction contribute high aortic systolic pressure thus development leave ventricular hypertrophy hypothesize besides structural vascular change functional change result hypervolemia increase vasoconstrictor activity particular angiotensin ii play role decrease aortic compliance nineteen hemodialysis patients study h dialyze dry weight applanation tonometry peripheral arteries use estimate aortic pulse wave velocity pwv know depend aortic compliance aortic systolic pressure augmentation augmentation index [ aix ] predialysis aortic pwv increase dialysis patients compare match healthy subject versus ms p aix also increase versus p volume reduction dialysis no significant effect pwv ms aix decrease p subset patients restudied wk angiotensinconverting enzyme inhibition acei enalapril mg daily acei decrease predialysis postdialysis bp no effect pulse pressure heart rate remain elevate compare healthy subject acei also decrease predialysis aortic pwv ms p no significant effect aix treatment acei volume reduction dialysis decrease aortic pwv ms p figure not different pwv healthy subject aix decrease even slightly subnormal value p conclude volume overload angiotensin ii contribute elevate pwv aix dialysis patients volume reduction acei improve aortic pwv aix combine volume reduction acei enhance effect present patients large pwv aix no longer elevate monitor correct arterial pressure wave feasible may important tool treatment patients endstage renal disease',\n",
       " 'seek compare neurohormonal responses clinical effect longterm highdose versus lowdose enalapril patients chronic heart failure chf',\n",
       " 'action angiotensin ii may contribute progression heart failure despite treatment currently recommend drug therefore evaluate longterm effect addition angiotensinreceptor blocker valsartan standard therapy heart failure',\n",
       " 'angiotensin convert enzyme inhibitors aceis clearly prove effective blood pressure control haemodynamic control heart failure patients moreover evidence aceis animal model humans also possess ability reduce remodel cardiovascular structure therefore reduction occurrence arterial stiffness lead increase distensibility also anticipate',\n",
       " 'pharmacodynamic effect combination therapy omapatrilat furosemide evaluate two group healthy subject receive furosemide mg dailyfor days coadministered either placebo days omapatrilat mg days mg days omapatrilat group urinary excretion atrial natriuretic peptide increase greater blood pressure reductions see compare placebo concomitant omapatrilat treatment not affect acute diuresis natriuresis kaliuresis observe chronic administration furosemide neither effective renal plasma flow glomerularfiltration rate change either treatment group no clinically significant safety issue observe daily coadministration omapatrilat mg furosemide mg not affect pharmacodynamics offurosemide steady state',\n",
       " 'blockade reninangiotensinaldosterone cascade recognise effective approach treat hypertensive heart failure high cardiovascular risk patients retard development renal failure purpose review discuss state development currently available drug block reninangiotensin system angiotensin convert enzyme ace inhibitors renin inhibitors angiotensin ii receptor antagonists special emphasis result recent trials conduct receptor antagonists heart failure type diabetes addition future perspectives drug dual mechanisms action nepace inhibitors also name vasopeptidase inhibitors present',\n",
       " 'many patients diabetic nephropathy dn level albuminuria gday blood pressure mmhg despite antihypertensive combination therapy include recommend dose ace inhibitors e g lisinoprilenalapril mg daily test concept patients might benefit dual blockade reninangiotensin system ras',\n",
       " 'one five canadians high blood pressure prevalence high women age years approximately stroke case myocardial infarction case end stage renal diseases attributable hypertension despite burden hypertension place women effect antihypertensive therapy cardiovascular complications not well establish address knowledge gap two metaanalyses sexspecific result include current randomize control trials evaluate hypertension treatment review individual data analysis antihypertensive indana intervention trials group quan colleagues analyze treatment benefit women men accord subgroup metaanalyses randomize control trials compare antihypertensive drug therapy placebo metaanalyses demonstrate statistically significant treatment benefit report clinical outcomes men age black women women age years antihypertensive treatment associate significant reduction fatal nonfatal stroke cardiovascular events cardiovascular mortality overall no significant difference relative treatment benefit women men however absolute treatment benefit lower women men thus number need treat end point fatal stroke nonfatal stroke cardiovascular events one threefold higher women men furthermore white women age years show no treatment benefit harm data year followup hypertension detection followup program hdfp trial suggest group younger women might benefit longer duration treatment indications pharmacological intervention seem quite clear subgroups exclude younger women evidence available low risk subgroup current recommendations lifestyle modification not challenge',\n",
       " 'case report fosinoprilinduced angioedema intestine chronic course accompany multiple acute exacerbations describe angiotensinconverting enzyme ace inhibitorinduced angioedema intestine aiai occur minority patients take ace inhibitor clinical presentation encompass acute abdominal symptoms pronounce bowel edema ascites occasional facial andor oropharyngeal swell aiai diagnose base temporal relationship symptomatic presentation drug use absence alternative diagnose include cause angioedema prompt resolution symptoms upon discontinuation ace inhibitor prompt radiological investigation abdominal computerize tomography andor ultrasound critical make early diagnosis prevent unnecessary surgical intervention female predominance aiai may reflect interaction estradiol various pathways involve pathophysiology aiai management aiai consist mainly conservative measure discontinuation ace inhibitor angiotensin ii receptor antagonists not consider appropriate alternatives awareness knowledge aiai important increase use ace inhibitors current delay make diagnosis obvious management strategies diagnosis make dysutility alternative diagnose may lead considerable morbidity aiai must consider patients take ace inhibitors develop gastrointestinal complaints irrespective duration therapy',\n",
       " 'objective study compare equal blood pressure bp reduction effect two different combinations metabolic control albuminuria type diabetic hypertensive patients albuminuria prospective randomise doubleblind parallel control trial carry spanish hospitals total type diabetic patients stable albuminuria bp not control monotherapy randomise finish study week singleblind placebo period patients randomise verapamil srtrandolapril mg vt enalaprilhydroclorothiazide mg eh treatment duration months main outcome measure change bp h albuminuria blood glucose glycated haemoglobin overall bp significantly reduce mm hg mm hg p albuminuria significantly decrease mg h mg h p without significant differences treatments glycated haemoglobin not modify vt baseline end treatment increase eh baseline final anova interaction p end study blood glucose mgdl attain vt groupimproving worsen patients p eh group patients improve worsen p no change body weight serum creatinine uric acid potassium cholesterol tryglicerides serum albumin hypertensive type diabetic patients not control monotherapy treatments similarly reduce albuminuria combination verapamil trandolapril seem allow better metabolic control enalaprilhydroclorothiazide',\n",
       " 'objective study compare quality life incidence dry persistent cough among patients treat eprosartan enalapril mildmoderate hypertension randomise week doubleblind control trial carry clinics nine countries north america europe south africa total patients age diastolic blood pressure mm hg mm hg study treatment comprise eprosartan enalapril monotherapy weeks option hydrochlorothiazide addition remain weeks primary outcome measure cough psychological general wellbeing index pgwb total subscales anxiety selfcontrol depression general health positive wellbeing vitality result enalapril patients eprosartan patients withdraw randomise treatment enalapril twice likely gain definite possible cough study end point eprosartan vs p monotherapy end point differences greater vs statistical significance p patients treat enalapril however small significant improvements measure selfcontrol total pgwb compare eprosartan effect size less indicate small differences conclusion eprosartan associate fewer cough enalapril perform less well aspects quality life',\n",
       " 'objective study compare quality life incidence dry cough angiotensin ii antagonist eprosartan aceinhibitor enalapril placebo hypertensive patients history aceinhibitor cough study multicentre randomise doubleblind parallel group control trial total patients judge aceinhibitor cough singleblind enalapril treatment lose subsequent placebo washout phase randomise receive either eprosartan mg twice daily enalapril mg daily placebo weeks selfcompletion questionnaires assess quality life cough examine baseline end study study end point patients enalapril group eprosartan placebo group report cough include definite probable possible cough p adjust multiple comparisons eprosartan group not significantly different either placebo enalapril no significant differences psychological general wellbeing index pgwb conclusion incidence selfreported cough eprosartan similar placebo lower enalapril difference not significant adjustments make multiple comparisons no differences quality life',\n",
       " 'purpose doubleblind randomise trial week placebo runin period follow active treatment period use either spirapril mg mg day clarify existence hypotensive episodes elderly hypertensive patients treat aceinhibitor forty hypertensive patients age years undergo h abpm end runin week active treatment week periods mean h systolic blood pressure sbp decrease mm hg mm hg p diastolic blood pressure dbp mm hg mm hg p no episodes mean arterial pressure map mm hg see placebo period instead episodes observe antihypertensive treatment one mg group mg group p two treatment group fiftyfour episodes map mm hg observe placebo period treatment period p placebo period low map observe night time treatment period see also pm conclusion aceinhibitor therapy spirapril significantly increase hypotensive episodes elderly hypertensive patients may worsen cerebral myocardial circulation',\n",
       " 'metaanalysis publish study evaluate effect selective alphablockers lipid carbohydrate profile blood pressure bp well tolerability patients hypertension type diabetes publications identify via medline use text bibliographies retrieve article examine additional reference clinical trials randomise comparative structure placebo active treatment arm control study structure include citations identify study select inclusion five reject efficacy safety data lipid carbohydrate profile study patient characteristics extract two investigators independently mean pool result show beneficial effect selective alphablockers total serum cholesterol tc highdensity lipoprotein hdl cholesterol systolic diastolic bp result also show doxazosin beneficial effect fast glucose level insulin sensitivity tc hdl cholesterol lowdensity lipoprotein ldl cholesterol hdltc ratio systolic diastolic bp risk difference equivalent alphablocker group control group postural hypotension syncope metaanalysis demonstrate number favourable effect therapy selective alphablockers hypertensive patients type diabetes agents provide effective modality reduce bp favourable effect lipid no deterioration glycaemic control little risk orthostatic hypotension',\n",
       " 'conflict report association chlamydia pneumoniae c pneumoniae infection coronary artery disease cad randomize trials antibiotics secondary prevention cad currently underway physicians may tempt believe choice antibiotic class treat infection may alter risk cad objective determine use antibiotics antichlamydial activity general population reduce risk myocardial infarction healthcare claim database patients continuous health pharmacy coverage least years january december use analyse hazard ratios derive proportional hazard model timedependent covariates relate antibiotic prescription first claim relate incident first myocardial infarction observation period adjust previous cad age sex diabetes hypertension hyperlipidemia chronic obstructive pulmonary disease total personyears observation incident myocardial infarctions adjust hazard ratios confidence intervals [ ci ] macrolides ci quinolones ci cephalosporins ci tetracyclines ci penicillins ci trimetroprimsulfamethoxazole hazard ratios individual antibiotics activity c pneumoniae within group similar use antibiotics activity c pneumoniae not reduce risk myocardial infarction general population',\n",
       " 'earlier interim report chinese cardiac study ccs trial patients hours onset suspect acute myocardial infarction ami randomize receive either oral captopril match placebo one month result show captopril associate nonsignificant reduction week mortality [ ] captoprilallocated vs [ ] placeboallocated deaths p longterm effect remain uncertain present study report longterm effect early captopril treatment mortality major events ami patients earlier ccs trial',\n",
       " 'analyse relationship age treatment captopril acute myocardial infarction ami',\n",
       " 'clinical symptoms druginduced lupus dil similar idiopathic systemic lupus erythematosus literature indicate patients dil sera generally contain antinuclear antibodies anas however ananegative dil report list medications implicate etiologic agents dil continue grow list include two different type angiotensinconverting enzyme inhibitors captopril enalapril report first case dil cause lisinopril patient negative result ana test histone antibodies igg anti [ hahb ] dna mirror disease course antibodies hahb dna complex see patients active dil exclude dil due hydralazine thus important recognize clinical significance igg anti hahb dna antibodies negative ana test result not preclude diagnosis dil',\n",
       " 'evaluation dyspnea often lead cardiac pulmonary diagnosis elderly however cause commonly multifactorial emergency physician always consider noncardiopulmonary etiologies treat patients present case newonset type iv renal tubular acidosis rta older patients take lisinopril present emergency department dyspnea patients chronic cardiopulmonary illnesses initially diagnose either congestive heart failure asthma exacerbations laboratory result rta specific diagnosis make ed',\n",
       " 'although several vitro study clinical observations suggest aceinhibitors acei promise treatment iga nephropathy igan metaanalysis publish data not yet conclusive therefore european doubleblinded prospective randomize therapeutic trial design evaluate acei treatment benefit young igan patients years old persistent moderate proteinuria gday fair renal function creatinine clearance mlmin patients enrol randomly assign benazepril mgkgday placebo patients enrol within five year recruitment period end december total duration followup six years end december hypertension genetic histological immunological factor evaluate clarify eventual role final response acei treatment',\n",
       " 'treatment systemic sclerosis scleroderma difficult remain great challenge clinician cause unknown therapies direct improve peripheral blood circulation vasodilators antiplatelet aggregation drug prevent synthesis release harmful cytokines immunosuppressant drug inhibit reduce fibrosis agents reduce collagen synthesis enhance collagenase production purpose review critically analyze conventional new treatments systemic sclerosis localize scleroderma therapeutic options discuss treatment systemic sclerosis include use vasodilators calcium channel blockers [ nifedipine ] angiotensinconverting enzyme inhibitors [ captopril losartan potassium ] prostaglandins [ iloprost epoprostenol ] immunosuppressant drug methotrexate cyclosporine cyclophosphamide extracorporeal photopheresis antifibrotic agents dpenicillamine colchicine interferon gamma relaxin treatment options review localize scleroderma include use corticosteroids vitamin analogues calcitriol calcipotriene uva methotrexate preliminary report new therapies systemic sclerosis also consider include use minocycline psoralenuva lung transplantation autologous stem cell transplantation etanercept thalidomide',\n",
       " 'management chronic heart failure elderly patients often complicate presence multiple comorbid condition polypharmacy psychosocial financial concern difficulties adherence complex medication dietary regimens addition patients years age enrol clinical trials efficacy current heart failure therapies remain uncertain age group take together factor contribute persistently high hospitalization mortality rat well poor quality life associate chronic heart failure elderly article nonpharmacologic aspects care pharmacotherapy systolic heart failure elderly patients review optimal management require systematic approach comprise key elements coordination care across discipline patient caregiver education enhancement selfmanagement skills effective followup judicious use medications however must recognize even ` ` best practice interventions prognosis establish heart failure remain poor future research must therefore direct develop effective strategies prevention heart failure age population',\n",
       " 'sympathetic nervous reninangiotensin systems play important roles essential hypertension study aim assess effect losartan combination quinapril cardiac nervous system neurohormonal status essential hypertension',\n",
       " 'angiotensinconverting enzyme ace inhibitors reduce mortality patients acute myocardial infarction ami benefit might limit acute hemodynamic change difficulties titrate recommend dose objective study compare hemodynamic change tolerability perindopril captopril ami randomize patients receive either captopril n perindopril n within hours ami captopril give initial dose mg mgday day mgday thereafter correspond dose perindopril mgday acute hemodynamic change percentage patients reach target dose inhospital month cardiovascular events monitor baseline clinical characteristics group identical patients randomize perindopril higher killip class vs p first hours treatment perindopril result higher minimal systolic vs mm hg p diastolic blood pressure bp vs mm hg p later occurrence minimal bp vs hour p lower incidence persistent hypotension systolic bp mm hg hour vs p compare captopril initial administration target dose perindopril captopril attain patients respectively p months no differences patients treat perindopril captopril mortality rat vs p need revascularization vs p thus patients ami perindopril treatment show better shortterm tolerance treatment captopril significantly less acute hemodynamic change fewer withdrawals',\n",
       " 'evaluate efficacy cyclosporin csa treatment idiopathic membranous nephropathy imn prospective control clinical study perform',\n",
       " 'blockade reninangiotensin system prove important principle pharmacotherapy cardiovascular diseases overwhelm documentation beneficial effect angiotensin convert enzyme inhibitors ace inhibitors mortality morbidity patients cardiovascular risk factor documentation still lack angiotensin ii receptor antagonists sell amount spend ace inhibitors denmark review assess therapeutic effect angiotensin ii antagonists compare ace inhibitors patients uncomplicated essential hypertension comparative study duration one year conclude lower blood pressure two class similar show relatively side effect difference higher incidence cough ace inhibitors larger comparative longterm study mortality morbidity conduct angiotensin ii antagonists use hypertensive patients experience unacceptable side effect ace inhibitors',\n",
       " 'vasopeptidase inhibitors group agents capable inhibit neutral endopeptidase angiotensinconverting enzymes lead potentiation natriuretic peptide action suppression reninangiotensinaldosterone system distinctively characteristic mechanism agents emerge new drug class management hypertension heart failure several vasopeptidase inhibitors clinical investigation omapatrilat study agent class clinical study omapatrilat hypertension consistently show agent effectiveness variety patient populations patients heart failure omapatrilat significantly improve neurohormonal hemodynamic status longterm effect omapatrilat patients heart failure recently compare conventional therapy large phase ii trial result study appear promise large clinical trials ongoing additional information regard safety efficacy study may help define place therapy agent',\n",
       " 'compare efficacy safety eprosartan enalapril lower systolic blood pressure elderly patients essential hypertension',\n",
       " 'evidence suggest light moderate alcohol consumption protect cardiovascular diseases however cardioprotective effect alcohol consumption adults absent population level approximately patients admit hospital alcohol abusers medical practice essential patients level consumption know many adverse effect might result course routine care ethanol damage heart evident alcohol consumption exceed gd heavy ethanol consumption lead increase risk sudden cardiac death cardiac arrhythmias patients coronary heart disease alcohol use associate increase mortality early response drink increase ventricular wall thickness diameter ratio possibly proceed continuous drink alcoholic cardiomyopathy worse outcome compare idiopathic dilative cardiomyopathy drink not stop least reduce gd icu patients chronic alcoholism cardiac complications postoperatively complications probably cause biventricular dysfunction particularly occurrence severe infections septic shock events three four time frequent among chronic alcoholics occasional drinkers nondrinkers prevent complications drink longterm management drink patients alcohol abuse heart failure treat brief intervention followup program prognosis good even patients new york heart association class iv heart failure cause cardiomyopathy complete abstinence accomplish noncompliance smoke alcohol restrictions amenable change dramatically increase risk hospital readmissions among patients heart failure',\n",
       " 'ace inhibitors calcium antagonists may modulate fibrinolysis conduct randomize control trial assess effect drug plasminogen activator inhibitor pai antigen inhibitor fibrinolysis',\n",
       " 'patients diabetes mellitus increase morbidity mortality cardiovascular disease coronary artery disease congestive heart failure chf largely responsible increase cardiovascular adverse events patients diabetes review discuss pathophysiology chf mechanisms leave ventricular lv dysfunction neurohormonal mechanisms involve lv dysfunction chf diabetes without hypertension important cause lv dysfunction chf diabetes may responsible metabolic ultrastructural cause lv dysfunction hypertension may responsible mark fibrotic change find experimental induction diabetes animals shed light biochemical ultrastructural change see role insulin reverse metabolic structural change review experimental data limit amount clinical data available therapy chf patients diabetes similar patients without diabetes therapy direct toward use betablockers angiotensin convert enzyme ace inhibitors morbidity mortality higher patients diabetes several study point importance subgroup opportunity make significant clinical impact exist significant opportunity exist reduce morbidity mortality betablockers ace inhibitors ischaemia chf present however study patients diabetes limit post hoc subgroup analyse rarely predefined subgroups clinical trials involve patients diabetes without hypertension lv dysfunction clearly need future adequately address need high risk subgroup',\n",
       " 'quinapril rapidly deesterified absorption quinaprilat active diacid metabolite potent angiotensin convert enzyme ace inhibitor quinapril produce favourable haemodynamic change improve ventricular endothelial function patients various cardiovascular disorder effect mediate bind quinaprilat tissue plasma ace quinapril mgday provide effective blood pressure control patients essential hypertension clinical trials patients require dosages mgday andor concomitant diuretic therapy general quinapril provide similar blood pressure control standard antihypertensive therapies include ace inhibitors calcium antagonists betaadrenoceptor antagonists comparative clinical trials combine therapy quinapril hydrochlorothiazide significantly greater antihypertensive effect either drug monotherapy two well design study quinapril also show reduce microalbuminuria patients hypertension andor diabetes mellitus patients congestive heart failure quinapril mgday produce beneficial haemodynamic echocardiographic change improve exercise tolerance symptoms functional class effect quinapril survival not investigate quinapril mgday show comparable efficacy captopril mg twice daily two well design trials patients coronary artery disease quinapril mgday significantly reduce incidence ischaemic events coronary artery bypass graft cabg well control study n however lower dosage quinapril mgday show no effect ischaemic events atherosclerotic progression years treatment similarly design study involve patients undergo coronary angioplasty tolerability quinapril similar ace inhibitors placebocontrolled trials cough occur hypotension occur quinapril recipients hypertension congestive heart failure respectively no increase adverse events observe dosage increase mgday',\n",
       " 'conduct economic analysis us antihypertensive treatment without benazepril patients chronic renal insufficiency',\n",
       " 'increase renal vascular resistance microalbuminuria associate hypertensive target organ damage may predictors hypertensive nephrosclerosis',\n",
       " 'objective study explore relationship psychological characteristics responses antihypertensive drug therapy twentytwo hypertensive subject undergo psychological evaluation treatment diuretic hydrochlorothiazide hctz angiotensinconverting enzyme ace inhibitor quinapril combine alpha beta blockade doxazosin betaxolol angerout score statetrait anger expression inventory positively correlate hctzinduced fall systolic blood pressure p angerin negatively correlate quinaprilinduced fall systolic pressure p target systolic blood pressure mm hg achieve either hctz quinapril subject without vs subject childhood trauma p responses doxazosin betaxolol not correlate psychological characteristics author conclude inhibit anger expression childhood trauma associate reduce response diuretic ace inhibitor combine alphabeta blockade may preferable ace inhibitor diuretic treat select hypertensive patients study include examination psychological factor term response combine ace inhibitor diuretic therapy',\n",
       " 'investigate reason withdrawal doubleblind randomize trials reason change treatment within randomize therapeutic group',\n",
       " 'seek determine effect angiotensin receptor blockers arbs mortality hospitalization patients heart failure hf',\n",
       " 'excess morning risk myocardial infarction stroke may attributable rapid rise blood pressure bp heart rate hours awaken aim randomize doubleblinded placebocontrolled multicenter study compare oncedaily controlledonset extendedrelease coer verapamil enalapril losartan bp heart rate postawakening morning phase well throughout h period',\n",
       " 'rise incidence stroke congestive heart failure chf end stage renal disease esrd signal need increase awareness treatment control hypertension continue need effective antihypertensive medications since hypertension major precursor various form cardiovascular disease reninangiotensin aldosterone system raas key component development hypertension one target drug therapy angotensin ii atii receptor blockers arbs recent class agents available treat hypertension work inhibit atii receptor level currently national consensus guidelines recommend arbs reserve hypertensive patients not tolerate angiotensin convert enzyme ace inhibitors aceis arbs however move forefront therapy promise role area renoprotection chf recent trials renoprotective effect angiotensinreceptor antagonist irbesartan patients nephropathy due type diabetes trial idnt effect irbesartan development diabetic nephropathy patients type diabetes irma effect losartan renal cardiovascular outcomes patients type diabetes nephropathy renaal study demonstrate renoprotective effect arbs patients type diabetes valsartan heart failure trial valheft add grow body evidence arbs may improve morbidity mortality chf patients class arbs well tolerate lower incidence cough angioedema compare aceis article review differences among arbs exist efficacy data hypertension explore role arbs chf renal disease',\n",
       " 'coexistence hypertension diabetes dramatically synergistically increase risk microvascular macrovascular complications overwhelm evidence support aggressive treatment hypertension diabetic patients however small percentage diabetic hypertensive patients reach treatment goal blood pressure bp mmhg tight bp control not costeffective also reward glycaemic control optimal goal bp control diabetics mmhg subject diabetes renal insufficiency bp lower mmhg delay progression renal failure choice antihypertensive agent base prove effect morbidity mortality rather surrogate parameters lipid glucose limit data suggest angiotensin convert enzyme inhibitor acei agent choice especially proteinuria renal insufficiency betablockers betabs firstline agent diabetics coronary heart disease thiazide diuretics td calciumchannel blockers ccbs secondline drug angiotensin iireceptor blockers arbs may prove effective aceis diabetics hypertension alphaadrenergic antagonists aaas avoid hypertensive patients require one agent control bp no evidence support one combination regimen others nevertheless combination acei td betab may costeffective regimens compare combinations',\n",
       " 'captopril enalapril lisinopril angiotensinconverting enzyme ace inhibitors widely prescribe hypertension heart failure cutaneous side effect captopril include angioedema anaphylactoid reactions maculopapular eruptions pitiryasis rosealike rash toxic erythema exfoliative dermatitis immunological captoprilinduced cutaneous adverse reactions diagnose recent years patch test case cutaneous immune adverse reaction captopril tolerance enalapril lisinopril demonstrate patch test doubleblind challenge test report first time yearold nonatopic woman suffer generalize pruriginous maculopapular rash two months earlier start oral treatment captopril mg glibenclamide mg daily rash appear stop drug reaction clear skin biopsy one lesions show perivascular lymphocytic infiltrate upper dermis skin prick test captopril glibenclamide patch test enalapril lisinopril glibenclamide pet mercaptobenzothiazole sulfhydryl groupcontaining chemical pet negative patch test captopril concentrations positive h oral doubleblind challenge test glibenclamide enalapril lisinopril placebo show good tolerance patient advise avoid captopril captopril ace inhibitor contain sulfhydryl group occasionally implicate complex immunological diseases chemical group consider culprit allergic reactions captopril lack crossreactivity captopril enalapril benazepril demonstrate patients patch test patient patch test identify captopril drug responsible probably immune adverse reaction not due sulfhydryl group patch test useful safe diagnostic workup allergic drug reactions study crosssensitivity among ace inhibitors',\n",
       " 'blood pressure bp lowering efficacy assess measurements take clinic set angiotensin iireceptor antagonists show similar efficacy angiotensinconverting enzyme inhibitors better tolerability search medline date however reveal no randomize doubleblind study use ambulatory bp monitor abpm compare bplowering efficacy irbesartan enalapril large number patients essential hypertension',\n",
       " 'report delated cutaneous reactions captopril seldom report captopril angiotensinconverting enzyme ace inhibitor cutaneous sideeffects document little publish concern usefulness patch test occur present case patient develop cutaneous reaction induce captopril positive patch test',\n",
       " 'early resolution stsegment deviation st recovery postthrombolytic electrocardiograms restoration ` ` normal blood flow infarctrelated artery associate improve outcomes myocardial infarction mi',\n",
       " 'purpose compare blood pressure response shortterm treatment captopril trandolapril patients leave ventricular lv dysfunction acute myocardial infarction ami',\n",
       " 'sibutramine treatment obesity result significantly greater weight reduction compare placebo although weight loss sibutramine may accompany small statistically significant mean increase blood pressure bp week placebocontrolled doubleblind randomise study investigate effect sibutramine mg daily placebo body weight obese body mass index bmi kgm hypertensive patients randomisation hypertension well control mm hg diastolic blood pressure dbp angiotensinconverting enzyme ace inhibitor without concomitant thiazide diuretic therapy therapy hypertension continue weeks study sibutramine mg produce significantly greater weight loss compare placebo kg sibutramine compare kg placebo last observation carry forward locf p total patients treat sibutramine lose body weight compare six patients treat placebo patients treat sibutramine lose body weight compare two patients treat placebo locf p comparisons hypertension remain well control weeks study sibutramine placebo treatment weeks differences placebo treatment sibutramine treatment mean supine systolic blood pressure sbp dbp approximately mm hg mean dbp mm hg placebo treatment compare mm hg sibutramine treatment locf p mean sbp mm hg placebo compare mm hg sibutramine locf p comparisons sibutramine vs placebo mean increase sbp dbp not appear change overall risk category coronary heart disease end point change pulse rate week decrease beat per minute bpm placebo treatment compare increase bpm sibutramine treatment p mandate withdrawals study due protocoldefined change bp not statistically different two treatment group greater favourable change lipid profile serum glucose uric acid could account greater weight losses occur sibutramine treatment group sibutramine well tolerate study indicate obese patients whose hypertension well control outset ace inhibitor without concomitant thiazide diuretic therapy sibutramine safely effectively achieve weight loss without compromise good bp control',\n",
       " 'gynaecomastia commonest benign condition male breast management consist primarily take complete history make thorough clinical examination ultrasound recommend firstline image investigation although mammography may add confirm diagnosis result fineneedle aspiration cytology may poor adequate yield pathological specimens low reserve suspect malignant lesions endocrine evaluation gynaecomastia rarely productive test best selectively many patients treat simply reassurance benign nature condition patients stimulus identify modification treatment may improve symptoms hormonal manipulation may appropriate younger patients testicular neoplasm must exclude operations reserve fail respond hormones severe cosmetic deformities',\n",
       " 'ace inhibitors group drug whose use last ten years largely expand new members group drug develop register today croatia exist dozen ace inhibitors different pharmaceutical company like lisinopril cilazapril ramipril trandolapril enalapril etc notable side effect ace inhibitors hypotension dry cough rash angioneurotical edema impair renal function acute renal failure aim article present year old patient reversible impairment renal function treatment ace inhibitor lisinopril',\n",
       " 'systeur study investigate whether active antihypertensive treatment could reduce cardiovascular complications elderly patients isolate systolic hypertension',\n",
       " 'although several important study perform hypertensive type diabetic patients not know whether lower blood pressure normotensive bp mm hg patients offer beneficial result vascular complications current study evaluate effect intensive versus moderate diastolic blood pressure dbp control diabetic vascular complications normotensive type diabetic patients',\n",
       " 'congestive heart failure affect age age uk level likely rise wake improve therapies hypertension myocardial infarction often multifactorial group common cause hypertension coronary heart disease valvular heart disease play increase role common precipitant preexisting heart failure noncompliance medication diet nonsteroidal antiinflammatory drug particularly likely exacerbate condition diagnosis may difficult since typical sign often absent mask older people plasma level brain natriuretic peptide appear reliable indicator may provide diagnostic test future systolic heart failure manage conventional therapy diuretics angiotensinconverting enzyme inhibitors betablockers management diastolic heart failure less well define symptoms manage ischaemia prevent underlie cause identify treat nursedirected multidisciplinary intervention include education patient family social support review medication dietary modification weight monitor result improvements eventfree survival quality life',\n",
       " 'present study describe effect losartan angiotensinconverting enzyme inhibitor enalapril blood pressure echocardiographically calculate leave ventricular mass renal function evaluate glomerular filtration rate quality life reninangiotensinaldosterone system importance cardiovascular growth substantial experimental documentation animals angiotensin ii antagonist losartan decrease cardiac hypertrophy response cause elevate arterial pressure well intravascular volume overload however data humans scarce year randomise doubleblind study parallel group design patients essential hypertension result show drug reduce blood pressure equally effectively also leave ventricular mass p years treatment glomerular filtration rate significantly increase losartan p serum uric acid fell modestly although significantly dosedependent losartan patients compare increase enalapril patients fall serum potassium prestudy period observe patients no difference treatments term patient satisfaction quality life drug relatively similar hormonal haemodynamic effect excellent tolerability profile appear induce comparable blood pressure fall hypertensive patients particular therapy base specific ang ii blockade may offer advantage high risk hypertensives leave ventricular hypertrophy present enalapril losartan improve renal function attenuate intrarenal effect angiotensin ii might able reverse pathophysiology essential hypertensive kidney disease firstchoice drug treatment essential hypertension',\n",
       " 'singlecenter study compare extent change conventional ambulatory blood pressure bp predict regression leave ventricular mass lvm index response antihypertensive treatment previously untreated treat patients sustain hypertension',\n",
       " 'compare efficacy treatment protocols angiotensin convert enzyme ace inhibitor alone enalapril mg angiotensin ii atii receptor blocker losartan mg enalapril plus losartan patients microalbuminuria prospective randomize clinical trial normotensive type diabetic patients microalbuminuria document least consecutive urinary albumin excretion analyse recruit study patients group randomly one protocols consist treatment mg enalapril daily group n mg losartan daily group n drug group n reevaluate regard hbac level lipid profile blood pressure urinary albumin excretion rat uaer month intervals months mean age duration diabetes body mass index plasma lipid profile blood pressure level similar initial visit group uaer return normal level patients normalization uaer occur patients group respectively percentage reduction uaers end months p p p respectively amount reduction uaer not differ significantly among three group p ace inhibitors angiotensin ii receptor blockers similar efficacy treat diabetic microalbuminuria combination two drug not add benefit',\n",
       " 'select clinical pharmacy interventions undertake day data capture period analyse seek gain greater understand nature drugrelated problems involve pharmacists ask record interventions potentially major significance total interventions submit analysis case initial total intervention report exclude analysis initial review remain interventions patients care medical unit cardiovascularantithrombotic agents account report majority interventions implement time inpatient medication order review clinical pharmacist n common category drugrelated problem address interventions relate prescription inappropriately high dose correct drug patient n deficiencies technical knowledge account less case',\n",
       " 'diabetic nephropathy dn no cause endstage renal disease unite state highly prevalent african americans almost dn african americans cause type diabetes glycemic control control blood pressure essential prolong renal survival protect cardiovascular events among african americans diabetic nephropathy seem affect women men may relate increase rat obesity diabetes african american women addition gender development albuminuria family history possibly birth weight factor predict progression renal disease african americans dn impact glycemic control appropriate antihypertensives optimal level blood pressure control african americans advance dn require study article review clinical characteristics risk factor predictors disease progression treatment diabetic nephropathy african americans',\n",
       " 'leave ventricular hypertrophy lvh commonly occur patients endstage renal disease esrd independent risk factor cardiovascular events angiotensin ii type receptor atr antagonists may able reverse lvh independent hypotensive effect esrd set thirty chronically hemodialyzed uremic patients hypertension randomly assign receive atr antagonist losartan n angiotensinconverting enzyme acd inhibitor enalapril n calcium antagonist amlodipine n leave ventricular mass lvm index measure echocardiography months treatment baseline demographic clinical characteristics not differ three group mean baseline lvm index also not differ three group months treatment losartan treatment significantly reduce lvm index amlodipine enalapril therapy three group similar decrease mean blood pressure treatment plasma angiotensin ii concentration increase fold losartan treatment contrast plasma angiotension ii concentration not change enalapril increase fold amlodipine thus present study indicate losartan effectively regress lvh patients esrd enalapril amlodipine despite comparable depressor effect three drug',\n",
       " 'study design fully characterize vascular tissue angiotensin ai angiotensin ii aii conversion change time vivo humans chronic angiotensinconverting enzyme ace inhibitor therapy',\n",
       " 'study examine association use angiotensin convert enzyme inhibitors aceis risk death elderly patients hospitalize leave ventricular systolic dysfunction lvsd',\n",
       " 'besides wellknown role angiotensin system blood pressure control interaction angiotensin pain perception suggest study seek investigate whether angiotensin convert enzyme inhibitor facilitate bradykinins algesic peptides andor receptor antagonist may modify hypertensionrelated hypoalgesia humans study approve ethical committee department',\n",
       " 'international nifedipine gits study intervention goal hypertension treatment insight show mean office blood pressure measurements longterm treatment nifedipine gits effective diuretics prevent cardiovascular cerebrovascular complications however since office blood pressure measurements reflect limit extent blood pressure outside office sidearm insight study patients undergo office measurement h ambulatory blood pressure monitor also perform',\n",
       " 'omapatrilat design inhibit simultaneously angiotensinconverting enzyme ace neutral endopeptidase nep ubiquitous involvement reninangiotensinaldosterone system originally conceive axis sodium fluid metabolism inflammation thrombosis cardiac smooth muscle hypertrophy major factor disease progression condition diverse hypertension heart failure coronary artery disease diabetes interruption angiotensin ii generation bradykinin degradation ace inhibition major therapeutic advance management diseases nep metabolize bradykinin natriuretic peptides atrial natriuretic peptide brain natriuretic peptide ctype natriuretic peptide adrenomedullin peptides counter adverse effect angiotensin ii vasodilator natriuretic diuretic autonomic neural action antitrophic effect suppress plasma renin activity two systems consider key components cardiorenal axis maintain blood pressure cardiopulmonary blood volume within stable range balance compromise set heart failure primary hypertension combination ace nep inhibition augment beneficial hemodynamic tissue effect bradykinin natriuretic peptides vasopeptidase inhibition therefore novel approach cardiovascular therapy implications hypertension heart failure renal function ischemic heart disease',\n",
       " 'angiotensinconverting enzyme inhibitors angiotensin ii receptor antagonists reduce hemoglobin hb level patients posttransplantation erythrocytosis pte however effect transplant recipients without pte not certain mechanism reduce hb level patients pte remain unclear study evaluate effect losartan enalapril hb level relation serum erythropoietin epo insulinlike growth factor igf level patients pte patients without pte patients treat sequentially weeks losartan therapy follow weeks enalapril therapy two treatment phase separate washout period patients pte show significantly greater baseline hb igf concentrations compare patients without pte losartan enalapril treatments baseline serum epo level similar patients without pte baseline hb level correlate significantly igf level r p not epo level treatment enalapril mg reduce hb level markedly treatment losartan mg patients pte patients without pte enalapril mg mildly reduce hb level whereas losartan mg no significant hblowering effect reduction hb level enalapril therapy patients pte associate significant reduction circulate igf level not epo level whereas losartan reduce hb level no significant change circulate igf epo level patients without pte no significant change note serum epo igf level either treatment differential hblowering effect losartan enalapril treatment patients without pte suggest pathogenesis pte complex heterogeneous different erythropoietic mechanisms may involve patients without pte largescale study need determine exact interaction reninangiotensin system regulation igf epo synthesis define exact mechanism losartan enalapril reduce hb level',\n",
       " 'angiotensinconvertingenzyme ace inhibitors reduce pack cell volume haemoglobin concentration polycythaemia follow renal transplantation like altitude polycythaemia erythropoietindependent form polycythaemia aim establish effect aceinhibitor treatment people altitude polycythaemia',\n",
       " 'mark heterogeneity characterise blood pressure bp responses antihypertensive drug efficacy drug act reninangiotensinaldosterone system raas predict albeit weakly plasma renin activity pra assume within individuals would concordance efficacy drug act different sit block raas',\n",
       " 'effect renal function efficacy angiotensin ii atreceptor blocker arb telmisartan compare angiotensinconverting enzyme inhibitor enalapril treatment mildtomoderate hypertension diastolic blood pressure [ dbp ] mmhg presence moderate renal failure creatinine clearance [ ccr ] mlminute study multicentre doubleblind doubledummy activecontrolled design patients randomise ratio receive telmisartanor enalapril twoweek placebo runin period eligible patients receive either telmisartan mg orenalapril mg oncedaily four weeks thereafter dose titrate telmisartan mg enalapril mg oncedaily supine trough dbp still mmhg four weeks dose titration perform require telmisartan mg enalapril mg frusemide give addition double dose already administer mean ccr decrease telmisartan forenalapril not clinically significant adverse events occur telmisartantreated patients patients receive enalapril mean reduction supine trough dbp baseline last available value mmhg telmisartan compare mmhg enalapril full reduction mmhg partial reduction mmhg response occur telmisartanpatients enalapril patients enalapril group patients require frusemide compare telmisartan group conclusion telmisartan lack detrimental effect renal function effective treatment mildtomoderate hypertension patients moderate renal failure comparable enalapril',\n",
       " 'compare pharmacotherapeutic approach diabetic hypertension family physicians fps general practitioners gps',\n",
       " 'recent years substantial evidence accumulate unambiguously implicate high plasma fibrinogen level major cardiovascular risk factor open prospective randomise pilot study therefore undertake mild moderate hypertensives evaluate effect various antihypertensive drug viz enalapril felodipine prazosin blood pressure plasma fibrinogen level systolic diastolic blood pressure determine weeks whereas plasma fibrinogen assay baseline end th week treatment drugtreated group observe although three drug effectively control blood pressure enalapril significantly reduce plasma fibrinogen level due additional effect enalapril potential control two major cardiovascular risk factor hypertension high plasma fibrinogen level simultaneously',\n",
       " 'bristolmyers squibb bms develop vasopeptidase inihibitor omapatrilat dual inhibitor angiotensin convert enzyme ace neutral endopeptidase nep potential treatment cardiovascular diseases hypertension heart failure [ ] nda use omapatrilat hypertension file fda regulatory authorities eu december [ ] [ ] april bms voluntarily withdraw nda response question raise fda regard comparative incidence severity infrequent side effect angioedema report within nda database prospective control clinical study patients hypertension heart failure continue may bms report blind omapatrilat hypertension study continue pending supportive result data analysis anticipate late summerearly autumn company expect refile nda fda [ ] july bms report plan conduct multinational patient study octave omapatrilat cardiovascular treatment assessment versus enalapril compare efficacy safety omapatrilat enalapril treatment hypertension [ ] octave trial expect generate data mid could allow launch early [ ] phase iii trials hypertension commence january [ ] january merrill lynch expect bms refile nda fda second half [ ] february credit suisse first boston make similar prediction add believe bms would launch drug late early analysts also predict peak sales drug million [ ] may merrill lynch estimate sales billion [ ]',\n",
       " 'review literature assess differences response angiotensinconverting enzyme ace inhibitors betablockers black patients compare response nonblack patients management systolic heart failure',\n",
       " 'microalbuminuria associate increase cardiovascular risk lipid abnormalities people type diabetes ace inhibitors calcium channel blockers ccbs reduce neutral total cholesterol triglycerides effect ace inhibitors ccbs lipid subfractions lp apolipoprotein apo apo b others however unclear current study test hypothesis fixeddose combination ace inhibitor benazepril b dihydropyridine ccb amlodipine reduce arterial pressure reduce atherogenic lipid fraction compare either agent alone',\n",
       " 'objective study assess factor relate occurrence microalbuminuria followup young adult group essential hypertension not previously treat normoalbuminuric essential hypertensives years old not previously treat antihypertensive drug not diabetes mellitus include initial evaluation patients treat use nonpharmacological measure n betablockers n ace inhibitors n calcium channel blockers n several class n measurements take office blood pressure biochemical profile hour urinary albumin excretion begin study measure yearly average years followup among patients include develop microalbuminuria progressors patientsy no differences present progressors remain normoalbuminuric nonprogressors term age gender body mass index disease duration blood pressure value biochemical profile familial history diabetes hypertension smoke habit presence ekg leave ventricular hypertrophy group lowest progression rate patients treat ace inhibitors n patientsy follow diet group n patientsy betablockers group n patientsy exclude patients treat calcium channel blockers change time different class treatment no significant differences incidence microalbuminuria observe among group progressors show higher slop fast glucose versus mgy p uric acid versus mgy p compare slop nonprogressors slop glucose systolic blood pressure time associate independently slope logarithm urinary albumin excretion adjust age gender treatment group cox proportional hazard model progression microalbuminuria show baseline urinary albumin excretion risk ratio [ rr ] confidence interval [ ci ] slope systolic blood pressure rr ci slope glucose rr ci independently associate development microalbuminuria conclusion group young adults essential hypertension not previously treat main factor influence occurrence microalbuminuria antihypertensive treatment value microalbuminuria baseline slop systolic blood pressure fast glucose',\n",
       " 'di deletion insertion polymorphism angiotensinconverting enzyme ace gene extensively study association number cardiovascular disease state however potential association differential clinical efficacy ace inhibitors acei administer patients suffer myocardial infarction mi e prevention leave ventricular lv remodel far not specifically study aim study investigate whether di polymorphism ace gene associate incidence postmi lv remodel patients draw healing early afterload reduce therapy heart study ace di polymorphism characterize polymerase chain reaction pcr subject healing early afterload reduce therapy study doubleblind placebocontrolled trial objective determine whether early delay administration acei ramipril patients acute anterior wall mi would optimal reduce lv enlargement select frequencies ace alleles placebohigh dose group low doselow dose group high dosehigh dose group respectively observe genotype frequencies hardyweinberg equilibrium no evidence association genotype outcome regard lv size function initial blood pressure response acei administration adjust covariates data provide no evidence association ace di polymorphism risk lv remodel postmi presence acei therapy therefore not suggest differential clinical efficacy aceinhibitors relate genetic marker',\n",
       " 'patients reduce leave ventricular function myocardial infarction risk lifethreatening ventricular arrhythmias randomize trial design evaluate effect implantable defibrillator survival patients',\n",
       " 'determine effect angiotensin convert enzyme inhibitor ramipril secondary prevention stroke',\n",
       " 'guidelines recommend lower threshold goal blood pressure bp patients proteinuria bp reduction could accompany different fall proteinuria depend antihypertensive drug objective compare proteinuria reduction bp lower level different drug',\n",
       " 'hypertension guidelines recommend initial treatment betablocker diuretic add drug blood pressure not control hypothesize systematic rotation major class antihypertensive drug would demonstrate substantial differences pattern individual patient response suggest rational approach choose best treatment',\n",
       " 'experimental data humans contribution angiotensinconverting enzyme inhibitors angiotensin ii type receptor blockers nitric oxide system renal vasculature inconsistent enalapril eprosartan alone combination use determine shortterm effect renal nitric oxide system renal hemodynamics human subject essential hypertension',\n",
       " 'automate systems currently widespread use assessment patients complete blood count evaluation peripheral blood smear however still constitute pivotal tool evaluation patients hematologic disorder article focus disorder affect number morphology platelets assess evaluation peripheral blood smear also outline important clinical find',\n",
       " 'renovascular hypertension usually cause atherosclerotic narrow origin renal artery much common think among patients peripheral vascular disease carotid stenosis heart failure renovascular hypertension must distinguish renal artery stenosis true renovascular hypertension kidney take charge blood pressure take push blood pressure high enough force blood block artery diagnose functional test measure glomerular filtration rate blockade reninangiotensin system angiotensin convert enzyme inhibitors antagonists subtype angiotensin receptor insufficient data make evidencebased recommendations management renovascular hypertension two randomise trials exist angioplasty versus medical therapy larger severely contaminate angioplasty among group initially assign medical therapy one trial exist angiotensin convert enzyme inhibition versus alternative medical therapy drug effective medical management renovascular hypertension angiotensin convert enzyme inhibitors angiotensin receptor blockers tend avoid fear rare complication acute renal failure patients severe stenosis renal arteries artery single remain kidney fear misplace not rare patients renovascular hypertension reversible treatable revascularisation patients renovascular hypertension evaluate nuclear medicine differential glomerular filtration rate enhance blockers reninangiotensin system medical therapy ineffective cause severe impairment renal function revascularisation require experts favour surgical revascularisation occasional angioplasty failure risk deterioration renal function angioplasty',\n",
       " 'vascular endothelial growth factor vegf think instrumental progression diabetic retinopathy indications exist reninangiotensin system involve vegf overexpression assess vitreous vegf concentrations patients relate antihypertensive treatment special interest use aceinhibitors',\n",
       " 'fosinopril recently add angiotensinconverting enzyme inhibitors induce pemphigus observation patient pemphigus vulgaris pv worsen take fosinopril prompt us study experimental way assess responsibility slice normal human skin nhs simultaneously incubate h degrees c progressively dilute fosinopril captopril solutions use indirect immunofluorescence iif substrates sera contain antidesmoglein antidsg antibodies dilution captopril iif negative irrespective dilution time incubation dilution iif positive fosinopril iif negative hourlong incubations turn positive h remain solutions incubation time iif negativity captopril suggest antidsg antibodies contain pv sera unable find molecules nhs bind captopril would therefore induce acantholysis block adhesion molecules fosinopril instead partial block adhesion molecules see concentrate solution unlikely occur vivo fosinopril therefore probably unable block adhesion molecules vivo method might use verify acantholytic properties drug',\n",
       " 'vasopeptidase inhibitors new class drug simultaneously inhibit angiotensiniconverting enzyme neutral endopeptidase two metallopeptidases responsible breakdown different vasoactive peptides least ten vasopeptidase inhibitors various stag development result obtain preclinical clinical study indicate promise future treatment hypertension heart failure renal disease however like angiotensiniconvertingenzyme inhibitors vasopeptidase inhibitors characterize acute chronic sideeffects need clarify',\n",
       " 'recent research pathophysiology congestive heart failure focus blockade neurohormonal systems large clinical trials clearly demonstrate morbidity mortality benefit angiotensinconvertingenzyme inhibitors beta blockers indeed patients heart failure treat agents unless specific contraindication otherwise despite treatment however mortality heart failure remain high current investigation focus pathophysiological mechanisms interruption pathways',\n",
       " 'progression renal parenchymal damage endstage renal disease seem largely independent initial insult final common pathway chronic proteinuric nephropathies animals humans key event enhance glomerular capillary pressure impair glomerular permeability proteins permit excessive amount proteins reach lumen proximal tubule secondary process reabsorption filter proteins contribute renal interstitial injury activate intracellular events include upregulation genes encode vasoactive inflammatory mediators interstitial inflammation progression disease control drug angiotensinconverting enzyme inhibitors strengthen glomerular permeability barrier proteins thereby limit proteinuria filter proteindependent inflammatory signal clinical data strongly suggest remission achieve patients chronic renal disease current lag time start treatment remission however substantial proportion patients still progress endstage renal disease renal function begin stabilize multimodal approach center reduce remove risk factor associate progression renal disease may decrease time remission disease patients proteinuric nephropathies',\n",
       " 'elderly patients nonchemotherapy druginduced agranulocytosis present commonly severe infections mortality least study whether granulocyte colonystimulating factor gcsf hematopoietic growth factor shorten duration neutropenia useful patients',\n",
       " 'nonselective nonsteroidal antiinflammatory agents show attenuate antihypertensive efficacy ace inhibitors average increase systolic blood pressure bp mm hg less know specific cyclooxygenase cox inhibitors widely use treatment arthritis objective study determine effect celecoxib compare placebo hour bp level ace inhibitortreated patients hypertension randomize doubleblind placebocontrolled parallelgroup clinical trial involve men women mean age years essential hypertension treat control lisinopril monotherapy mg daily baseline bp value obtain use hour ambulatory record patients receive either celecoxib mg twice daily twice recommend dose osteoarthritis n placebo n weeks change hour bp body weight clinical laboratory parameters assess mean change baseline hour systolic diastolic bp mm hg celecoxib versus mm hg placebo p systolic bp p diastolic bp proportion patients whose hour bp increase least mm hg also similar celecoxib placebo no change body weight serum creatinine potassium occur either group thus data demonstrate high dose celecoxib no significant effect antihypertensive effect ace inhibitor lisinopril placebosubtracted change observe hour bp mm hg less report nonselective nonsteroidal antiinflammatory agents ace inhibitortreated patients',\n",
       " 'increase evidence suggest endothelial dysfunction critical factor vascular diseases genetically predispose spontaneously hypertensive rat shr treat inhibitors nitric oxide no synthase develop severe hypertensive nephrosclerosis without necessity surgical reduction renal mass nephrectomy renal infarction nephrotoxic drug animals endothelial dysfunction consider valid model assessment efficacy cardiovascular therapy shr treat either angiotensinconverting enzyme inhibitor enalapril angiotensin ii ang ii receptor antagonist aiia valsartan subhypotensive dose effect survival rat cardiac renal change monitor rat treat valsartan alone combination enalapril show markedly higher survival rat respectively untreated animals treat enalapril alone valsartan dose attenuate blood pressure increase lead even greater survival rat despite improve survival rat nonhypotensive dose drug no effect histological appearance kidney function improve plasma creatinine level reduce valsartan alone combination enalapril proteinuria persist treatments weeks study aldosterone level significantly reduce treatments result suggest beneficial role endothelium hypertension reduce renal perfusion pressure probably underlie beneficial renal effect highdose valsartan',\n",
       " 'angiotensinconverting enzyme inhibitors acei different modes action different durations inhibition effect acei various components reninangiotensin system ras trough hours study patients diabetes mellitus receive longterm acei treatment',\n",
       " 'purpose study determine whether differences restoration endothelial function angiotensinconverting enzyme inhibition base severity hypertension forearm blood flow fbf measure patients essential hypertension mild n moderate n severe n randomly assign treatment either imidapril amlodipine weeks doubleblind fashion reactive hyperemia sublingual administration nitroglycerin imidapril augment fbf response reactive hyperemia weeks treatment mild moderate hypertensive group not severe hypertensive group augmentation fbf response reactive hyperemia induce imidapril significantly greater moderate hypertensive group mild hypertensive group amlodipine not alter fbf response reactive hyperemia increase fbf sublingually administer nitroglycerin similar group infusion ngmonomethyllarginine nitric oxide synthase inhibitor abolish enhancement reactive hyperemia mild moderate hypertensive group treat imidapril find suggest effect imidapril endothelial function affect severity hypertension angiotensinconverting enzyme inhibitorinduced augmentation reactive hyperemia may due increase nitric oxide production',\n",
       " 'calciumchannel blockers ccbs use treatment hypertension years recent clinical trials support efficacy safety longacting dihydropyridine dhp ccbs wide spectrum hypertensive patients include diabetic hypertensive patients dhp ccbs effective agents overall particularly effective use combination agents lercanidipine novel dhp ccb effective treatment mildtomoderate hypertension compare dhp ccbs lercanidipine molecular design impart greater solubility within arterial cellular membrane bilayer membranecontrolled kinetics high cholesterol tolerance factor favorable membranecontrolled kinetics impart gradual onset vasodilation long duration action unique pharmacokinetic pharmacodynamic properties lercanidipine appear contribute efficacy favorable safety profile clinical trials treatment mildtomoderate hypertension lercanidipine administer start dose mg daily increase mg daily nonresponders study show lercanidipine hour antihypertensive effect cause no significant increase heart rate lercanidipine show effective wide range hypertensive patients include mildtomoderate hypertension severe hypertension elderly isolate systolic hypertension associate low rate adverse events efficacy favorable safety profile lercanidipine potential improve blood pressure control wide range patients include not respond unable tolerate antihypertensive agents',\n",
       " 'recently approve drug may likely unrecognized adverse drug reactions adrs establish drug no recent study examine frequently postmarketing surveillance identify important adrs',\n",
       " 'review discuss new aspects normal abnormal renal development expand insight adaptation neonatal kidneys stress extrauterine life highlight pitfalls measure glomerular filtration rate neonate mainly cause postnatal fluctuations serum creatinine level serum creatinine level correlate author recent find tubular reabsorption creatinine immature neonatal kidney renal maldevelopment premature smallfordate baby show relate serious medical problems adult life include hypertension find present pediatrician new role timehonored vocation prevent disease mutations several genes may responsible case congenital hereditary renal aberrations two renal disorder congenital nephrotic syndrome neonatal acute renal failure one form treatment modality newborn infants renal replacement therapy discuss detail condition rare general pediatric practice illustrate new developments renal care newborn word caution offer use nonsteroidal antiinflammatory drug pregnancy newborn period nonsteroidal antiinflammatory drug administer indirectly unborn fetus directly young newborn impair renal structure fetus function fetus newborn new data obtain genetic molecular biology techniques establish methods developmental renal physiology better understand pathogenesis neonatal renal disorder result new diagnostic procedures improve preventive therapeutic possibilities relevant neonate renal disorder',\n",
       " 'article review select recent literature specifically concern pediatric hypertension much focus measurement monitor blood pressure well evaluate antihypertensive medications normative data blood pressure children widely available time base upon seat inoffice measurements recent years ambulatory blood pressure monitor abpm facilitate userfriendly instrumentation become commonplace though norms not base large populations however abpm important use assess blood pressure well monitor antihypertensive review discuss issue involve determine blood pressure well utility abpm several situations recent developments concern pediatric antihypertensive therapy consider well new information relevant diagnosis course treatment hypertension children adolescents',\n",
       " 'since angiogenesis essential growth solid tumor emerge efforts make develop antiangiogenic therapy date however no antiangiogenic agent become widely available clinical set angiotensin iconverting enzyme ace inhibitors commonly use antihypertensive agents recently suggest decrease risk cancer study find ace inhibitor perindopril potent inhibitor experimental tumor development angiogenesis clinically comparable dose potent angiogenic factor vascular endothelial growth factor vegf significantly suppress perindopril also inhibit vegfinduced tumor growth vitro study show perindopril not cytotoxic either tumor cells endothelial cells since perindopril already widespread clinical use without serious side effect may represent potential new strategy anticancer therapy',\n",
       " 'tinnitus perceive sensation sound absence acoustic stimulation commonest otological disorder refer either general practitioner earnosethroat surgeon short review examine prevalence aetiology associate clinical symptoms investigations management despite current usage vast number treatment modalities remain no specific cure condition however currently great emphasis tinnitus retrain therapy trt management applications result trt indeed encourage also briefly discuss',\n",
       " 'study compare effect losartan perindopril plasma plasminogen activator inhibitor pai fibrinogen hypertensive type diabetic patients',\n",
       " 'measure effect angiotensin ii blockade arterial stiffness augmentation index ai pulse wave velocity pwv blood pressure bp hypertensive patients mean years week randomize crossover study compare valsartan mgday captopril mgday week washout period subsequently therapies combine reductions pwv ai remain significant correct bp combine therapy reduce pwv ai p monotherapy even correct bp study show angiotensin receptor antagonists reduce arterial stiffness hypertension comparable possibly additive angiotensin convert enzyme inhibition',\n",
       " 'many drug injure kidneys cause renal injury via common mechanisms many patients develop renal injury drug exposure identifiable risk factor could modify preclude use drug first place',\n",
       " 'angiotensin ii type receptor antagonists share not pharmacological action angiotensinconverting enzyme inhibitors latter belong standard heart failure therapy prove benefit term morbidity mortality promise data provide angiotensin ii type receptor antagonists experimental model heart failure patients hypertension diabetic nephropathy favourable result observe regard blood pressure control reversibility structural change prevention progression disease currently available clinical trials heart failure patients angiotensin ii type receptor antagonists suggest may equivalent angiotensinconverting enzyme inhibitors superiority not prove no doubt effectiveness regard symptoms however effect hospitalisation mortality not unequivocally demonstrate trials warrant particularly define role comparison addition angiotensinconverting enzyme inhibitors characterise heart failure patient populations derive benefit angiotensin ii type receptor blockers beyond angiotensinconverting enzyme inhibitors betablockers spironolactone',\n",
       " 'treatment strategies patients heart failure leave ventricular systolic dysfunction continue evolve complex pathophysiology disease better understand number advance make recent years notably addition betareceptor antagonists addition recent study provide important information regard utility angiotensin receptor antagonists aldosterone receptor antagonists natriuretic peptides management heart failure nonpharmacologic advance include resynchronization therapy appear confer symptomatic improvement patients improvements ventricular assist device technology importance neurohormonal activation progression heart failure become increasingly apparent new therapeutic strategies target neurohormonal systems investigate',\n",
       " 'angiotensin convert enzyme ace inhibitors well angiotensin ii receptor antagonists able prevent vasoconstrictive effect angiotensin ii efferent renal vessels believe play important role renovascular hypertension effect assume essential demonstration renovascular hypertension captopril renography study renographic change induce captopril receptor antagonist valsartan compare patients high probability renovascular hypertension twentyfive patients stenosed renal arteries grade stenosis hypertension study captopril valsartan baseline renography perform within h use technetiumm mercaptoacetyltriglycine blood pressure monitor plasma renin concentration intervention determine urinary flow estimate urinary output hydrate patients alterations renographic curve intervention evaluate accord santa fe consensus ace inhibitor renography captopril renography positive indicate renovascular hypertension stenosed vessels whereas valsartan renography positive ten blood pressure captopril valsartan renography not different reduction blood pressure valsartan captopril plasma renin concentration comparable valsartan captopril study show suppress value intervention many patients urinary flow valsartan higher captopril p however difference could not explain markedly higher sensitivity captopril compare valsartan demonstrate renal artery stenosis patients blood pressure response revascularisation monitor show much better predictive value captopril renography conclude captopril renography much sensitive valsartan renography detect clinically significant renal artery stenosis furthermore data suggest effect prostaglandinbradykinin system least similar importance ace inhibition high diagnostic sensitivity captopril renography regard renovascular hypertension',\n",
       " 'present study design examine whether production aldosterone heart suppress angiotensinconverting enzyme ace inhibition patients heart failure fortyone patients leave ventricular systolic dysfunction randomly divide either perindopril group n perindopril mgday placebo group n plasma level aldosterone ace activity measure anterior interventricular vein coronary sinus aortic root cardiac catheterization level aldosterone well ace activity significantly higher anterior interventricular vein coronary sinus aortic root placebo group aldosterone vs pgml [ p ] vs pgml [ p ] respectively ace activity vs iul [ p ] vs iul [ p ] respectively hand no differences level aldosterone ace activity anterior interventricular vein aortic root coronary sinus aortic root aldosterone vs pgml [ p ns ] vs pgml [ p ns ] respectively ace activity vs iul [ p ns ] vs iul respectively perindopril group level aldosterone well ace activity significantly lower anterior interventricular vein coronary sinus perindopril group placebo group difference level aldosterone anterior interventricular vein aortic root delta aldosterone [ anterior interventricular vein aortic root ] significant positive correlation ace activity delta ace [ anterior interventricular vein aortic root ] r p whereas ace activity aortic root no significant correlation either aldosterone level aortic root delta aldosterone anterior interventricular vein aortic root perindopril suppress cardiac aldosterone production mainly suppress cardiac ace activity patients heart failure thus aldosterone production activate fail ventricle suppress perindopril mainly via suppression cardiac ace activity patients heart failure',\n",
       " 'compare effect antihypertensive efficacy produce addition indomethacin angiotensin ii ang ii antagonist valsartan angiotensinconverting enzyme inhibitor lisinopril hypertensive patients chronic osteoarthritis',\n",
       " 'report aspirin asa may interfere blood pressure bp lowering effect various antihypertensive agents attenuate beneficial effect angiotensinconverting enzyme ace inhibitors patients congestive heart failure',\n",
       " 'study design assess compliance hypertensive patients oncedaily regimen angiotensin convert enzyme ace inhibitor trandolapril evaluate antihypertensive efficacy drug relation time interval take final dose measure blood pressure bp',\n",
       " 'hepatocellular canalicular transport proteins major determinants hepatic uptake biliary excretion xenobiotics metabolites recent advance molecular clone result characterization many transport systems advance enable identification number drug substrates transporters facilitate study mechanisms druginduced cholestasis review summarize normal function hepatobiliary transporters alteration drug foreign compound although investigations perform animal model druginduced cholestasis application human form druginduced cholestasis also discuss possible one important find genetic polymorphisms result change drug transporter expression function could increase susceptibility cholestatic drug reactions',\n",
       " 'role angiotensinreceptor blockers arbs therapy chronic heart failure chf not clarify no large placebocontrolled trials agents second evaluation losartan elderly trial eliteii compare arb losartan captopril patients years old new york heart association nyha class iiiv leave ventricular ejection fraction not establish efficacy arb equivalent angiotensinconverting enzyme inhibitor valsartan heart failure trial design determine whether addition valsartan improve outcomes patients receive standard therapy heart failure case include ace inhibitor',\n",
       " 'present study carry patients acute myocardial infarction ami treat angiotensin convert enzyme ace inhibitor another patients conventional treatment without ace inhibitor period may august medical college calcutta clinical laboratory investigations include echocardiographic parameters note record meticulously within hours ami repeat th week present study base noninvasive methods haemodynamic methods show echocardiographic assessment leave ventricular functional parameters weeks ace inhibitor therapy n better treat group comparison control group without ace inhibitor n difference statistically significant level confidence overall mortality ace inhibitor group control group short term study early intervention ace inhibitor within hours ami show statistically significant evidence beneficial effect ace inhibitor improve ventricular functional parameters also reduce short term mortality cardiac cause within weeks compare group not receive ace inhibitors',\n",
       " 'severe reactions due vancomycin uncommon describe case vancomycininduced linear immunoglobulin bullous disease review literature pertinent entity rare subepidermal blister disorder heterogenous clinical presentation characterize iga deposition linear pattern along basement membrane zone seem autoantibodymediated not dosedependent spontaneous complete skin heal follow vancomycin withdrawal rechallenge reproduce disease rapid severe onset vancomycin almost never suspect cause manifestations awareness rare autoimmune reaction crucial early diagnosis direct immunofluorescence perilesional skin would avoid unnecessary laboratory investigations therapeutic measure would shorten significantly pain suffer patients',\n",
       " 'although hypertension recognise one major health hazard develop world compliance antihypertensive regimens still undesirably low bring important cost patients increase morbidity mortality society hospitalisations lose productivity review survey possible reason noncompliance treatments generally antihypertensive medications specifically also look insights reason noncompliance help us design effective treatments discuss current emerge medications context compliance one reason low compliance think impact drug patient lifestyle recently develop agents angiotensin iireceptor blockers may expect less effect patients daily live earlier treatments bring hope increase compliance regimens',\n",
       " 'angiotensinconverting enzyme ace inhibitors effective several disease state congestive heart failure myocardial infarction diabetes article review evidence support clinical use efficacy cost effectiveness ace inhibitors various disease state find heart outcomes prevention evaluation trial agents may positive impact primary prevention coronary artery disease new ongoing trials provide information role ace inhibitors coronary artery disease',\n",
       " 'although angiotensinconverting enzyme ace inhibitors decrease mortality heart failure incompletely suppress angiotensin ii longterm therapy since angiotensin receptor blockers arbs block biologic effect angiotensin ii completely ace inhibitors could beneficial treatment heart failure',\n",
       " 'angiotensinconverting enzyme ace inhibitors often associate increase incidence cough bronchial responsiveness may cause deterioration patients impair pulmonary function',\n",
       " 'current recommendations treat elevate blood pressure bp acute stroke base largely expert opinion vary regard treatment thresholds choice antihypertensive agents study investigate influence recommendations compare management hypertension acute stroke tertiary care hospital current guidelines',\n",
       " 'compare inpatient cost process quality treatment acute myocardial infarction france germany italy netherlands sweden switzerland u k',\n",
       " 'omapatrilat simultaneously inhibit neutral endopeptidase angiotensinconverting enzyme increase level vasodilatory peptides decrease production angiotensin ii study evaluate clinical effect withdrawal omapatrilat patient hypertension control seat diastolic blood pressure mm hg omapatrilat least months without adjunctive antihypertensive medications doubleblind study randomize patients receive either establish omapatrilat dose placebo weeks concomitant antihypertensive medications keep constant patients continue omapatrilat no change blood pressure patients whose chronic omapatrilat treatment replace placebo clinically important increase systolic mm hg diastolic mm hg blood pressure p increase blood pressure also see patients take adjunctive antihypertensive medications prior withdrawal omapatrilat study demonstrate compare withdrawal placebo omapatrilat maintain clinically statistically significant blood pressure reductions',\n",
       " 'doxazosin remain commonly use antihypertensive medication although use taint recent find antihypertensive lipidlowering treatment prevent heart attack trial allhat allhat large simple trial design fashion closely mimic clinical practice occur highrisk hypertensive patients age years older goals determine whether incidence primary outcome composite fatal coronary heart disease nonfatal myocardial infarction differ treatment diuretic chlorthalidone mgday treatment three type antihypertensive drugsa calciumchannel blocker amlodipine angiotensinconverting enzyme inhibitor lisinopril peripheral alphaadrenergic blocker doxazosin mgday doxazosin recently withdraw trial interim analysis show secondary end point combine cardiovascular disease greater patients doxazosin assign treatment chlorthalidone find largely drive congestive heart failure practice clinician not abandon doxazosin completely allhat find although find indisputably important result represent interim analysis application clinical practice need occur carefully value member therapeutic armamentarium need not lay entirely rest rather doxazosin view secondary tertiary antihypertensive therapy pending complete review allhat data',\n",
       " 'reninangiotensinaldosterone system play key role regulation fluid electrolyte balance angiotensinconverting enzyme inhibitors inhibit angiotensinconverting enzyme show effective many cardiovascular diseases consider treatment hypertension patients heart failure previous myocardial infarction diabetes proteinuria number sideeffects associate angiotensinconverting enzyme inhibitors especially persistent dry cough angiotensin ii receptor antagonists sartans provide specific blockade reninangiotensinaldosterone system associate fewer sideeffects include cough longterm efficacy tolerability treatment patients hypertension however yet establish periodic monitor renal function electrolytes require patients treat angiotensinconverting enzyme inhibitor sartan',\n",
       " 'systemic lupus erythematosus chronic inflammatory autoimmune disorder affect organ system predominant manifestations include arthralgia rash photosensitivity pleuritis renal central nervous system involvement fortunately pleuritis systemic lupus erythematosus not usually life threaten may renal central nervous system complications nevertheless pleuritis occur systemic lupus erythematosus may significant cause morbidity addition primary pleuritis attribute systemic lupus erythematosus secondary pleural complications especially infections may occur consequence systemic lupus erythematosus pleuritis patients systemic lupus erythematosus may therefore frequently challenge diagnostic therapeutic acumen physicians',\n",
       " 'cholesterollowering agents know statins use years among commonly prescribe drug animal study premarketing clinical trials give signal hepatotoxicity primarily minor elevations serum alanine aminotransferase enzyme alt level reason cholesterollowering drug label require monitor liver enzymes postmarketing experience however suggest hepatotoxicity rare thus timely revisit issue first statins lovastatin approve acquire million patientyears clinical experience minor elevations liver enzymes e alt x upper limit normal uln occur patients lovastatin dose mgday respectively elevations reversible continue therapy dose relate probably relate cholesterol lower per se rare case acute liver failure alf report cholesterollowering drug lovastatin rate approximately million patienttreatment years background rate cause alf approximately equal background rate idiopathic alf monitor hepatotoxicity not effective prevent serious liver disease largely rarity poor predictive value minor alt elevations fact may increase patient risk needle discontinuation cholesterollowering therapy falsepositive result patients benefit treatment',\n",
       " 'suggest patients undergo acute intervention coronary syndromes may not receive adequate secondary prevention',\n",
       " 'evaluate effect arteriolar dilator diltiazem hydrochloride versus venodilator isosorbide dinitrate digoxin kinetics estimate efficacy tolerability vasodilators combine digoxin days therapy patients congestive heart failure secondary ischemic heart disease',\n",
       " 'communitybased study conduct determine degree therapeutic interventions succeed real world settings large practicebased clinical trial assess efficacy tolerability fixeddose combination therapy amlodipinebenazepril compare amlodipine monotherapy patients mildtomoderate hypertension',\n",
       " 'contribution angiotensin [ ang ] antihypertensive action omapatrilat novel vasopeptidase inhibitor evaluate saltsensitive low renin hypertensive subject substudy multicenter randomize doubleblind parallel study weeks duration total subject receive lisinopril active control omapatrilat mg produce sustain control blood pressure bp assess h ambulatory bp measurements significantly greater produce mg daily lisinopril antihypertensive response either drug accompany similar sustain inhibition angiotensin convert enzyme activity plasma level angiotensin ang angiotensin ii ang ii ang not alter treatment either omapatrilat lisinopril even though regimens produce modest rise plasma renin activity contrast urinary excretion rat ang ang not ang ii increase significantly throughout dose period subject give omapatrilat whereas smaller antihypertensive response produce lisinopril smaller transient effect increase urinary excretion rat ang omapatrilat single molecule inhibit neutral endopeptidase convert enzyme simultaneously control saltsensitive hypertension mechanism associate sustain increase urinary ang excretion suggest ang may component mechanisms omapatrilat induce antihypertensive response salt sensitive hypertension',\n",
       " 'inhibition metallo protease bms randomize exercise symptoms study subject heart failure impress clinical trial randomize patients congestive heart failure daily regimen either omapatrilat lisinopril weeks patients randomize omapatrilat significant reduction combine end point death hospitalization discontinuation study drug worsen heart failure compare patients randomize lisinopril also significantly fewer serious cardiac adverse events',\n",
       " 'recent data suggest dietary protein restriction improve survival delay progression endstage renal disease esrd nondiabetic nephropathies purpose study determine effect dietary protein restriction survival progression esrd diabetic nephropathy',\n",
       " 'increase pulse pressure indicator conduit vessel stiffness strong independent predictor cardiovascular events hypertensive cohorts suggest reduction conduit vessel stiffness may desirable hypertension',\n",
       " 'critical review literature effect antihypertensive drug fetus pregnant women present survey cover alphaadrenergic receptor agonists betablockers include topical eye medications alphabeta blockers calcium antagonists diuretics angiotensinconverting enzyme ace inhibitors lack data angiotensin ii receptor blockers note although effect consider similar report ace inhibitors therefore avoid analysis literature underscore antihypertensive drug use safely certain stag pregnancy others suspect avoid cost lack placebocontrolled study treatment severe hypertension pregnancy due ethical considerations discuss background press need treat women despite possible deleterious effect antihypertensive drug',\n",
       " 'seek compare short longterm clinical effect atrial synchronous preexcitation one univentricular ventricles biventricular provide cardiac resynchronization therapy crt',\n",
       " 'type ii diabetic patients albuminuria high risk cardiovascular complications intense antihypertensive treatment require often involve use drug combinations aim present study compare effect two different reninangiotensin block combinations blood pressure bp albuminuria glycemic control design prospective randomise control parallel branch perform one endocrinology department spain typeii diabetic patients stable albuminuria mgday include preinclusion time weeks patients randomise verapamil srtrandolapril vt losartanhydrochlorothiazide lh mgday duration treatment year evaluate parameters change blood pressure urinary albumin excretion hours glycated hemoglobin plasmatic urea overall bp significantly decrease mmhg mmhg p value treatment vt mmhg baseline mmhg conclusion lh mmhg baseline mmhg conclusion albuminuria significantly decrease mgday mgday parameters show no significant difference treatments glycated hemoglobin decrease vt group lh group anova p change adjust baseline value show trend difference treatments p plasmatic urea increase mgdl tv group mgdl mgdl lh group anova p conclusion treatments reduce blood pressure albuminuria similar way type ii diabetic patients verapamiltrandolapril combination contribute better carbohydrate metabolism losartanhydroclorothiazide',\n",
       " 'angiooedema rare potentially life threaten sideeffect angiotensinconvertingenzyme ace inhibitor treatment identification individuals risk adverse effect not possible angiooedema associate raise concentrations bradykinin mainly inactivate ace assess plasma activity two enzymes catabolise bradykinin aminopeptidase p carboxypeptidase n hypertensive patients history angiooedema ace inhibitor treatment hypertensive patients never ace inhibitor associate sideeffects patients previous angiooedema lower plasma activity aminopeptidase p never present angiooedema p data suggest low plasma concentrations aminopeptidase p could predispose factor development angiooedema patients treat ace inhibitors',\n",
       " 'determine factor predict whether patients hospitalise acute myocardial infarction ami receive care discordant recommendations clinical practice guidelines ii whether discordant care result worse outcomes compare receive guidelineconcordant care',\n",
       " 'study seek investigate cardiac renal effect rigorous versus standard bp control autosomaldominant polycystic kidney disease adpkd prospective randomize yr study perform examine effect rigorous mmhg versus standard mmhg bp control leave ventricular mass index lvmi kidney function hypertensive adpkd patients leave ventricular hypertrophy lvmi measure echocardiogram baseline yr renal function assess measure serum creatinine h creatinine clearance every mo yr annually additional yr baseline characteristics comparable two group study average mean arterial pressure mmhg rigorous group mmhg standard group p lvmi decrease standard group rigorous group mix model longitudinal data analysis reveal rigorous bp control significantly effective decrease lvmi p no statistically significant difference renal function two group conclusion leave ventricular hypertrophy major cardiovascular risk factor decrease significantly greater extent rigorous standard bp control find particular clinical importance cardiovascular complications common cause death adpkd patients',\n",
       " 'aim study analyze effect captopril c blood pressure patients acute myocardial infarction ami year treatment patients less years old systolic blood pressure sbp mm hg qualify study administration c start first days ami mean h pts treat c control group pts finally analyze dose c gradually increase first day till mg th day significant decrease sbp administration c observe min st nd rd dose first day min first c dose th day dbp decrease min st dose first day min first dose th day hypotension st nd dose c first day cause exclusion pts study conclusion hypotension seem quite often encounter captopril therapy early phase ami appear not first also follow dose initial dose mg seem safe sufficient assess hypotensive action',\n",
       " 'ace inhibitors acei angiotensin receptor blockers arb renoprotective beyond effect blood pressure bp widespread use limit tendency provoke hyperkalemia comparative effect acei arb potassium handle not investigate objective study determine whether differences dynamic renal potassium handle acei arb response oral potassium challenge randomize crossover study candesartan versus lisinopril titrate control bp follow inpatient study renal potassium handle hypertensive patients type ii diabetes mellitus dmii preserve renal function follow oral potassium challenge mmolkg differences hourly serum k mmoll rate urinary potassium excretion ukv micromolmin fractional excretion potassium fek assess repeatedmeasures anova hourly ukv p fek p similar candesartan lisinopril although fek hours candesartan tend exceed lisinopril [ ] vs [ ] approach significance p ukvfor candesartan hour lisinopril also approach significance p serial serum potassium not differ p no statistical differences discover renal potassium handle candesartan lisinopril patients dmii preserve renal function whether differences drug class renal impairment remain determine',\n",
       " 'hypervolemic hemodilution hh hydroxyethyl starch hes significantly increase cerebral blood flow thus may reduce ischemic tissue damage penumbra zone give within therapeutic time window objective study investigate safety solution hes versus saline solution acute ischemic stroke incidence adverse events aes',\n",
       " 'investigate relationship soluble markers platelet endothelial rheological function target organ damage response intensify management population middleage hypertensive patients high risk cardiovascular complications study consecutive patients men mean age years sd along normotensive control free cardiovascular disease patients divide target organ damage tod n free endorgan damage plasma level soluble pselectin spsel marker platelet activation von willebrand factor vwf index endothelial damagedysfunction enzymelinked immunosorbent assay rheological indices fibrinogen plasma viscosity hematocrit platelet white cell count measure patients variables measure months intensify cardiovascular risk management patients tod significantly higher vwf sd versus sd iudl p greater proportion smokers versus p no statistically significant differences plasma viscosity fibrinogen hematocrit white blood cell count platelet count spsel subgroups multivariate analysis vwf significant independent predictor tod months intensify management patients enter trial significant reductions systolic blood pressure total cholesterol hematocrit plasma viscosity spsel vwf p no significant change fibrinogen conclusion relationship tod endothelial damagedysfunction hypertension intensify management result improvements hemorheology endothelial platelet function',\n",
       " 'study undertake determine whether enalapril comparable efficacy black white patients asymptomatic leave ventricular dysfunction alvd prevent development symptomatic heart failure hf',\n",
       " 'provide update evidencebased recommendations therapy hypertension adults',\n",
       " 'adverse drug reactions effect account pharmacological profile drug may distinguish sometimes bizarre unpredictable events ` ` idiosyncrasies majority case latter due reactive intermediate form members cytochrome p family enzymes products usually form low quantities however genetic disposition e g enhance expression catalyze enzyme failure protective factor glutathione certain external condition example comedication inducers drug metabolism may lead toxic intermediate available relevant quantities generate metabolites react macromolecules finally cause cell necrosis necrosis may result direct damage function essential cell secondary harmful immune reactions activate recognition new structure neoantigens principal site drug metabolism liver frequently affect idiosyncratic reactions often enough recognize large number patients treat idiosyncratic potential drug relate chemical structure rather pharmacological mechanism risk evident biotransformation yield products chemical substructures quinones phenoles acyl halides aromatic hydroxyl amines numerous case precursor drug idiosyncratic potential replace marginalize agents favorable chemical properties examples include beta preferential betaadrenoceptor antagonists toxic precursor practolol choline esterase inhibitors use treatment alzheimer disease latter group tacrine cas give rise high liver enzyme level patients effect not share recent chemically different entities similar case make insulin sensitizer troglitazone cas market withdraw usa successors rosiglitazone cas pioglitazone cas due different chemical structure troglitazone transform reactive quinone metabolite process may accelerate drug induce metabolism agreement view no evidence specific hepatic toxicity two successor drug ongoing progress molecular toxicology may aid minimize idiosyncratic hazard already early stag drug development',\n",
       " 'cigarette smoke accelerate progression renal failure primary kidney diseases not know however whether stop smoke slow accelerate loss renal function',\n",
       " 'asymmetrical n g n g dimethylarginine adma associate impair endotheliumdependent vasodilation humans',\n",
       " 'african american study kidney disease hypertension aask ongoing trial evaluate effect blood pressure choice antihypertensive drug rate decline renal function',\n",
       " 'compare antihypertensive efficacy tolerability imidazoline ireceptor agonist moxonidine administer single daily dose mg angiotensinconverting enzyme inhibitor enalapril mg patients mild moderate essential hypertension',\n",
       " 'multicentre openlabel extension study four control trials involve patients mildtomoderate primary hypertension patients receive telmisartan mg daily addon hydrochlorothiazide hctz mg necessary andor antihypertensives achieve diastolic blood pressure dbp control mmhg treatment continue years treatment end patients telmisartan monotherapy telmisartan hctz mg telmisartan hctz mg telmisartan another antihypertensive hctz overall patients achieve dbp control highest proportion responders telmisartan monotherapy mg treatment category patients ] mean change systolic blood pressure sbp dbp previous trial baseline last available trough mmhg telmisartan alone mmhg telmisartan hctz mmhg telmisartan another antihypertensive hctz adverse events mildtomoderate intensity unrelated treatment proportion patients discontinue study due adverse events treatment onset telmisartan monotherapy telmisartan hctz telmisartan another antihypertensive hctz deaths study none consider drug relate thus telmisartan alone combination antihypertensives achieve maintain clinically relevant reductions dbp sbp longterm analysis support favourable efficacy safety profile telmisartan monotherapy combination antihypertensive drug',\n",
       " 'diabetic nephropathy associate high risk cardiac mortality include sudden death presumably relate imbalance sympathetic parasympathetic tone result decrease heart rate variability hrv nondiabetic patients decrease hrv know strong predictor cardiovascular death study nondiabetic patients show betablockers improve hrv parameters know reflect parasympathetic function aim study investigate effect additional betablocker treatment cardiac autonomic function blood pressure urine albumin excretion aceinhibitor treat type insulindependent diabetes mellitus patients abnormal albuminuria',\n",
       " 'worsen renal function patients hospitalize heart failure portend poor prognosis however criteria use define worsen renal function arbitrary implications different definitions remain unclear therefore compare prognostic importance various definitions worsen renal function patients hospitalize congestive heart failure chf',\n",
       " 'earliest awareness new evidence beat trial sit first generate evidence hypothesize sit take part survival ventricular enlargement save trial demonstrate angiotensinconverting enzyme ace inhibitors beneficial follow myocardial infarction would likely adopt use group patients',\n",
       " 'little know essential hypertension hispanic americans despite fact fastestgrowing minority unite state disproportionate degree hypertensive target organ damage author study caribbean hispanic hypertensive patients participate six doubleblind randomize trials antihypertensive agents demographics laboratory data sodium excretion plasma renin activity atrial natriuretic peptide obtain weeks placebo blood pressure responses angiotensinconverting enzyme ace inhibitors beta blockers calcium channel blockers hydrochlorothiazide hctz fix combinations ace inhibitors hctz compare placebo value weeks treatment patients multiple risk factor profile obesity diabetes wide spectrum blood pressure elevation leave ventricular hypertrophy hypertensive renal damage urine sodium excretion rat indicate inability comply salt restriction patients plasma renin activity lower hispanic normotensive control patients lowrenin essential hypertension renin profile sodium excretion analysis variance blood pressure reductions calcium channel blockers hctz ace inhibitorhctz combinations significantly greater placebo ace inhibitors beta blockers monotherapy not author conclude essential hypertension caribbean hispanics associate multiple risk factor largely lowrenin type responses therapy consistent observe populations lowrenin phenotype suggest saltsensitivity blood pressure population confirmation latter implications prevention treatment essential hypertension hispanics',\n",
       " 'least four independent study different clinical settings show angiotensinconverting enzyme inhibitors aceis enalapril effectively decrease plasma level circulate adhesion molecules cams examine whether effect may mediate decrease action angiotensin compare effect enalapril direct angiotensinii antagonist losartan plasma level cams monocyte chemotactic protein mcp randomize trial recruit untreated patients male age years hypertension receive either enalapril mean dose mgday losartan mean dose mgday equipotent dose enalapril decrease plasma level cams weeks treatment ceselectin level decrease p intercellular adhesion molecule cicam p vascular cell adhesion molecule cvcam p similarly enalapril decrease plasma level mcp p losartan not significantly change cam mcp plasma concentrations weeks treatment ceselectin level decrease cicam cvcam whereas mcp increase pns not significant enalapril effect percentage change cvcam significantly different losartan p eight weeks antihypertensive treatment enalapril not losartan significantly decrease plasma level cams mcp hypertensive patients beneficial effect aceis cams may implications atherogenesis reduction cardiovascular events not fully explain antihypertensive effect alone',\n",
       " 'antihypertensive treatment reduce risk thromboembolic events hypertension aim study examine influence angiotensinconverting enzyme inhibition blood coagulation subject mildtomoderate essential hypertension fibrinogen thrombinantithrombin complex tat factor vii determine plasma rest mental stress test follow placebo weeks ramipril weeks months ramipril reduce rest tat tend reduce fibrinogen factor vii remain unchanged mental stress increase fibrinogen not alter tat factor vii activity reduce thrombin generation patients take ramipril may explain part angiotensinconverting enzyme inhibitors reduce thromboembolic complications patients cardiovascular disease',\n",
       " 'aim study examine whether circulate cell adhesion molecules von willebrand factor vwf endothelin elevate patients essential hypertension no risk factor atherosclerosis thus may serve markers endothelial dysfunction uncomplicated hypertension furthermore effect treatment ace inhibitor quinapril level endothelial dysfunction markers study level adhesion molecules intercellular cell adhesion molecule [ icam ] eselectin pselectin von willebrand factor vwf endothelin measure patients hypertension without risk factor atherosclerosis treatment quinapril n normotensive control n compare normotensive subject hypertensive patients significantly higher level icam vs ngml p vwf vs iudl p endothelin vs fmolml p threemonth treatment hypertensive patients quinapril lead significant decrease level endothelin vs fmolml p not observe significant change level adhesion molecules vwf ace inhibitor treatment although trend toward decrease apparent parameters patients uncomplicated hypertension no risk factor atherosclerosis significantly elevate level icam vwf endothelin data suggest factor may serve markers endothelial damage even uncomplicated hypertension hypertensive patients treatment ace inhibitor quinapril result significant decrease endothelin level find indicate beneficial effect ace inhibitors endothelial dysfunction hypertensive patients',\n",
       " 'study assess percentage patients year persist initially prescribe antihypertensive therapy medical record patients newly diagnose hypertension prescribe initial antihypertensive monotherapy general practitioners germany france unite kingdom evaluate comparisons make among angiotensin ii receptor antagonist aiira irbesartan antihypertensive class include aiiras irbesartan aiira losartan patients initiate aiira irbesartan score highest persistence rate follow patients receive aiira agents persistence rate angiotensinconverting enzyme inhibitors calcium channel blockers betablockers losartan associate comparable persistence rat patients receive diuretics score lowest persistence rate persistence emerge essential factor blood pressure control prescribe antihypertensive agent provide favourable efficacy tolerability profile may provide greater persistence therapy hence higher level blood pressure control',\n",
       " 'pharmacological clinical study effect angiotensinconverting enzyme ace inhibitors support idea central role play angiotensin ii able cause cardiovascular renal diseases also independently blood pressure elevate effect present investigation aim evaluate effect three different pharmacological regimens blood pressure sympathetic drive uncomplicated essential hypertension mean blood pressure laboratory measurements ambulatory monitor h heart rate variability plasma noradrenaline level thus aceinhibitor monotherapy trandolapril mgday receptor antagonist monotherapy irbesartan mgday lowdose combination mgday plus mgday respectively placebo give randomise singleblind crossover fashion period weeks mild essential hypertensives power spectral analysis short record noradrenaline measurements also perform supine position postural challenge degrees headup tilt test hut lowdose combination therapy induce greatest reduction lf component lfhf ratio rest tilt position well blood pressure however physiological autonomic response hut maintain noradrenaline plasma level lower combine therapy drug alone data demonstrate mild uncomplicated essential hypertension chronic lowdose combination therapy aceinhibitor antagonist effective recommend fulldose monotherapy either drug influence autonomic regulation heart suggest relative reduction sympathetic drive cardiac systemic level',\n",
       " 'essential hypertension one important risk factor cardiovascular diseases pathophysiological mechanism unknown recent data suggest deformability aggregation red blood cells may play important role regulation blood rheology hypertension simultaneously report suggest antihypertensive effect angiotensin convert enzyme inhibitors acei could counteract high dose aspirin postulate effect could relate change blood rheology accordingly design study evaluate effect low high dose aspirin deformability aggregability red blood cells patients essential hypertension deformability aggregability red blood cells measure laser diffractometer rheodyn ssd myrenne gmbh computerize automatic aggregometer myrenne gmbh germany respectively effect aspirin deformability aggregation red blood cells study ex vivo whole blood three group patients essential hypertension group patients receive placebo group ii patients receive mgday p aspirin days group iii patients receive mgday p aspirin days subject group receive combination antihypertensive agents consist one acei enalapril perindopril one betaantagonists metoprolol bisoprolol diuretic agent indapamid patients receive high dose aspirin mgday observe erythrocyte aggregability higher placebo group mea sd vs mea sd p aspirin no effect deformability erythrocytes arterial blood pressure high dose aspirin possibly also nonsteroidal antiinflammatory drug nsaid patients receive antihypertensive therapy directly affect rheological properties blood due activation red blood cell aggregation increase aggregation red blood cells antihypertensive therapy may important indicator worsen organ perfusion',\n",
       " 'amadorialbumin major glycated protein involve experimental hyperglycaemiainduced microvascular complications associate advance nephropathy type diabetic patients humans aim assess association amadorialbumin early nephropathy retinopathy type diabetic patients involvement chronic lowdegree inflammation therein',\n",
       " 'efficacy tolerability eplerenone selective aldosterone blocker assess add exist antihypertensive therapy ace inhibitor angiotensin ii receptor blocker arb hypertensive patients n whose blood pressure bp not control despite ace inhibitor arb randomize doubleblind receive mg eplerenone increase mg require daily placebo weeks diastolic systolic bp adverse events record study end week mean seat diastolic bp significantly reduce week among patients receive eplerenonearb mm hg compare receive placeboarb mm hg change mean seat diastolic bp mm hg eplerenoneace inhibitor patients mm hg placeboace inhibitor patients pns systolic bp level also significantly lower week eplerenoneace inhibitor mm hg eplerenonearb mm hg patients respectively compare placeboace inhibitor mm hg placeboarb patients mm hg adverse events generally nonsevere not significantly different eplerenone placebo study demonstrate patients whose bp not control ace inhibitor arb addition eplerenone week period significantly lower systolic bp group diastolic bp arb patients selective aldosterone blockade eplerenone therefore may useful addon therapy hypertensive patients inadequately control ace inhibitor arb alone',\n",
       " 'association change glucose metabolism change skeletal muscle magnesium mg concentration induce antihypertensive treatment evaluate patients essential hypertension randomly treat either lisinopril bendrofluazide months treatment skeletal muscle biopsies perform glucose tolerance determine oral ogtt intravenous glucose tolerance test ivgtt insulin sensitivity assess hyperinsulinemic euglycemic clamp technique inverse relationship find treatmentinduced change fast plasma glucose concentration change skeletal muscle mg concentration r p however no significant correlation skeletal muscle mg content either insulin sensitivity measure hyperinsulinemic euglycemic clamp test glucose tolerance evaluate ivgtt ogtt conclusion increase circulate glucose concentration correlate decrease mg concentration skeletal muscle antihypertensive treatment however mg concentration skeletal muscle not significantly predict insulin sensitivity glucose tolerance',\n",
       " 'despite widespread use treat childhood hypertension enalapril never study systematically determine effectiveness dose response safety pediatric population study conduct prospectively hypertensive children age years two sequential phase primary outcome variable phase study trough h postdose sit diastolic blood pressure primary objective first phase study determine whether enalapril lower blood pressure children dosedependent manner week doubleblind randomize doseresponse period patients stratify weight kg kg assign one three dose group low mg middle mg high dose mg reduction blood pressure examine function dose ratio weightadjusted basis completion doseresponse phase study patients enter week doubleblind randomize withdrawal either enalapril placebo antihypertensive effectiveness define difference sit diastolic blood pressure placebo enalapril group determine adverse events carefully record throughout study doseresponse relationship enalapril negative slope linear choose dose range suggest larger dose enalapril associate greater reduction blood pressure randomize withdrawal active drug orplacebo confirm antihypertensive effectiveness enalapril middle highdose group antihypertensive effect enalapril maintain across age gender race tanner stage enalapril appear effective generally welltolerated antihypertensive agent children age years initial dose mg children weigh kg mg children weigh kg mean mgkg administer daily effectively lower blood pressure within weeks patients blood pressure reduce dosedependent fashion larger dose result greater reduction',\n",
       " 'despite accumulate evidence efficacy angiotensinconverting enzyme inhibitors acei still provide imperfect renoprotection uptitration conventional dose combine therapy antiproteinuric agents may serve achieve renoprotection patients risk rapid disease progression',\n",
       " 'thyroid hormone unique action make novel possibly useful agent treatment heart failure potential adverse effect thyroid hormone however interest develop analogues fewer undesirable side effect screen compound structurally relate levothyroxine identify diiodothyropropionic acid ditpa analogue inotropic selectivity low metabolic activity hypothyroid rat ditpa administer alone combination captopril rat rabbit postinfarction model heart failure cardiac output increase leave ventricular enddiastolic pressure lv edp decrease without increase heart rate pilot clinical study undertake evaluate safety efficacy ditpa doseranging study normal volunteer drug well tolerate doubleblind comparison make ditpa versus placebo group patients moderately severe heart failure patients randomly assign receive either mgkg ditpa placebo daily weeks drug increase mgkg daily additional weeks heart failure patients receive drug weeks cardiac index increase p systemic vascular resistance index decrease p total serum cholesterol p triglycerides p also decrease significantly result indicate ditpa well tolerate could represent useful new agent treatment congestive heart failure',\n",
       " 'diabetic nephropathy one major cause endstage renal disease often associate macrovascular complications ischemic heart disease peripheral vascular disease angiotensin convert enzyme inhibitors acei angiotensin ii receptor blockers aiir show protective effect progression diabetic nephropathy thus become first choice treatment hypertension andor renal involvement patients diabetes however patients especially type diabetes require two medications order reduce blood pressure level propose recently publish consensus paper target blood pressure level mm hg diabetic subject proteinuria gday mm hg proteinuria excess gday combinations different medications may synergistic effect early study use combination either nondihydropyridine dihydropyridine calcium channel blocker acei demonstrate synergistic effect proteinuria patients diabetic nephropathy however study not substantiate calcium channel blockers prove ability reduce blood pressure play important role treatment patients diabetic nephropathy hypertension combination acei aiir may several theoretical advantage many study use combination perform animal model diabetes patients diabetic nondiabetic renal disease study demonstrate synergistic effect combination proteinuria hypertension result not consistent study may conclude additional study provide convince evidence combination could use patients whose proteinuria hypertension not respond either one agents monotherapy combination medications',\n",
       " 'major depressive disorder mdd occur patients acute coronary syndromes constitute independent risk factor morbidity mortality however no publish evidence exist antidepressant drug safe efficacious patients unstable ischemic heart disease',\n",
       " 'reninangiotensin system think involve progression chronic renal diseases diabetic nondiabetic origin confirm angiotensinconverting enzyme inhibitors reduce urinary protein excretion upe attenuate development renal injury angiotensin ii receptor blockers alternative class drug inhibit reninangiotensin system activity preliminarily confirm renoprotective activity however lack data concern renoprotective action small dose drug',\n",
       " 'describe compare effect six different antihypertensive medications cognitive performance',\n",
       " 'doseranging antihypertensive agents optimize diastolic blood pressure dbp reduction little information systolic sbp mean mbp pulse pp pressure lowdose combination perindopril per indapamide ind show reduce sbp atenolol dbp reduction however possible influence gender find never test',\n",
       " 'determine clinical prognostic differences patients heart failure preserve deteriorate systolic function define leave ventricular ejection fraction respectively within two weeks admission hospital',\n",
       " 'combine inhibition angiotensinconverting enzyme ace neutral endopeptidase nep may produce greater benefit heart failure ace inhibition alone',\n",
       " 'angiotensin convert enzyme inhibitors high dose show improve prognosis heart failure patients beneficial effect exercise capacity less convince large parallel group study objective investigation explore mechanisms involve doserelated functional effect test hypothesis trial recommend high dose lisinopril would improve aerobic exercise capacity cardiovascular function low dose',\n",
       " 'considerable advance drug treatments use treat osteoarthritis development selective cyclooxygenase inhibitors coxii confirmation efficacy gastrointestinal safety reduce treatment morbidity elderly guidelines safe appropriate use coxii drug available role antiinflammatory drug precipitate cardiorenal events highlight remain fully evaluate glucosamine diacerein hyaluronan may diseasemodifying drug osteoarthritis confirmatory study still need',\n",
       " 'uncertainty risk newonset diabetes hypertensive individuals treat different blood pressuredecreasing drug',\n",
       " 'erectile dysfunction ed common patients congestive heart failure chf ed reduce quality life may affect compliance thereby impair success chf treatment',\n",
       " 'angiotensinconverting enzyme ace inhibitors effectively reduce proteinuria however optimal antiproteinuric dose still unknown conduct study determine whether increase aceinhibitor dose maximal antihypertensive effect additional antiproteinuric potential',\n",
       " 'week randomize parallelgroup multicenter study compare fix combinations delapril mg plus indapamide mg fosinopril f mg plus hydrochlorothiazide h mg adult patients mild moderate essential hypertension week placebo runin sit stand systolic sbp diastolic blood pressure dbp measure conventional sphygmomanometry primary efficacy endpoint percentage normalize sit dbp mm hg responder sit dbp reduction mm hg dbp mm hg patients treatment effect analyze intentiontotreat itt n perprotocol pp n populations percentage normalize responder patients not differ significantly f h itt group similar result see pp population itt pp patients sit stand sbp dbp value comparable baseline two group significantly p similarly reduce weeks neither treatment induce reflex tachycardia regimens well tolerate four patients f h group drop adverse events study efficacy safety comparable f h patients mild moderate essential hypertension',\n",
       " 'evolution revascularization medical therapy increase probability improve survival patients stable angina present investigation test hypothesis medical practice generate lower mortality randomly assign bypass surgery european coronary surgery study ecss two decades earlier',\n",
       " 'antihypertensive lipidlowering treatment prevent heart attack trial report treatment initiate doxazosin compare chlorthalidone double risk heart failure highrisk hypertensive patients relative risk [ ci ] patients assign doxazosin therapy mean intrial systolicdiastolic blood pressure mm hg higher patients assign chlorthalidone sixtyeight percent former patients latter patients give additional medications achieve target blood pressure less mm hg',\n",
       " 'troponin plan ptcastent implantation without administration glycoprotein iibiiia receptor antagonist tirofiban topstar trial investigate amount troponin tnt release nonacute elective percutaneous coronary intervention pci patients pretreated aspirin clopidogrel effect additional glycoprotein gp iibiiia receptor inhibiton postinterventional tnt release',\n",
       " 'evaluate effect longterm therapy angiotensinconverting enzyme ace inhibitor ramipril major cardiovascular cv outcomes highrisk women',\n",
       " 'goal study compare myocardial perfusion reserve mpr longterm treatment lisinopril losartan patients hypertension leave ventricular hypertrophy lvh',\n",
       " 'angiotensinconverting enzyme ace inhibitors exert effect modulate neurohumoral milieu vasopeptidase inhibitors vpi ace neutral endopeptidase inhibitors may increase natriuretic peptides bradykinin perhaps endothelin patients congestive heart failure patients n ischemic dilate cardiomyopathy new york heart association functional class ii iii leave ventricular ejection fraction ace inhibitor therapy randomize either vpi omapatrilat mgday ace inhibitor lisinopril mgday trough level neurohormones hours dose assess baseline weeks followup cterminal atrial natriuretic peptide canp level decrease lisinopril p not omapatrilat contrast nterminal anp level not change brain natriuretic peptide bnp level tend decrease similarly group endothelin level increase group increase reach statistical significance omapatrilat p level proinflammatory cytokine interleukin tend decrease antiinflammatory cytokine interleukin increase group statistical significance interleukin omapatrilat therapy neither agent change catecholamines angiotensin ii thus even trough level omapatrilat potentiate canp lisinopril potentially important effect omapatrilat endothelin antiinflammatory cytokines identify provide potential explanations differences clinical outcome',\n",
       " 'although cornerstone treatment heart failure angiotensinconverting enzyme inhibitors underused partly due side effect prove least similarly efficacious angiotensinconverting enzyme inhibitors angiotensinreceptor blockers may replace due superior tolerability aim compare efficacy safety valsartan enalapril heart failure patients stabilise angiotensinconverting enzyme inhibitor randomise patients mean years males stable mildmoderate heart failure leave ventricular ejection fraction less valsartan mg q n enalapril mg b n weeks change minwalk test primary efficacy variable patients wellbeing leave ventricular size function not differ significantly treatment group valsartan significantly noninferior enalapril walk test distance change leastsquare mean treatment difference confidence interval noninferiority p leave ventricular size p function p improve significantly valsartan group fewer patients experience adverse events valsartan group enalapril group although statistically nonsignificant valsartan similarly efficacious safe enalapril patients stable mildmoderate heart failure previously stabilise angiotensinconverting enzyme inhibitor directly switch study medication',\n",
       " 'author identify elderly kansas medicaid patients congestive heart failure examine angiotensinconverting enzyme ace inhibitor use use retrospective claim data ace inhibitor use quantify daily dose compare target enalaprilequivalent dose mg cohort patients average years age female reside primarily nurse home receive ace inhibitor users younger nonusers p no gender difference odds ratio [ ] confidence interval [ ci ] ace inhibitor users average eight prescriptions annually provide approximately medication days study period average enalaprilequivalent daily dose mg receive target dose nurse home residents less likely receive ace inhibitor ambulatory patients ci equally likely receive target dose ci ace inhibitor use kansas medicaid congestive heart failure population not consistent practice guidelines particularly among older andor nurse home patients',\n",
       " 'picxel study design evaluate effect longterm administration lowdose combination perindopril mgindapamide mg perind vs enalapril reduce leave ventricular hypertrophy lvh hypertensive patients multicentre control randomise doubleblind parallel group study carriedout assess variation leave ventricular mass index lvmi treatment use centralise control mmode echocardiography determinations dedicate software semiautomatic measurement follow week placebo runin period hypertensive outpatients age years lvh lvmi gm men women respectively randomise receive daily weeks either perind enalapril accord blood pressure level dose may adjust addition clinical examinations ecg blood pressure heart rate laboratory assessments echocardiographic determinations perform selection baseline weeks end study main outcome criteria change baseline lvmi consider primary efficacy criterion change blood pressure echodoppler parameters constitute secondary criteria twosided student ttest independent sample use differentiate effect treatment group alpha intergroup difference lvmi variation analyse power sample size patients require make necessary randomise least patients base proportion potentially nonassessable patients result study obtain apply strict methodological procedures requirements expect provide valuable reliable information effect longterm administration perind lvh potential superiority enalapril',\n",
       " 'aldosterone implicate pathogenesis progressive cardiovascular disease drospirenone drsp novel progestin aldosterone receptor antagonist activity develop hormone replacement therapy hrt drspbetaestradiol drsp e investigate additive effect drspe versus placebo h ambulatory blood pressure bp postmenopausal women hypertension treat enalapril maleate ena',\n",
       " 'concern exist quality care provide heart failure patients primary care physicians use evidencebased clinical guideline evaluate care give patients systolic heart failure',\n",
       " 'reninangiotensin system play important role elevation asymmetric dimethylarginine adma endogenous inhibitor nitric oxide synthase hypertensive patients present study design examine whether angiotensinconverting enzyme ace activity also involve mechanism adma elevation type diabetes mellitus niddm crossover study perform determine ace inhibition perindopril mgday weeks decrease serum adma concentration plasma von willebrand factor vwf level marker endothelial injury patients niddm none patients treat insulin oral hypoglycemic drug none major diabetic complications protocol begin serum adma plasma vwf significantly higher niddm patients compare control subject without diabetes perindopril not affect blood pressure glucose metabolism significantly decrease serum adma plasma vwf result suggest endothelial injury associate adma elevation may present even patients noncomplicated niddm increase activity ace may involve endothelial dysfunction',\n",
       " 'seek conduct randomize trial compare late revascularization conservative therapy symptomfree patients acute myocardial infarction ami',\n",
       " 'objective study evaluate effect angiotensin receptor blocker leave ventricular lv structure function add prescribe heart failure therapy',\n",
       " 'several systemic factor show contribute acceleration large vessel atheroma correction factor lead reduction progression plaque formation associate arterial wall thickness atheroma remain however focal disease develop characteristic sit within arterial tree sit typically areas vessel branch mark curvature correspond regions high tensile stress low sheer stress lead hypothesis local haemodynamic factor vessel wall mechanics potentiate focal development atheroma current assessment vascular haemodynamics suffer inability handle complex flow not allow accurate determination locally vary flow shear stress pattern application computational fluid dynamic cfd flow simulation techniques ultrasound local pressure data however allow comprehensive noninvasive appraisal haemodynamic flow parameters perform candesartan cilexetil atenolol carotid haemodynamic endpoint trial cachet study compare effect two antihypertensive regimens one bblockerbased angiotensin receptor blocker base carotid intimamedia thickness collection ultrasound pressure data subject provide unique opportunity apply data cfd model study effect antihypertensive regimens local fluid dynamics lead greater understand relationship factor atheroma formation regression',\n",
       " 'elderly patients heart failure risk postprandial hypotension pph orthostatic hypotension oh concomitant cerebral oxygenation change alter cardiovascular balance use cardiovascular medications furosemide captopril patients heart failure new york heart association class ii iii stable condition receive cardiovascular medication [ age years ] blood pressure bp measure finapres cortical concentrations oxyhemoglobin deoxyhemoglobin measure use nearinfrared spectroscopy stand kcal carbohydrate meal test perform therapy furosemide mg daily n captopril mg twice daily n doubleblind randomize trial treatment patients pph patients oh first dose furosemide significantly decrease postprandial systolic bp p postprandial frontal cortical oxygenation p whereas first dose captopril not furosemide captopril not significantly affect postprandial orthostatic bp cortical oxygenation weeks treatment thus pph common phenomenon elderly patients heart failure whereas oh not first dose furosemide mg decrease postprandial systolic bp frontal cortical oxygenation contrast first dose captopril mg week treatment furosemide mg daily captopril mg twice daily find indicate initiate furosemide treatment worsen pph furosemide less safe elderly patients heart failure',\n",
       " 'ace inhibitors attenuate detrimental effect angiotensin ii improve survival reduce morbidity patients acute myocardial infarction evidence heart failure leftventricular dysfunction selective antagonism angiotensin type receptor represent alternative approach inhibition reninangiotensin system multicentre randomise trial test hypothesis angiotensin ii antagonist losartan would superior noninferior ace inhibitor captopril decrease allcause mortality highrisk patients acute myocardial infarction',\n",
       " 'study aim estimation influence enalapril captopril emotional process hypertensive patients hypertensive subject evaluate introduce drug treatment normotensive persons comprise control group group examine psychological methods bdi hsc raven matric test bdi no significant differences group total score particular factor well hsc significant differences total rat untreated hypertensive subject normotensive group p depressionanxiety profile main contribute factor significantly different p group enalapril captopril reverse negative behavioural change cause hypertension moderately no statistical significance no alterations intellectual abilities test raven matric test group examine conclusion significant negative emotional effect high blood pressure partly reverse antihypertensive dose enalapril captopril',\n",
       " 'estimate glomerular cell number normotensive type diabetic patients raise albumin excretion rate aer investigate change years subgroup placebotreated patients biopsies normal kidney donors use control mesangial endothelial cell number increase diabetic patients start study compare control subject no difference podocyte number glomerular volume increase diabetic patients surface area glomerular basement membrane gbm underlie podocytes not differ group aer correlate positively mesangial cell number microalbuminuric patients r p negatively podocyte number proteinuric patients r p placebotreated patients glomerular volume increase years owe matrix accumulation increase gbm surface area although overall cell number not differ significantly baseline decrease podocyte number followup correlate aer followup r p conclusion crosssectional analysis podocyte number type diabetic patients raise aer normal blood pressure show no significant reduction compare nondiabetic control subject longitudinal data provide evidence association podocyte loss aer whether cellular change response cause concomitant progression nephropathy remain uncertain',\n",
       " 'autonomic nervous system ans disturbances consider one important factor development essential hypertension however information effect antyhypertensive treatment angiotensinconverting enzyme inhibitors acei cardiac ans activity ccscarce',\n",
       " 'control lifethreatening arrhythmias prevention sudden cardiac death longstanding challenge clinicians largescale randomize control trials contribute immensely understand management lifethreatening arrhythmias many cause lifethreatening ventricular arrhythmias occur mostly set heal myocardial infarction available treatments management ventricular arrhythmias include antiarrhythmic drug implantable cardioverter defibrillators catheter ablation therapy provide unique advantage select patients lifethreatening arrhythmias goal arrhythmia management not provide single best therapy provide greatest assurance symptomatic arrhythmia control use combine therapy become standard treatment strategy patients sustain ventricular arrhythmias review discuss different modes treatment available treatment lifethreatening ventricular arrhythmias potential risk benefit rationale use hybrid combination therapy present finally betterknown primary secondary prevention trials treatment ventricular tachycardias review',\n",
       " 'compare quality life elderly patients isolate systolic hypertension allocate randomly group receive placebo active treatment systolic hypertension elderly trial',\n",
       " 'therapeutic agents treatment hypertension may differ efficacy earlymorning period time morbid mortal cardiovascular events increase compare time day',\n",
       " 'sulfhydryl group donors nacetylcysteine nac may enhance antihypertensive effect drug nitric oxide no mechanism observe hypotensive effect angiotensinconverting enzyme inhibitors aceis least partially mediate no perform within patient crossover study aim investigate potential effect nac acei antihypertensive action via nodependent mechanism study smoker years habit cigarettes daily hypertensive patients males three females age years acei therapy captopril seven enalapril patients randomly allocate two treatment arm one arm patients n initially receive addition nac mg acei regimen group n patients remain acei days therapeutic pattern cross first group receive acei second group receive acei nac complete day treatment period evaluate effect nac patient ambulatory blood pressure monitor abpm perform end therapeutic regimen significant decrease systolic diastolic h blood pressure hbp daytime bp dtbp achieve combination acei nac acei nac compare period acei hbp vs p vs mmhg p dtbp vs vs p no significant difference observe nighttime bp ntbp nac effect not statistically different two aceis conclusion addition nac acei potentiate antihypertensive effect hbp dtbp smoker hypertensives effect may mediate nodependent mechanism probably protective effect nac no oxidation',\n",
       " 'aim multicentre prospective randomise open study compare trough effect telmisartan perindopril p diastolic blood pressure dbp week treatment use self blood pressure measurement sbpm',\n",
       " 'determine association angiotensinconverting enzyme ace inhibitor therapy survival older heart failure patients condition perceive physicians contraindications ace inhibitors',\n",
       " 'cold exposure decrease ischemic threshold patients coronary artery disease preserve leave ventricle lv function impact cold exposure effect acute angiotensinconverting enzyme ace inhibitor therapy maximal exercise capacity not study patients symptomatic congestive heart failure',\n",
       " 'enrol older patients isolate systolic hypertension mm hg investigate whether ambulatory measurement pulse pressure mean pressure refine risk stratification patients years randomize nitrendipine mgday possible addition enalapril mgday hydrochlorothiazide mgday match placebos baseline pulse pressure mean pressure determine six conventional blood pressure bp read h ambulatory record adjustment significant covariables compute mutually adjust relative hazard rat associate mm hg increase pulse pressure mean pressure placebo group h nighttime pulse pressure consistently predict total cardiovascular mortality cardiovascular events stroke cardiac events daytime pulse pressure predict cardiovascular mortality cardiovascular end point stroke hazard rat mm hg increase pulse pressure range conventionally measure pulse pressure predict cardiovascular mortality hazard rate active treatment group compare placebo patients relation outcome ambulatory pulse pressure attenuate nonsignificant level mean pressure determine ambulatory conventional bp measurements not associate poorer prognosis conclusion older patients isolate systolic hypertension higher pulse pressure estimate h ambulatory monitor better predictor adverse outcomes conventional pulse pressure whereas conventional ambulatory mean pressure not correlate worse outcome',\n",
       " 'not know whether strict control blood pressure bp mild posttransplant hypertension give benefit primary objective test antihypertensive effect lisinopril add standard therapy ambulatory bp abp posttransplant patients secondary objective monitor echocardiographic hemodynamic end point',\n",
       " 'doubleblind placebocontrolled systolic hypertension europe systeur trial end february randomize patients offer active study medication period observation',\n",
       " 'compare diagnose obtain unenhanced ultrasonography us contrastenhanced us captoprilenhanced renal scintigraphy determine whether use contrast agent improve ability assess renal arteries duplex doppler us',\n",
       " 'fibrosis leave ventricle commonly occur end stage renal disease esrd patients independent risk factor cardiovascular events angiotensin ii type receptor antagonist may able reverse fibrosis leave ventricle esrd patients ultrasonographyintegrated backscatter ibs myocardial wall directly relate morphometrically evaluate collagen content humans study chronically hemodialyzed patients hypertension randomly allocate receive antihypertensive therapy either angiotensin ii type receptor atr antagonist losartan n angiotensinconverting enzyme ace inhibitor enalapril n calcium antagonist amlodipine n ibs posterior wall leave ventricule measure ibs months treatment baseline demographic clinical characteristics not differ three subgroups although losartan db p treatment demonstrate significant reduce ibs value enalapril db p amlodipine db p not change significantly months treatment three group reduce leave ventricular mass index losartan gm p enalapril gm p amlodipine gm p three group manifest similar significant decrease mean blood pressure plasma angiotensin ii concentration markedly increase fold relative control level treatment losartan treatment contrast unchanged enalapril fold increase amlodipine treatment study indicate losartan reduce fibrosis leave ventricule effect may via antiatr effect',\n",
       " 'recent study suggest differential influence mean pressure pulse pressure myocardial infarction stroke differences among major drug efficacy prevent individual endpoints hypothesize antihypertensive drug differ influence upon pulse wave even effect blood pressure study untreated hypertensive patients age years rotate six week periods daily treatment amlodipine mg doxazosin mg lisinopril mg bisoprolol mg bendrofluazide mg placebo best drug repeat end rotation blood pressure read radial pulse tonometry sphygmocor perform visit blood take measurement level atrial natriuretic peptide brain natriuretic peptide bnp sphygmocor derivation central aortic pulse wave use measure time transmission reflect wave r augmentation index ai proportional increase systolic pressure due reflect wave dissociation effect drug blood pressure pulse wave analysis bisoprolol cause greatest fall blood pressure r drug increase ai paradoxical response bisoprolol associate fold increase plasma bnp level smaller elevation bnp women compare men describe previously elevation also associate significantly higher value ai drug reduce ai associate significant decrease bnp amlodipine conclusion antihypertensive drug differ shortterm effect augmentation systolic pulse wave secretion bnp heart regard sensitive measure strain cardiomyocytes differences may help explain causespecific differences outcome recent trials',\n",
       " 'experimental observational study suggest vitamin e may reduce risk cardiovascular cv events microvascular complications people diabetes however data randomize clinical trials limit therefore evaluate effect vitamin e supplementation major cv outcomes development nephropathy people diabetes',\n",
       " 'limit number study evaluate effect angiotensin ii receptor antagonists aiias leave ventricular hypertrophy lvh comparison antihypertensive drug no large study compare aiias angiotensinconverting enzyme inhibitors aceis',\n",
       " 'study investigate differences effect angiotensin convert enzyme inhibitor acei compare angiotensin receptor blocker arb blood pressure bp pulse pressure pp measure clinic cbp cpp respectively home hbp hpp ambulatory monitor abp app twentyseven hypertensive patients randomise receive lisinopril mg losartan mg weeks subsequently crossedover alternative treatment second week period measurements cbp h abp days hbp perform randomisation end treatment period measurement methods show lisinopril effective losartan reduce bp however difference two drug demonstrate greater precision use hbp p h abp p whereas poorest precision demonstrate difference provide cbp p lisinopril also find effective losartan reduce hpp p h app p whereas no difference detect use measurements cpp conclude antihypertensive drug may differ effect not bp also pp hbp monitor appear reliable h abp monitor detect differences effect drug bp pp clinic measurements seem least reliable method particularly detection differences pp',\n",
       " 'examine impact treatment ramipril versus angiotensinconverting enzyme ace inhibitors clinical outcome unselected patients prospective multicenter registry maximal individual therapy acute myocardial infarction plus registry mitra plus consecutive patients stelevation acute myocardial infarction receive acute therapy ramipril receive ace inhibitor therapy receive no ace inhibitor therapy multivariate analysis treatment ramipril compare treatment without ace inhibitors associate significantly lower hospital mortality lower rate nonfatal major adverse coronary cerebrovascular events compare generic ace inhibitors ramipril therapy independently associate significantly lower hospital mortality odds ratio [ ] confidence interval [ ci ] lower rate nonfatal major adverse coronary cerebrovascular events ci not lower rate heart failure discharge ci',\n",
       " 'hypertension lead cause endstage renal disease esrd unite state no know treatment prevent progressive decline lead esrd',\n",
       " 'irrespective clinical relevance side effect not consider negligible problem antihypertensive therapy aim trial evaluate tolerability profile lercanidipine two calcium antagonists amlodipine lacidipine elderly hypertensives',\n",
       " 'treatment nocturnal hypertension report beneficial primary secondary prevention stroke compare effect angiotensin ii antagonist losartan angiotensin convert enzyme inhibitor quinapril nocturnal blood pressure bp sympathetic nervous activity patients hypertension stroke',\n",
       " 'singledrug treatment essential hypertension ht often insufficient normalize blood pressure bp high dose antihypertensive agents adverse effect glucose tolerance gt insulin sensitivity study test whether aggressive bp lower combination treatment influence gt insulin action nonobese body mass index [ bmi ] kgm normolipidemic patients establish ht mm hg normal gt recruit eleven normotensive mm hg subject match patients anthropometric metabolic variables follow baseline study serum lipid profile oral gt insulin release insulin sensitivity assess insulin clamp technique patients randomize doubleblind fashion two combination regimens verapamil mgday trandolapril mgday atenolol mgday nifedipine mgday restudied months later blood pressure normalize group decrements mm hg respectively lipid profile gt insulin release insulin sensitivity glucose uptake lipolysis unchanged follow treatments author conclude nonobese normolipidemic glucosetolerant hypertensive patients bp normalization combination therapy feasible no cost term undesired effect glucose lipid metabolism insulin sensitivity',\n",
       " 'aim study compare longterm effect amlodipine fosinopril monotherapy combination urinary albumin excretion uae hypertensive diabetic patients',\n",
       " 'blood pressure control mm hg rat hypertension fall far short us national goal achievable control rat vary practice settings geographic regions factor predict improve blood pressure control not well identify',\n",
       " 'sexual dysfunction associate hypertension antihypertensive therapies may impact ability patients stay therapy lead deterioration patients quality life therefore important practitioners become familiar wide variation sexual side effect produce antihypertensive agents discuss potential occurrence side effect patients many case change patient drug regimen may help patients overcome specific sexual side effect experience certain treatments practitioners consider select antihypertensive therapy highly effective lower blood pressure preserve patients quality life effect medications sexual function remain controversial blind trials report little difference placebo specific medications whereas study indicate antihypertensive medications increase sexual dysfunction impact quality life recent evidence suggest losartan angiotensin ii antagonist not typically associate development sexual dysfunction may actually positively impact several indices sexual function erectile function sexual satisfaction frequency sexual activity well perceive quality life thus angiotensin ii antagonists may offer therapeutic option prevent correct erectile dysfunction patients hypertension favorable effect agents sexual function may relate part ability block angiotensin ii recently become recognize important mediator detumescence possibly erectile dysfunction',\n",
       " 'ace inhibition reduce plasminogen activator inhibitor pai risk factor myocardial infarction whereas effect angiotensin receptor antagonism pai uncertain present study compare time course effect ace inhibition angiotensin type receptor antagonism morning plasma pai antigen blood pressure endocrine metabolic fibrinolytic variables measure insulinresistant define fast glucose mmoll body mass index kgm fast serum triglyceride mmoll hypertensive subject mean age years week hydrochlorothiazide mgd weeks addition ramipril escalate mgd losartan escalate mgd hydrochlorothiazide decrease systolic p diastolic p pressure ramipril mm hg losartan mm hg reduce systolic p diastolic p pressure pressure effect drug similar hydrochlorothiazide increase plasma pai p not tissuetype plasminogen activator tpa p antigen addition either ramipril losartan significantly decrease plasma pai antigen p however effect losartan pai antigen not sustain throughout week treatment period significant drugxtime interaction p tpa antigen decrease either ramipril losartan p tpa activity decrease losartan p shortterm interruption reninangiotensinaldosterone system either ace inhibition receptor antagonism decrease pai antigen duration effect greater ace inhibition receptor antagonism',\n",
       " 'antihypertensive therapy well establish reduce hypertensionrelated morbidity mortality optimal firststep therapy unknown',\n",
       " 'investigate markers predict modes death patients chronic heart failure',\n",
       " 'many trials prove benefit early systematic treatment angiotensinconverting enzyme inhibitors patients acute myocardial infarction ami pathophysiological study however suggest potential harm excessive reduction blood pressure bp hypertensive patients ischemic heart disease',\n",
       " 'hypertensive hemodialysis patients noncompliant medications not benefit pharmacologic advance treatment high blood pressure increase already high risk cardiovascular complications medical staff often become frustrate severe hypertension refuse take medicine home drink excessive fluids miss multiple dialysis sessions signoff dialysis early addition address psychosocial financial educational substance abuse problems contribute noncompliance develop medication strategy serve least interim mean lower blood pressure antihypertensive agents long halflives renal failure lisinopril andor intrinsically long act transdermal clonidine amlodipine administer dialysis days unit personnel patients not would not take dose lisinopril amlodipine assure take least dialysis days thrice weekly clonidine patch replace weekly sixteen patients thus treat fail reliably selfadminister medications significant decline predialysis systolic pressure mm hg mm hg diastolic mm hg mm hg mean pressure mm hg mm hg improvement postdialysis bood pressure mean pressure decline mm hg mm hg many individuals erratic blood pressure control intermittently miss dialysis hence unitadministered medicine well continue fluid drug abuse patients uniformly excellent acceptance regimen even spontaneously request no appreciable adverse effect summary noncompliance address entire medical team dialysis unit administration longacting medicine help many hypertensive dialysis patients would otherwise increase risk severe cardiovascular complications',\n",
       " 'ace inhibitors know effective prevent progression diabetic nephropathy activation reninangiotensin system ras report contribute intrarenal hemodynamic abnormality diabetic patients examine whether ras blockade captopril induce intrarenal hemodynamic change normotensive patients type diabetes',\n",
       " 'statins angiotensinconverting enzyme ace inhibitors important component armamentarium stroke prevention class agents primary mechanism action reduce level respective risk factor also mechanisms action may confer benefit beyond believe primary action agent lead speculation statins reduce stroke risk mean beyond cholesterol lower ace inhibitors reduce stroke risk mean beyond blood pressure lower review mount evidence suggest statins ace inhibitors socalled pleiotropic effect may lead stroke prevention',\n",
       " 'although medical technologic revolution last decades improve clinical outcome patients sustain acute stelevation myocardial infarction stemi residual morbidity mortality remain major health concern critical roles temporal delay optimal sustain patency modulators successful reperfusion repeatedly demonstrate investigation ideal interface pharmacologic mechanical reperfusion continue despite physician awareness patient education program time symptom onset treatment stemi remain stall approximately hours pharmacologic reperfusion document major clinical trials multifaceted improvements advance paramedic train transmittable lead electrocardiograms bolus fibrinolytics facilitate potential prehospital diagnosis treatment thus proceed st century essential reexamine strategies address issue relate process deliver optimal care patients stemi especially notable opportunities provide prehospital management initiation therapy triage appropriate hospitals major potential avenues enhance patient outcomes review past research prehospital therapy stemi practical impediments implementation establish framework interpretation future developments',\n",
       " 'angiotensinconverting enzyme ace inhibitors report effective placebocontrolled trials various subsets patients acute myocardial infarction mi however no direct comparisons perform different ace inhibitors patient population',\n",
       " 'blood pressure bp control variety systems activities vary throughout day drug develop selectively block systems fall bp may not consistent h',\n",
       " 'recent metaanalyses suggest oncedaily dihydropyridines angiotensinconverting enzyme inhibitors cause similar decrease leave ventricular lv mass comparable decrease blood pressure bp however dihydropyridines felodipineextended release er still increase sympathetic activity may therefore less effective decrease lv mass',\n",
       " 'multicentre study aim compare trough effect telmisartan perindopril diastolic blood pressure dbp use self blood pressure measurement sbpm second objective compare data obtain sbpm provide automatic office bp measurement total mildtomoderate hypertensive patients randomise receive either telmisartan mg perindopril mg period weeks patients whose clinic dbp remain higher equal mmhg end th week w give doubledose regimen office bp sbpm perform baseline w w week w automatic device greater diminution trough dbp obtain telmisartan mmhg perindopril mmhg p regard clinic bp result observe double dose significantly less frequent telmisartan n perindopril n p mean value sbpm lower office bp value difference greater importance w w vs mmhg systolic blood pressure p vs mmhg dbp p w isolate office hypertension find patients n patients n isolate home hypertension conclusion trough effect dbp statistically higher telmisartan perindopril sbpm value lower office bp value greater differences treatment quarter patients find control method not one',\n",
       " 'compare antihypertensive effect two daily single dose drug act reninangiotensin axis two different ways',\n",
       " 'angiotensinreceptor blockers part antihypertensive treatment armamentarium since mids period number agents increase greatly number indications drug test randomize control clinical trials begin efficacious well tolerate antihypertensives angiotensinreceptor blockers show benefit patients diabetes heart failure not attributable reduce blood pressure support recently conclude trials expand treatment areas agents widen interest applicability across entire cardiovascular continuum number largescale study set report within next years determine effect angiotensinreceptor blockers range cardiovascular indications beyond hypertension',\n",
       " 'multicentre prospective randomize openlabel blindedendpoint probe study efficacy weeks treatment oncedaily telmisartan mg enalapril mg evaluate use ambulatory blood pressure monitor abpm patients mildtomoderate essential hypertension patients titrate higher dose study drug week mean seat diastolic blood pressure dbp mmhg primary endpoint change baseline ambulatory dbp last h h dose interval weeks treatment telmisartan enalapril produce similar reductions baseline dbp systolic blood pressure sbp abpm periods evaluate last h h daytime nighttime telmisartan produce significantly greater reduction mean seat trough dbp measure unblinded automate abpm device clinic amount difference mmhg p significantly greater proportion patients achieve seat diastolic response telmisartan enalapril versus p also measure abpm device treatments well tolerate compare telmisartan enalapril associate higher incidence cough versus hypotension versus therefore telmisartan may provide better longterm compliance consequently better blood pressure control enalapril',\n",
       " 'nitric oxide involve regulation rest vascular tone adaptation blood flow metabolic demand tissue adaptation vessel diameter volume inflow ie flowmediated dilation arterial hypertension associate increase vascular tone resistance vessels reduce compliance conduit arteries along thicken intimamedia lead vascular remodel dysfunctional endothelium trigger maladaptive process reduce bioavailability nitric oxide show hypertensive individuals dependent duration severity arterial hypertension angiotensinconverting enzyme inhibitors reverse endothelial dysfunction whereas concomitant reduction significant cardiac events due improve bioavailability yet establish longterm followup study individuals manifest endothelial dysfunction offspring hypertensive patients underscore prognostic genetic significance reduce nitric oxide bioavailability pathophysiology arterial hypertension',\n",
       " 'present angiotensinconvertingenzyme inhibitor treatment fail prevent progression nondiabetic renal disease aim assess efficacy safety combine treatment angiotensinconvertingenzyme inhibitor angiotensinii receptor blocker monotherapy drug maximum dose patients nondiabetic renal disease',\n",
       " 'aim study compare effect bp sympathetic activity chronic treatment angiotensin ang converting enzyme ace inhibitor angii receptor blocker hypertensive patients chronic renal failure crf ten stable hypertensive crf patients creatinine clearance mlmin per muscle sympathetic nerve activity msna plasma renin activity pra baroreceptor sensitivity h ambulatory bp measure absence antihypertensive drug except diuretics wk enalapril mg orally wk losartan mg orally order three phase randomize normovolemia control diuretics confirm extracellular fluid volume measurements throughout study enalapril losartan reduce msna burstsmin respectively p average h bp mmhg p pra not different treatments change bp change msna treatments correlate r r respectively p baroreceptor sensitivity not affect treatments first study compare effect ace inhibition angii blockade msna hypertensive crf patients enalapril losartan equally reduce bp msna differences modes action two drug not result differences effect msna support view angiimediated mechanisms contribute importantly pathogenesis sympathetic hyperactivity patients',\n",
       " 'elevate blood pressure one potent risk factor first ever recurrent stroke well influence early outcome acute stroke number significant randomize control trials may influence management three categories',\n",
       " 'cardiovascular morbidity major burden patients type diabetes steno study compare effect target intensify multifactorial intervention conventional treatment modifiable risk factor cardiovascular disease patients type diabetes microalbuminuria',\n",
       " 'levosimendan novel calcium sensitiser improve cardiac performance symptoms without increase oxygen consumption decrease mortality patients lowoutput heart failure',\n",
       " 'dyslipidemia frequently complicate chronic nephropathies increase risk renal cardiovascular events might ameliorate drug angiotensinconverting enzyme inhibitors effectively reduce proteinuria',\n",
       " 'compare efficacy safety losartan enalapril mild moderate hypertension',\n",
       " 'determine effect enalapril angiotensinconvertingenzyme inhibitor acei progression renal insufficiency primary membranoproliferative glomerulonephritis mild moderate renal insufficiency',\n",
       " 'treatment patients stable angina three goals minimize eliminate ischemia silent symptomatic reduce morbidity decrease mortality surgical angiographic revascularization procedures increasingly popular approach management patients result randomize control trials suggest revascularization may not improve survival useful improve symptoms exercise capacity however trials limit value not reflect current state art revascularization techniques optimal medical management many study conduct decade ago patients recruit survival benefit antiplatelet therapy bblockers angiotensinconverting enzyme inhibitors aggressive lipid lower accept clinical outcomes utilize revascularization aggressive drug evaluation courage trial help us determine best approach patients multicenter randomize trial compare aggressive medical therapy aggressive medical therapy current state art percutaneous coronary intervention pci patients stable coronary disease courage protocol target global risk reduction emphasize lifestyle modification maximal use drug lower blood pressure joint national committee prevention detection evaluation treatment high blood pressure jnc vi goals maximal use drug lower cholesterol national cholesterol education program adult treatment panel iii goals secondary prevention maximal use drug alleviate anginal symptoms without best interventional devices conduct pci',\n",
       " 'reninangiotensinaldosterone system raas play fundamental role development atherosclerosis adverse cardiovascular events traditionally pathologic effect raas assume result vasoconstriction induce angiotensin ii salt water retention due aldosterone however hormones also powerful trophic effect stimulate increase mass arterial wall leave ventricle addition angiotensin ii aldosterone predispose vascular inflammation thrombosis oxidative stress sudden cardiac death therapy direct raas overactivity essential normalize prognosis patients atherosclerosis angiotensinconverting enzyme ace inhibitor improve prognosis patients atherosclerosis andor diabetes even set normal baseline blood pressure angiotensin receptor block agents also improve cardiovascular structure prognosis although agents better tolerate ace inhibitors not appear effective reduce event rat aldosterone receptor block agents also improve cardiovascular structure function prognosis aldosterone receptor blockers appear provide additive benefit use conjunction either ace inhibitor angiotensin receptor blocker',\n",
       " 'aortic pulse wave contour isolate systolic hypertension often show prominent reflection peak combine incident wave arise cardiac ejection widen pulse pressure investigate effect extendedrelease nitrate preparation angiotensin ii aii inhibitors aii receptor antagonist ace inhibitor aortic pulse wave contour systemic blood pressure hypertensive subject high augmentation index cause exaggerate pulse wave reflection two doubleblind randomize placebocontrolled crossover study carry total elderly patients systolic hypertension resistant conventional antihypertensive therapy study pharmacodynamic responses single dose placebo isosorbide mononitrate eprosartan captopril determine singledose isosorbide mononitrate placebo compare subject treat aii inhibitors baseline blood pressure measure sphygmomanometry pulse wave components applanation tonometry radial artery agents show decrease brachial systolic blood pressure aortic systolic blood pressure aortic pulse pressure qualitative effect aortic pulse wave contour differ augmentation index not significantly alter either captopril eprosartan decrease p approximately placebo value isosorbide mononitrate study group propose isosorbide mononitrate correct magnify wave reflection systolic hypertension elderly patients effect distinct exercise either acute chronic aii inhibition',\n",
       " 'aim study evaluate efficacy tolerability two different fix combinations angiotensinconverting enzyme inhibitor diuretic delaprilindapamide di captoprilhydrochlorothiazide ch administer months patients mild moderate essential hypertension centre participate randomise parallel group control study total patients uncomplicated mild moderate hypertension randomise eligible analysis efficacy intention treat patients sex age years newly diagnose untreated last month include study diastolic blood pressure dbp mmhg start dose drug delapril mgindapamide mg tablets captopril mghydrolchlorothiazide mg tablets month treatment period nonresponders dbp mmhg decrease dbp mmhg daily dose increase either delapril mgindapamide mg captopril mghydrochlorothiazide mg tablets months primary assessment antihypertensive efficacy percentage patients respond month drug treatment responder rat di ch p treatments days treatment di ch p treatments end treatment period final value systolic blood pressure mmhg di mmhg ch p treatments final visit dbp mmhg di group mmhg control group p treatments patients di group patients ch group withdraw study adverse events patients di patients ch experience adverse events conclusion di effective ch term overall reduction blood pressure response rate greater efficacy obtain without increase adverse effect since treatments equally well tolerate',\n",
       " 'test hypothesis salt fluid retention hearttransplant recipients htrs cause failure reflexively suppress reninangiotensinaldosterone system raas',\n",
       " 'peripheral arterial disease pad diabetes associate high risk ischemic events role intensive blood pressure control pad not establish',\n",
       " 'chronic renal failure clearance ace inhibitors include enalapril reduce hence conventional dosage plasma enalaprilat may markedly elevate unclear whether excess drug exposure afford improve control blood pressure aim present study evaluate shortterm blood pressure response two different plasma level enalaprilat',\n",
       " 'treatment hypertension diuretics betablockers lead improve outcomes postulate agents inhibit reninangiotensin system confer benefit beyond reduction blood pressure alone compare outcomes older subject hypertension treat angiotensinconvertingenzyme ace inhibitors outcomes treat diuretic agents',\n",
       " 'antihypertensive treatment patients clinical manifestations diabetic nephropathy especially reninangiotensin system ras inhibition slow may not fully arrest progression towards endstage renal disease study use hard endpoints double serum creatinine dialysis death initiate emergence renal functional abnormalities diabetes would impractical length size therefore undertake primary prevention study reninangiotensin system study rass determine inhibition ras could slow development key diabetic glomerulopathy structural endpoint increase mesangial fractional volume vv [ mesglom ]',\n",
       " 'people diabetes renal disease tend progress microalbuminuria clinical proteinuria renal insufficiency little evidence publish nondiabetic population study retrospectively analyze change proteinuria yr hope heart outcomes prevention evaluation study compare ramipril effect placebo participants include diabetes microalbuminuria report restrict participants albuminuria data baseline followup inclusion criteria know vascular disease diabetes plus one cardiovascular risk factor exclusion criteria include heart failure know impair leave ventricular function dipstickpositive proteinuria serum creatinine mgdl microm baseline microalbuminuria predict subsequent clinical proteinuria study participants overall adjust odds ratio [ ] confidence interval [ ci ] participants without diabetes ci participants diabetes ci progression albuminuria define new microalbuminuria new clinical proteinuria occur participants develop new microalbuminuria participants develop clinical proteinuria ramipril reduce risk progression ci p people without diabetes high risk cardiovascular disease also risk progressive rise albuminuria microalbuminuria predict clinical proteinuria nondiabetic diabetic people ramipril prevent delay progression albuminuria',\n",
       " 'hope study demonstrate ramipril beneficial ie prevent cardiovascular death myocardial infarction stroke broad range patients without evidence leave ventricular dysfunction heart failure high risk cardiovascular event study report cost implications unite state canada use ramipril hope study',\n",
       " 'prevalence end stage renal disease esrd grow western countries patients esrd frequently elderly diabetic expose high cardiovascular morbidity mortality main aim fosidial study assess efficacy safety fosinopril angiotensin convert enzyme ace inhibitor reduce mortality cardiovascular events haemodialysis patients present leave ventricular hypertrophy total number patients include study age years average years undergo haemodialysis years leave ventricular hypertrophy cardiac mass index gm women gm men measure within months prior inclusion baseline cardiac mass index gm week placebo period patients randomise two group receive either fosinopril mgday placebo duration months target dose reach sixth seventh eighth week treatment depend tolerance patients reach maximum recommend dose patients subsequently assess clinically every months end study primary outcome composite endpoint fatal nonfatal major cardiovascular events secondary endpoints individual cardiovascular events eventfree survival overall mortality allcause hospitalisations trial begin october patients include december followup ongoing last visit last patient schedule december report study design baseline characteristics study population',\n",
       " 'diabhycar type diabetes hypertension cardiovascular events ramipril study allow investigators analyze factor lead development congestive heart failure chf type diabetic patients abnormal urinary albumin concentration',\n",
       " 'despite wellestablished benefit aceinhibitors chronic heart failure chf current treatment rat prescribe dose lower prove improve survival evaluate whether participation specialist network use common database would impact compliance chf guidelines',\n",
       " 'optimaal optimal trial myocardial infarction angiotensin ii antagonist losartan first major study compare angiotensin ii type antagonist losartan cozaar trade mark merck ace inhibitor captonpril capoten trade mark elan myocardial infarction patients leave ventricular dysfunction patients assign target dose losartan mgday captopril mg tolerate primary end point allcause mortality deaths losartan captopril group respectively p however significantly cardiovascular deaths losartan captopril p losartan better tolerate captopril fewer patients discontinue medication versus losartan captopril respectively conclusion tolerate captopril remain prefer treatment patients complicate acute myocardial infarction',\n",
       " 'aim study evaluate effect benazepril addition amlodipine antihypertensive treatment anklefoot volume afv pretibial subcutaneous tissue pressure pstp two objective measure ankle oedema total mild moderate essential hypertensives dbp mmhg age years study week placebo period randomize amlodipine mg benazepril mg amlodipine mg plus benazepril mg weeks accord crossover design end placebo period active treatment period blood pressure afv pstp evaluate afv measure use principle water displacement pstp assess use system subcutaneous pretibial interstitial environment water manometer amlodipine benazepril monotherapy significantly reduce sbp mmhg respectively p vs baseline dbp mmhg respectively p reduction increase combination mmhg sbp p mmhg dbp p amlodipine monotherapy significantly increase afv p vs baseline pstp p vs baseline compare amlodipine alone combination produce less pronounce increase afv p vs baseline p vs amlodipine pstp p vs baseline p vs amlodipine ankle oedema clinically evident patients amlodipine monotherapy three patients combination result suggest aceinhibitors partially counteract microcirculatory change responsible caantagonistsinduced oedema formation',\n",
       " 'congestive heart failure represent grow health issue significant morbidity expense mortality unfortunately despite heart failure affect men women equally women historically represent minority heart failure trials despite disparity treatment decisions rely heavily trials women heart failure often different clinical feature men age onset comorbidities compare men women also demonstrate differences remodel response injury volume pressure overload myocardial infarction begin understand clinical implications gender differences impact pharmacologic treatments discuss differences review agents useful systolic failure make include angiotensinconverting enzyme inhibitors bblockers digoxin aldosterone inhibition treatment diastolic heart failure empiric guidelines follow',\n",
       " 'previous trials prevention heart failure restrict patients low ejection fraction hypertension assess angiotensinconverting enzyme ace inhibitor ramipril prevent development heart failure highrisk patients without know low ejection fraction heart failure',\n",
       " 'diabetes mellitus predictor morbidity mortality patients heart failure effect angiotensinconverting enzyme ace inhibitors prevention diabetes patients leave ventricular dysfunction unknown aim retrospective study assess effect ace inhibitor enalapril incidence diabetes group patients montreal heart institute enrol study leave ventricular dysfunction solvd',\n",
       " 'information regard cardiorenal axis patients myocardial infarction mi limit examine change renal function first mi protective effect angiotensin convert enzyme ace inhibition prognostic value baseline renal function',\n",
       " 'determine effect perindoprilbased blood pressure lower regimen major cardiac events among hypertensive nonhypertensive patients history cerebrovascular disease',\n",
       " 'compare blood pressure response dynamic exercise hypertensive patients take trandolapril captopril',\n",
       " 'blood pressure level strongly predictive risk firstever recurrent stroke benefit blood pressurelowering therapy prevention fatal nonfatal stroke middleaged individuals well establish however recently uncertainty consistency benefit across different patient group particular older people history stroke paper discuss evidence surround effectiveness blood pressurelowering therapy specifically older patients history stroke particular attention pay result perindopril protection recurrent stroke study progress progress randomise doubleblind placebocontrolled trial individuals history cerebrovascular disease recruit hospital outpatient clinics ten countries participants mean age years range years randomly assign receive active treatment ace inhibitorbased blood pressurelowering regimen perindopril without addition diuretic indapamide match placebo end follow mean years active treatment reduce incidence total stroke ci rate major vascular events ci importantly benefit treatment consistent across key patient subgroups include without hypertension patients asian nonasian ischaemic haemorrhagic stroke subtypes current evidence strong clinicians consider blood pressurelowering therapy pivotal prevention stroke especially patients know history cerebrovascular disease vascular disease general irrespective blood pressure level soon patients clinically stable acute stroke vascular event additional agespecific analyse progress data together complete trials provide reliable information size benefit blood pressurelowering therapy specifically different age group particularly oldest old age years meantime though ace inhibitor plus diuretic treatment regimen maximise degree blood pressure reduction good safety profile effective treatment consider patients stroke include elderly',\n",
       " 'endothelin et first characterize potent vasoconstrictor overexpressed vasculature different model hypertension deoxycorticosterone acetatesalt rat dahl saltsensitive rat strokeprone spontaneously hypertensive rat moreover patients moderate severe hypertension present increase vascular level preproet mrna addition blood pressurelowering effect et receptor antagonists able reduce vascular growth recent data suggest involvement inflammatory response effect et contribute vascular remodel endothelial dysfunction increase evidence underscore potential therapeutic benefit et receptor antagonists different hypertensionrelated complications not essential hypertension also patients type diabetes',\n",
       " 'reninangiotensin system play key role progression kidney disease addition welldescribed role maintenance extracellular fluid volume blood pressure recent study show blockade reninangiotensin system level angiotensin ii type receptor important effect proteinuria rate progression kidney disease patients type diabetes mellitus review first discuss recent experimental study relate angiotensin ii kidney function diabetes mellitus change glomerular permselectivity focus recent clinical trials angiotensin ii receptor blockers patients type diabetes mellitus',\n",
       " 'insulin resistance syndrome consist cooccurrence metabolic risk factor type diabetes cardiovascular disease include overall obesity central obesity dyslipidemia characterize elevate level triglycerides low level highdensity lipoprotein cholesterol hyperglycemia hypertension use criteria propose national cholesterol education program adult treatment panel iii national survey data suggest insulin resistance syndrome common affect us adults age greater years syndrome common older people mexican americans increase prevalence populations age become obese identification syndrome warrant aggressive interventions know prevent type diabetes cardiovascular disease include weight reduction increase physical activity control hypertension dyslipidemia',\n",
       " 'first report year health plan employer data information set organization note significant difference proportion patients control blood pressure bp target change mm hg mm hg compare data second larger dataset determine find isolate common phenomenon determine factor influence difference',\n",
       " 'microalbuminuria diabetes risk factor early death indicator aggressive blood pressure bp lower compare combination mg perindopril mg indapamide enalapril monotherapy albumin excretion rate aer patients type diabetes albuminuria hypertension month randomize doubleblind parallelgroup international multicenter study four hundred eightyone patients type diabetes hypertension systolic bp mm hg mm hg diastolic bp mm hg randomly assign age years previously treat hypertension result patients intentiontotreat analysis available week placebo period patients albuminuria microgmin randomly assign combination mg perindopril mg indapamide mg daily enalapril week dose adjust basis bp maximum mg perindopril mg indapamide mg enalapril main outcome measure overnight aer supine bp treatments reduce bp perindoprilindapamide treatment result statistically significant higher fall bp [ ci ] p systolic bp [ ci ] diastolic bp p aer ci versus ci enalapril greater aer reduction remain significant adjustment mean bp adverse events similar group thus firstline treatment lowdose combination perindoprilindapamide induce greater decrease albuminuria enalapril partially independent bp reduction bpindependent effect combination may increase renal protection',\n",
       " 'present study design evaluate effect combination therapy use angiotensinconverting enzymeinhibitor lisinopril dihydropyridine calcium antagonist nifedipine gits degree homogeneity hour blood pressure reduction essential hypertensive patients week placebo runin period patients mean age years essential hypertension clinic diastolic blood pressure mm hg randomize week treatment lisinopril mg nifedipine gits mg combination accord multicenter randomize doubleblind crossover study trough clinic blood pressure hour ambulatory blood pressure measure end runin period weeks treatment addition clinic hour average blood pressure reduction troughtopeak ratio smoothness index new measure homogeneity blood pressure reduction also calculate although lisinopril nifedipine gits produce significant reduction clinic hour average blood pressure value reduction obtain combination significantly p greater moreover combination therapy increase p smoothness index compare single drug systolic lisinopril nifedipine gits combination diastolic lisinopril nifedipine gits combination blood pressure value whereas troughtopeak ratio value express median systolic lisinopril nifedipine gits combination diastolic lisinopril nifedipine gits combination blood pressure value not significantly increase combination therapy thus antihypertensive treatment combination lisinopril nifedipine gits effective balance hours combination components administer alone confirm smoothness index superior troughtopeak ratio assess homogeneity pharmacologic blood pressure reduction',\n",
       " ...]"
      ]
     },
     "execution_count": 36,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "clean_abs_list = df_acei['clean_abs'].tolist()\n",
    "clean_abs_list"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "hidden": true
   },
   "source": [
    "**Feature representation by uni-, bi-, and trigrams**"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "hidden": true
   },
   "source": [
    "`CounterVectorize()` function renders text into bag-of-words representation"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {
    "hidden": true
   },
   "outputs": [],
   "source": [
    "import pandas as pd\n",
    "from sklearn.feature_extraction.text import CountVectorizer\n",
    "\n",
    "# Instantiate CountVectorizer()\n",
    "cv1 = CountVectorizer() # bag-of-words model in unigram\n",
    "cv2 = CountVectorizer(ngram_range=(2,2)) # bag-of-words model in bigram\n",
    "cv3 = CountVectorizer(ngram_range=(3,3)) # bag-of-words model in trigram\n",
    " \n",
    "# this steps generates a matrix whose rows are instances and columns are features\n",
    "uni_count_vector = cv1.fit_transform(clean_abs_list)\n",
    "bi_count_vector = cv2.fit_transform(clean_abs_list)\n",
    "tri_count_vector = cv3.fit_transform(clean_abs_list)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "hidden": true
   },
   "source": [
    "Show the list of features in unigram"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {
    "hidden": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "array(['aa', 'aaa', 'aaas', ..., 'zofenoprilat', 'zone', 'zung'],\n",
       "      dtype=object)"
      ]
     },
     "execution_count": 19,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "cv1.get_feature_names_out()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "hidden": true
   },
   "source": [
    "Number of unigram features"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {
    "hidden": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(2235, 9449)"
      ]
     },
     "execution_count": 20,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "uni_count_vector.shape # returns 9449 unique words (unigram)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "hidden": true
   },
   "source": [
    "Number of bigram features"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "metadata": {
    "hidden": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(2235, 100008)"
      ]
     },
     "execution_count": 21,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "bi_count_vector.shape # returns 100008 unique features in bigrams"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "hidden": true
   },
   "source": [
    "Number of trigram features"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "metadata": {
    "hidden": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(2235, 159420)"
      ]
     },
     "execution_count": 22,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "tri_count_vector.shape # returns 159420 unique features in trigrams"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "heading_collapsed": true
   },
   "source": [
    "# Predictive Analysis"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "hidden": true
   },
   "source": [
    "**Please run the code cell below to reveal the video.**"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {
    "hidden": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<iframe width=\"705\" height=\"537\" src=\"https://www.youtube.com/embed/U-74EvcOnKE?list=PL6IN6GlGifEytPcv5HR_iaNBekwXYZIpR\" frameborder=\"0\" allowfullscreen></iframe>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "execution_count": 3,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "HTML('<iframe width=\"705\" height=\"537\" src=\"https://www.youtube.com/embed/U-74EvcOnKE?list=PL6IN6GlGifEytPcv5HR_iaNBekwXYZIpR\" frameborder=\"0\" allowfullscreen></iframe>')"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "hidden": true
   },
   "source": [
    "Import necessary packages"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 37,
   "metadata": {
    "hidden": true
   },
   "outputs": [],
   "source": [
    "from sklearn.feature_selection import chi2, SelectKBest\n",
    "from sklearn.metrics import accuracy_score\n",
    "from sklearn.model_selection import train_test_split\n",
    "from sklearn.linear_model import LogisticRegression\n",
    "from sklearn.neighbors import KNeighborsClassifier\n",
    "from sklearn.metrics import roc_curve, auc \n",
    "import matplotlib.pyplot as plt\n",
    "import numpy as np"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "heading_collapsed": true,
    "hidden": true
   },
   "source": [
    "## Logistic Regression (LR) Model"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "heading_collapsed": true,
    "hidden": true
   },
   "source": [
    "### Accuracy"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "hidden": true
   },
   "source": [
    "**Increase the number of features by 1,000 until 100,000 and identify the number of features where we can get the highest accuracy score**"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "metadata": {
    "hidden": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Max Accuracy of LR Model: 0.9239373601789709\n"
     ]
    }
   ],
   "source": [
    "# call logistic regression classifier\n",
    "clf = LogisticRegression()\n",
    "'''\n",
    "We will examine the optimal number of features (in either uni-, bi-, or trigrams)\n",
    "but limit the maximum number of features to 100,000.\n",
    "'''\n",
    "veczr = CountVectorizer(max_features=100000, ngram_range=(1,3))\n",
    "x = veczr.fit_transform(clean_abs_list)\n",
    "target= df_acei['decision'].values.astype(str)\n",
    "\n",
    "scores_lr = []\n",
    "\n",
    "# We will examine the accuracy score with 1000, 2000, 3000,..., 99,000, and 100,000 features\n",
    "for n in np.arange(1000,100000,1000):\n",
    "    # choose n chi-squared features \n",
    "    ch2 = SelectKBest(chi2, k=n)\n",
    "    # split the dataset into training and testing sets by 80:20 \n",
    "    x_train, x_test, y_train, y_test = train_test_split(x, target, test_size = 0.2, random_state=10)\n",
    "    # train the classifier\n",
    "    x_train_chi2_selected = ch2.fit_transform(x_train, y_train)\n",
    "    # prepare testing sets\n",
    "    x_test_chi2_selected = ch2.transform(x_test)\n",
    "    # make a prediction model based on training dataset\n",
    "    clf.fit(x_train_chi2_selected, y_train)\n",
    "    # predict the class of testing sets and calculate accuracy \n",
    "    score_lr = accuracy_score(y_test, clf.predict(x_test_chi2_selected))\n",
    "    # store each accuracy score earned at n features and add the score to the list 'scores_lr'\n",
    "    scores_lr.append(score_lr)\n",
    "    \n",
    "# the maximum accuracy is the maximum value in the 'scores_lr' list\n",
    "max_score_lr = max(scores_lr)\n",
    "print(\"Max Accuracy of LR Model:\", max_score_lr)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "hidden": true
   },
   "source": [
    "**Plot the relationship between the number of features and accuracy scores**"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "metadata": {
    "hidden": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Text(0, 0.5, 'Validation set accuracy of logistic regression model')"
      ]
     },
     "execution_count": 25,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 800x600 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "plt.figure(figsize=(8,6))\n",
    "plt.plot(np.arange(1000,100000,1000), scores_lr, color='orangered')\n",
    "\n",
    "plt.title(\"Features within reduced dimensions with chi2\")\n",
    "plt.xlabel(\"Number of features\")\n",
    "plt.ylabel(\"Validation set accuracy of logistic regression model\")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "hidden": true
   },
   "source": [
    "We can see the best accuracy was achieved with 3,000 features.  \n",
    "(The number of features at which you can achieve the best accuracy score can be different from my result)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "heading_collapsed": true,
    "hidden": true
   },
   "source": [
    "### AUC"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "metadata": {
    "hidden": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "AUC of LR Model: 0.7550013517166801\n"
     ]
    }
   ],
   "source": [
    "# we will examine false positive rates at every point (e.g., 1%,2%,...,99%,100%)\n",
    "mean_fpr_lr = np.linspace(0,1,100)\n",
    "\n",
    "# split dataset into training and testing sets by 80:20\n",
    "x_train, x_test, y_train, y_test = train_test_split(x, target, test_size = 0.2, random_state=10)\n",
    "# predict class of instances in testing set\n",
    "prediction_lr = clf.fit(x_train, y_train).predict_proba(x_test)\n",
    "# Get false positive rate, true positive rate, and threshold\n",
    "fpr_lr, tpr_lr, t_lr = roc_curve(y_test, prediction_lr[:, 1], pos_label='1')\n",
    "# Get AUC score\n",
    "auc_lr = auc(fpr_lr, tpr_lr)\n",
    "\n",
    "print('AUC of LR Model:', auc_lr)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "heading_collapsed": true,
    "hidden": true
   },
   "source": [
    "## k-Nearest Neighbor (KNN) Model"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "heading_collapsed": true,
    "hidden": true
   },
   "source": [
    "### Accuracy"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "hidden": true
   },
   "source": [
    "**Increase the number of features by 1,000 until 100,000 and identify the number of features where we can get the highest accuracy score**"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "metadata": {
    "hidden": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Max Accuracy of KNN Model: 0.9194630872483222\n"
     ]
    }
   ],
   "source": [
    "# call knn classifier\n",
    "knn = KNeighborsClassifier()\n",
    "\n",
    "scores_knn = []\n",
    "\n",
    "for n in np.arange(1000,100000,1000):\n",
    "    ch2 = SelectKBest(chi2, k=n)\n",
    "    x_train, x_test, y_train, y_test = train_test_split(x, target, test_size = 0.2, random_state=10)\n",
    "    x_train_chi2_selected = ch2.fit_transform(x_train, y_train)\n",
    "    x_test_chi2_selected = ch2.transform(x_test)\n",
    "    knn.fit(x_train_chi2_selected, y_train)\n",
    "    score_knn = accuracy_score(y_test, knn.predict(x_test_chi2_selected))\n",
    "    mean_score_knn = score_knn.mean()\n",
    "    scores_knn.append(mean_score_knn)\n",
    "\n",
    "max_score_knn = max(scores_knn)\n",
    "print(\"Max Accuracy of KNN Model:\", max_score_knn)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "hidden": true
   },
   "source": [
    "**Plot the relationship between the number of features and accuracy scores**"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "metadata": {
    "hidden": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Text(0, 0.5, 'Validation set accuracy of KNN model')"
      ]
     },
     "execution_count": 28,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 800x600 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "plt.figure(figsize=(8,6))\n",
    "plt.plot(np.arange(1000,100000,1000), scores_knn, color='orangered')\n",
    "\n",
    "plt.title(\"Features within reduced dimensions with chi2\")\n",
    "plt.xlabel(\"Number of features\")\n",
    "plt.ylabel(\"Validation set accuracy of KNN model\")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "hidden": true
   },
   "source": [
    "We can see the best accuracy was achieved with a range of 1,000-9,000 features.  \n",
    "(The number of features at which you can achieve the best accuracy score can be different from my result)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "heading_collapsed": true,
    "hidden": true
   },
   "source": [
    "### AUC"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "metadata": {
    "hidden": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "AUC of KNN Model: 0.5647810218978103\n"
     ]
    }
   ],
   "source": [
    "mean_fpr_knn = np.linspace(0,1,100)\n",
    "\n",
    "x_train, x_test, y_train, y_test = train_test_split(x, target, test_size = 0.2, random_state=10)\n",
    "prediction_knn = knn.fit(x_train, y_train).predict_proba(x_test)\n",
    "fpr_knn, tpr_knn, t_knn = roc_curve(y_test, prediction_knn[:, 1], pos_label='1')\n",
    "auc_knn = auc(fpr_knn, tpr_knn)\n",
    "\n",
    "print('AUC of KNN Model:', auc_knn)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "heading_collapsed": true,
    "hidden": true
   },
   "source": [
    "## Concluding Visualization"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "hidden": true
   },
   "source": [
    "Make a table that shows the accuracy and AUC scores of each model"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "metadata": {
    "hidden": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "  Models  Accuracy       AUC\n",
      "0     LR  0.923937  0.755001\n",
      "1    KNN  0.919463  0.564781\n"
     ]
    }
   ],
   "source": [
    "models = []\n",
    "accuracies = []\n",
    "AUCs = []\n",
    "\n",
    "models.append('LR')\n",
    "models.append('KNN')\n",
    "\n",
    "accuracies.append(max_score_lr)\n",
    "accuracies.append(max_score_knn)\n",
    "\n",
    "AUCs.append(auc_lr)\n",
    "AUCs.append(auc_knn)\n",
    "\n",
    "model_perform = pd.DataFrame({'Models': models, 'Accuracy': accuracies, 'AUC':AUCs})\n",
    "#final_models_auc_sorted = final_models_auc.sort_values('Accuracy', ascending=False)\n",
    "print(model_perform)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "hidden": true
   },
   "source": [
    "**Plot bar graph of final Accuracy**"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "metadata": {
    "hidden": true
   },
   "outputs": [
    {
     "data": {
      "image/png": "iVBORw0KGgoAAAANSUhEUgAAAjcAAAGwCAYAAABVdURTAAAAOXRFWHRTb2Z0d2FyZQBNYXRwbG90bGliIHZlcnNpb24zLjcuMSwgaHR0cHM6Ly9tYXRwbG90bGliLm9yZy/bCgiHAAAACXBIWXMAAA9hAAAPYQGoP6dpAAAqQ0lEQVR4nO3de3SNd77H8U8SyU7iTiQRDaEo6h6EqvbUpKIcRS9j1LikLmWkdDKjRFUGHUHHpS5lqnXpheTUJdOZqi4NYRxRI0G1LnUZjSLBQUKqCclz/jire86exGWnO9nx836ttddqnv17nv3dWUvzzrOfveNhWZYlAAAAQ3i6ewAAAABXIm4AAIBRiBsAAGAU4gYAABiFuAEAAEYhbgAAgFGIGwAAYJRK7h6gvBUVFens2bOqWrWqPDw83D0OAAC4C5Zl6erVqwoJCZGn5+3Pzdx3cXP27FmFhoa6ewwAAFAKp0+f1gMPPHDbNfdd3FStWlXS/31zqlWr5uZpAADA3cjNzVVoaKj95/jt3Hdx89NLUdWqVSNuAAC4x9zNJSVcUAwAAIxC3AAAAKMQNwAAwCjEDQAAMApxgwplyZIlCgsLk6+vryIiIrRnz55brr1x44amT5+uBx98UL6+vmrTpo02b97ssCYhIUEdO3ZU1apVFRgYqH79+uno0aMOa1566SU9+OCD8vPzU506ddS3b18dOXLEYU1KSooeeeQRVa1aVcHBwZo4caJu3rzpuicOAHAZ4gYVRlJSkmJjYxUfH6+MjAy1adNGUVFROn/+fInrp0yZoj//+c9atGiRDh06pNGjR6t///7at2+ffc327ds1duxY7d69W1u2bNGNGzfUo0cP5eXl2deEh4dr5cqVOnz4sD7//HNZlqUePXqosLBQknTgwAH16tVLPXv21L59+5SUlKRPPvlEkyZNKttvCGAYV//ysmPHDvXp00chISHy8PBQcnJyseNkZ2dr2LBhCgkJkb+/v3r27Kljx445rPmP//gPeXh4ONxGjx7tkucMN7HuMzk5OZYkKycnx92j4N906tTJGjt2rP3rwsJCKyQkxEpISChxfd26da3Fixc7bHvmmWesQYMG3fIxzp8/b0mytm/ffss1Bw4csCRZx48ftyzLsuLi4qwOHTo4rPnkk08sX19fKzc3947PC4BlJSYmWj4+PtaKFSusb775xho5cqRVo0YNKzs7u8T1r776qhUSEmJ9+umn1okTJ6y3337b8vX1tTIyMuxrNm3aZL322mvWhg0bLEnWxo0bHY5RVFRkde7c2erWrZu1Z88e68iRI9aoUaOs+vXrW9euXbOve/zxx62RI0da586ds9/4GVHxOPPzmzM3qBAKCgqUnp6uyMhI+zZPT09FRkYqLS2txH3y8/Pl6+vrsM3Pz087d+685ePk5ORIkmrVqlXi/Xl5eVq5cqUaNmxo/yTrWz3Ojz/+qPT09Ds/OQCaN2+eRo4cqejoaLVo0ULLli2Tv7+/VqxYUeL6Dz74QJMnT1avXr3UqFEjjRkzRr169dLcuXPta5566im98cYb6t+/f4nHOHbsmHbv3q2lS5eqY8eOeuihh7R06VJdv35da9eudVjr7++v4OBg+43PQbu3ETeoEC5evKjCwkIFBQU5bA8KClJWVlaJ+0RFRWnevHk6duyYioqKtGXLFm3YsEHnzp0rcX1RUZFeeeUVde3aVS1btnS47+2331aVKlVUpUoVffbZZ9qyZYt8fHzsj7Nr1y6tXbtWhYWFOnPmjKZPny5Jt3wsAP9SXr+8lHQMSQ7H8fT0lM1mK3acjz76SAEBAWrZsqXi4uL0ww8/3PXjoOIhbnDPeuutt9SkSRM1a9ZMPj4+iomJUXR09C3/oNrYsWP19ddfKzExsdh9gwYN0r59+7R9+3Y1bdpUv/zlL/Xjjz9Kknr06KE333xTo0ePls1mU9OmTdWrVy9JuuMfbwNQPr+8lKRZs2aqX7++4uLidPnyZRUUFGj27Nn6/vvvHY7zwgsv6MMPP9S2bdsUFxenDz74QL/+9a9L92RRIfB/ZlQIAQEB8vLyUnZ2tsP27OxsBQcHl7hPnTp1lJycrLy8PH333Xc6cuSIqlSpokaNGhVbGxMTo7/97W/atm1biX9wrXr16mrSpIkee+wxrVu3TkeOHNHGjRvt98fGxurKlSvKzMzUxYsX1bdvX0kq8bEA/HzO/vJSEm9vb23YsEHffvutatWqJX9/f23btk1PPfWUw3FGjRqlqKgotWrVSoMGDdL777+vjRs36sSJE2Xx1FAOiBtUCD4+PgoPD1dKSop9W1FRkVJSUtSlS5fb7uvr66t69erp5s2bWr9+vT08JMmyLMXExGjjxo3aunWrGjZseMdZLMuSZVn2U9o/8fDwUEhIiPz8/LR27VqFhoaqffv2Tj5T4P5T1r+83E54eLj279+vK1eu6Ny5c9q8ebP+53/+57bHiYiIkCQdP37cqcdCxUHcoMKIjY3V8uXLtXr1ah0+fFhjxoxRXl6eoqOjJUlDhgxRXFycff2XX36pDRs26OTJk/r73/+unj17qqioSK+++qp9zdixY/Xhhx9qzZo1qlq1qrKyspSVlaXr169Lkk6ePKmEhASlp6crMzNTu3bt0vPPPy8/Pz/7S0+S9Oabb+rgwYP65ptvNGPGDM2aNUsLFy6Ul5dXOX13gHtXWf3y4ozq1aurTp06OnbsmPbu3Xvb4+zfv1+SVLdu3VI9FiqAsn7rVkXDW8ErtkWLFln169e3fHx8rE6dOlm7d++23/f4449bQ4cOtX+dmppqNW/e3LLZbFbt2rWtwYMHW2fOnHE4nqQSbytXrrQsy7LOnDljPfXUU1ZgYKDl7e1tPfDAA9YLL7xgHTlyxOE4TzzxhFW9enXL19fXioiIsDZt2lRm3wPARImJiZbNZrNWrVplHTp0yBo1apRVo0YNKysry7Isyxo8eLA1adIk+/rdu3db69evt06cOGHt2LHD6t69u9WwYUPr8uXL9jVXr1619u3bZ+3bt8+SZM2bN8/at2+f9d1339nX/Nd//Ze1bds268SJE1ZycrLVoEED65lnnrHff/z4cWv69OnW3r17rX/+85/WX/7yF6tRo0bWY489VvbfFDjFmZ/fxA0AoFy4+peXbdu2lfjLy/8/zltvvWU98MADlre3t1W/fn1rypQpVn5+vv3+zMxM67HHHrNq1apl2Ww2q3HjxtaECRP4GVEBOfPz28OyLKv8zxe5T25urqpXr66cnJwy/RyD8Anvl9mxgXtV+ptD3D0CgHuUMz+/K5XTTABgjMzprdw9AlDh1J960N0j2HFBMQAAMApxAwAAjELcAAAAoxA3AADAKMQNAAAwCnEDAACMQtwAAACjEDcAAMAoxA0AADAKcQMAAIxC3AAAAKMQNwAAwCjEDQAAMApxAwAAjELcAAAAoxA3AADAKMQNAAAwCnEDAACMQtwAAACjEDcAAMAoxA0AADAKcQMAAIxC3AAAAKMQNwAAwCjEDQAAMApxAwAAjELcAAAAoxA3AADAKMQNAAAwCnEDAACMQtwAAACjEDcAAMAoxA0AADAKcQMAAIxC3AAAAKMQNwAAwCjEDQAAMApxAwAAjELcAAAAoxA3AADAKMQNAAAwitvjZsmSJQoLC5Ovr68iIiK0Z8+e265fsGCBHnroIfn5+Sk0NFS//e1v9eOPP5bTtAAAoKJza9wkJSUpNjZW8fHxysjIUJs2bRQVFaXz58+XuH7NmjWaNGmS4uPjdfjwYb333ntKSkrS5MmTy3lyAABQUbk1bubNm6eRI0cqOjpaLVq00LJly+Tv768VK1aUuH7Xrl3q2rWrXnjhBYWFhalHjx4aOHDgHc/2AACA+4fb4qagoEDp6emKjIz81zCenoqMjFRaWlqJ+zzyyCNKT0+3x8zJkye1adMm9erV65aPk5+fr9zcXIcbAAAwVyV3PfDFixdVWFiooKAgh+1BQUE6cuRIifu88MILunjxoh599FFZlqWbN29q9OjRt31ZKiEhQdOmTXPp7AAAoOJy+wXFzkhNTdXMmTP19ttvKyMjQxs2bNCnn36qGTNm3HKfuLg45eTk2G+nT58ux4kBAEB5c9uZm4CAAHl5eSk7O9the3Z2toKDg0vc5/XXX9fgwYM1YsQISVKrVq2Ul5enUaNG6bXXXpOnZ/FWs9lsstlsrn8CAACgQnLbmRsfHx+Fh4crJSXFvq2oqEgpKSnq0qVLifv88MMPxQLGy8tLkmRZVtkNCwAA7hluO3MjSbGxsRo6dKg6dOigTp06acGCBcrLy1N0dLQkaciQIapXr54SEhIkSX369NG8efPUrl07RURE6Pjx43r99dfVp08fe+QAAID7m1vjZsCAAbpw4YKmTp2qrKwstW3bVps3b7ZfZJyZmelwpmbKlCny8PDQlClTdObMGdWpU0d9+vTRH//4R3c9BQAAUMF4WPfZ6zm5ubmqXr26cnJyVK1atTJ7nPAJ75fZsYF7VfqbQ9w9gktkTm/l7hGACqf+1INlenxnfn7fU++WAgAAuBPiBgAAGIW4AQAARiFuAACAUYgbAABgFOIGAAAYhbgBAABGIW4AAIBRiBsAAGAU4gYAABiFuAEAAEYhbgAAgFGIGwAAYBTiBgAAGIW4AQAARiFuAACAUYgbAABgFOIGAAAYhbgBAABGIW4AAIBRiBsAAGAU4gYAABiFuAEAAEYhbgAAgFGIGwAAYBTiBgAAGIW4AQAARiFuAACAUYgbAABgFOIGAAAYhbgBAABGIW4AAIBRiBsAAGAU4gYAABiFuAEAAEYhbgAAgFGIGwAAYBTiBgAAGIW4AQAARiFuAACAUYgbAABgFOIGAAAYhbgBAABGIW4AAIBRiBsAAGAU4gYAABiFuAEAAEYhbgAAgFGIGwAAYBTiBgAAGIW4AQAARiFuAACAUYgbAABgFOIGAAAYhbgBAABGIW4AAIBRiBsAAGAU4gYAABiFuAEAAEYhbgAAgFGIGwAAYBTiBgAAGIW4AQAARiFuAACAUYgbAABgFOIGAAAYxe1xs2TJEoWFhcnX11cRERHas2fPbddfuXJFY8eOVd26dWWz2dS0aVNt2rSpnKYFAAAVXSV3PnhSUpJiY2O1bNkyRUREaMGCBYqKitLRo0cVGBhYbH1BQYGefPJJBQYGat26dapXr56+++471ahRo/yHBwAAFZJb42bevHkaOXKkoqOjJUnLli3Tp59+qhUrVmjSpEnF1q9YsUKXLl3Srl275O3tLUkKCwu77WPk5+crPz/f/nVubq7rngAAAKhw3PayVEFBgdLT0xUZGfmvYTw9FRkZqbS0tBL3+eSTT9SlSxeNHTtWQUFBatmypWbOnKnCwsJbPk5CQoKqV69uv4WGhrr8uQAAgIrDbXFz8eJFFRYWKigoyGF7UFCQsrKyStzn5MmTWrdunQoLC7Vp0ya9/vrrmjt3rt54441bPk5cXJxycnLst9OnT7v0eQAAgIrFrS9LOauoqEiBgYF655135OXlpfDwcJ05c0Zvvvmm4uPjS9zHZrPJZrOV86QAAMBd3BY3AQEB8vLyUnZ2tsP27OxsBQcHl7hP3bp15e3tLS8vL/u25s2bKysrSwUFBfLx8SnTmQEAQMXntpelfHx8FB4erpSUFPu2oqIipaSkqEuXLiXu07VrVx0/flxFRUX2bd9++63q1q1L2AAAAElu/pyb2NhYLV++XKtXr9bhw4c1ZswY5eXl2d89NWTIEMXFxdnXjxkzRpcuXdL48eP17bff6tNPP9XMmTM1duxYdz0FAABQwbj1mpsBAwbowoULmjp1qrKystS2bVtt3rzZfpFxZmamPD3/1V+hoaH6/PPP9dvf/latW7dWvXr1NH78eE2cONFdTwEAAFQwbr+gOCYmRjExMSXel5qaWmxbly5dtHv37jKeCgAA3Kvc/ucXAAAAXIm4AQAARiFuAACAUYgbAABgFOIGAAAYhbgBAABGIW4AAIBRiBsAAGAUp+MmLCxM06dPV2ZmZlnMAwAA8LM4HTevvPKKNmzYoEaNGunJJ59UYmKi8vPzy2I2AAAAp5Uqbvbv3689e/aoefPmevnll1W3bl3FxMQoIyOjLGYEAAC4a6W+5qZ9+/ZauHChzp49q/j4eL377rvq2LGj2rZtqxUrVsiyLFfOCQAAcFdK/Yczb9y4oY0bN2rlypXasmWLOnfurOHDh+v777/X5MmT9cUXX2jNmjWunBUAAOCOnI6bjIwMrVy5UmvXrpWnp6eGDBmi+fPnq1mzZvY1/fv3V8eOHV06KAAAwN1wOm46duyoJ598UkuXLlW/fv3k7e1dbE3Dhg31q1/9yiUDAgAAOMPpuDl58qQaNGhw2zWVK1fWypUrSz0UAABAaTl9QfH58+f15ZdfFtv+5Zdfau/evS4ZCgAAoLScjpuxY8fq9OnTxbafOXNGY8eOdclQAAAApeV03Bw6dEjt27cvtr1du3Y6dOiQS4YCAAAoLafjxmazKTs7u9j2c+fOqVKlUr+zHAAAwCWcjpsePXooLi5OOTk59m1XrlzR5MmT9eSTT7p0OAAAAGc5farlT3/6kx577DE1aNBA7dq1kyTt379fQUFB+uCDD1w+IAAAgDOcjpt69erpq6++0kcffaQDBw7Iz89P0dHRGjhwYImfeQMAAFCeSnWRTOXKlTVq1ChXzwIAAPCzlfoK4EOHDikzM1MFBQUO259++umfPRQAAEBpleoTivv376+DBw/Kw8PD/te/PTw8JEmFhYWunRAAAMAJTr9bavz48WrYsKHOnz8vf39/ffPNN9qxY4c6dOig1NTUMhgRAADg7jl95iYtLU1bt25VQECAPD095enpqUcffVQJCQkaN26c9u3bVxZzAgAA3BWnz9wUFhaqatWqkqSAgACdPXtWktSgQQMdPXrUtdMBAAA4yekzNy1bttSBAwfUsGFDRUREaM6cOfLx8dE777yjRo0alcWMAAAAd83puJkyZYry8vIkSdOnT9d//ud/qlu3bqpdu7aSkpJcPiAAAIAznI6bqKgo+383btxYR44c0aVLl1SzZk37O6YAAADcxalrbm7cuKFKlSrp66+/dtheq1YtwgYAAFQITsWNt7e36tevz2fZAACACsvpd0u99tprmjx5si5dulQW8wAAAPwsTl9zs3jxYh0/flwhISFq0KCBKleu7HB/RkaGy4YDAABwltNx069fvzIYAwAAwDWcjpv4+PiymAMAAMAlnL7mBgAAoCJz+syNp6fnbd/2zTupAACAOzkdNxs3bnT4+saNG9q3b59Wr16tadOmuWwwAACA0nA6bvr27Vts23PPPaeHH35YSUlJGj58uEsGAwAAKA2XXXPTuXNnpaSkuOpwAAAApeKSuLl+/boWLlyoevXqueJwAAAApeb0y1L//gcyLcvS1atX5e/vrw8//NClwwEAADjL6biZP3++Q9x4enqqTp06ioiIUM2aNV06HAAAgLOcjpthw4aVwRgAAACu4fQ1NytXrtTHH39cbPvHH3+s1atXu2QoAACA0nI6bhISEhQQEFBse2BgoGbOnOmSoQAAAErL6bjJzMxUw4YNi21v0KCBMjMzXTIUAABAaTkdN4GBgfrqq6+KbT9w4IBq167tkqEAAABKy+m4GThwoMaNG6dt27apsLBQhYWF2rp1q8aPH69f/epXZTEjAADAXXP63VIzZszQqVOn9Itf/EKVKv3f7kVFRRoyZAjX3AAAALdzOm58fHyUlJSkN954Q/v375efn59atWqlBg0alMV8AAAATnE6bn7SpEkTNWnSxJWzAAAA/GxOX3Pz7LPPavbs2cW2z5kzR88//7xLhgIAACgtp+Nmx44d6tWrV7HtTz31lHbs2OGSoQAAAErL6bi5du2afHx8im339vZWbm6uS4YCAAAoLafjplWrVkpKSiq2PTExUS1atHDJUAAAAKXl9AXFr7/+up555hmdOHFC3bt3lySlpKRozZo1WrduncsHBAAAcIbTcdOnTx8lJydr5syZWrdunfz8/NSmTRtt3bpVtWrVKosZAQAA7lqp3greu3dv9e7dW5KUm5urtWvX6ve//73S09NVWFjo0gEBAACc4fQ1Nz/ZsWOHhg4dqpCQEM2dO1fdu3fX7t27XTkbAACA05w6c5OVlaVVq1bpvffeU25urn75y18qPz9fycnJXEwMAAAqhLs+c9OnTx899NBD+uqrr7RgwQKdPXtWixYtKsvZAAAAnHbXcfPZZ59p+PDhmjZtmnr37i0vLy+XDbFkyRKFhYXJ19dXERER2rNnz13tl5iYKA8PD/Xr189lswAAgHvbXcfNzp07dfXqVYWHhysiIkKLFy/WxYsXf/YASUlJio2NVXx8vDIyMtSmTRtFRUXp/Pnzt93v1KlT+v3vf69u3br97BkAAIA57jpuOnfurOXLl+vcuXN66aWXlJiYqJCQEBUVFWnLli26evVqqQaYN2+eRo4cqejoaLVo0ULLli2Tv7+/VqxYcct9CgsLNWjQIE2bNk2NGjW67fHz8/OVm5vrcAMAAOZy+t1SlStX1osvvqidO3fq4MGD+t3vfqdZs2YpMDBQTz/9tFPHKigoUHp6uiIjI/81kKenIiMjlZaWdsv9pk+frsDAQA0fPvyOj5GQkKDq1avbb6GhoU7NCAAA7i2lfiu4JD300EOaM2eOvv/+e61du9bp/S9evKjCwkIFBQU5bA8KClJWVlaJ++zcuVPvvfeeli9fflePERcXp5ycHPvt9OnTTs8JAADuHaX6EL9/5+XlpX79+pX5hb1Xr17V4MGDtXz5cgUEBNzVPjabTTabrUznAgAAFYdL4qa0AgIC5OXlpezsbIft2dnZCg4OLrb+xIkTOnXqlPr06WPfVlRUJEmqVKmSjh49qgcffLBshwYAABXaz3pZ6ufy8fFReHi4UlJS7NuKioqUkpKiLl26FFvfrFkzHTx4UPv377ffnn76aT3xxBPav38/19MAAAD3nrmRpNjYWA0dOlQdOnRQp06dtGDBAuXl5Sk6OlqSNGTIENWrV08JCQny9fVVy5YtHfavUaOGJBXbDgAA7k9uj5sBAwbowoULmjp1qrKystS2bVtt3rzZfpFxZmamPD3deoIJAADcQ9weN5IUExOjmJiYEu9LTU297b6rVq1y/UAAAOCexSkRAABgFOIGAAAYhbgBAABGIW4AAIBRiBsAAGAU4gYAABiFuAEAAEYhbgAAgFGIGwAAYBTiBgAAGIW4AQAARiFuAACAUYgbAABgFOIGAAAYhbgBAABGIW4AAIBRiBsAAGAU4gYAABiFuAEAAEYhbgAAgFGIGwAAYBTiBgAAGIW4AQAARiFuAACAUYgbAABgFOIGAAAYhbgBAABGIW4AAIBRiBsAAGAU4gYAABiFuAEAAEYhbgAAgFGIGwAAYBTiBgAAGIW4AQAARiFuAACAUYgbAABgFOIGAAAYhbgBAABGIW4AAIBRiBsAAGAU4gYAABiFuAEAAEYhbgAAgFGIGwAAYBTiBgAAGIW4AQAARiFuAACAUYgbAABgFOIGAAAYhbgBAABGIW4AAIBRiBsAAGAU4gYAABiFuAEAAEYhbgAAgFGIGwAAYBTiBgAAGIW4AQAARiFuAACAUYgbAABgFOIGAAAYhbgBAABGIW4AAIBRiBsAAGCUChE3S5YsUVhYmHx9fRUREaE9e/bccu3y5cvVrVs31axZUzVr1lRkZORt1wMAgPuL2+MmKSlJsbGxio+PV0ZGhtq0aaOoqCidP3++xPWpqakaOHCgtm3bprS0NIWGhqpHjx46c+ZMOU8OAAAqIrfHzbx58zRy5EhFR0erRYsWWrZsmfz9/bVixYoS13/00Uf6zW9+o7Zt26pZs2Z69913VVRUpJSUlHKeHAAAVERujZuCggKlp6crMjLSvs3T01ORkZFKS0u7q2P88MMPunHjhmrVqlXi/fn5+crNzXW4AQAAc7k1bi5evKjCwkIFBQU5bA8KClJWVtZdHWPixIkKCQlxCKT/LyEhQdWrV7ffQkNDf/bcAACg4nL7y1I/x6xZs5SYmKiNGzfK19e3xDVxcXHKycmx306fPl3OUwIAgPJUyZ0PHhAQIC8vL2VnZztsz87OVnBw8G33/dOf/qRZs2bpiy++UOvWrW+5zmazyWazuWReAABQ8bn1zI2Pj4/Cw8MdLgb+6eLgLl263HK/OXPmaMaMGdq8ebM6dOhQHqMCAIB7hFvP3EhSbGyshg4dqg4dOqhTp05asGCB8vLyFB0dLUkaMmSI6tWrp4SEBEnS7NmzNXXqVK1Zs0ZhYWH2a3OqVKmiKlWquO15AACAisHtcTNgwABduHBBU6dOVVZWltq2bavNmzfbLzLOzMyUp+e/TjAtXbpUBQUFeu655xyOEx8frz/84Q/lOToAAKiA3B43khQTE6OYmJgS70tNTXX4+tSpU2U/EAAAuGfd0++WAgAA+HfEDQAAMApxAwAAjELcAAAAoxA3AADAKMQNAAAwCnEDAACMQtwAAACjEDcAAMAoxA0AADAKcQMAAIxC3AAAAKMQNwAAwCjEDQAAMApxAwAAjELcAAAAoxA3AADAKMQNAAAwCnEDAACMQtwAAACjEDcAAMAoxA0AADAKcQMAAIxC3AAAAKMQNwAAwCjEDQAAMApxAwAAjELcAAAAoxA3AADAKMQNAAAwCnEDAACMQtwAAACjEDcAAMAoxA0AADAKcQMAAIxC3AAAAKMQNwAAwCjEDQAAMApxAwAAjELcAAAAoxA3AADAKMQNAAAwCnEDAACMQtwAAACjEDcAAMAoxA0AADAKcQMAAIxC3AAAAKMQNwAAwCjEDQAAMApxAwAAjELcAAAAoxA3AADAKMQNAAAwCnEDAACMQtwAAACjEDcAAMAoxA0AADAKcQMAAIxC3AAAAKMQNwAAwCjEDQAAMApxAwAAjELcAAAAoxA3AADAKBUibpYsWaKwsDD5+voqIiJCe/bsue36jz/+WM2aNZOvr69atWqlTZs2ldOkAACgonN73CQlJSk2Nlbx8fHKyMhQmzZtFBUVpfPnz5e4fteuXRo4cKCGDx+uffv2qV+/furXr5++/vrrcp4cAABURG6Pm3nz5mnkyJGKjo5WixYttGzZMvn7+2vFihUlrn/rrbfUs2dPTZgwQc2bN9eMGTPUvn17LV68uJwnBwAAFVEldz54QUGB0tPTFRcXZ9/m6empyMhIpaWllbhPWlqaYmNjHbZFRUUpOTm5xPX5+fnKz8+3f52TkyNJys3N/ZnT315h/vUyPT5wLyrrf3fl5eqPhe4eAahwyvrf90/HtyzrjmvdGjcXL15UYWGhgoKCHLYHBQXpyJEjJe6TlZVV4vqsrKwS1yckJGjatGnFtoeGhpZyagClVX3RaHePAKCsJFQvl4e5evWqqle//WO5NW7KQ1xcnMOZnqKiIl26dEm1a9eWh4eHGydDecjNzVVoaKhOnz6tatWquXscAC7Ev+/7i2VZunr1qkJCQu641q1xExAQIC8vL2VnZztsz87OVnBwcIn7BAcHO7XeZrPJZrM5bKtRo0bph8Y9qVq1avzPDzAU/77vH3c6Y/MTt15Q7OPjo/DwcKWkpNi3FRUVKSUlRV26dClxny5dujisl6QtW7bccj0AALi/uP1lqdjYWA0dOlQdOnRQp06dtGDBAuXl5Sk6OlqSNGTIENWrV08JCQmSpPHjx+vxxx/X3Llz1bt3byUmJmrv3r1655133Pk0AABABeH2uBkwYIAuXLigqVOnKisrS23bttXmzZvtFw1nZmbK0/NfJ5geeeQRrVmzRlOmTNHkyZPVpEkTJScnq2XLlu56CqjAbDab4uPji700CeDex79v3IqHdTfvqQIAALhHuP1D/AAAAFyJuAEAAEYhbgAAgFGIGwAAYBTiBkYYNmyY+vXrV+J9YWFh8vDwkIeHh/z9/dWqVSu9++675TsggDsq6d/xunXr5Ovrq7lz52rYsGHy8PDQrFmzHNYkJyc7fOJ8amqqPDw89PDDD6uw0PHvgNWoUUOrVq0qq6eACoK4wX1h+vTpOnfunL7++mv9+te/1siRI/XZZ5+5eywAt/Huu+9q0KBBWrp0qX73u99Jknx9fTV79mxdvnz5jvufPHlS77//flmPiQqIuMF9oWrVqgoODlajRo00ceJE1apVS1u2bHH3WABuYc6cOXr55ZeVmJho/1BXSYqMjFRwcLD9g11v5+WXX1Z8fLzy8/PLclRUQMQN7itFRUVav369Ll++LB8fH3ePA6AEEydO1IwZM/S3v/1N/fv3d7jPy8tLM2fO1KJFi/T999/f9jivvPKKbt68qUWLFpXluKiAiBvcFyZOnKgqVarIZrPpueeeU82aNTVixAh3jwXg33z22WeaM2eO/vKXv+gXv/hFiWv69++vtm3bKj4+/rbH8vf3V3x8vBISEpSTk1MW46KCIm5wX5gwYYL279+vrVu3KiIiQvPnz1fjxo3dPRaAf9O6dWuFhYUpPj5e165du+W62bNna/Xq1Tp8+PBtjzd8+HDVrl1bs2fPdvWoqMCIG9wXAgIC1LhxY3Xr1k0ff/yxxo0bp0OHDrl7LAD/pl69ekpNTdWZM2fUs2dPXb16tcR1jz32mKKiohQXF3fb41WqVEl//OMf9dZbb+ns2bNlMTIqIOIG953Q0FANGDDgjv9TBOAeDRo00Pbt25WVlXXbwJk1a5b++te/Ki0t7bbHe/755/Xwww9r2rRpZTEuKiC3/1VwwFVycnK0f/9+h221a9cuce348ePVsmVL7d27Vx06dCiH6QA4IzQ0VKmpqXriiScUFRWlzZs3F1vTqlUrDRo0SAsXLrzj8WbNmqWoqKiyGBUVEGduYIzU1FS1a9fO4Xar39RatGihHj16aOrUqeU8JYC79cADDyg1NVUXL15UVFSUcnNzi62ZPn26ioqK7nis7t27q3v37rp582ZZjIoKxsOyLMvdQwAAALgKZ24AAIBRiBsAAGAU4gYAABiFuAEAAEYhbgAAgFGIGwAAYBTiBgAAGIW4AQAARiFuABgnNTVVHh4eunLlyl3vExYWpgULFpTZTADKD3EDoNwNGzZMHh4eGj16dLH7xo4dKw8PDw0bNqz8BwNgBOIGgFuEhoYqMTFR169ft2/78ccftWbNGtWvX9+NkwG41xE3ANyiffv2Cg0N1YYNG+zbNmzYoPr166tdu3b2bfn5+Ro3bpwCAwPl6+urRx99VP/4xz8cjrVp0yY1bdpUfn5+euKJJ3Tq1Klij7dz505169ZNfn5+Cg0N1bhx45SXl1fibJZl6Q9/+IPq168vm82mkJAQjRs3zjVPHECZI24AuM2LL76olStX2r9esWKFoqOjHda8+uqrWr9+vVavXq2MjAw1btxYUVFRunTpkiTp9OnTeuaZZ9SnTx/t379fI0aM0KRJkxyOceLECfXs2VPPPvusvvrqKyUlJWnnzp2KiYkpca7169dr/vz5+vOf/6xjx44pOTlZrVq1cvGzB1BmLAAoZ0OHDrX69u1rnT9/3rLZbNapU6esU6dOWb6+vtaFCxesvn37WkOHDrWuXbtmeXt7Wx999JF934KCAiskJMSaM2eOZVmWFRcXZ7Vo0cLh+BMnTrQkWZcvX7Ysy7KGDx9ujRo1ymHN3//+d8vT09O6fv26ZVmW1aBBA2v+/PmWZVnW3LlzraZNm1oFBQVl9B0AUJY4cwPAberUqaPevXtr1apVWrlypXr37q2AgAD7/SdOnNCNGzfUtWtX+zZvb2916tRJhw8fliQdPnxYERERDsft0qWLw9cHDhzQqlWrVKVKFfstKipKRUVF+uc//1lsrueff17Xr19Xo0aNNHLkSG3cuFE3b9505VMHUIYquXsAAPe3F1980f7y0JIlS8rkMa5du6aXXnqpxOtmSrp4OTQ0VEePHtUXX3yhLVu26De/+Y3efPNNbd++Xd7e3mUyIwDX4cwNALfq2bOnCgoKdOPGDUVFRTnc9+CDD8rHx0f//d//bd9248YN/eMf/1CLFi0kSc2bN9eePXsc9tu9e7fD1+3bt9ehQ4fUuHHjYjcfH58S5/Lz81OfPn20cOFCpaamKi0tTQcPHnTFUwZQxjhzA8CtvLy87C8xeXl5OdxXuXJljRkzRhMmTFCtWrVUv359zZkzRz/88IOGDx8uSRo9erTmzp2rCRMmaMSIEUpPT9eqVascjjNx4kR17txZMTExGjFihCpXrqxDhw5py5YtWrx4cbGZVq1apcLCQkVERMjf318ffvih/Pz81KBBg7L5JgBwKc7cAHC7atWqqVq1aiXeN2vWLD377LMaPHiw2rdvr+PHj+vzzz9XzZo1Jf3fy0rr169XcnKy2rRpo2XLlmnmzJkOx2jdurW2b9+ub7/9Vt26dVO7du00depUhYSElPiYNWrU0PLly9W1a1e1bt1aX3zxhf7617+qdu3arn3iAMqEh2VZlruHAAAAcBXO3AAAAKMQNwAAwCjEDQAAMApxAwAAjELcAAAAoxA3AADAKMQNAAAwCnEDAACMQtwAAACjEDcAAMAoxA0AADDK/wJSDXzHAipklgAAAABJRU5ErkJggg==",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "import seaborn as sns\n",
    "\n",
    "axis = sns.barplot(x = 'Models', y = 'Accuracy', data = model_perform)\n",
    "axis.set(xlabel = 'Models', ylabel = 'Accuracy')\n",
    "\n",
    "for p in axis.patches:\n",
    "    height = p.get_height()\n",
    "    axis.text(p.get_x() + p.get_width()/2, height + 0.005, '{:1.4f}'.format(height), ha='center')\n",
    "#plt.bar(6, height, color = ('blue','green','red','cyan','magenta','yellow','black'))\n",
    "#plt.ylim([0.0, 1.0])\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "hidden": true
   },
   "source": [
    "**Plot bar graph of AUC**"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "metadata": {
    "hidden": true
   },
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "axis = sns.barplot(x = 'Models', y = 'AUC', data = model_perform)\n",
    "axis.set(xlabel = 'Models', ylabel = 'AUC')\n",
    "\n",
    "for p in axis.patches:\n",
    "    height = p.get_height()\n",
    "    axis.text(p.get_x() + p.get_width()/2, height + 0.005, '{:1.4f}'.format(height), ha='center')\n",
    "#plt.bar(6, height, color = ('blue','green','red','cyan','magenta','yellow','black'))\n",
    "#plt.ylim([0.0, 1.0])\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "metadata": {
    "hidden": true
   },
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "plt.plot([0,1],[0,1],linestyle = '--',lw = 2,color = 'black')\n",
    "\n",
    "plt.plot(fpr_lr, tpr_lr, color='red',\n",
    "         label=r'LR (AUC = %0.4f)' %auc_lr, lw=2, alpha=0.75)\n",
    "\n",
    "plt.plot(fpr_knn, tpr_knn, color='blue',\n",
    "         label=r'KNN (AUC = %0.4f)' %auc_knn, lw=2, alpha=0.75)\n",
    "\n",
    "plt.ylim(0,1)\n",
    "plt.xlim(0,1)\n",
    "plt.xlabel('False Positive Rate (1-specificity)', fontsize = 12)\n",
    "plt.ylabel('True Positive Rate (sensitivity)', fontsize = 12)\n",
    "plt.legend(loc=\"lower right\", fontsize = 8, title = 'Mean ROC of')\n",
    "plt.grid(True)\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "hidden": true
   },
   "source": [
    "Logistic regression performs much better than KNN!"
   ]
  }
 ],
 "metadata": {
  "hide_input": false,
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.8.10"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 4
}
